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This thesis outlines the design and application of new routes towards a range of novel 
bisindolylmaleimide and indolo[2,3-a]carbazole derivatives, and evaluation of their 
biological effects and their chemotherapeutic potential. 
 
A key part of this work focussed on utilising a hydroxymaleimide as a replacement for 
the prevalent lactam/maleimide functionality and forming a series of novel derivatives 
through substitution on the indole nitrogens. To achieve this, a robust synthetic strategy 
was developed which allowed access to key maleic anhydride intermediates using 
Perkin-type methodology. These hydroxymaleimides were further modified via a 
Lossen rearrangement to furnish a series of analogues containing a 6-membered F-ring. 
 
The theme of F-ring modulation was further expanded through the utilisation of a 
second route involving the design and synthesis of β-keto ester intermediates, which 
afforded novel derivatives containing pyrazolone and isocytosine headgroups, and 
various N-substituents. Work on a further route involving a dione intermediate resulted 
in the isolation of a bisindolyl derivative with a novel imidazole F-ring. 
 
Following the synthesis of 42 novel compounds, extensive screening was undertaken 
using the NCI-60 cell line screen, with twelve candidates progressing to evaluation via 
the five dose assay. This led to the identification of several lead compounds with high 
cytotoxicity and excellent selectivity profiles, which included derivatives with low 
nanomolar GI50 values against specific cancer cell lines, and also derivatives with 
selective cytotoxicity. Preliminary results from a kinase screen indicated noteworthy 
selectivity towards GSK3α/β and PIM1 kinases, with low micromolar IC50 values being 
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One of the leading causes of morbidity and mortality worldwide, cancer causes about 
13% of all human deaths and at least one fifth of all deaths in Europe and North 
America.
1,2
 Although commonly referred to as a singular illness, cancer is in fact a class 
of related diseases in which a group of cells displays uncontrolled growth, invasion and 
progresses to metastasis. Cancer can start almost anywhere in the body and affects men 
and women of all ages and ethnicities (Figure 1.1.1) although certain factors can 
increase an individual’s risk of developing cancer; such as increasing age, differences in 
exposure to carcinogens or radiation, or genetic susceptibility. 
 
 





There are three main approaches for the treatment of cancer: surgery, radiotherapy and 
chemotherapy the usefulness of each of these approaches depends on the type of tumour 
and the stage of its development. Surgery is the oldest known treatment for cancer and 
can often initially be effective if the cancerous tissue is entirely removed by surgical 
excision, but this is not possible if the cancer has metastasized to other sites in the body. 
In such instances, radiotherapy and chemotherapy are usually required and are often 
used in combination with surgery or with each other. Chemotherapy is increasingly 




cell division of rapidly dividing cells. However, as this approach also affects all rapidly 
dividing normal cells, it can cause a range of side effects, such as myelosuppression, 
impaired wound healing and alopecia among others.
3
 Newer treatments comprise of 
targeted therapies which are currently the focus of much anticancer drug development. 
Targeted cancer therapies involve drugs that block the growth and spread of cancer by 
interfering with specific molecular targets that are involved in the growth, progression, 
and spread of cancer. Current chemotherapy drugs can be classified into general 





Type Mode of Action Examples 
Alkylating agents Effect DNA covalently Cyclophosphamide, 
lomustine, cisplatin 
Antimetabolites Substitute for normal cell building 





Anthracyclins DNA damage Doxorubicin, idarubicin 
Hormones/ 
antagonists 






Complex DNA and topoisomerase 
together (see Section 1.3.2) 
Irinotecan, topotecan 
Taxanes Prevent disassociation of 
microtubules 
Paclitaxel, docetaxol 
Vinca Alkaloids Bind to tubulin, interferes with 
mitosis 
Vincristine, vinblastine 
Kinase Inhibitors Block the action of kinases which 






Attach to cancer cells and mark for 
destruction by the immune system 
Rituximab, trastuzumab 
 
Table 1.1.1: Current chemotherapy drugs 
 
Cancer types have traditionally been classified according to the site of origin, cell type 
and stage of progression; however, it is now clear that many significant differences can 
occur even between tumours derived from the same organ. In order to successfully treat 
the vast majority of cancers, it has become evident that the most effective combination 






 Therefore, it is vital to continue the search for and development of novel 




The indolocarbazole family of compounds, including the biosynthetically related 
bisindolylmaleimides, are a class of compounds that are currently under study due to 
their potential as targeted anticancer drugs. Since their discovery, much work has been 
undertaken on the elucidation of their mechanism of action and on the development of 
analogues with improved biological properties, and these topics are discussed in detail 




The first isolation of an indolocarbazole from a natural source was reported in 1977. 
This compound, later named staurosporine 1, was discovered in a culture of an 
actinomycete, Streptomyces staurosporeus, from a Japanese soil sample while screening 
for microbial alkaloids.
6
 The X-ray crystal structure was determined shortly after but 
this original structure 2 was found to be assigned as the incorrect enantiomer.
7
 The 
correct relative stereochemistry was established in 1994 and was later confirmed by 





Figure 1.2.1: Structure of staurosporine 1 and ent-staurosporine 2 
 
Early biological studies showed that staurosporine 1 displayed inhibitory action against 
fungi, possessed strong hypotensive activity and also inhibited platelet aggregation.
6,10
 




it was found to be a nanomolar inhibitor of protein kinase C (IC50 = 2.7 nM) and also 
strongly inhibited the growth of a number of cancer cell lines.
11
 Unfortunately, 
staurosporine itself was not suitable as a pharmaceutical candidate as it was soon found 






Staurosporine 1 and very close derivatives have been isolated from a wide variety of 
different environments.
13
 In addition to their widespread production among 
actinomycetes, a bacterial group commonly found in soil samples, these compounds 
have been isolated from diverse groups of organisms from prokaryotes (actinomycetes, 
cyanobacteria, β-proteobacteria) to eukaryotes (myxomycetes, basidiomycetes, marine 
invertebrates). 
 
Of the five different isomeric ring systems available for indolocarbazoles only the 
indolo[2,3-a]carbazole isomer 3 has been isolated from nature and interest has mostly 
focused on this structure (Figure 1.2.2). In addition, the vast majority of these 
biologically active compounds also possess a sixth ring which is fused to the central 
benzene ring 4. 
 
Figure 1.2.2: Structure of indolo[2,3-a]carbazole 3 and general structure of biologically active 
indolocarbazoles 4 
 
In the 1980s, staurosporine 1 along with new analogues containing a hydroxy lactam 
(UCN-01 5 and UCN-02 6, Figure 1.2.3) were isolated from several Streptomyces, and 
these 7-hydroxy staurosporines were also found to be potent inhibitors of protein kinase 
C and possess significant antitumour activity.
14
 In 1985, a new indolocarbazole was 
isolated from cultures of Lechevalieria aerocolonigens and named rebeccamycin 7 after 
the daughter of the scientist who isolated the compound.
15
 The structure and absolute 
stereochemistry were determined by X-ray crystallography and total synthesis and this 






compound was subsequently found to be active against leukaemia and melanoma in 
mice and inhibited the growth of human adenocarcinoma cells, and produced single 





Figure 1.2.3: Structure of UCN compounds 5 and 6, and rebeccamycin 7 
 
Many aglycone derivatives have also been isolated from various sources. The aglycone 
of staurosporine itself 8 (Figure 1.2.4) was first isolated from another actinomycete 
strain Nocardiopsis sp. K-290 and related arcyriaflavin A 9, arcyriaflavin B 10 and 
arcyriaflavin C 11 were found to be contained in Arcyria denudata and Arcyria nutans 
slime moulds by Steglich et al.
18
 Interestingly, a group of bisindolylmaleimides – 
arcyriarubin A 12, arcyriarubin B 13 and arcyriarubin C 14, were also isolated from the 
slime moulds in the same study. These non-planar analogues are considered to be part 




Figure 1.2.4: Structure of staurosporine aglygone 8, arcyriaflavins A 9,  B 10 and C 11, and 
arcyriarubins A 12, B 13 and C 14 
 
In 1991, the tjipanazoles, such as tjipanazole A 15 (Figure 1.2.5), were isolated from 
culture extracts of Tolypothrix tjipanasensis.
19
 Unlike most other natural 




exhibited only weak cytotoxicity against tumour cells and did not inhibit protein kinase 
C, demonstrating the importance of the F-ring for kinase inhibition. 
 
 
Figure 1.2.5: Structure of tjipanazole A 15 
 
The indolocarbazoles isolated to date are a structurally diverse family of natural 
products. The various types of aglycones can be divided into four major groups: 1) the 
parent indolo[2,3-a]carbazole nucleus, such as that found in the tjipanazoles 15; 2) an 
imide, as in rebeccamycin 7; 3) hydroxy lactams, as in the UCN compounds 5 and 6; 
and 4) simple lactams, such as those found in staurosporine 1. In all of these aglycone 
types, substitution (i.e., halides, ethers, phenols) at various positions on the aromatic 




In the 1980s and 1990s biosynthetic studies were carried out on staurosporine 1 and 
rebeccamycin 7 using isotope labelled precursors. From these it was determined that the 
indolocarbazole portion of the molecule was formed from two tryptophan molecules 
and the carbohydrate moiety is derived from glucose and methionine (Figure 
1.2.6).
20,21,22
 However, it was not possible to determine the origin of the nitrogen of the 
lactam or maleimide moiety in these studies.  
 
 




1.2.4 Biological activity 
 
Anticancer activity has been by far the most extensively researched and reported aspect 
of the biological effects of indolocarbazoles, with a wide range of both natural and 
synthetic analogues displaying cytotoxic or antitumour properties.
13,23
 This aspect of 
their biological action will also be the focus of this thesis. In addition to their direct 
action on tumour cells, some derivatives were also found to increase the effect of other 




Several analogues have also shown antibacterial activity.
17,18,26
 This action was 
generally only observed against Gram positive bacteria, although there are a few 




Indolocarbazoles have also displayed many other biological activities including 
hypotensive properties, inhibition of platelet aggregation and inhibition of smooth 




1.3 Modes of biological action 
 
A significant number of both natural and synthetic indolo[2,3-a]carbazoles and 
bisindolylmaleimides have shown excellent antitumour activity and their modes of 
biological action can be divided into two main types: inhibition of protein kinases and 
interaction with DNA.  
 
1.3.1 Kinase inhibition 
 
Protein kinases are enzymes which modify other proteins by transferring phosphate 
groups from a high-energy donor molecule, such as adenosine triphosphate (ATP), to a 
specific substrate amino acid on the target protein. This phosphorylation results in a 
conformational change in the protein, affecting its function in areas such as enzyme 
activity, association with other proteins or cellular location. The majority of known 
protein kinases are tyrosine kinases, which phosphorylate the phenolic hydroxyl group 




longer participate in hydrogen bonding and the newly added negatively charged 
oxygens can form strong ionic bonds to suitably positioned positively charged groups in 






Figure 1.3.1: Phosphorylation of tyrosine residue 
 
In this way kinases regulate other proteins and the activities of cells, playing an 
important role in many intracellular signalling pathways including those that control cell 
growth and cell division. Up to 518 different kinases have so far been identified in 
humans and this enormous diversity, as well as their role in signalling, makes them an 
object of study for drug design.
30,31
 In addition to the treatment of disease, kinase 
inhibitors are also important as molecular probes to give us a better insight into the 
physiological roles of kinases. Figure 1.3.2 illustrates kinases of note for 











1.3.1.1 Kinases as drug targets 
 
Deregulated kinase activity has been implicated in a variety of human health conditions 
including disorders of the immune system, neurodegenerative disorders and diabetes, as 
well as cancer.
33
 Since the discovery that staurosporine 1 was a nanomolar inhibitor of 
PKC in 1986, great interest has been generated into obtaining highly active and 
Tyrosine kinase-like (TKL) 
Serine/threonine  
kinases (STE) 
Casein kinase 1 (CK1) 
Protein A, G and  
C kinase (AGC) 
Calcium/calmodulin 
dependent kinase (CAMK) 
Cyclin-dependent 
kinase (CMGC) 



















selective protein kinase inhibitors either through chemical synthesis or screening of new 
natural products. The first kinase inhibitor to be approved by the FDA was imatinib 16 
in 2001 (Figure 1.3.3), as a treatment for chronic myeloid leukemia. By April 2015, a 
total of 28 small-molecule kinase inhibitors have been approved for clinical use by the 
FDA, half of which were approved in the past 3 years.
34
 These include erlotinib 17, 
which is marketed as a treatment for non-small cell lung cancer, and sunitinib 18, which 
is marketed as a treatment for renal cell carcinoma and imatinib-resistant 
gastrointestinal stromal tumour.
35,36
 A large number are also currently undergoing 
human clinical trials for cancer and other conditions.  
 
 
Figure 1.3.3: Structure of imatinib 16, erlotinib 17 and sunitinib 18 
 
Many biologically relevant kinase inhibitors, including staurosporine 1, have been 
shown to work by competing with ATP.
37
 The interaction of staurosporine with the 
ATP-binding has been proven through the resolution of crystal structures of 
staurosporine bound to CDK2 (Figure 1.3.4) and PKA. This interaction has also been 
observed in crystal structures of various other indolocarbazoles with several kinases. 
These crystal structures show the indolocarbazole derivative being located in the ATP 
binding site, in the cleft between the two lobes of the protein kinase. The lactam group 
mimics the hydrogen bonding pattern of the adenine base of ATP by forming two 
hydrogen bonds to the backbone of the hinge between the N-terminal and C-terminal 
domains of the kinase. The sugar moiety then forms hydrogen bonds within the ribose 





                  
Figure 1.3.4: Binding site of staurosporine 1 in CDK2
38,39
; structure of ATP 
 
Due to the similarity between ATP binding sites in different kinases, this approach can 
be limited in terms of selectivity. Staurosporine is a very close match for the ATP 
binding which makes it a highly potent but unspecific kinase inhibitor (Figure 1.3.5). 
However, it has been possible to obtain some selectivity by exploiting differences in the 




     
Figure 1.3.5: Comparison between binding site of staurosporine 1
38
 (left) and that of ATP
41
 (right) 




1.3.1.2 Staurosporine analogues as kinase inhibitors 
 
Although staurosporine 1 was unsuitable as a drug candidate itself, many groups have 














and these analogues will be discussed in this section. To date, structural modifications 
have included: (i) substitution or use of various functional groups on the F-ring, (ii) 
substitutions on the A and E rings, (iii) removal of the C(2)-C(2′) bond and (iv) 







Figure 1.3.6: Derivatisation of indolo[2,3-a]pyrrolo[3,4-c]carbazole 
 
These modifications led to the synthesis of kinase inhibitors with a wide variety of 
different structures with structural-activity relationships only being reliable for a 
particular kinase and a specific type of indolocarbazole. A number of general 
comparisons can be drawn, however.
13
 Fully aromatic indolocarbazoles tend to be more 
active than their bisindolyl analogues.
42
 The presence of a sugar moiety generally 
increased activity compared to the unsubstituted aglycone.
43
 Also, the presence of a 
second carbonyl group in the F-ring is often better for non-glycosylated compounds, 




1.3.1.3 F-ring analogues 
 
The only naturally occurring indolocarbazole derivative that has undergone clinical 
trials to date is UCN-01 5 (Figure 1.3.7). This close derivative of staurosporine only 
differs from the parent compound in that it contains an extra hydroxy group on the 
lactam moiety.
14
 UCN-01 has anticancer properties itself and can also enhance the 
cytotoxicity of other anticancer drugs.
24
 UCN-01 inhibits several protein kinases, 
including Ca
2+
-dependant PKC isoforms (IC50 ~30 nM), Ca
2+
-independent isoforms 
(ii) Substitution (ii) Substitution 
(iv) Replacement of R groups (iii) Removal of C(2)-C(2)′ bond 





(~600 nM), cyclin-dependant kinases (IC50 = 300-600 nM), and PDK1 (IC50 = 5.0 
nM).
45
 This compound has entered several phase I/II clinical trials for treating various 
cancer types; however, its clinical development has been hindered by its high binding to 





Figure 1.3.7: Structure of UCN-01 5 
 
1.3.1.4 Analogues with modified sugar moiety 
 
A similar synthetic derivative, midostaurin 19 (Figure 1.3.8), which differs in structure 
from staurosporine only by the presence of a benzoyl group on the sugar moiety, is a 
potent inhibitor of a number of protein kinases including PKC, VEGF and FLT3.
48
 
Midostaurin has entered numerous clinical trials for treating various cancer types and its 
ability to suppress tumour growth is thought to be as a result of the inhibition of tumour 





Figure 1.3.8: Structure of midostaurin 19 
 
Gani et al. compared the binding strengths of staurosporine and midostaurin using 
kinase inhibition profile data from Karaman et al. to illustrate the effects of 
benzoylation on the selectivity of kinase inhibition across the kinome.
50,51




binding strength is weakened by two orders of magnitude (green circles) on addition of 
the benzoyl group; however, this effect is not the same for every kinase. Kinases of the 
STE family are now inhibited to a much lesser extent (4-5 order of magnitude, 
red/orange circles), whereas MLK1, MLK3 and JAK3 are unaffected and their low nM 
binding is retained (blue circles). This demonstrates how even a small change in 
structure can lead to significant changes in the potency and selectivity of kinase 
inhibition of an indolocarbazole. 
 
 
Figure 1.3.9: Comparison of staurosporine and midostaurin binding.
51
 The disk sizes represent the 
strength of staurosporine binding and the colours represent the effect of addition of the benzoyl 







Switching from a pyranose sugar to a furanose, as found in the naturally occurring 
K252a 20 (Figure 1.3.10), gave lestaurtinib 21, a potent inhibitor of JAK2 kinase (IC50 
= 1 nM).
52
 Lestaurtinib has displayed antitumour effects against pancreatic ductal 
adenocarcinoma, to inhibit growth of a trk-B overexpressing neuroblastoma, and to 
induce apoptosis in Hodgkin’s lymphoma cells.
53,54,55
 It has also been found to potently 
inhibit PRK1 (IC50 = 8.6 nM), leading to anti-proliferative effects against prostate 





Figure 1.3.10: Structure of K252a 20 and lestaurtinib 21 
 
Another pyranose analogue, CEP-751 22 (Figure 1.3.11), has also been shown to have 
similar activity against trk-B, FLT3 and RET tyrosine kinase. A water-soluble prodrug 
of CEP-751, named CEP-2563 23, was developed and entered clinical trials for patients 
with advanced solid tumours, however these trials have been discontinued. 
 
 
Figure 1.3.11: Structure of CEP-751 22 and CEP-2563 23 
 
A 3,9-bis(ethylthiomethyl) derivative, CEP-1347 24 (Figure 1.3.12), was reported to 
have neuroprotective properties and to be a potent MLK kinase inhibitor. CEP-1347 
entered clinical trials for determining its success in the prevention of the progression of 








Figure 1.3.12: Structure of CEP-1347 24 and SB-218078 25 
 
A simplified analogue with a maleimide and THF ring, SB-218078 25 (Figure 1.3.12), 
showed a 15-fold selectivity for CHK1 (IC50 = 15 nM) compared to CDK1 (IC50 = 250 






Removal of the central C2-C2′ bond leads to the bisindolylmaleimides. Due to their 
increased conformational flexibility, the binding mode of bisindolylmaleimides may be 
more complex than that of planar indolocarbazoles.
61
 Initially, GF 109203 X 26 and Ro 
318220 27 (Figure 1.3.13) were reported to be potent and selective inhibitors of protein 
kinase C (IC50 = 10 nM and 20 nM, respectively).
62,63
 However, they were later found to 
also potently inhibit several other kinases, such as MAPKAP kinase-1β (IC50 = 50 nM 










Another analogue, ruboxistaurin 28 (Figure 1.3.14), has been found to be a specific 
inhibitor of the PKC isoforms, PKCβ1 (IC50 = 4.7 nM) and PKCβ2 (IC50 = 5.9 nM).
66
 It 
displays selectivity over other protein kinases and PKC isoforms such as PKCα (IC50 = 
360 nM), PKCγ (IC50 = 300 nM), PKCε (IC50 = 600 nM) and PDK1 (IC50 = 750 nM).
67
 
Ruboxistaurin entered clinical trials for the treatment of diabetic peripheral retinopathy 
and was being investigated by Eli Lilly. In 2006, the company submitted a new drug 
application and received an approvable letter with requests for additional efficacy data. 




Figure 1.3.14: Structure of ruboxistaurin 28 and enzastaurin 29 
 
Enzastaurin 29 (Figure 1.3.14) is a highly potent inhibitor of PKCβ (IC50 = 6nM) and 
the AKT/PI3 pathway.
68
 It shows moderate selectivity over other PKC isoforms 
including PKCα (IC50 = 39nM), PKCγ (IC50 = 83nM) and PKCε (IC50 = 110 nM). 
Enzastaurin was also being investigated by Eli Lilly and underwent clinical trials for 
cancers such as glioblastoma, non-small cell lung cancer and colorectal cancer, but its 
development was halted in 2013. 
 
In 2003, Kuo et al. synthesised a panel of novel macrocyclic bisindolylmaleimide 
derivatives which were found to be potent inhibitors of GSK-3β (Figure 1.3.15).
69
 
Although the bisindolyl analogue 30 was highly active against GSK-3β, it was not 
specific and was also active against several other kinases such as CDK1 and CDK2, 
VEGF-R and several PKC isoforms. Replacing one of the indole rings with 7-azaindole 
(compound 31) had little effect on the potency or selectivity at GSK-3β but the 




selectivity. The bis-7-azaindolylmaleimide showed very low activity against a panel of 









Figure 1.3.15: IC50 (μM) of kinase assays and structure of bisindolylmaleimide GSK-3β inhibitors 
30, 31 and 32 
 
As inhibition of GSK-3β has been shown to reduce apoptosis signals it may be useful 
for the treatment of Alzheimer’s disease and protection against cell death.
70,71
 More 
recently, these bisindolylmaleimide GSK-3β inhibitors have been used to reveal the 
involvement of GSK-3β in the regulation of murine embryonic stem cell self-renewal.
72
 
These molecules were found to promote embryonic stem cell self-renewal which could 
enable the expansion of pluripotent embryonic stem cells for use in regenerative 
medicine and tissue engineering and as a source of differentiated cells for drug 
discovery and safety testing. 
 
1.3.2 Topoisomerase I and other DNA interactions 
 
DNA topoisomerases are found in all living organisms and are involved in the 
regulation of DNA supercoiling. As a result, they are enzymes which are involved in 
many cellular processes involving the separation of DNA strands such as replication, 
transcription, recombination and repair.
73
 There are two types of DNA topoisomerases: 
type I which make a nick in a single strand of DNA and pass a single strand through the 
Kinase 
assay 
30 31 32 
GSK-3β 0.02 0.02 0.03 
CDK1 1.25 4.43 >10 
CDK2 0.99 2.44 >10 
VEGF-R 1.45 3.56 >10 
PKCα 0.09 0.67 >10 
PKCβII 0.01 0.05 1.16 
PKCθ 0.07 0.84 >10 




nick and topoisomerase II which makes a nick in both strands of DNA and passes 
another double-stranded DNA segment through the nick.  
 
The mechanism of topoisomerase I (topo I) action begins with the enzyme binding to DNA to form 
DNA to form a macrocyclic complex ( 
Figure 1.3.16). This is followed by the nicking step, where nucleophilic attack of the 
phenolic oxygen of an active site tyrosine residue on a DNA phosphodiester bond 
induces a single strand break in the DNA. Topo I then forms a covalent linkage to the 
3′-end of the broken strand, while leaving a 5′-hydroxy group on the end free end. The 
DNA is then relaxed by controlled rotation of the 5′-hydroxy end of the break around 





Figure 1.3.16: Single strand DNA break by topo I 
 
1.3.2.1 Topoisomerase I as a chemotherapeutic target 
 
DNA topoisomerase I activity has been shown to be significantly raised in a number of 
different cancers, including colorectal, prostate and ovarian cancers, and is a target for 
different classes of drugs with antitumour or antibacterial applications.
74,75,76
 In 1985, 
the DNA-topo I complex was found to be the target for the potent anticancer alkaloid, 
camptothecin 33 (Figure 1.3.17), which had been isolated from the Chinese tree 
Camptotheca acuminate by Wall et al. in 1966.
77,78
 Although camptothecin did not 
progress beyond clinical trials due to harmful side-effects, derivatives such as topotecan 
34 have since been developed.
79
 In 1996, topotecan became the first topo I inhibitor to 
be approved for clinical use, initially in the treatment of ovarian cancer and later for use 
in the treatment of cervical and non-small cell lung cancer and has shown great promise 





These topo I poisons act as uncompetitive inhibitors by binding specifically to the 
DNA-enzyme complex resulting in a stabilised ternary complex, as shown in Figure 
1.3.17. Topotecan intercalates at the site of DNA cleavage and mimics a DNA base 
pair. The topotecan molecule is stabilised by base-stacking interactions with both the 
upstream and downstream base pairs and displaces the reactive 5′-OH of the cleaved 
strand. This prevents religation of the DNA and so converts topo I into a DNA-
damaging agent, causing cell damage which results in apoptosis.  
 
                





1.3.2.2 Indolocarbazoles with topo I activity 
 
On the discovery of rebeccamycin 7, the exact mechanism for its antitumour activity 
was unknown, although it was reported that it was associated with extensive 
fragmentation of DNA in cancer cells.
17
 Several years later, topo I was reported to be 
the cellular target for rebeccamycin by Yamashita et al.
80
 The same study also found 
that although rebeccamycin itself was a moderately weak inducer of DNA cleavage, two 
related indolocarbazoles, KT6006 35 and KT6528 36 (Figure 1.3.18) also targeted topo 
I and were much more potent. Interestingly, in the absence of the topo I enzyme 
KT6528 36 behaved as a DNA intercalator. This opened up new possibilities in that 
indolocarbazole compounds could not only selectively interact with ATP-binding sites 









Figure 1.3.18: Structure of rebeccamycin 7 and related indolocarbazoles KT6006 35 and  
KT6528 36 
 
Work by Bailly et al., who investigated the DNA-binding properties of 21 
indolocarbazoles by means of complementary spectroscopic techniques including 
electric linear dichroism, indicated that three necessary functional domains exist for 
anti-topo I activity (Figure 1.3.19).
81
 Their results showed that the planar 
indolocarbazole core intercalates between two consecutive base pairs, aryl substitution 
with bulky groups being detrimental to activity. Bulky substituents were better tolerated 
on the maleimide nitrogen as long as they contained a hydrogen bond donor, suggesting 
interaction with the enzyme itself. The results also indicated the importance of the sugar 
moiety which they postulated to reside in one of the helical grooves. For analogues 
where the sugar links both indole nitrogens or where the non-glycosylated nitrogen is 
methylated, significant topo I inhibition is unlikely to be displayed.    
 
 




The crystal structure of the indolocarbazole SA315F 37 bound to the topo I-DNA 
complex, reported by Staker et al. in 2005, supported these conclusions and revealed 




fashion to topotecan (Figure 1.3.20).
79
 The glycosylated indole ring stacks with bases on 
the intact DNA strand and the non-glycosylated indole ring stacks with bases on the 
cleaved strand. The maleimide ring projects into the minor groove side of the 
intercalation binding pocket, with one of its two carbonyls being 2.7 Å from Arg364, 
while the glycoside portion of the molecule is in the major groove close to Asn352. The 
indolyl hydroxy groups are also likely to interact with the topo I enzyme, one being 
located 4.0 Å from Glu 356 and the other being 3.3 Å from Ser 722. 
 
             
Figure 1.3.20: Indolocarbazole SA315F 37 bound to Topoisomerase I-DNA complex.
79,39
 The topo I 
enzyme is green with specific amino acids highlighted in orange, the DNA strand is blue/red and the 
indolocarbazole is pale blue.  
 
Indolocarbazoles are the most studied family of topoisomerase I inhibitors after the 
camptothecins. Despite the potent antitumour activity of rebeccamycin 7, its limited 
aqueous solubility posed problems for further evaluation and so the design of analogues 
with improved solubility was initiated. Substitution with an N-diethylaminoethyl group 
on the maleimide moiety gave becatecarin 38 (Figure 1.3.21), which possessed the 
desired solubility and also an increase in antitumour activity.
83
 Unlike rebeccamycin 
which was only a weak DNA intercalator, becatecarin exhibited strong DNA 
intercalation resulting in effective topoisomerase I and II inhibition.
84
 Becatecarin has 








leukemias and cancers of the colon, breast, ovary and lung among others.
49
 Although 
initial results from phase I clinical studies were promising, phase II trials revealed only 





Figure 1.3.21: Structure of becatecarin 38 
 
During precursor feeding fermentation experiments of L. aerocolonigenes with fluorine-
substituted tryptophans a series of novel fluoroindolocarbazoles (39, 40, 41 and 42, 
Figure 1.3.22) were produced and found to be more active against leukaemia than 
rebeccamycin.
88
 Compound 41, in particular, was found to be a potent inducer of topo I 
mediated DNA cleavage (IC50 = 18 nM), more potent than camptothecin 33 in the same 
experiment (IC50 = 38 nM).
84,89
 A derivative of this, BMS-250749 (42), was later 
synthesised with improved antitumour effects and topo I activity (IC50 = 2 nM) and this 





Figure 1.3.22: Structure of fluoroindolocarbazoles (39, 40, 41 and 42) 
 
In 1991, a new compound, BE-13793C 43 (Figure 1.3.23), was isolated during a 
screening program for new antitumour substances.
90




compound was found to be active against topoisomerases and inhibited the growth of 
doxorubicin-resistant or vincristine-resistant P388 murine leukaemia cell lines as well 
as the parent P388 cell line. Again, the low water solubility of this compound hampered 
its biological evaluation; however, it did become the basis of another series of clinical 
candidates. The main aim of the derivatisation studies was to improve aqueous 
solubility and this was achieved by adding a carbohydrate unit and by modifying the 
maleimide moiety. A 6-N-formylamino derivative, NB-506 44, had increased water 
solubility and significant anticancer activity.
91,93
 NB-506 entered phase I clinical trials 






Figure 1.3.23: Structure of BE-13793C 43 and NB-506 44 
 
It is interesting to note that topo I is a dual enzyme which, in addition to its DNA-
relaxing activity, also has an independent protein kinase action.
94
 The enzyme 
specifically phosphorylates arginine-serine-rich splicing factors which control the 
expression of particular genes. Several indolocarbazole antitumour agents displayed 
inhibitory action against the kinase activity of topo I in addition to inhibiting its DNA-
relaxing activity, including NB-506 44 and a hydroxymaleimide R-3 45 (Figure 
1.3.24).
92,95
 These effects were studied in detail using hydroxymaleimide R-3 45 which 
is a highly active topo I inhibitor and cytotoxic against murine leukaemia cell line P388 
(IC50 = 0.28 μM) but also shows discrete anti-topo I kinase activity in the absence of 
DNA (IC50 = 1-2 μM). A mutant topo I enzyme that lacked DNA cleavage/religation 
activity but still retained its phosphotransferase activity, was used without loss of kinase 
action indicating that the two effects are separate.
95
 This action is specific as 









Figure 1.3.24: Structure of hydroxymaleimide R-3 45 
 
Further modifications to NB-506 44 by replacing the formylamino group with a more 
polar group and moving the hydroxy groups on the indolocarbazole portion from 
positions 1 and 11 to positions 2 and 10 gave edotecarin 46 (Figure 1.3.25).
97
 
Edotecarin had greater water solubility and plasma stability while possessing the same 
topo I inhibitory activity and cytotoxicity as NB-506.
98,99
 The compound was developed 
by Pfizer and has undergone phase III clinical trials for treatment of glioblastoma 
multiforme and several phase I and II clinical trials against breast and gastric cancers; 
















The biological activity of a particular indolocarbazole was thought to be effected 
through a single mode of action; however, it is now clear that many analogues act 
through more than one mechanism. Although rebeccamycin 7 is a topo I inhibitor, the 
antitumour activities of different rebeccamycin derivatives could often not be explained 
by their anti-topo I or DNA-binding activities.
23,101
 Similarly, although K252a is active 
through kinase inhibition, some K252a derivatives were found to be active against topo 
I, as well as being kinase inhibitors.
102,103
 This demonstrates that even small 
modifications to the indolocarbazole structure can cause a change in the preferred mode 
of its biological action.
 
 
The prediction of the biological targets for these molecules is challenging at present due 
to the literature not being complete in respect of bioactivity. This is because in the past 
large scale protein kinase profiling was not possible and most inhibitors could only be 
screened against a limited number of kinases. Inhibitors can now be tested against 
panels of hundreds of kinases and this information will greatly assist the design and 
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2.1 Chemical routes to indolo[2,3-a]carbazole derivatives 
 
Indolocarbazoles are a class of pentacyclic heteroaromatic compounds consisting of a 
carbazole moiety fused to an indole unit via its five-membered ring. There are five 
different isomeric ring systems available for indolocarbazoles, however as almost all 
indolocarbazoles isolated from nature are indolo[2,3-a]carbazoles 3 (Figure 2.1.1), 
synthetic interest has mostly focused on this isomer.   
 
 
Figure 2.1.1: Structure of indolo[2,3-a]carbazoles 
 
Prior to the isolation of the first natural indolocarbazole, staurosporine 1, syntheses of 
indolo[2,3-a]carbazoles were scarce and focussed on the synthesis of the parent 
indolocarbazole 3. The discovery of the biological potential of these compounds, which 
generally contain an extra F-ring (47, Figure 2.1.1), attracted a much greater interest and 
a variety of different approaches and methods were developed.  
 
For review purposes, the methods for the synthesis of indolo[2,3-a]carbazole platform 3 
can be broadly classified into 3 types depending on the final ring closing step: B/D type 
(Section 2.2), C type (Section 2.3) and multiple ring closing (Section 2.4). B/D type 
routes target indolocarbazoles by indole ring synthesis to close the 2 five-membered 
rings. C type routes involve the initial synthesis of a bisindolyl intermediate, some of 
which have been found to be very interesting compounds in their own right, followed by 
cyclisation to form the central C ring. The multiple ring closing strategies involve the 
closing of more than one ring simultaneously. In general, each of these strategies is 
useful for the synthesis of particular classes of derivatives and the choice of method 






2.2 B/D type 
 
B/D type routes are characterised by the key formation of one or both of the five-
membered B and D rings. This has been accomplished using a Bischler-Möhlau indole 
synthesis, Fischer cyclisation or Cadogan nitrene insertion to close the rings.  
 
2.2.1 Bischler-Möhlau indole synthesis 
 
The first synthesis of an indolo[2,3-a]carbazole was achieved via a Bischler-Möhlau 
indole synthesis.
1,2
 In 1956, Tomlinson and co-workers reported that the condensation 
of 8-amino-1,2,3,4-tetrahydro-9-methyl-9H-carbazole 48 with 2-hydroxycyclohexanone 
49, followed by dehydrogenation produced the N-methyl derivative 50 (Scheme 2.2.1).
3
 






2.2.2 Fischer indole synthesis 
 
These routes are characterised by the reaction of phenylhydrazine with cyclohexanone 
derivatives in a classical Fischer indole synthesis.
4,5
   
 
In 1957, Bhide et al. developed a double Fischer indole synthesis of 2-
chlorocyclohexanone 51 or 2-hydroxycyclohexanone 49 with phenylhydrazine which, 
upon dehydrogenation, provided indolo[2,3-a]carbazole 3 (Scheme 2.2.2).
6
 Mann and 
Willcox used a similar method to synthesise indolo[2,3-a]carbazole 3 by Fischer indole 











Several years later, another application of this methodology was reported by Royer et 
al. who described the synthesis of various pentacyclic molecules including some 
indolocarbazoles from tricyclic ketones 53.
8
 The Fischer indole synthesis was 
performed in a mixture of acetic acid and trifluoroacetic acid, reacting the ketones with 





In 2005, Hu and Chen utilised a one-pot double Fischer indole synthesis in the synthesis 
of a number of novel biologically active tjipanazoles 55.
9
 In this route, the reaction of 2-
amino-cyclohexanone hydrochloride 56 with a substituted arylhydrazine hydrochloride 






In 1988, Bergman and Pelcman described the synthesis of a number of symmetrical 




using a similar double Fischer indole synthesis.
10
 The bis(phenylhydrazone) 59 was 
synthesised by reacting 2,3-bis[(trimethylsilyl)oxy]butadiene 60 with maleimide 61 in a 
Diels-Alder reaction and then treating the resulting cycloadduct 62 with 3 equivalents of 
phenylhydrazine. Polyphosphoric acid trimethylsilyl ester (PPSE) induced cyclisation 
was then achieved to give the dihydro compound 63 which partially converted to fully 
aromatic 58 on recrystallisation. Indolocarbazole 58 was prepared more successfully by 





Gribble and Berthel concurrently developed a similar route with an alternative method 
for achieving the bis(phenylhydrazone) intermediate.
11
 Tetrahydrophthalimides 64 were 
subjected to ozonolysis at -78 °C, followed by treatment with dimethyl sulfide to give 
the dialdehyde intermediates 65, which were not isolated due to problematic 
polymerisation. The crude dialdehydes were then reacted with an arylhydrazine to give 
the desired bis(phenylhydrazone)s 66 in 70-80% yield. Fischer indole cyclisation with 
PPSE and nitromethane then gave the indolocarbazoles 67 in 10-12% yield (Scheme 








2.2.3 Nitrene insertion 
 
In 1965 Cadogan et al. reported a new route to carbazoles via reduction of nitro 
compounds by triethyl phosphite or triphenylphosphine.
12
 This strategy has since been 
utilised in a number of routes to indolo[2,3-a]carbazoles and has been found to proceed 
through nitrene insertion.  
 
The first of these routes was reported by Raphael and co-workers, in 1990, with the aim 
of synthesising a lactam N-protected staurosporinone whose protecting group could be 
either removed to form staurosporinone 8 or retained for an N-glycosylation step to 
form staurosporine 1.
13
 Initially, a benzyl group was employed and the route began with 
a Diels-Alder reaction between N-benzyl maleimide 68 and dinitro compound 69 to 
give the adduct which was oxidised to give compound 70 using DDQ. The maleimide 
was then reduced with sodium borohydride to give the hydroxyl lactam, which was 
further reduced with triethylsilyl hydride-trifluoroacetic acid to give the lactam 71. 
Attempted deoxygenation with triethyl phosphite resulted in the formation of a mixture 
of the mono- and di-N-ethylated products; however, deoxygenation with 
triphenylphosphine achieved the required double nitrene insertion to give N-benzyl 
staurosporinone 72. Unfortunately 72 could not be deprotected to form staurosporinone 
8 (Scheme 2.2.7). The route was also attempted with variety of other protecting groups; 








The route was then attempted without a protecting group starting from a Diels-Alder 
reaction of dimethyl acetylenedicarboxylate 73 and compound 69, followed by 
palladium-mediated aromatisation and conversion to the anhydride (Scheme 2.2.8). The 
anhydride was then treated with aqueous ammonia to form the maleimide 74. The 
lactam 8 was then formed through treatment with sodium borohydride, followed by 
triethylsilyl hydride-trifluoroacetic acid. Although double nitrene insertion was 
successfully achieved with triphenylphosphine, the resulting staurosporinone 8 could 
not be separated from the triphenylphosphine oxide side product. The lactam nitrogen 
was instead protected using dihydropyran with p-toluenesulfonic acid which was then 
smoothly converted to the protected staurosporinone using triphenylphosphine and 





Several years later, Lowinger et al. followed a similar route to synthesise a p-












In 1992, Moody et al. developed a route to staurosporinone 8 with an intramolecular 
Diels-Alder reaction followed by a nitrene insertion as the key steps (Scheme 2.2.10).
15
 
This was achieved without the need for protecting groups on either the lactam or indole 
nitrogens. Starting from the acylation of ethyl indole-2-acetate 77 with oxalyl chloride, 
the resulting indole-3-glyoxalyl chloride 78 was quenched with 2-nitrocinnamyl amine 
79 to form the amide 80. Hydrolysis to the acid 81 was effected using potassium 
hydroxide prior to cyclodehydration using acetic anhydride to give the Diels-Alder 
substrate 82. The Diels-Alder reaction was initially attempted by heating 82 in refluxing 
bromobenzene open to air but although the indolocarbazole was formed, the lactam had 
also been oxidised to the maleimide. When heated under nitrogen, a reduced 
dihydrocarbazole was formed after 4 hours. However, it was found that if the nitrogen 
inlet on the reaction vessel was removed at this point and heating was continued for a 
further 4 hours, air oxidation led to the formation of the desired carbazole 83. Triethyl 
phosphite induced nitrene insertion then yielded the indolo[2,3-a]carbazole 8. A small 









Tomé and co-workers developed a different route with a nitrene insertion as the final 
step (Scheme 2.2.11).
16
 Starting from commercially available 2-nitrobenzaldehyde 84, 
the first step was a Wittig reaction to form an enone which was treated with t-
butyldimethylsilyl triflate and triethylamine to form diene 85. The diene then reacted 
with N-phenylmaleimide 86 in a Diels-Alder step, similar to some reported previously 
by the group, and the silyl ether was hydrolysed forming 87.
17
 A Fischer indole 
synthesis with p-methoxyphenylhydrazine 88 followed by treatment with DDQ formed 
the carbazole 89, which was then heated with triethyl phosphite to form the final indole 
ring 90. This route provided a more versatile route to the synthesis of unsymmetrical 
staurosporine analogues as a variety of substituted aryl hydrazones could be used in the 








The same methodology was also successfully applied to the synthesis of arcyriaflavin A 
58, using an unprotected succinimide 91 and phenylhydrazine 92, with the steps 





Rajeshwaren and Mohanakrishnan have recently reported a route to a series of 
unsymmetrical indolocarbazoles starting from 2-methylindole 93, involving 
electrocyclisation and nitrene insertion reactions (Scheme 2.2.13).
18
 Treatment of 2-
methylindole with methylacetoacetate 94 in the presence of iron(III) chloride (20 
mol%), followed by phenylsulfonylation gave protected 95. Selective bromination at the 
2-methyl position was achieved using NBS in the presence of a catalytic amount of 
AIBN and the bromide was reacted with triethylphosphite to form the phosphonate 
ester. A Wittig-Horner reaction with a series of functionalised 2-nitroarylaldehydes, 
containing chloro, fluoro or methoxy substituents 96, was accomplished using sodium 




an electrocyclisation step. The lactam moiety 99 was formed by initial treatment with 
NBS in the presence of AIBN, followed by treatment with aqueous ammonia in THF. 
The final ring-closing step was effected using triethylphosphite in 1,2-dichlorobenzene 
which, following deprotection, gave the desired substituted indolo[2,3-a]carbazoles 
100. The author noted that N-ethylation was not observed during the nitrene insertion 
step and postulated that the higher yield could be attributed to the nitrene insertion 
taking place meta- to the amide carbonyl unlike Moody’s route where the insertion 




Recently, Borrero et al. reported a new strategy to mono-substituted indolocarbazoles 
involving a gold-catalysed tandem dehydrative cyclisation/Diels-Alder reaction of a 
propargyl alcohol (Scheme 2.2.14).
19
 The route begins with the known Boc-protected 2-
aminobenzyl alcohol 101 which was converted to the alkyne 102 by initial bromide 
formation followed by palladium-catalysed cross-coupling with 
tris(trimethylsilylacetylene)-indium before deprotection of the silyl group with 
potassium carbonate. Deprotonation followed by the addition of 2-nitrobenzaldehyde 
formed a substrate 103 for the Au-mediated cyclisation which was achieved using the 
optimised conditions of JohnPhos.AuCl with silver triflate and benzene as solvent. The 
resulting 2-substituted indole 104 was then heated with maleimide in toluene and 
following DDQ oxidation 105 was formed. The final nitrene insertion proved difficult 
with attempted conditions involving trivalent organophosphorus reagents, Grignard 




decomposition or partial removal of the Boc group. The transformation was finally 






2.3 C Type 
 
C type routes are some of the most highly versatile and heavily utilised routes to 
indolocarbazoles and their analogues. They are characterised by initial formation of 
bisindole precursor prior to cyclisation to form the final C ring. The two indoles of the 
bisindole precursors can either be connected at the C-3 position, as in the 
bisindolylmaleimides, or the C-2 position. 
 
2.3.1 Cyclisation from bisindolylmaleimide intermediates  
 
As well as being useful intermediates in the synthesis of indolo[2,3-a]carbazoles, many 
bisindolylmaleimides have been shown to be potent inhibitors of various protein kinases 
in their own right. Therefore, in this section the syntheses of bisindolylmaleimides not 
synthesised as precursors to indolo[2,3-a]carbazoles will also be included. The final 








2.3.1.1 Early routes 
 
The first synthesis of staurosporinone 8 was reported by Winterfeldt and co-workers in 
1983 and involved a final C-ring closing step (Scheme 2.3.1).
20
 Initially, bisindole 
amide 107 was oxidised using DDQ to form trione 108. The trione was then partially 
reduced using sodium borohydride and polyacetylation was performed forming 109. 
Deacylation using titanium trichloride in aqueous acetone followed by sodium 
bicarbonate in aqueous methanol gave the bisindole compound 110, which was 





The group later reported a variation which allowed the synthesis of unsymmetrically N-
substituted indolocarbazoles and also changed the reductive cyclisation step to a more 
simple base hydrolysis (Scheme 2.3.2).
21
 The bisindole amide intermediate 111 was 
prepared by reacting the N-alkylated acid 112 with amino ketone 113 in the presence of 
N-N′ carbonyl diimidazole (CDI). Preliminary experiments indicated the necessity of 
the protection of both indole nitrogens for the base hydrolysis and so a SEM group was 
introduced prior to lactam formation. This was achieved through treatment with 
potassium tert-butoxide followed by deprotection to form the unsaturated lactam 114. A 
final photocyclisation step then formed the indolo[2,3-a]carbazole 115. It is interesting 




indole N-substituent is present in 115, compared to the 65% yield achieved to form 





2.3.1.2 Grignard and related routes 
 
These routes involve a type of indole electrophilic substitution where the indoles are 
initially treated with a Grignard reagent or non-nucleophilic base to activate the C-3 
position, prior to reaction with 3,4-dihalomaleimides. 
 
The first reported synthesis of a bisindolylmaleimide was reported by Steglich et al. in 
1980.
22
 This was accomplished by reaction of indolyl magnesium bromide 116 with 
2,3-dibromo-N-methylmaleimide 117 to give the methyl protected bisindolylmaleimide 







This method was later applied by Weinreb and Kaneko for their syntheses of benzyl 




Weinreb et al. coupled indole magnesium bromide 116 with N-benzyl-3,4-
dibromomaleimide 119 to form the bisindolylmaleimide 120 which was then cyclised to 
the indolocarbazole via DDQ oxidation (Scheme 2.3.4). A Clemmenson reduction was 
then used to convert the maleimide to the required lactam 72, the first reported use of 






For rebeccamycin 7, Kaneko et al. coupled 7-chloroindole 121 with N-
benzyloxymethyl-2,3-dibromomaleimide 122 under Grignard conditions in benzene 
containing a catalytic amount of HMPA and the desired bisindolylmaleimide product 
123 was formed in 27% yield (Scheme 2.3.5). Cyclisation to indolocarbazole 124 could 
be effected by irradiating with mercury lamps in the presence of iodine and air but a 
one-pot method was also developed where cyclisation and glycosylation could both be 
effected in refluxing benzene in the presence of silver oxide and the bromo glycoside 
125 with the N-glycoside 126 being obtained in 32% yield. Deprotection of the 
benzyloxymethyl group by hydrogenation and the acetyl groups by ammonolysis gave 








Several years later Brenner et al. used a similar Grignard reaction from a protected 
dibromomaleimide 117 to achieve the synthesis of unsymmetrically substituted 
arcyriarubin B 127 (Scheme 2.3.6).
25
 The condensation of indole Grignard 116 with 
2,3-dibromo-N-methylmaleimide 117 previously carried out in ether/benzene mixtures 
gave a mixture of the mono- and bisindolylmaleimides. They found that the outcome of 
this reaction is strongly dependent on the solvent with toluene giving the bisindolyl 
compound 118 in 70% yield and THF giving the monoindolyl compound 128 in 74% 
yield. The monoindolyl compound could then be used for the preparation of the 
unsymmetrically substituted bisindolylmaleimide through initial conversion to its N-
tert-butyloxycarbonyl derivative to prevent salt formation followed by reaction with 2 
equivalents of substituted indole Grignard 129 in THF to give the Boc-protected 130 in 
85% yield. Deprotection was carried out by heating the compound to 180°C to give 131. 
Conversion of the methylmaleimide to the maleimide was then carried out in the usual 









Faul et al. investigated the Grignard route in greater detail.
26
 They found the 
dichloromaleimides 132 to have comparable reactivity to the dibromo analogues as well 
as being cheaper and more readily available. They also found the synthesis to be solvent 
dependent and found the optimal solvent system toluene/ether/THF (5:1:1) for the 
reaction. Addition of aqueous ammonium chloride to the reaction mixture eliminated 
the need for chromatography and, on incorporation of all these improvements, the 





One disadvantage of the Grignard route is that it requires a large excess of the indole 
Grignard reagent 116 to obtain a high yield. This is due to the monoindolylmaleimide  
reacting with the other indolylmagnesium bromide 116 to form 133 and indole when 








Ohkubo et al. examined several bases including n-BuLi, LDA, LiHMDS, NaHMDS and 
KHMDS as an alternative to the Grignard reagent, finding LiHMDS to be the most 
effective.
27
 They found that just one equivalent of indole is sufficient for indolylation 
when using a non-nucleophilic base and used this method to synthesise arcyriaflavin A 
9, arcyriaflavin B 10 and arcyriaflavin C 11 (Scheme 2.3.9). One equivalent of 6-
benzyloxyindole 134 and 2,3-dibromo-N-methyl-maleimide 117 were coupled using a 
two equivalents of LiHMDS in THF to give the monoindolyl 135 compound in 93% 
yield. With 1 equivalent of indole, use of LDA also gave a relatively high yield of 76%, 
but NaHMDS and KHMDS gave lower yields with nBuLi only giving a trace of the 
desired product. The indole product was then protected with a Boc group and then 
reacted with several different indoles in the presence of two equivalents of LiHMDS to 
form the corresponding bisindole compounds 136 in good yields. Following 
deprotection, cyclisation and conversion from the methylmaleimide 137 to the 








Neel et al. employed a different strategy utilising a Suzuki cross coupling reaction as a 
key step from an indolylmaleimide triflate intermediate 138 (Scheme 2.3.10).
28
 This 
intermediate was obtained via initial methylation of indole-3-acetamide 139 or by 
methylation of indole acetonitrile 140 followed by conversion to the amide 141. The 
amide 141 was then cyclised with dimethyl oxalate 142 and potassium tert-butoxide in 
DMF to form the maleimide 143 which was subsequently methylated and converted to 
the triflate 138. The triflate was then coupled with protected 3-indole boronic acid 144 
in a Suzuki reaction with the Pd2(dba)3 chloroform complex in the presence of cesium 
fluoride and caesium bromide to give the desired bisindolylmaleimide 145 in 55% yield. 
The tosyl group was then removed using potassium carbonate in aqueous methanol 





2.3.1.3 F-ring routes 
 
This section discusses routes where the F-ring is formed directly from two 
functionalised indole precursors. 
 
In 1990, Davis et al. reported a new route to indolylaryl maleic anhydrides using a 
Perkin condensation between indolyl-3-glyoxylyl chlorides with aryl acetic acids 
(Scheme 2.3.11).
29




was treated with oxalyl chloride to form 1-methylindol-3-glyoxylyl chloride 149 which 
was then used directly in the reaction with 1-methyl-3-indolylacetic acid 150 in the 
presence of triethylamine to give the maleic anhydride in 36% isolated yield. One 






Later that year the group reported a mild conversion of maleic anhydrides 151 into 
maleimides 152 using HMDS/MeOH (Scheme 2.3.12).
30
 This procedure gave excellent 
yields for a variety of maleic anhydrides and did not affect more sensitive functional 





In 1993, Bit et al. developed a new coupling reaction which allowed direct access to the 
bisindolylmaleimide system involving the reaction of glyoxylyl chlorides with 
acetimidates (Scheme 2.3.13).
31
 Reaction of an N-substituted indole-3-glyoxylyl 
chloride 153 with an indole-3-carboximidate 154 in the presence of excess triethylamine 
gave the hydroxypyrrolone 155, which underwent dehydration and hydrolysis to the 
maleimide 156 upon treatment with p-toluenesulfonic acid. An alternative method for 
the dehydration and hydrolysis of acid sensitive groups was also developed using 
trifluoroacetic acid in pyridine and a panel of N-substituted bisindolylmaleimides were 




nitrogen on the imidate and is higher yielding than the Perkin route based on the indole 




In 1998, Faul et al. described a synthesis of N-substituted bisindolylmaleimides 157 
involving the reaction of indole-3-acetamides 158 with methyl indolyl-3-glyoxylates 
159 using a 1.0 M solution of potassium tert-butoxide in THF (Scheme 2.3.14).
32
 As 
indolyl-3-glyoxylyl chlorides were successful in Davis’s Perkin condensation, the 
reaction was also attempted with indolyl-3-glyoxylyl chloride instead of indolyl-3-
glyoxylyl ester however the yield dropped from a quantitative yield to 68%. This 
reaction was found to tolerate an unprotected indole nitrogen on either starting material 
and indole-3-acetamides with alkyl N-substituents containing a variety of functional 
groups (OH, OTr, and NMe2) with yields ranging from 84% to 100%. The main 





In 2006, Roy et al. developed a method for the synthesis of bisindolylmaleimides 160 




methylindole-3-glyoxylamide 161 with methyl aryl acetates 162 in the presence of 
potassium tert-butoxide in THF (Scheme 2.3.15).
33
 N-Methylindole-3-glyoxylamide 
161 was prepared from N-methylindole 148 through treatment with oxalyl chloride 
followed by aqueous ammonium hydroxide. This method was found to be successful for 






2.3.1.4 Via other 3,3′-bisindolyl intermediates 
 
These routes initially form a functionalised bisindolyl compound which can 
subsequently be reacted to form the F-ring. 
 
In 1987, Bergman and Pelcman developed a biomimetic synthesis via oxidative 
coupling of the dianion derived from indolylmethylacetate 163 (Scheme 2.3.16).
34
 
Diester 164 was formed by the addition of 2 equivalents of LDA to 
indolylmethylacetate 163 in THF, followed by coupling with 0.5 equivalents of iodine 
and an acidic workup. Heating with benzylamine gave the succinimide 165, which upon 
oxidation with DDQ afforded the bisindolylmaleimide 120. Heating the succinimide 








In 2006, Orito and co-workers reported a method for the synthesis of staurosporinones 
via a bisindolyl intermediate functionalised with a nitrile 167 (Scheme 2.3.17).
35
 The 
route began with the reaction of gramine methyl iodide 168 with 3-(N-
benzylindolyl)acetonitrile 169 in the presence of t-butyllithium to form bisindole 167. 
Oxidative cyclisation to indolocarbazole 170 was successfully achieved through 
treatment with trifluoroacetic acid followed by DDQ. Reduction of the cyano group to 
form a primary amine was achieved using sodium borohydride and cobalt chloride, and 
the amine was condensed with (2,4,6-trimethoxy)benzylaldehyde to form an imine 
which was subsequently reduced using sodium borohydride to the secondary amine  
171. Carbonylation was then achieved with palladium acetate and copper acetate in 
DMSO under a carbon monoxide atmosphere to form the protected lactam 172 before 









In 2006, Braña et al. reported a route to bisindolylpyrazolones 173 via a β-ketoester 
intermediate 174 (Scheme 2.3.18).
36
 The β-ketoester was formed by initial 
deprotonation of ethyl-(1-methyl-1H-indol-3-yl)acetate 175 using LDA, followed by the 
addition of acid chloride 176 previously synthesised by the treatment of 1-methyl-1H-
indole-3-carboxylic acid with thionyl chloride and DMF. The pyrazolones 173 were 






Pierce et al. developed a similar method for synthesising a β-ketoester intermediate in 
their route to novel 5,6-bisindolylpyrimidin-4-ones (Scheme 2.3.19).
37
 This route began 




LDA and treated with 1-methyl-1H-indole-3-carbonyl chloride 176 to form the β-
ketoester 178. In this case the acid chloride was obtained by treating the corresponding 
carboxylic acid with oxalyl chloride resulting in a much cleaner reaction compared to 
the previously reported thionyl chloride reaction, which was limited by formation of a 
considerable amount of the 2-chlorinated acid chloride side product. Coupling of the β-
ketoester intermediate with guanidine and with thiourea was then successfully achieved 






Isocytocine derivative 179 was then cyclised to the corresponding indolocarbazole 181 




2.3.2 Cyclisation from 2,2′-bisindolyl derivatives 
 
C-ring type routes have also been achieved from a 2,2′-bisindolyl starting material using 
a variety of different approaches. The first of these routes was reported by Somei and 
Kodama in 1992 and used a Diels-Alder reaction as the key step (Scheme 2.3.20).
39
 1-
Methoxyindole 182 was lithiated using n-butyllithium to form 2-lithio-1-methoxyindole 
which was then treated with anhydrous copper sulfate under an oxygen atmosphere with 




groups was achieved by hydrogenation with 10% Pd/C affording 2,2′-bisindole 184. 
Diels-Alder cycloaddition with N-phenylmaleimide 86 containing a catalytic amount of 





In 1995, Pindur et al. reported a different strategy utilising a photochemically induced 
cyclisation (Scheme 2.3.21).
40
 2,2′-Bis(N-methylindole) 186 was formed by treating N-
methyl indole 148 with n-butyllithium, followed by anhydrous copper (II) chloride. The 
bisindole intermediate 186 was then reacted with dimethyl acetylenedicarboxylate 73 to 
form 187. Photochemically induced 1,6-electrocyclisation of 187 gave indolo[2,3-








In 1997, Wood et al. employed novel rhodium carbenoid chemistry to synthesise a 
range of different indolo[2,3-a]carbazoles including staurosporinone 8.
41
 This was 
achieved by treating 2,2′-bisindole 184 with a number of diazo lactams  in the presence 
of a rhodium catalyst (Scheme 2.3.22). 2,2′-Bisindole 184 was synthesised using a 
double Madelung cyclisation procedure from 190 that had been reported a couple of 
years earlier by Bergman et al.
42
 Reaction with diazo lactam 191 and rhodium (II) 
acetate followed by electrocyclisation and dehydration via the proposed intermediates 
shown (192 and 193), yielded the indolo[2,3-a]carbazole 8. The identification of a 
suitable solvent for this step proved challenging with the substrate only being sparingly 
soluble in most solvents typically employed in rhodium carbenoid reactions resulting in 
very low yields. The use of sterically bulky pinacolone and also more rigorous 
deoxygenation techniques increased the yield to 25%, with the introduction of a lactam 





In 2004, Cai and Snieckus developed a route starting from a 2,2′-bisindole intermediate 
synthesised using a Stille cross-coupling reaction (Scheme 2.3.23).
43
 While initial 
attempts at forming the bisindole 194 using Suzuki-Miyaura conditions had proved 
unsuccessful, the reaction of 2-bromoindole carboxamide 195 with the 2-stannylated N-
carboxyindole 196 gave the desired decarboxylated bisindolyl intermediate 194 in good 
yield. The intermediate was treated with Eschenmoser’s salt to give the gramine 197, 




crown-6 yielding the nitrile 198. Cyclisation was then achieved using LDA and the 





Another strategy involved the use of a metathesis reaction as the key step and was 
reported by Pelly et al. in 2005 (Scheme 2.3.24).
44
 2,2′-Bisindole 184 was synthesised 
as before, using the route reported by Bergman et al. (see Scheme 2.3.22), before being 
subjected to standard Vilsmeier-Haack reaction conditions to give the dialdehyde 200. 
Protection as the bis-carbamate 201 was followed by use of the Wittig reaction to form 
dialkene 202, which was then treated with Grubbs second generation catalyst 203 to 









2.4 Multiple ring 
 
A few routes employ strategies which involve the formation of the B and/or D rings and 
the C ring simultaneously. This has been achieved using [4 + 2] cycloaddition and 
palladium(0)-catalysed polyannulation as the key step. 
 
In 1983, Magnus et al. reported a route involving an indole-2,3-quinodimethane 
intermediate to synthesise an indolo[2,3-a]carbazole (Scheme 2.4.1).
45
 Formylation of 
N-4-methoxybenzenesulfonyl-3-methylindole 205 was achieved through treatment with 
stannic chloride in DCM and 1,1-dichlorodimethyl ether. Condensation of the resulting 
aldehyde 206 with 2-amino styrene 207 gave the imine 208 which formed the 
pentacyclic carbamate 209 when treated with methylchloroformate and DDQ-mediated 





Several months later, the group reported an adaptation of the route to synthesise a 
tryptamine derivative which could then be used to access indolo[2,3-a]pyrrolo[3,4-
c]carbazoles (Scheme 2.4.2).
46
 The phthalimide protected tryptamine intermediate 211 
was synthesised and converted to the indolo[2,3-a]carbazole 212 using the same route 
as originally published. The phthalimide protecting group was then removed using 
hydrazine hydrate and treatment of the resulting amine 213 with phosgene followed by 
titanium tetrachloride formed the pyrrole ring 214. It was found that each protecting 
group could be selectively removed, with lithium and ammonia in THF removing just 




removing the carbamate forming 216, which would allow for the regioselective 





In 1995, Saulnier et al. reported the synthesis of a rebeccamycin analogue by a novel 
palladium(0)-catalysed polyannulation reaction, which formed 4 bonds and 3 rings in a 
single step from a 1,3-diacetylene intermediate (Scheme 2.4.3).
47
 Diacetylene 217 was 
formed from 2-ethynylaniline 218 using copper acetate in a mixture of pyridine and 
diethyl ether and was then treated with trifluoroacetic anhydride to form the precursor 
for the polyannulation step 219. The key reaction was carried out by combining 219 
with N-benzyl-3,4-dibromomaleimide 119 in the presence of anhydrous potassium 
carbonate and tetrakis(triphenylphosphine)-palladium (0) (7 mol%) in dry acetonitrile 
under argon, simultaneously forming the indole B and D rings and the central C ring of 








2.5 Synthesis of substituted bisindolylmaleimides 
 
Much of the earlier work on the synthesis of substituted staurosporine analogues 
focussed on the use of carbohydrate N-substituents similar to that of the original natural 
product. However, several of the analogues evaluated in clinical trials contain more 
simplified alkyl or macrocyclic N-substituents. Addition of the substituents can be 
easily achieved using sodium hydride and the appropriate alkyl halide; however, the 
difficulties arise when differentiation between the two indole nitrogens is required for 
the synthesis of unsymmetrically substituted indolocarbazole/bisindolylmaleimide 
targets. The formation of a macrocycle by linking the indole nitrogens with a carbon 
chain also presents its own complications. The various strategies towards overcoming 
these challenges are discussed in the following section. 
 
2.5.1 Synthesis of macrocycles  
 
The first work towards synthesis of macrocyclic bisindolylmaleimide derivatives was 
reported by Jirousek et al. who in 1995 reported the synthesis of a panel of N,N′ bridged 
derivatives.
48
 One of these compounds, later named ruboxistaurin 28, was subsequently 
found to be a highly potent and selective protein kinase inhibitor and was developed for 





The initial route involved the stepwise alkylation of 2,3-(bis)indolyl-N-methyl-
maleimide 118 by a previously formed N-N′ bridging component before being further 
developed to combine both alkylation steps.
49
 This was achieved by slowly adding a 
mixture of the bisindolylmaleimide 118 and bismesylate 220 to a slurry of caesium 
carbonate in DMF to form the macrocycle 221 (Scheme 2.5.1). The maleimide methyl 
group was then removed through treatment with potassium hydroxide followed by 
HMDS and methanol in DMF and the alcohol was deprotected under acidic conditions 
forming 222. The alcohol was activated via the mesylate 223 which was then displaced 





In 2003, Zhang et al. reported a route to a series of novel macrocyclic 
bisindolylmaleimides containing linkers with multiple heteroatoms (Scheme 2.5.2). 
Lead compound 224 was found to be highly active against PKC-β and GSK-3β and 
showed high selectivity in a screening panel of ten other kinases. These workers took a 
different approach to Jirousek et al. and initially attached two separate but identical N-
substituents before linking those to form the macrocycle. Starting from N-methyl 
maleimide 118, bis-N-alkylation of the indole nitrogens was achieved using an excess of 




heated with 13 equivalents of ethylamine in the presence of Hünig’s base and THF in a 
pressure tube to form a mixture of the desired cyclised amine 226 and acyclic mono- 
and di-amines. To ensure the monoamine was converted to the cyclised product 226 and 
not the unwanted diamine, all volatiles were evaporated before the residue was heated 
in refluxing dioxane for 6 hours. Removal of the N-methyl group from the maleimide 
was then achieved by initial treatment with potassium hydroxide followed by citric acid 





2.5.2 Synthesis of mono-alkylated bisindolylmaleimides 
 
There are two main strategies for the synthesis of mono-alkylated or unsymmetrically 
alkylated bisindolylmaleimides: one involves the addition of the substituent to one of 
the indole precursors prior to coupling to forming the bisindolyl structure and the other 
involves synthesising a suitable bisindolyl intermediate and achieving selective mono-
alkylation at this point.   
 
In 2003, Faul et al. reported the synthesis of a series of N-(azacycloalkyl) 
bisindolylmaleimides, one of which was selected for clinical evaluation for 






bisindolylmaleimide portion was synthesised using methodology previously reported by 
the group involving the reaction of an indole-3-glyoxylate ester with an indole-3-
acetamide. Two comparable routes were then developed to introduce the N-
(azacycloalkyl) group (Scheme 2.5.3). The first involved preparation and conversion of 
the HCl salt of N-(azacycloalkyl) indole 227 to the corresponding glyoxylate ester 228 
and reacting this with 2-(1-methyl-1H-indol-3-yl)acetamide 139 in the presence of 
potassium tert-butoxide to form the bisindolylmaleimide 29. The second involved the 
initial synthesis of the substituted indole-3-acetamide 229 which could then be reacted 
with methyl 2-(1-methyl-1H-indol-3-yl)-2-oxoacetate 230 under the same base-





Toullec et al. used a different approach to the synthesis of a mono-alkylated 
bisindolylmaleimide in their synthesis of GF 109203 X 26 (Scheme 2.5.4).
51
 Instead of 
introducing the indole substituent from the beginning of the synthesis, their route began 
with the synthesis of an unsubstituted bisindolylmaleimide 118 using Steglich’s 
procedure which was then mono-alkylated using sodium hydride and the appropriate 
acid chloride to form 231. The free maleimide 26 was then formed through treatment 








The yields for the late-stage selective mono-alkylation of a bisindolyl intermediate are 
generally observed to be lower than the yields for the routes where the substituent is 
incorporated onto one of the indole precursors. Also, N-protection of the maleimide is 
required for the routes involving alkylation at a later stage and usually involves the use 
of a methyl or benzyl group which can be difficult to remove, further reducing the yield; 
and so, introducing the substituent at the beginning is a better choice when a single 
target is desired. However, the mono-alkylation of a common intermediate is still 








Due to the diverse and extensive biological profiles of compounds of the 
indolocarbazole family, much progress has been achieved on the development of 
synthetic strategies of indolocarbazoles since the first reported synthesis in 1956. While 
early syntheses were generally based on methods used for general indole synthesis, with 
the growing interest in this field a much wider range of diverse routes have been 
reported.  
 
The indole forming B/D routes were successful in forming certain types of 
indolocarbazoles; however, they were not without limitations. Although routes based on 
Fischer indole synthesis can successfully achieve symmetrical and unsubstituted 
indolocarbazoles in high yields and are formed from easily accessible starting materials, 
derivatisation is difficult and they are limited to employing only 2 or 4-substituted 
phenylhydrazine substrates as precursors.
52
 Cadogen insertions can suffer from low 
yields and unwanted N-ethylated side-products; although some groups reported high 
yields and postulated that substitution patterns influenced the success. High yields could 
also be obtained from 2,2′ bisindole precursors but these routes often required harsh 
conditions and it was more difficult to obtain an unsymmetrical indolocarbazole. The 
cyclisation of bisindolylmaleimides is by far the most popular route due to the short 
routes to the bisindolylmaleimide intermediates from readily available starting material, 
but the cyclisation itself can be difficult and the success is strongly influenced by 
changes to the F-ring and the presence of N-substituents. Many routes also suffer from 
poor solubility which can be a particular problem in routes with intermediates 
containing unmasked polar heterocyclic functionality.  
 
Synthesis of unsymmetrically N-substituted analogues has been achieved both by initial 
alkylation of the indole precursors and by selective alkylation of bisindolylmaleimide 
intermediate and the choice of route depends on the desired target. The synthesis of 
macrocyclic bisindolylmaleimides with interesting and potent biological activity has 





It can be noted that the vast majority of reported compounds contain either a lactam or 
maleimide F-ring and there have been few reports of F-ring derivatisation in the 
literature to date. Thus, the development of novel synthetic strategies to these novel F-
ring analogues is of paramount interest to explore their potential effects on biological 










1. R. Möhlau, Ber. Dtsch. Chem. Ges., 1881, 14, 171–175. 
2. A. Bischler, Ber. Dtsch. Chem. Ges., 1892, 25, 2860–2879. 
3. R. J. Brunton, F. K. Drayson, S. G. P. Plant, and M. L. Tomlinson, J. Chem. Soc. 
Resumed, 1956, 4783. 
4. E. Fischer and F. Jourdan, Ber. Dtsch. Chem. Ges., 1883, 16, 2241–2245. 
5. E. Fischer and O. Hess, Ber. Dtsch. Chem. Ges., 1884, 17, 559–568. 
6. G. V. Bhide, N. L. Tikotkar, and B. D. Tilak, Chem. Ind., 1957, 363. 
7. F. G. Mann and T. J. Willcox, J. Chem. Soc., 1958, 1525–1529. 
8. H. Royer, D. Joseph, D. Prim, and G. Kirsch, Synth. Commun., 1998, 28, 1239–1251. 
9. Y.-Z. Hu and Y.-Q. Chen, Synlett, 2005, 42–48. 
10. J. Bergman and B. Pelcman, J. Org. Chem., 1989, 54, 824–828. 
11. G. W. Gribble and S. J. Berthel, Tetrahedron, 1992, 48, 8869–8880. 
12. J. I. G. Cadogan, M. Cameron-Wood, R. K. Mackie, and R. J. G. Searle, J. Chem. 
Soc., 1965, 4831–4837. 
13. I. Hughes, W. P. Nolan, and R. A. Raphael, J. Chem. Soc. [Perkin 1], 1990, 2475–
2480. 
14. T. B. Lowinger, J. Chu, and P. L. Spence, Tetrahedron Lett., 1995, 36, 8383–8386. 
15. C. J. Moody, K. F. Rahimtoola, B. Porter, and B. C. Ross, J. Org. Chem., 1992, 57, 
2105–2114. 
16. M. Adeva, F. Buono, E. Caballero, M. Medarde, and F. Tomé, Synlett, 2000, 2000, 
0832–0834. 
17. M. Adeva, E. Caballero, F. García, M. Medarde, H. Sahagún, and F. Tomé, 
Tetrahedron Lett., 1997, 38, 6893–6896. 
18. G. G. Rajeshwaran and A. K. Mohanakrishnan, Org. Lett., 2011, 13, 1418–1421. 
19. N. V. Borrero, L. G. DeRatt, L. Ferreira Barbosa, K. A. Abboud, and A. Aponick, 
Org. Lett., 2015, 17, 1754–1757. 
20. E. Winterfeldt and B. Sarstedt, Heterocycles, 1983, 20, 469. 
21. J. Brüning, T. Hache, and E. Winterfeldt, Synthesis, 1994, 1994, 25–27. 
22. W. Steglich, B. Steffan, L. Kopanski, and G. Eckhardt, Angew. Chem. Int. Ed. Engl., 
1980, 19, 459–460. 
23. S. M. Weinreb, R. S. Garigipati, and J. A. Gainor, Heterocycles, 1984, 21, 309. 
24. T. Kaneko, H. Wong, K. T. Okamoto, and J. Clardy, Tetrahedron Lett., 1985, 26, 
4015–4018. 
25. M. Brenner, H. Rexhausen, B. Steffan, and W. Steglich, Tetrahedron, 1988, 44, 
2887–2892. 
26. M. M. Faul, K. A. Sullivan, and L. L. Winneroski, Synthesis, 1995, 1995, 1511–
1516. 
27. M. Ohkubo, T. Nishimura, H. Jona, T. Honma, and H. Morishima, Tetrahedron, 
1996, 52, 8099–8112. 
28. D. A. Neel, M. R. Jirousek, and J. H. McDonald III, Bioorg. Med. Chem. Lett., 1998, 
8, 47–50. 
29. P. D. Davis, R. A. Bit, and S. A. Hurst, Tetrahedron Lett., 1990, 31, 2353–2356. 
30. P. D. Davis and R. A. Bit, Tetrahedron Lett., 1990, 31, 5201–5204. 
31. R. A. Bit, P. H. Crackett, W. Harris, and C. H. Hill, Tetrahedron Lett., 1993, 34, 
5623–5626. 





33. S. Roy, S. Roy, and G. W. Gribble, Org. Lett., 2006, 8, 4975–4977. 
34. J. Bergman and B. Pelcman, Tetrahedron Lett., 1987, 28, 4441–4444. 
35. Y. Wada, H. Nagasaki, M. Tokuda, and K. Orito, J. Org. Chem., 2007, 72, 2008–
2014. 
36. M. F. Braña, A. Gradillas, A. G. Ovalles, B. López, N. Acero, F. Llinares, and D. M. 
Mingarro, Bioorg. Med. Chem., 2006, 14, 9–16. 
37. L. T. Pierce, M. M. Cahill, and F. O. McCarthy, Tetrahedron, 2010, 66, 9754–9761. 
38. L. T. Pierce, M. M. Cahill, H. J. Winfield, and F. O. McCarthy, Eur. J. Med. Chem., 
2012, 56, 292–300. 
39. M. Somei and A. Kodama, Heterocycles, 1992, 34, 1285. 
40. U. Pindur, Y. S. Kim, and D. Schollmeyer, J. Heterocycl. Chem., 1995, 32, 1335–
1339. 
41. J. L. Wood, B. M. Stoltz, H.-J. Dietrich, D. A. Pflum, and D. T. Petsch, J. Am. Chem. 
Soc., 1997, 119, 9641–9651. 
42. J. Bergman, E. Koch, and B. Pelcman, Tetrahedron, 1995, 51, 5631–5642. 
43. X. Cai and V. Snieckus, Org. Lett., 2004, 6, 2293–2295. 
44. S. C. Pelly, C. J. Parkinson, W. A. L. van Otterlo, and C. B. de Koning, J. Org. 
Chem., 2005, 70, 10474–10481. 
45. P. D. Magnus, C. Exon, and N. L. Sear, Tetrahedron, 1983, 39, 3725–3729. 
46. P. D. Magnus and N. L. Sear, Tetrahedron, 1984, 40, 2795–2797. 
47. M. G. Saulnier, D. B. Frennesson, M. S. Deshpande, and D. M. Vyas, Tetrahedron 
Lett., 1995, 36, 7841–7844. 
48. M. R. Jirousek, J. R. Gillig, D. A. Neel, C. J. Rito, D. O’Bannon, W. F. Heath, J. H. 
McDonald III, M. M. Faul, L. L. Winneroski, A. Melikian-Badalian, M. Baevsky, L. 
M. Ballas, and S. E. Hall, Bioorg. Med. Chem. Lett., 1995, 5, 2093–2096. 
49. M. M. Faul, L. L. Winneroski, C. A. Krumrich, K. A. Sullivan, J. R. Gillig, D. A. 
Neel, C. J. Rito, and M. R. Jirousek, J. Org. Chem., 1998, 63, 1961–1973. 
50. M. M. Faul, J. L. Grutsch, M. E. Kobierski, M. E. Kopach, C. A. Krumrich, M. A. 
Staszak, U. Udodong, J. T. Vicenzi, and K. A. Sullivan, Tetrahedron, 2003, 59, 
7215–7229. 
51. D. Toullec, P. Pianetti, H. Coste, P. Bellevergue, T. Grand-Perret, M. Ajakane, V. 
Baudet, P. Boissin, E. Boursier, and F. Loriolle, J. Biol. Chem., 1991, 266, 15771–
15781. 















3 Aims and Objectives 
  





As outlined in the introductory chapters, the discovery of the excellent anticancer 
properties of the natural product staurosporine 1, has provoked great interest from 
medicinal chemists, biologists and pharmaceutical companies alike.
1,2
 Staurosporine 
was also found to be a nanomolar inhibitor of protein kinase C and so much of this 
interest has focused on the development of selective and potent protein kinase inhibitors 
with potential therapeutic applications.
3
 Staurosporine and other indolocarbazoles have 
been shown to inhibit kinases by competing with ATP, but due to the similarity between 
ATP binding sites in different kinases this approach can be limited in terms of 
selectivity.
4
 Critically there are differences to exploit, however, and therefore it is 
imperative to discover new chemical entities that are both potent and selective.  
 
 
Figure 3.1.1: Structures of staurosporine 1, SB-218078 25, ruboxistaurin 28 and enzastaurin 29. 
 
Some success has been achieved in the synthesis of analogues with a higher selectivity 
towards individual kinases. One such compound, SB-218078 25, showed a 15-fold 
selectivity for CHK1 (IC50 = 15 nM) compared to CDK1 (IC50 = 250 nM), and a 65-fold 
selectivity compared to PKC (IC50 = 1000 nM).
5
 A simple modification has led to the 
bisindolylmaleimides many of which have been shown to be highly selective inhibitors 
of individual protein kinases. Examples are ruboxistaurin 28 and enzastaurin 29, which 
are highly active and selective inhibitors of protein kinase C-β.
6,7
 However, although a 
small number of this class of compounds have undergone clinical trials, to date none 
have progressed to be used in anticancer therapy.  
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3.2 Overall Aims 
 
The overall objective of this project is to synthesise novel anticancer agents by 
modification of the bisindolemaleimide structure 232 and indolocarbazole structure 233 
with the aim of improving the key enzyme binding characteristics to increase selectivity 





This will be achieved by firstly utilising novel heterocycles on the connecting F-ring. A 
common motif in these biologically active indolocarbazoles is the lactam/maleimide 
and it was proposed that changes to this ring will result in promising diversification of 
existing H-bonding networks necessary for biological activity. Further diversification 
will be achieved through substitution on the indole nitrogens, adding further 
possibilities for protein-ligand interactions and also giving additional properties such as 
increased solubility. Work can then be carried out on the final ring closing stage to 
achieve the indolocarbazole analogues of these compounds. Once synthesised, the 
biological activity of all target compounds will then be assessed. 
  
3.3 Development of Synthetic Targets 
 
Previous work within the group developed a synthetic strategy to N-methyl 
azaindolylmaleimides and their hydroxymaleimide analogues synthesised via a maleic 
anhydride intermediate 234 and starting from N-methyl azaindole precursors 235. It was 
anticipated that the incorporation of a hydroxy group would modify the F-ring protein-
interacting pharmacophore by altering the position of the H-bond donor, which could 
lead to novel derivatives with interesting biological profiles. This identified a lead 
hydroxymaleimide 236 which was highly active in NCI screening and also possessed a 
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very high correlation with a series of camptothecin derivatives using the COMPARE 
algorithm, indicating action through topo I inhibition.
8
 This topo I activity is 
unsurprising as indolocarbazoles such as rebeccamycin 7 and its analogues are known 







The original approach involves the use of N-methylated indole starting materials which 
limits modification at this position as these cannot be removed later in the synthesis. As 
N-substituents can greatly influence both the mode and level of biological activity, one 
of the main aims in this thesis is to develop a more flexible route which would allow for 
a variety of different N-substituents to be incorporated from a key maleic anhydride 
intermediate 237. The design of a route capable of yielding derivatives with 
unsubstituted indole nitrogens was also essential, as the presence or absence of one free 
indolic nitrogen has been shown to influence the mode of action of indolocarbazoles, 
and also as the final ring closing step to form the planar indolocarbazole core tends to 
be more successful if at least one indole nitrogen is unprotected. This would be 
achieved starting from indole building blocks that were either unprotected or possessed 
a protecting group 238 that could be removed later in the synthesis, and used to 
synthesise a panel of novel hydroxymaleimide derivatives of structures 239 and 240 
239,240239,240(Scheme 3.3.2). 
 






Once a suitable route had been identified, the next goal would be to synthesise a series 
of novel hydroxymaleimides with varied alkyl N-substituents to incorporate 
lipophilicity in both the bisindole 241 and the indolocarbazole 242 series (Figure 3.3.1). 
The addition of functionalised chains incorporating hydrophilicity would also be 
explored yielding derivatives such as 243 and 244. The functionalised carbon chains are 
similar to that found on ruboxistaurin 28 and enzastaurin 29.  
 
 
Figure 3.3.1: Structures of target compounds 
 
Once the synthesis of a panel of novel hydroxymaleimides had been completed, the 
emphasis would then turn to replacement of the hydroxy group to form compounds of 
general structure 245 and 246. Very little work has been described in the area of F-ring 
modification and in particular very few 6-membered rings have been reported.
10
 Six-
membered uracil rings were of particular interest due to the possibility for more H-
bonding interactions leading to greater specificity. Also, the uracil moiety plays a 
significant role in biological systems as it is a fundamental component of DNA, being 
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present in the pyrimidine bases thymine and cytosine, and so derivatives containing this 
structure may be more likely to interact with DNA and act as topoisomerase inhibitors.  
 
 
Figure 3.3.2: Structures of target compounds 
 
3.4 Biological Evaluation 
 
The biological effects of novel final compounds synthesised would then be assessed via 
several different methods. Submission to the NCI 60-cell line screen gives an overall 
picture of the anticancer activity of the compounds as well as any specificity of a 
compound towards individual cancer cell lines. Each compound is screened for activity 
against 60 human cancer cell lines including lines from cancers such as leukaemia, non-
small cell lung cancer, melanoma, and cancers of the colon, CNS, ovary, kidney, 
prostate and breast. This screening program is run by the Developmental Therapeutics 
Program (DTP) of the NCI. 
 
For further insight into the biological mechanism of these derivatives, final compounds 
would also be screened against a panel of individual kinases. This assessment is carried 
out in collaboration with the Kinase Inhibitor Specialised Screening Facility (KISSf) in 
Station Biologique de Roscoff, France. Compounds will also be suitable for evaluation 
using a topo I-mediated DNA cleavage assay to assess their ability to act as topo I 
inhibitors.  
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4.1 Initial synthetic strategy 
 
Indolylaryl maleic anhydrides were first prepared by a Perkin-type condensation by 
Davis et al.
1
 For the synthesis of the bisindolyl compound they reacted 1-methylindol-3-
glyoxylyl chloride 149 with 1-methyl-3-indolylacetic acid 150 in the presence of 
triethylamine to give the maleic anhydride 147 in 36% isolated yield, (Scheme 4.1.1). 





Previous work within the group used a variation of this reaction involving the 
condensation of the acetic acid 247 with the potassium glyoxylate salt 248 in acetic 
anhydride to synthesise a bis(7-azaindol-3-yl) maleic anhydride 234.
2
 Photocyclisation 
of the maleic anhydride was unsuccessful, however on conversion to the maleimide 
249, cyclisation to the indolocarbazole 250 proceeded smoothly. The hydroxymaleimide 
236 was obtained via initial Boc-protection followed by treatment with hydroxylamine 








These routes involve the use of indoles with methyl substituents on the indole nitrogen 
which cannot be replaced later in the synthesis. As a result, the goal was to adapt the 
synthesis to include cleavable protecting groups to form a versatile intermediate which 
could then be used to synthesise a panel of compounds with varying substituents on one 
or both nitrogens.  
 
4.2 Synthesis and derivatisation of 1-hydroxy-3,4-di(1H-indol-3-yl)-
1H-pyrrole-2,5-diones 
 
4.2.1 Synthesis of maleic anhydride intermediates  
 
A solution of indole 251 in diethyl ether was treated with oxalyl chloride to form the 
glyoxalyl chloride intermediate as a yellow suspension. After stirring for 30 minutes at 
room temperature, a solution of sodium bicarbonate was added cautiously to quench any 
remaining oxalyl chloride and to hydrolyse the acid chloride. After 16 hours of stirring 
the yellow solid was collected by vacuum filtration and then dried overnight at 40 °C to 
give 2-(1H-indol-3-yl)-2-oxoacetic acid 252 in 88% yield. Treatment with 1 equivalent 
of potassium hydroxide in ethanol gave the potassium salt 253 as a white solid which 
was collected by vacuum filtration and dried overnight at 40 °C in 85% yield. Initial 
attempts to couple the potassium 2-(1H-indol-3-yl)-2-oxoacetate 253 with unprotected 
indole-3-acetic acid 254 using acetic anhydride to form the unsubstituted maleic 
anhydride 255 were unsuccessful (Scheme 4.2.1) as for the similar procedure reported 
by Davis et al. (see Scheme 4.1.1).  
 






The next attempt involved the use of a benzenesulfonyl protected indole-3-acetic acid. 
This was achieved using a method outlined by Roy et al. which involved the addition of 
n-BuLi to a solution of indole-3-acetic acid 254 in THF while maintaining the 
temperature at -70 °C followed by stirring for 1 hour at this temperature.
3
 A solution of 
benzenesulfonyl chloride in THF was then added and the reaction was stirred for 16 
hours while slowly warming to room temperature. Following an acidic work-up and 
recrystallisation from ethyl acetate this method gave 2-[1-(phenylsulfonyl)-1H-indol-3-
yl]acetic acid 256 as an off-white solid in 70% yield. It was found that allowing the 
reaction mixture to warm to room temperature more rapidly significantly increased the 
reaction yield. When the reaction vessel was removed from the low temperature bath 
immediately after the addition of benzenesulfonyl chloride, the internal temperature 
rose to room temperature after ~1 hour and the yield increased to 90% (Scheme 4.2.2), 
slightly higher than the reported yield of 84%.  
 
Protected acid 256 was then reacted with potassium 2-(1H-indol-3-yl)-2-oxoacetate 253 
in acetic anhydride at reflux for 4 hours. TLC analysis of the dark brown solution 
showed a bright yellow spot characteristic of bisindolyl maleic anhydrides and 
significantly less polar than either starting material, but also indicated a mixture of other 
side products. Following removal of solvent under reduced pressure and washes with 
saturated sodium bicarbonate, the crude residue was purified using careful column 
chromatography to give a bright yellow solid. Analysis using proton NMR confirmed 
the presence of a bisindolyl structure but showed an unexpected 3H singlet at 2.69 ppm 
and the absence of an NH signal. Further analysis using 
13
C NMR and mass 
spectrometry confirmed the product to be novel 3-(1-acetyl-1H-indol-3-yl)-4-[1-
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(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 257 which had been isolated in 24% 
yield.  
 
In an attempt to reduce the number of side products being formed the reaction was 
repeated at a lower temperature of 80 °C and for a longer reaction time of 24 hours. 
This resulted in the formation of a yellow suspension which, after cooling, was 
collected by vacuum filtration. Suspension in boiling ethyl acetate followed by hot 
filtration and removal of solvent under reduced pressure gave the desired product 257 in 
33% yield. Work-up of the original acetic anhydride filtrate followed by 
recrystallisation from ethyl acetate gave additional product increasing the yield to 40% 
(Scheme 4.2.2). Although only moderate, this yield was considered quite satisfactory 
due to the bulk of the substituents at the N-position. A limited probe of equivalent ratios 





Removal of both protecting groups was achieved by heating to reflux with potassium 
hydroxide in 4:1 methanol/water for 24 hours (Scheme 4.2.3). As the starting material 
and product spots overlapped on TLC analysis, the reaction had to be monitored by 
proton NMR. Upon completion, the solvent was removed and an acidic work-up gave 
3,4-di(1H-indol-3-yl)furan-2,5-dione 255 as a red foamy solid which was recrystallised 
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Work then began on the synthesis of substituted maleic anhydrides. It was predicted that 
coupling an alkylated potassium 2-(1H-indol-3-yl)-2-oxoacetate and 2-[1-
(phenylsulfonyl)-1H-indol-3-yl]acetic acid 256 would increase the yield of the Perkin-
type step compared to using unprotected potassium 2-(1H-indol-3-yl)-2-oxoacetate. 
This would incorporate one N-substituent from the start while still having a removable 
protecting group on the second indole nitrogen which could be replaced later on. Indole 
251 was methylated by initial deprotonation using sodium hydride in DMF followed by 
the addition of iodomethane. After work-up, 1-methyl-1H-indole 148 was isolated as a 
pale yellow oil in 95% yield. 1-Isopropyl-1H-indole 258 was synthesised in a similar 
manner although with a longer reaction time due to the less reactive nature of 2-
iodopropane compared to iodomethane and following purification using hexane/ethyl 
acetate column chromatography gave the product as a pale yellow oil in 59% yield. The 
two substituted indoles were then converted to the oxoacetic acids 259 and 260 and 
subsequently to their corresponding glyoxalate salts to give potassium 2-(1-methyl-1H-
indol-3-yl)-2-oxoacetate 261 and potassium 2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetate 





Potassium 2-(1-methyl-1H-indol-3-yl)-2-oxoacetate 261 was then reacted with 2-[1-
(phenylsulfonyl)-1H-indol-3-yl]acetic acid 256 in acetic acid at 80 °C for 24 hours, 
resulting in an orange solution. The solvent was removed and following work-up an 
orange gummy residue was obtained. In this case, recrystallisation of the maleic 
anhydride product 263 was unsuccessful and so purification was achieved using 
hexane/ethyl acetate column chromatography to give pure product 263, isolated in 31% 
yield. The reaction was also carried out using potassium 2-(1-isopropyl-1H-indol-3-yl)-
2-oxoacetate 262 with similar results and a yield of 264 of 24%. It is likely that the 
lower yields in these two cases is caused by the fact that a considerable amount is lost 
on purification due to very close spots on TLC analysis, whereas the initial maleic 
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anhydride 257 (Scheme 4.2.2) could be purified by recrystallisation, avoiding this issue. 
In both cases, deprotection was achieved in high yields of 95% and 87% to give 3-(1H-
indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-2,5-dione 265 and 3-(1H-indol-3-yl)-4-(1-





As only protection of the indole-3-acetic acid nitrogen was needed for the reaction to be 
successful, synthesis of 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-2,5-dione 
265 was also attempted using 2-(1-methyl-1H-indol-3-yl)acetic acid 150 and 
unprotected potassium 2-(1H-indol-3-yl)-2-oxoacetate 253, eliminating two steps for 
the protection and deprotection. 2-(1-Methyl-1H-indol-3-yl)acetic acid 150 was formed 
by treatment of a solution of indole-3-acetic acid 254 in THF with sodium hydride, 
followed by iodomethane to give the product in 64% yield (Scheme 4.2.6). Again, the 
product of the Perkin-type reaction 265 had to be purified by column chromatography 





As 3-(1-acetyl-1H-indol-3-yl)-4-[1-(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 257 
was the maleic anhydride formed with the highest yield and took the shortest amount of 
time to purify, it was decided to use this as the main intermediate. Although the fully 
deprotected maleic anhydride derivative 255 would be useful for forming compounds 
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with two identical nitrogen substituents, a maleic anhydride intermediate with just one 
indolic nitrogen protected and the other free was also desired as a starting point to final 
compounds with differing nitrogen substituents. 3-(1-Acetyl-1H-indol-3-yl)-4-[1-
(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 257 was treated with the milder base, 
potassium carbonate, in 4:1 methanol/water for 1 hour at room temperature. Following a 
similar work-up to the previous deprotection, 3-(1H-indol-3-yl)-4-[1-(phenylsulfonyl)-
1H-indol-3-yl]furan-2,5-dione 267 was formed as an orange solid in an excellent yield 





In another route to 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-2,5-dione 265, 
benzenesulfonyl protected maleic anhydride intermediate 267 was treated with sodium 
hydride in DMF, allowed to stir for 30 minutes and then treated with iodomethane. 
Following work-up, 3-(1-methyl-1H-indol-3-yl)-4-[1-(phenylsulfonyl)-1H-indol-3-
yl]furan-2,5-dione 263 was isolated in 84% yield as an orange foamy solid. 
Deprotection could again be achieved by heating to reflux with potassium hydroxide in 
4:1 methanol/water for 24 hours to give 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-
yl)furan-2,5-dione 265 as a red solid in 95% yield (Scheme 4.2.8). The major advantage 
to this route was that as it avoids the need for column chromatography of complex 
mixtures, it could be successfully scaled up to be carried out on a multigram scale. 
 
A similar route was used to synthesise an analogous allyl derivative. For this, 3-(1H-
indol-3-yl)-4-[1-(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 267 was treated with 
sodium hydride in DMF, followed by allyl bromide to give 3-(1-allyl-1H-indol-3-yl)-4-
[1-(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 268 as an orange foamy solid in 82% 
yield which was then treated with potassium hydroxide in aqueous methanol to give 3-
(1-allyl-1H-indol-3-yl)-4-(1H-indol-3-yl)furan-2,5-dione 269 as a red solid in 87% yield 
(Scheme 4.2.8). 






4.2.1.1 Spectroscopic properties 
 
HMBC experiments were used to identify which set of indole protons corresponded to 
which N-substituted indole. In the case of 257 (Figure 4.2.1), a correlation is seen 
between the carbonyl group carbon of the acyl group and one of the C(2)-H protons 
(blue arrows) confirming those to be on the same indole moiety. The C(2)-H proton also 
shows a correlation to a quaternary carbon (green arrow), which also shows a 
correlation to a C(5)-H and a C(7)-H proton (both green arrows). The corresponding 











Figure 4.2.1: HMBC (Heteronuclear Multiple Bond Correlation) 2D spectrum for 257 in DMSO-d6 
at 300 MHz 
 
All other benzenesulfonyl protected maleic anhydride intermediates were assigned in a 
similar fashion as the alkyl carbon attached to the indolic nitrogen showed a correlation 
to the nearby C(2)-H proton. 
 
The proton NMR spectra of the bisindolyl compounds containing a benzenesulfonyl 
protecting group show some interesting characteristics (Figure 4.2.2). The mono-
methylated maleic anhydride 265 shows only a slight separation of peaks from 
symmetrical precursor 255. A much bigger change is observed on addition of a benzene 
sulfonyl group (263), however. All protons on the benzenesulfonyl protected indole are 
significantly deshielded, due to the addition of the electron withdrawing group. The 
C(2)-H proton of the methylated indole is also deshielded. Interestingly, significant 
shielding is observed of the C(6 and 7)-H protons of the methylated indole. On 
changing the methyl group to an acyl group (257), the most noticeable difference is the 
deshielding of the C(4)-H proton on that ring, which undergoes a change in chemical 
shift of over 0.8 ppm (green arrows). 






Figure 4.2.2: Stacked proton NMR plot of maleic anhydride derivatives 255, 265, 263, 267 and 257  
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It is also useful to note that the C(2)-H proton of indoles with an unsubstituted indole 
nitrogen are often split due to coupling with the NH proton (see spectra for 255 and 265 
Figure 4.2.2). Although not always observed, this splitting can mean that the C(2)-H 
protons of an N-substituted and unsubstituted indole can be distinguished easily. 
 
4.2.2 Derivatisation of maleic anhydride intermediates 
 
With some key intermediates now synthesised, derivatisation of three of these (255, 265 
and 266) was undertaken to form a panel of maleic anhydride derivatives which could 
then be converted to their hydroxymaleimide analogues 239 (Scheme 4.2.9). A selection 
of N-substituents was chosen to incorporate (i) lipophilicity with both small and bulkier 
groups, (ii) hydrophilicity in the form of functionalised 6-carbon chains and (iii) 





4.2.2.1 Derivatisation of unsubstituted intermediate 
 
The possibility that mono-alkylation of unsubstituted 255 could be achieved was next 
explored. 3,4-Di(1H-indol-3-yl)furan-2,5-dione 255 was treated with 1.05 equivalents 
of sodium hydride and allowed to stir for 30 minutes changing from a red to a deep 
purple solution. 6-Bromohexane nitrile was then added and the reaction was stirred for 
16 hours, slowly returning to a red solution. TLC analysis showed three spots close 
together which, following work-up, were separated using careful column 
chromatography. Mono-alkylated product 270 was isolated in 15% yield, di-alkylated 
product 271 was isolated in 21% yield and 29% unreacted starting material was also 
recovered (Scheme 4.2.10). Although selective mono-alkylation was not achieved, this 
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strategy did incorporate more diversity which could subsequently be used in the 





Conformationally restricted macrocyclic bisindolylmaleimides have been shown to be 
highly potent and selective inhibitors of individual kinases and even of individual 
isoforms. For example, the bisindolylmaleimide ruboxistaurin 28 selectively inhibits 
PKCβ and PKCβ2 over PKCα.
4
 Initially, a bisindolyl hydroxymaleimide with a 6 
carbon chain was synthesised, the same length as seen in ruboxistaurin (Scheme 4.2.11). 
The maleic anhydride precursor was formed by first treating 3,4-di(1H-indol-3-yl)furan-
2,5-dione 255 with 2.2 equivalents of sodium hydride and stirring for 40 minutes 
resulting in a dark blue solution. 1,6-Dibromohexane was then added and the mixture 
was allowed to warm to room temperature slowly while stirring for 16 hours. The 
reaction was carried out at 0 °C and with 1.05 equivalents of dibromohexane to limit di-
alkylation and the reaction mixture was at a much higher dilution than usual to limit 
dimer formation. Despite initial solvation problems with column chromatography while 
using hexane/ethyl acetate as eluent, employing a hexane/DCM solvent system gave a 
reddish/purple solid found to be the desired macrocyclic maleic anhydride 272 in 29% 
yield. The remainder of the crude material contained a complex mixture which was not 
successfully separated. 
 






4.2.2.2 Derivatisation of N-methyl and N-isopropyl intermediate 
 
Derivatisation of the methyl 265 and isopropyl intermediates 266 was then undertaken. 
For each, the indole nitrogen was deprotonated using sodium hydride in DMF and then 
treated with iodomethane, iodoethane or 6-bromo hexanenitrile to give a panel of 
unsymmetrically di-alkylated bisindolyl maleic anhydrides (Table 4.2.1). All derivatives 









 X Yield 
147 Me Me I 80% 
273 Me Et I 72% 
274 Me -CH2(CH2)4CN Br 40% 
275 iPr Me I 46% 
276 iPr Et I 51% 
277 iPr -CH2(CH2)4CN Br 33% 
Table 4.2.1: Isolated yields of disubstituted maleic anhydrides 
 
The hexane nitrile derivatives were formed in lower yields than the other derivatives, 
probably due to the fact that the bromo alkane was used which would be less reactive 
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than the iodo alkanes. The yields for alkylation of the isopropyl intermediate were also 
found to be lower, possibly due to the presence of a more bulky substituent. 
 
4.2.2.3 Synthesis of acids 
 
To incorporate a more polar side chain, the two compounds with hexanenitrile side 
chains 270 and 274 were converted to their corresponding carboxylic acids. This was 
achieved by treating the nitriles with potassium hydroxide in aqueous methanol and 
heating to reflux for 16 hours until TLC showed complete consumption of starting 
material and the presence of a new, highly polar component. After acidic work-up, the 
two carboxylic acids 6-{3-[4-(1H-indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H-
indol-1-yl}hexanoic acid 278 and 6-{3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-2,5-
dihydrofuran-3-yl]-1H-indol-1-yl}hexanoic acid 279 were obtained as red solids in 
yields of 84% and 76% respectively (Scheme 4.2.12). In each case, IR analysis showed 
the expected disappearance of the characteristic nitrile signal at ~2245 cm
-1
 and the 
appearance of a new signal at ~1700 cm
-1






4.2.3 Synthesis of hydroxymaleimide analogues 
 
All maleic anhydrides were then converted to their corresponding hydroxymaleimide 
derivatives to form a panel of bisindolylmaleimide analogues with potentially 
interesting and potent biological activity. The transformation was achieved using 5 
equivalents of hydroxylamine hydrochloride and 5 equivalents of triethylamine in DMF 
at 70 °C for 24 hours and the hydroxymaleimides were isolated in high yields (Table 
4.2.2). All hydroxymaleimides in this panel are novel with the exception of 





 The majority of compounds in this table were selected for 
assessment using the NCI 60 cell line screen and certain compounds were also selected 
for assessment of activity against a panel of individual kinases. The results of this 




































H H 86% 
272 284 -CH2(CH2)4CH2- 82% 
265 285 Me H 83% 
147 286 Me Me 84% 
273 287 Me Et 69% 














266 290 iPr H 77% 
275 291 iPr Me 93% 
276 292 iPr Et 80% 







Table 4.2.2:  Isolated yields of hydroxymaleimides 
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4.2.3.1 Spectroscopic properties 
 
Again, 2D NMR experiments were used to aid the assignments of these unsymmetrical 
bisindolyl compounds. The assignment of hydroxymaleimide 281 is shown as an 
example (Figure 4.2.3). A correlation is seen between the CH2 protons adjacent to the 
indole nitrogen and a quaternary carbon on the same indole moiety (blue arrows). This 
quaternary carbon also shows a correlation to the C(2)-H proton, identified as the only 
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A COSY experiment is then used to assign those protons and the remaining protons 
(Figure 4.2.4).  The doublet at 7.49 ppm shows a correlation to the triplet at 7.05 ppm 
(identified from the HMBC to be on the hexanenitrile substituted indole), confirming 
these to be C(4′)-H and C(5′)-H. Both the C(5′)-H proton and the C(7′)-H proton at 6.87 
ppm (identified from the HMBC to be on the hexanenitrile substituted indole) show a 
correlation to the 2H mutiplet at 6.67-6.74 ppm, indicating that the multiplet contains 
the C(6′)-H proton. The remaining signals can be attributed to the other indole ring and 




Figure 4.2.4: COSY (Correlation Spectroscopy) 2D spectrum for 281 in DMSO-d6 at 300 MHz 
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The peaks in the aliphatic region were also assigned using a COSY experiment (Figure 
4.2.5). The most deshielded triplet at 4.23 ppm is identified as C(6′′)-H2 due to the 
correlations seen to atoms in the indole ring in the HMBC experiment. The C(6′′)-H2 
protons couple to a quintet at 1.73 ppm corresponding to the C(5′′)-H2 protons, which 
also couple to the multiplet at 1.25-1.36 ppm corresponding to the C(4′′)-H2 protons. 
These in turn couple to the C(3′′)-H2 protons at 1.56 ppm, which also couple to the 
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The NMR spectra of the hydroxymaleimides are very similar to those of the maleic 
anhydrides with some slight shielding and the addition of a broad singlet at about 10.5 
ppm corresponding to the hydroxyl proton (Figure 4.2.6). The aromatic regions of 
hydroxymaleimide 281 and the corresponding maleic anhydride 270 are shown below 
for comparison. Due to the similarity between the two, 2D experiments were routinely 
run for the hydroxymaleimides to aid their assignments and the maleic anhydrides were 
then assigned from their corresponding hydroxymaleimide. 
 
 
Figure 4.2.6: Stacked proton NMR spectra of 270 and 281 in DMSO-d6 at 300 MHz 
 
4.3 Synthesis of indolo[2,3-a]carbazoles 
 
It has been well documented in the literature that indolo[2,3-a]carbazoles possess 
unique and more potent activity compared to their bisindole analogues. For example, 
Sanchez-Martinez et al. revealed how a series of indolo[2,3-a]pyrrolo[3,4-c]carbazoles 
consistently displayed greater inhibitory activity towards CDK2 and CDK4 compared to 
their corresponding bisindolyl analogues.
6
 The group reported that a series of ten 
substituted indolocarbazoles of structure 294 were 8-42 fold more active in head-to-
head comparison with their corresponding bisindolylmaleimides 295. Thus, attention 
then turned to forming these fully aromatic analogues via oxidative cyclisation to form 









Figure 4.3.1: General structure of series of indolocarbazoles and bisindolylmaleimides 
 
4.3.1 Aromatisation of unsubstituted bisindoles 
 
As the success of these reactions can vary greatly depending on the substrate, with both 
F ring type and N-substitution having a considerable effect, it was decided that the 
optimum strategy would be to identify a substrate that cyclises cleanly with a high yield 
and use this as the starting material for further derivatisation. The three most commonly 





 and (iii) oxidative photocyclisation.
11,12
 A photocyclisation step 
was the most desirable as it would be considerably cheaper than the other two options, 
especially palladium based reagents which often have to use used in excess. A light-
mediated reaction would also potentially be much cleaner, especially compared to DDQ 
where the reduced by products can be difficult to remove. These two points would be of 
particular importance if the step was scaled up to a multi-gram scale as planned.  
 
4.3.1.1 Synthesis of furo[3,4-c]indolo[2,3-a]carbazole-5,7(12H,13H)-dione 
 
Maleic anhydride derivative 255 was initially selected for cyclisation as the cyclised 
maleic anhydride indolocarbazole would serve as a highly versatile intermediate with 
numerous options for N-alkylation and further F-ring derivatisation. The bisindolyl 
compound was dissolved in acetonitrile and a catalytic amount of iodine was added. 
Light irradiation was achieved using a standard high pressure mercury lamp. Over the 
course of the reaction the original bright red solution slowly changed to a yellow 
suspension which, when TLC analysis showed complete consumption of starting 
material, was collected by vacuum filtration and washed with saturated aqueous sodium 
thiosulfate to remove traces of iodine. Initially, this reaction was carried out on a 100 
mg scale with a concentration of 1 mg/mL forming 76 with a moderate yield of 54%. 
Fortunately, as the scale of the reaction was increased an increase in yield was also 
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observed, with 1 g of starting material being converted to aromatised product in 72% 
yield with the same reaction concentration (Scheme 4.3.1). The difference in yield is 
most likely caused by a difference in reaction temperature. The small volume of the 100 
mL reaction is efficiently heated by the bulb and is observed to reflux for the duration 
of the reaction while the heat from the bulb is not sufficient to heat the larger 1 L 
reaction to its boiling point. Due to the yield differential, it can be postulated that fewer 
impurities are formed at the lower temperature in the larger flask resulting in a higher 





The cyclisations of unsubstituted hydroxymaleimide 280 and bis-methyl maleic 
anhydride 147 were also attempted (Scheme 4.3.2). However, in both cases only 
starting material was recovered. This was unsurprising as there are no reports in the 
literature of the cyclisation of a bisindolyl compound with a hydroxymaleimide F-ring 








4.3.1.2 Spectral comparison with bisindoles 
 
The aromatic regions of proton NMR spectra for three related maleic anhydride 
derivatives are stacked for comparison (Figure 4.3.2): one is the unsubstituted bisindolyl 
maleic anhydride 255 where the indoles are relatively free to rotate, the second has 
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restricted movement due to the nitrogens being linked by a tether 272 and the third is 
fully aromatic 76. The most interesting feature is the change in chemical shift of the 
C(4)-H proton from 7.43 ppm in bisindolyl 255 to 8.69 ppm in indolocarbazole 76, with 
the partially conformationally restricted  272 being about midway between the two. This 
is due to a magnetic anisotropic effect caused by the π-electrons in the carbonyl group. 
As the indoles become more fixed in position the C(4)-H protons are also pushed closer 
to the magnetic anisotropy deshielding zone of the carbonyl group causing them to be 
shifted downfield.  
 
Figure 4.3.2: Stacked proton NMR spectra of 255, 272 and 76 in DMSO-d6 at 300 MHz 
 
It is also interesting to note that C(6)-H and C(7)-H are also shifted downfield going 
from  255 to 272 to 76,  however C(5)-H is much less affected. The disappearance of 
the C(2)-H signal in 76 confirms the formation of the final carbon-carbon bond in the 
fully aromatic system.  
 
The maleic anhydride 76 was then converted to the corresponding hydroxymaleimide 
using 5 equivalents of hydroxylamine hydrochloride and 5 equivalents of triethylamine 
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in DMF at 80 °C for 24 hours. After cooling to room temperature, the reaction mixture 
was poured into 1 M aqueous HCl to precipitate the product and remove any excess 
triethylamine. The red solid was then collected using vacuum filtration to give 296 in 





4.3.2 Incorporation of methyl and allyl substituents 
 
4.3.2.1 Synthesis of mono-alkylated derivatives 
 
A similar method was used to prepare a mono-methylated derivative. Photocyclisation 
of the appropriate bisindolyl maleic anhydride 265 under the same conditions outlined 
in the previous section gave indolocarbazole 297 as a yellow solid in 41% yield. The 
fully aromatic maleic anhydride was then converted to the corresponding 
hydroxymaleimide 298 with a yield of 87%. Transformation of maleic anhydride 
derivative 297 to an aminomaleimide 299 was also achieved using a similar method by 
heating to reflux in THF with 5 equivalents of hydrazine hydrate for 16 hours forming 
the product as an orange solid in 67% yield (Scheme 4.3.4).  
 






Expanding the alkyl chain to incorporate an alkene which could subsequently be 
converted to a number of different functional groups was next attempted. 
Photocyclisation of the allylated bisindolyl compound 269 was initially undertaken but 
the yellow precipitate formed was shown to be deallylated indolocarbazole 76 on 
analysis which was formed in 57% yield. Concentration of the filtrate resulted in the 
precipitation of more yellow solid which was found upon analysis to be the desired 
product 300 but with a less than 10% yield (Scheme 4.3.5). Due to the low yield it was 
decided not to continue with this route; however, due to the high yield of deallylated 76, 






4.3.2.2 Spectroscopic properties 
 
Complete assignment of the 
1
H NMR spectra of the unsymmetrically substituted 
indolocarbazoles proved more challenging than for the analogous bisindolyl compounds 
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due to more overlapping of the related signals from each indole ring. As can be seen 
from the stacked spectra of mono methyl bisindolyl compound 285 and indolocarbazole 
298 (Figure 4.3.3) the C(7)-H protons in 285 are clearly distinguishable and can be 
assigned using 2D experiments, whereas in 298 they overlap almost completely and 
cannot be separately assigned. The same can be seen for the C(4)-H and C(5)-H protons 
which can be distinguished in 285 but completely overlap in 298. The C(2)-H protons 
again disappear in 298 due to the formation of the final C-C bond and an overall 
deshielding effect is observed.  
 
 
Figure 4.3.3: Stacked spectra of bisindolyl 285 and indolocarbazole 298 in DMSO-d6 at 300 MHz 
(*assigned proton on methylindole ring, 
o
assigned proton on unsubstituted indole). 
 
4.3.2.3 Synthesis of di-alkylated derivatives 
 
With the cyclisation of unsubstituted 255 to 76 occurring cleanly, in high yield and on a 
reasonable scale it was decided to keep this as the main cyclisation step and to form all 
further derivatives from indolocarbazole 76. Synthesis of a dimethyl maleic anhydride 
derivative 301 was then undertaken by initial deprotonation using 3 equivalents of 
sodium hydride, resulting in a dark blue solution, followed by the addition of 
iodomethane. TLC analysis of the resulting pale yellow solution after 16 hours indicated 
the presence of remaining starting material and so a further portion of sodium hydride 
was added followed by iodomethane and the reaction was stirred for a further 6 hours. 
The reaction mixture was poured into water and the precipitate collected by vacuum 
C(6)-H C(7)-H C(5)-H C(4)-H 
* 
* 






Chemical Results and Discussion 
113 
 
filtration as an off-white solid. Analysis using proton NMR showed a symmetrical 
molecule with an extra 6H singlet at 4.03 ppm as well as the expected 6H singlet at 4.24 
ppm for the N-methyl protons indicating two extra methyl groups. HRMS analysis 
confirmed the presence of an extra four methyl groups and an oxygen from the starting 
material and it was proposed that this compound formed due to ring opening of the 





Conversion of the diester 188 to the desired maleic anhydride 301 was achieved by 
initial treatment with potassium hydroxide in aqueous methanol and heating to reflux 
for 24 hours before the solvent was evaporated under reduced pressure and the resulting 
residue dissolved in water and acidified to pH 2 to form the diacid 302 which due to 
solubility issues was not analysed and was used directly in the next step. The off-white 
precipitate was collected using vacuum filtration and allowed to dry fully overnight at 
40 °C. The di-acid intermediate was then heated to reflux for 4 hours in acetic 
anhydride to form the maleic anhydride in 80% yield (Scheme 4.3.6).  
 
In an attempt to obtain dimethyl 301 without unwanted ring opening of the maleic 
anhydride, the reaction was repeated at a lower temperature. A solution of the 
unsubstituted maleic anhydride 76 in DMF was stirred in an ice/salt bath until the 
internal temperature dropped to -12 °C before the addition of sodium hydride. The 
reaction was stirred for 45 minutes resulting in a dark blue solution to ensure complete 
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deprotonation before iodomethane (2.1 eq) was added dropwise. The reaction mixture 
was allowed to warm slowly to room temperature in the bath over 16 hours. TLC 
analysis at this point showed the complete consumption of starting material and so the 
now yellow reaction mixture was poured into 1 M aqueous HCl and the precipitate 
collected using vacuum filtration. Recrystallisation from DMSO gave maleic anhydride 
derivative 301 in 71% yield. 
 
The proposed mechanism for the formation of the diester in outlined in Scheme 4.3.7. 
Excess sodium hydride results in the deprotonation of both indole nitrogens of the 
yellow suspension of 76 resulting in the dianion. Formation of the dianion is 
characterised by a dark blue coloured solution, in contrast to the monoanion which is 
purple regardless of whether the second indole unit is alkylated or not. On addition of 
the methyl iodide there is a colour change from blue to purple over a period of five 
minutes and this purple solution then eventually changes to yellow. The first step after 
addition of methyl iodide is likely to be addition of one methyl group to one indole 
nitrogen; however addition of a methyl group to the second indole nitrogen is more 
difficult due to steric hindrance from the first group and, as a result, is slower. The 
electrons delocalised onto the carbonyl group of the maleic anhydride can then attack 
the iodomethane resulting in methylation at this position. As iodomethane is a very 
reactive methylating agent, it is possible for methylation to occur through the attack of a 
lone pair, without the presence of an anion. It is likely that the lone pair of the 
unsubstituted indole nitrogen aided by delocalisation of electrons on the now-
methylated oxygen can attack a third molecule of iodomethane resulting in methylation 
at this position. Water added to quench the reaction reacts with excess sodium hydride 
and iodomethane resulting in the formation of sodium methoxide which can then attack 
the second carbonyl resulting in ring opening to form the diester 188.  
 






The 82% yield suggests that this is an efficient process under these conditions; however, 
in reactions where an excess of iodomethane but not sodium hydride was present, ring 
opening did not occur (see Section 4.3.4.1). This suggests that in the absence of excess 
base to form the methoxide necessary for ring opening, addition of water results in the 
loss of the methyl group from initial O-methylation as methanol. 
 
The anisotropic effect from the π-electrons in the carbonyl group on the C(4)-H protons 
in the maleic anhydrides is again evident when the proton NMR spectrum of the maleic 
anhydride 301 is compared to the diester 188 (Figure 4.3.4). A difference in chemical 
shift of 0.89 ppm upfield is observed going from the maleic anhydride where the 
carbonyl groups are fixed in position to the di-ester where they can move away from the 
top of the indole ring.  




Figure 4.3.4: Stacked spectra of 301 and 188 in DMSO-d6 at 300 MHz 
 
Treatment of unsubstituted 76 with sodium hydride followed by allyl bromide at room 
temperature again resulted in ring opening of the maleic anhydride with the addition of 
four allyl groups 303. Repetition of the reaction at -12 °C formed the desired diallyl 





Both the dimethyl 301 and diallyl 304 maleic anhydrides were successfully transformed 
to their hydroxymaleimide analogues, 305 and 306 respectively, in high yields (Scheme 
4.3.9). 
 
C(6)-H C(7)-H C(5)-H C(4)-H 
Maleic anhydride 188 
Diester 301 






4.3.3 Synthesis and derivatisation of 6-[5,7-dioxofuro[3,4-c]indolo[2,3-a]carbazol-
12(5H,7H,13H)-yl]hexanenitrile 
 
Work then began on the synthesis of an indolocarbazole maleic anhydride with a longer 
functionalised chain N-substituent. Initially, attempts focussed on the conversion of 
bisindole compound 270 to indolocarbazole 307 in a photocyclisation step, however 
irradiation of 270 for 24 hours as for previous reactions only returned starting material 
(Scheme 4.3.10). This is probably due to the bulkier N-substituent making it more 





Fortunately, treatment of the unsubstituted cyclised maleic anhydride 76 with sodium 
hydride followed by 6-bromohexane nitrile and sodium iodide resulted in mono-
alkylation again probably due to steric hindrance of the more bulky chain combined 
with the less reactive alkyl halide compared to iodomethane and allyl bromide. The 
mono-alkylated product 307 was isolated as a yellow solid in 65% yield (Scheme 
4.3.11).  
 






Treatment of nitrile 307 with hydroxylamine hydrochloride and triethylamine in DMF 
only returned starting material. The reaction was repeated with 10 equivalents of both 
hydroxylamine hydrochloride and triethylamine with a higher reaction temperature of 
120 °C but even after 48 hours none of desired hydroxymaleimide 308 had formed. The 
reaction was then repeated with hydroxylamine hydrochloride and pyridine as the amine 
base and solvent, at reflux, for 24 hours before TLC analysis showed complete 
consumption of starting material. This reaction was not as clean as the usual method 
with several unidentified side products forming, but, after careful column 
chromatography hydroxymaleimide 308 was isolated as an orange solid in 27% yield. 
 
4.3.3.1 Derivatisation of nitrile 
 
In order to access a series of functionalised chains it was decided to first convert the 
nitrile to the more versatile carboxylic acid. The was achieved through treatment of 
nitrile 307 with potassium hydroxide in aqueous methanol and heating to reflux for 60 
hours until TLC analysis confirmed complete consumption of starting material. After an 
acidic work-up, the yellow solid was recrystallised from acetone to give carboxylic acid 








Transformation of acid 309 to the corresponding hydroxymaleimide was achieved using 
the usual method to give 310 as a red solid in 49% yield (Scheme 4.3.12).  
 
The preparations of two amides and a methyl ester were then carried out via initial 
activation of carboxylic acid 309 to the acid chloride (Scheme 4.3.13). This was 
achieved through addition of oxalyl chloride and a catalytic amount of DMF to the 
yellow suspension in DCM resulting in a slight fizzing and gradual dissolution to form a 
pale yellow solution. When gas evolution had ceased, the solvent was evaporated under 
reduced pressure and the residue was treated with an amine or alcohol. When 
morpholine was added, amide 311 was isolated as a yellow solid in 60% yield after 
trituration with hot acetone. Addition of diethylamine resulted in a gummy material 
which stuck to the sides of the flask and so a small amount of DCM was added after 2 
hours to increase solubility. The resulting solution was stirred for a further 1 hour before 
work-up and purification by trituration with hot acetone gave amide 312 in 73% yield. 
Addition of methanol to the acid chloride resulted in the formation of a bright yellow 
precipitate which, after 2 hours, was collected by vacuum filtration and triturated with 
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The three maleic anhydrides 311, 312 and 313 were then transformed to their 
corresponding hydroxymaleimides through treatment with hydroxylamine 
hydrochloride and triethylamine in DMF (Scheme 4.3.14). Morpholine derivative 314 
was isolated in 57% yield after column chromatography as a red solid, diethyl 
derivative 315 was isolated in 76% yield as a yellow/orange solid without the need for 






Due to the partial double-bond character of amides leading to restricted rotation around 




This can be seen in the proton NMR spectrum of 315 (Figure 4.3.5) where the CH3 
signals appear as two triplets at 0.83 and 0.85 ppm (red arrows) and the CH2 signals 
appear as two quartets at 3.04 and 3.11 ppm (blue arrows). Separate signals are also 
seen in the 
13
C spectrum where the CH3 peaks appear at 13.4 and 14.6 ppm (red arrows) 
and the CH2 peaks appear at 39.7 and 41.6 ppm (blue arrows). This effect is also seen 
for morpholine derivatives 311 and 314. 
 
 





Figure 4.3.5:  HSQC 2D spectrum of diethyl amide 315 
 
4.3.3.2 Synthesis of 6-[6-hydroxy-13-methyl-5,7-dioxo-6,7-dihydro-5H-indolo[2,3-
a]pyrrolo[3,4-c]carbazol-12(13H)-yl]hexanenitrile 
 
The presence or absence of one free indolic nitrogen has been shown to influence the 
mode of action of indolocarbazoles and so the effect of the addition of a second N-
substituent was investigated. Initially, compounds where one of the substituents was a 
methyl group were targeted. The initial strategy involved the alkylation of 12-
methylfuro[3,4-c]indolo[2,3-a]carbazole-5,7(12H,13H)-dione 297 with a second 
functionalised substituent, starting with a hexanenitrile chain to form di-substituted 317. 
Although treatment of 297 with sodium hydride resulted in a dark purple solution 
indicating deprotonation had occurred, subsequent addition of 6-bromohexanenitrile 
followed by stirring for 24 hours returned only starting material.  
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Conversion of the 6-bromohexane nitrile 318 to more reactive 6-iodohexanenitrile 319 
in a Finkelstein reaction with sodium iodide in acetone was achieved in 84% yield 
(Scheme 4.3.15). However, alkylation of 297 with 6-iodohexanenitrile 319 also failed, 
again with only starting material recovered.  
 
Another method for N-alkylation of indolocarbazole-type compounds reported in the 
literature is via a Mitsonobu reaction.
15
 6-Hydroxyhexanenitrile 320 was synthesised 
from 6-bromohexanenitrile 318 through treatment with 10% aqueous sodium hydroxide 





For the Mitsonobu reaction, mono-methylated 297 along with triphenylphosphine, 6-
hydroxyhexanenitrile 320 and THF were cooled to -78 °C under a nitrogen atmosphere. 
Diisopropyl azodicarboxylate was then added and the mixture was allowed to warm to 
room temperature over 16 hours. After work-up,
 
proton NMR analysis showed only 





Alkylation of the hydroxymaleimide analogue was then attempted with the prediction 
that sodium hydride would be a strong enough base to deprotonate both the hydroxy 
group and indolic nitrogen and that alkylation would occur on the more nucleophilic 
nitrogen. Treatment of a solution of 6-hydroxy-12-methyl-12,13-dihydro-5H-
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indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 298 in DMF with sodium hydride 
followed by 6-bromohexanenitrile gave a yellow/orange solid which proton NMR 
analysis showed to have an extra 5 CH2 signals indicating alkylation had occurred. 
However, the absence of a singlet between 10 and 11 ppm characteristic of the 
hydroxymaleimides and the presence of a singlet at 12.02 ppm, which is characteristic 
of the proton attached to the indole nitrogen suggested alkylation had occurred on the 





The order of substitution was then reversed with an attempt to alkylate 6-[5,7-
dioxofuro[3,4-c]indolo[2,3-a]carbazol-12(5H,7H,13H)-yl]hexanenitrile 307 with the 
more reactive and less sterically hindered iodomethane. Treatment of a solution of 307 
in DMF with sodium hydride followed by iodomethane gave desired di-substituted 
product 317 as a yellow solid in 33% yield (Scheme 4.3.18).  
 
In this case, the maleic anhydride was successfully converted to the hydroxymaleimide 
using hydroxylamine hydrochloride and triethylamine in DMF although the reaction 
time had to be increased to 72 hours with the temperature increased to 120 °C after the 
first 24 hours. After work-up and purification using column chromatography, 
hydroxymaleimide 322 was isolated in 63% yield as an orange solid.  
 






4.3.3.3 Synthesis of 6,6'-(6-hydroxy-5,7-dioxo-6,7-dihydro-5H-indolo[2,3-a]pyrrolo 
[3,4-c]carbazole-12,13-diyl)dihexanenitrile 
 
Due to the promising results from 6,6'-[3,3'-(1-hydroxy-2,5-dioxo-2,5-dihydro-1H-
pyrrole-3,4-diyl)bis(1H-indole-3,1-diyl)]dihexanenitrile 282 in NCI screening, an 
analogous indolocarbazole was a key target. The alkylation of unsubstituted 
indolocarbazole 76 with bromohexanenitrile and sodium iodide had been shown to give 
exclusively mono-substituted product 307 as did a repeat of the reaction employing 
caesium carbonate as base, which has been shown in the literature to be successful in 
some similar reactions (although not while a maleic anhydride F-ring is present),
7
 and 
so an alternative route had to be identified.  
 
Previous work within the group had successfully cyclised a bis-methylated azaindole 
analogue 323 with a maleimide F-ring in place of the hydroxymaleimide to the 
indolocarbazole form 324 via photocyclisation.
2
 The maleimide could then be Boc-
protected 325 and converted to the hydroxymaleimide 326 under similar conditions to 
those used in this project to convert the maleic anhydrides (Scheme 4.3.19). 
 






Therefore, an attempt was made to cyclise 6,6'-[3,3'-(2,5-dioxo-2,5-dihydro-1H-pyrrole-
3,4-diyl)bis(1H-indole-3,1-diyl)]dihexanenitrile 327 in a light-mediated reaction to form 
indolocarbazole 328. Unfortunately, even after being irradiated with a high pressure 
mercury lamp for four days analysis by proton NMR showed only starting material to 
be present (Scheme 4.3.20). 




Following on from Section 4.3.3.2 and the difficulties in indolocarbazole substitution, 
while there are no reports of bis-substitution of an indolocarbazole possessing a maleic 
anhydride F-ring in the literature, there are reports of a second substituent being added 
where different F-rings were in place. A benzylmaleimide is most commonly employed, 
however Slater et al. reported the alkylation of an indolocarbazole with a Boc-protected 
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maleimide F-ring and where the second indole was also Boc protected.
16
 In this case, 
the double Boc protection of the unsubstituted maleimide 58 was achieved using 
sodium hydride so it was theorised that by using a weaker base, selective protection of 
the maleimide could be achieved to give 329 (Scheme 4.3.21).  
 
Maleic anhydride derivative 76 was treated with 1,1,1,3,3,3-hexamethyldisilazane and 
methanol in DMF to give the maleimide 58 as an orange solid in 91% yield. The 
maleimide was then suspended in acetonitrile and Boc anhydride and DMAP were 
added. After stirring for 2 hours, TLC analysis showed incomplete consumption of 
starting material and so a further 1 equivalent of Boc anhydride was added and the 
reaction was stirred for a further 1 hour. After work-up,
 
proton NMR analysis showed 
the presence of two 9H singlets indicating the presence of two Boc groups. The reaction 
was repeated and this time worked up after 2 hours. Proton NMR analysis showed the 
presence of just 2 components – the original starting material 58 and di-Boc protected 
330. This indicates that the second Boc protection occurs very quickly after the first and 






The benzylmaleimide 166 was then synthesised by heating the unsubstituted maleic 
anhydride 76 with benzylamine in DMF at 100 °C for 16 hours. The orange precipitate 
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was collected by vacuum filtration and washed with 1 M aqueous HCl to remove traces 
of DMF and benzylamine to give benzylmaleimide 166 in 76% yield. Alkylation using 
sodium hydride and iodohexanenitrile in DMF gave exclusively mono-substituted 331 
in 85% yield. However, when the base was changed to caesium carbonate TLC analysis 
after 24 hours showed complete consumption of starting material and 2 spots, one of 
which corresponded to mono-alkylated 331. The reaction was allowed to stir for a 
further 36 hours until TLC analysis showed just one component. Following work-up, 






Attempts were made to convert the benzylmaleimide directly to the hydroxymaleimide 
using hydroxylamine hydrochloride and triethylamine in DMF, but even at a higher 
reaction temperature of 120 °C only starting material 332 was recovered. The 
benzylmaleimide 332 was then transformed back to the maleic anhydride 333 through 
treatment with potassium hydroxide in aqueous ethanol. After acidic work-up and 
purification using DCM/MeOH column chromatography, the maleic anhydride was 
isolated in 56% yield. The maleic anhydride was then converted to the 
hydroxymaleimide 334 using hydroxylamine hydrochloride and triethylamine in DMF, 
to give the product in 73% yield (Scheme 4.3.23).  







4.3.4 Synthesis and derivatisation of 12-(6-bromohexyl)-12,13-dihydrofuro[3,4-
c]indolo[2,3-a]carbazole-5,7-dione 
 
A bromohexyl chain was next introduced as this gave scope for further derivatisation. 
The alkylation procedure was altered slightly to reduce the possibility of dimer 
formation where two molecules of the indolocarbazole could attack either end of one 
1,6-dibromohexane molecule. The unsubstituted maleic anhydride 76 was deprotonated 
as usual using excess sodium hydride in DMF and then this dark blue solution was 
transferred to a dropping funnel which was connected to a second flask containing a 
solution of 5 equivalents of dibromohexane and added slowly so there was always a 
large excess of dibromohexane compared to the dianion of the indolocarbazole. 
Following additional stirring for 16 hours and work-up, the alkylated product 335 was 
isolated in 65% yield (Scheme 4.3.24).  
 
The maleic anhydride was then treated with hydroxylamine hydrochloride and 
triethylamine in DMF as usual to form the hydroxymaleimide. However, although the 
hydroxymaleimide moiety was formed successfully, analysis using mass spectrometry 
indicated the presence of an alkyl chloride rather than the expected alkyl bromide on the 
side chain. It is likely that the formation of this product was as a result of halide 
displacement caused by the excess of triethylammonium chloride which is formed as a 
by-product of the reaction, and 12-(6-chlorohexyl)-6-hydroxy-12,13-dihydro-5H-
indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 336 was isolated as a red solid in 
40% yield.  







A morpholine derivative was consequently prepared from bromide 335. The maleic 
anhydride was suspended in ethanol, 10 equivalents of morpholine were added and the 
reaction was heated to reflux for 24 hours. The solvent was evaporated under reduced 
pressure and the residue dissolved in 10% methanol/DCM. The solution was washed 
with 1 M aqueous HCl to remove any remaining morpholine, followed by saturated 
aqueous sodium bicarbonate to convert the HCl salt back to the free amine. Initial 
attempts at purification using column chromatography with DCM/MeOH were 
unsuccessful even when a few drops of triethylamine were added to the eluent. 
Purification by recrystallisation from acetone was successful with the product 337 being 
isolated as a yellow solid in 55% yield (Scheme 4.3.25).  
 
Conversion of maleic anhydride 337 to the corresponding hydroxymaleimide 338 was 
achieved under the usual conditions of hydroxylamine hydrochloride and triethylamine 
in DMF. The work-up was altered slightly with the reaction mixture being poured into 
water instead of 1 M aqueous HCl, in an attempt to isolate the free amine. Analysis 
using 
1
H NMR showed the absence of the characteristic hydroxy proton and so to 
confirm the transformation had occurred, the red solid was suspended in water and 
acidified using 1M aqueous HCl. The solid was collected by vacuum filtration and 
1
H 
NMR analysis now indicated the presence of the hydroxy group and also showed a 
broad singlet at 10.52 ppm indicating formation of the morpholine salt, which had been 
formed in 54% yield. 
 






Morpholine usually exists as rapidly interconverting chair forms where an axial proton 
becomes an equatorial proton and vice versa resulting in a single averaged peak being 
observed in the proton NMR spectrum. In other words, the axial and equatorial protons 
are equivalent by rapid exchange. This is observed for the maleic anhydride 337 (Figure 
4.3.6) where just two peaks are observed (shown in green), one for the protons on the 
carbon by the oxygen and one for the protons on the carbon by the nitrogen. In 
hydroxymaleimide 338, however, the morpholinium salt has been formed, stopping the 
interconversion. As a result, the axial and equatorial protons are now diastereotopic and 





Figure 4.3.6: Stacked proton NMR plots showing the alkyl region of morpholine 337 and 
morpholinium salt 338 
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Salt formation also has a deshielding effect on the neighbouring C(6′)-H2 protons and 
the morpholine CH2 protons adjacent to the nitrogen due to the positively charged 
nitrogen, shifting the peaks between 0.8 and 1.0 ppm downfield. This effect can also be 
seen to a lesser extent on the C(5′)-H2 protons and the protons neighbouring the oxygen 
of the morpholine ring. 
 
A HSQC experiment confirms that the morpholine salt has two sets of equivalent 




Figure 4.3.7: HSQC 2D spectrum of alkyl region of morpholinium salt 338 
 
4.3.4.1 Methylation of 12-(6-bromohexyl)-12,13-dihydrofuro[3,4-c]indolo[2,3-a] 
carbazole-5,7-dione 
 
Following on from section 4.3.3.2, the effect of the addition of a methyl substituent on 
the unsubstituted indole unit of bromohexyl substituted maleic 335 was then 
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investigated. Maleic anhydride derivative 335 was suspended in DMF and treated with 
2.5 equivalents of sodium hydride, followed by 2.5 equivalents of iodomethane after 40 
minutes. After 16 hours of stirring, TLC analysis showed the presence of some 
remaining starting material and so a further 1 equivalent of sodium hydride followed by 
iodomethane were added. After a further 16 hours stirring, TLC analysis showed a 
single spot and so the reaction was quenched with water and, following work-up, gave a 
pale yellow solid. Analysis using proton NMR showed the presence of three 3H singlets 
indicating N-methylation and also ring opening of the maleic anhydride to form the 
diester 339, which was isolated in 57% yield (Scheme 4.3.26). Carbon NMR analysis 
showed a peak at 8.8 ppm indicating the presence of an iodide instead of the expected 
bromide, which was confirmed by high resolution mass spectrometry. It is likely that 
the sodium iodide formed as a by-product in the reaction lead to the displacement of the 
bromide with an iodide in a Finkelstein reaction. 
 
In a further attempt to form the maleic anhydride, the reaction was repeated with a 
reduced amount of sodium hydride, decreasing the number of equivalents from three to 
slightly over one, while keeping the equivalents of iodomethane the same. This time the 
maleic anhydride 340 was formed predominantly. Analysis using carbon NMR and high 
resolution mass spectrometry again indicated the conversion of the bromide to an iodide 





The maleic anhydride 340 was treated with hydroxylammonium chloride and 
triethylamine in DMF to form the hydroxymaleimide 341 with an alkyl chloride side 
chain, which was isolated in 74% yield (Scheme 4.3.27). 
 





Attempts were then made to convert diester 339 back to the maleic anhydride using the 
same conditions as for dimethyl 11,12-dimethyl-11,12-dihydroindolo[2,3-a]carbazole-
5,6-dicarboxylate 188 with the expectation that the iodide would be converted to first a 
hydroxy group and then acylated with acetic anhydride in the ring closing step. The 
diester 339 was suspended in aqueous methanol and treated with potassium hydroxide 
and heated to reflux for 24 hours. A pale yellow solid was obtained after work-up 
which, due to solubility issues was used directly in the next step and not characterised. 
This material was suspended in acetic anhydride and heated to reflux for 2 hours before 
work-up and purification using column chromatography gave a bright yellow solid. 
Analysis using proton NMR showed the expected presence of a 3H singlet, however 
there was no extra carbonyl peak in the 
13
C NMR indicating the presence of a methoxy 
group instead of the expected acetoxy group. This was confirmed using mass 
spectrometry and the methoxy compound 342 was isolated in 49% yield (Scheme 
4.3.28).  
 
The maleic anhydride 342 was transformed to the hydroxymaleimide 343 under the 
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4.3.5 Lossen rearrangement 
 
Pursuing the development of the theme of F-ring modulation towards the synthesis of 6-
membered rings, attention then turned to the use of a modified Lossen rearrangement of 
hydroxymaleimide indolocarbazoles. Previous work within the group had achieved this 
transformation by reacting hydrazine hydrate with the tosyl derivative of both a mono- 
and bisazaindolocarbazole to give the corresponding 3-amino uracils.
2
 This section 
details the work towards the adaptation of this chemistry to include indolocarbazoles 
without a pyridine nitrogen and to synthesise a panel of novel uracil indolocarbazoles 
with varying substituents on the uracil F-ring and the indole nitrogens. 
 
4.3.5.1 Synthesis of 3-substituted uracils 
 
The original procedure involved initial activation of the hydroxyl group to the tosylate 
ester which was isolated and then used in the next step where it was treated with 
hydrazine hydrate in ethanol and heated to reflux for 16 hours. This procedure was 
attempted for unsubstituted hydroxymaleimide 296 with the crude tosyl intermediate 
344 being formed in 68% yield. The presence of the tosyl group was confirmed by the 
characteristic peaks for the S=O stretch in the IR spectrum at 1327 and 1178 cm
-1
. The 
disappearance of the hydroxy peak in the NMR section was also observed along with 
the appearance of a 3H singlet and four more aromatic protons. This material was found 
to be quite unstable on heating or on prolonged contact with water and so was not fully 
purified or characterised. Unfortunately, when treated with hydrazine hydrate in ethanol 
and heated to reflux for 16 hours only deprotected starting material 296 was recovered 
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The reaction was repeated using distilled ethanol, with flame-dried glassware and under 
nitrogen with the expectation that excluding as much water as possible would slow 
down degradation, giving more time for the hydrazine to attack. The reaction was also 
repeated with 10 equivalents of hydrazine hydrate. A final attempt was made using the 
original conditions but at a lower temperature of 60 °C. In all attempts, however, only 
hydroxymaleimide 296 was recovered; an unexpected result due to the similarity 
between this compound and the azaindole analogues which had previously been 
successful. 
 
The procedure was then attempted from the mesylate ester with the expectation that the 
more stable intermediate would take longer to convert back to the hydroxymaleimide 
and also that the smaller group would result in less hindrance of the carbonyl group to 
allow faster attack of the hydrazine. However, again, only hydroxymaleimide 296 was 
recovered. 
 
There are several reports in the literature of base-catalysed Lossen rearrangements, 
where the reaction is catalysed by a tertiary amine and so it was postulated that the 
pyridine and DMAP used in the tosylation reaction might be enough to catalyse the 
rearrangement. A suspension of hydroxymaleimide 296 was treated with DMAP and 
tosyl chloride as before and after stirring for 2 hours, hydrazine hydrate was added to 
the yellow solution and the reaction was heated to 80 °C for 16 hours. The solvent was 
then evaporated under reduced pressure and the residue suspended in ethanol. The grey 
precipitate was collected by vacuum filtration and washed with ethanol to give desired 
indolocarbazole with a 6-membered F-ring 345 in 69% yield (Scheme 4.3.30) as an off-
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The mechanism is proposed to proceed via initial nucleophilic attack of the hydrazine 
on one of the carbonyl groups, followed by ring opening to give a hydroxamic acid 
derivative on one side. This can then undergo Lossen rearrangement where the R group 
attached to the carbonyl migrates to the nitrogen as the tosylate ion leaves, forming an 
isocyanate intermediate. Nucleophilic attack of the amide nitrogen on the isocyanate 





The reaction was then carried out under the same conditions with hydroxylamine 
hydrochloride replacing hydrazine hydrate to give 3-hydroxy uracil 346 in 71% yield 
(Scheme 4.3.32). The reaction was also attempted using benzylamine to form the benzyl 
uracil 347 and also using a 7N solution of ethanolic ammonia to form the unsubstituted 
uracil 348 but, in both cases, only hydroxymaleimide starting material 296 was 
recovered. This suggests that a strong nucleophile is needed to react with the tosyl 
intermediate first, before it degrades back to starting material. 
 










H NMR spectra of hydroxymaleimide 296 and amino uracil 345 are stacked for 
comparison (Figure 4.3.8). Conversion of the hydroxymaleimide to a uracil has a 
dramatic effect on the protons nearest the F-ring on the benzene ring (highlighted in 
orange). The shape of the 6-membered ring pushes the carbonyl group even closer to the 
C(9)-H proton, increasing the influence of the anisotropic effect and further deshielding 
the proton. Conversely, on the other side the carbonyl group has now moved further 
away from the C(4)-H proton reducing the effect and as a result, the proton is less 
deshielded. The other protons are affected to a much lesser extent. 
  









Figure 4.3.8: Stacked 
1
H NMR spectra of 296 and 345 in DMSO-d6 at 300 MHz 
 
The rearrangement was also carried out on the bis-methyl hydroxymaleimide 305 to 
form the 3-amino 349 and 3-hydroxy uracils 350 in 87% and 57% yields respectively 
(Scheme 4.3.33). The bis-hexanenitrile hydroxymaleimide 334 was also reacted with 
hydrazine hydrate to give the 3-amino uracil 351 in 61% yield. Due to a lack of 
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4.3.5.3 Synthesis of unsubstituted uracils 
 
3-Amino uracil 345 was then deaminated to the unsubstituted analogue using nitrous 
acid. The amino uracil was initially treated with 5 equivalents of sodium nitrite in a 
50:50 mixture of acetic acid and water and stirred at 50 °C for 16 hours. The crude 
proton NMR spectrum showed a mixture of products had formed with some starting 
material remaining. However, it was found that heating the DMSO-d6 NMR sample in 
the NMR tube converted everything besides the unreacted starting material to the 
desired product 348. As nitrous acid degrades quickly when heated, the reaction was 
repeated with the addition of a 2 further portions of sodium nitrite after 2 hours and 
again after 4 hours before being allowed to stir for a further 16 hours. This time, 
analysis of the heated proton NMR sample showed the reaction had gone to completion 
and so the remaining solid that had been collected by vacuum filtration from the 
reaction was suspended in DMSO and heated to 80 °C for 1 hour, resulting in a brown 
solution. Water was then added to precipitate the product which was collected by 
vacuum filtration in 85% yield. This reaction was repeated for the bis-methyl 349 and 
bis-hexanenitrile 3-amino uracils 351 to form uracils 352 and 353 in 86% and 61% 





4.4 Synthesis and derivatisation of novel methyl 2,3-di(1H-indol-3-yl)-
3-oxopropanoates 
 
In 2006, Braña et al. reported the synthesis of β-keto ester 174 via base mediated 
coupling of ethyl ester 175 and acid chloride 176 in the presence of LDA. From this 
intermediate, a series of pyrazolones similar to 354 were formed through treatment with 
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the appropriate hydrazine in the presence of camphoric acid (Scheme 4.4.1).
17
 The 






Concurrently, work within our group developed a similar route, utilising methyl ester 
177 in place of ethyl ester 175 and increasing the yield of β-keto ester 178 formation to 
80%.
18
 Condensation of this versatile intermediate with guanidine gave isocytosine 179 
with photochemical cyclisation giving the indolocarbazole 181 (Scheme 4.4.2).
19
 On 
assessment via the NCI-60 cell line screen, this indolocarbazole reduced growth to less 
than 50% in over 25 cell lines at a concentration 10 μM, with many displaying GI50 





The first of the two main goals for this section was to synthesise a fully aromatic 
indolocarbazole analogue of pyrazolone 354 as, to date, only bisindole analogues have 
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been reported. The second goal involved the incorporation of a hexane nitrile N-
substituent into isocytosine 181, due to the success of compounds with this side chain in 
the hydroxymaleimide series in the NCI-60 cell line screen. 
 
4.4.1 Synthesis of 13-methyl-5,6,12,13-tetrahydro-7H-indolo[2,3-a]pyrazolo[3,4-c] 
carbazol-7-one 
 
The methyl ester of benzenesulfonyl protected indole-3-acetic acid 256 was synthesised 
by treating a solution of the acid in distilled methanol with thionyl chloride to give the 
ester 355 as a pale yellow oil in 82% yield. The acid chloride 176 of N-methyl indole-3-
carboxylic acid 356 was formed via treatment with oxalyl chloride as an off-white solid 
in quantitative yield. The β-keto ester 357 was then formed using the same methodology 
described by Braña et al. and previously used within the group. A solution of ester 355 
in THF was added to a solution of LDA in THF under a nitrogen atmosphere while 
maintaining the temperature at -78 °C during addition and for a further 1 hour. A 
suspension of the acid chloride 176 in THF was then added and the reaction was 
allowed to warm slowly to room temperature over 16 hours. After work-up and 
purification using column chromatography followed by recrystallisation from ethyl 
acetate the β-keto ester 357 was isolated as a white solid in 45% yield (Scheme 4.4.3). 
In preparation for this reaction, the usual precautions to eliminate water from the 
reaction were observed e.g. flame-drying of apparatus, use of freshly distilled solvents 
etc. The LDA was prepared in situ as it was found this gave more consistent results than 
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The β-keto ester 357 was then reacted with hydrazine hydrate in a cyclocondensation 
reaction to form pyrazolone 358 in 45% yield (Scheme 4.4.4). Deprotection was 
initially attempted using potassium carbonate in refluxing aqueous methanol, but after 
24 hours proton NMR analysis showed that only starting material was present. The 
stronger base potassium hydroxide was then employed. As the protected and 
deprotected materials overlapped completely on TLC analysis, the reaction had to be 
monitored by proton NMR analysis. After 24 hours, analysis showed a mixture of 
starting material and product and so the reaction was continued. After 48 hours, some 
starting materials still remained and some unwanted side products had begun to form. 
However, as the starting material and product would not be separable by column 
chromatography the reaction was continued until, after a total of 60 hours, the starting 
material had been completely consumed. After work-up and purification using column 






Several other deprotecting strategies were attempted to increase the yield of this step. 
Deprotection using magnesium and ammonium chloride in methanol also gave a 
complex mixture of products that could not be separated. It was suspected that the 
strongly basic conditions of this reaction were too harsh for the pyrazolone and 
degradation of this was leading to the formation of side-products. Deprotection using 
milder TBAF in THF gave no reaction.  
 
It has been reported in the literature that removal of a benzenesulfonyl group can be 
achieved in a light-mediated reaction.
20
 As the end goal of this route was to synthesis 
the indolocarbazole 360 in a photocyclisation step, it was theorised that it might be 
possible that both transformations could be carried out simultaneously. In contrast to the 
photochemical reactions previously carried out in this project, the literature procedure 
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was carried out in the absence of iodine and, as deprotection was the original aim, initial 
attempts were carried out without iodine. Pyrazolone 358 was dissolved in methanol 
and irradiated using a standard high pressure mercury bulb for 2 hours, until TLC 
analysis indicated the complete consumption of starting material and the appearance of 
a new spot which fluoresced brightly when viewed under U.V. light, a characteristic of 
the indolocarbazoles. Following work-up and recrystallisation from MeOH/DCM, 
pyrazolone 360 was isolated in 25% yield (Scheme 4.4.5) and the absence of the C(2)-H 
proton signals from the 
1






H NMR spectra of bisindolyl pyrazolone 359 and the indolocarbazole analogue 
360 are stacked for comparison (Figure 4.4.1). Again, the protons most affected by the 
transformation are those on the benzene rings which are closest to the F-ring, with the 
proton below the carbonyl group being particularly deshielded due to the anisotropic 
effect and is shifted downfield by approximately 1.6 ppm, consistent with other 
indolocarbazoles. The other protons are also shifted slightly downfield. 
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4.4.2 Synthesis of 6-[6-amino-13-methyl-8-oxo-8,13-dihydroindolo[2,3-
a]pyrimido [4,5-c]carbazol-14(7H)-yl]hexanenitrile 
 
Due to the success of fully cyclised isocytosine 181 in NCI testing it was decided to 
synthesise a derivative of this compound with a hexane nitrile N-substituent replacing 
one of the methyl groups.  
 
Indole-3-carboxylic acid 361 was alkylated using 2 equivalents of sodium hydride 
followed by 6-bromohexanenitrile to give alkylated product 362 in 93% yield as a white 
solid. This was then converted to the acid chloride 363 via treatment with oxalyl 





The N-methyl ester of indole-3-acetic acid 254 was synthesised following treatment 
with dimethyl carbonate with potassium carbonate in DMF giving the ester as a light 
brown oil 177 in 79% yield. The ester 177 and acid chloride 363 were then coupled 
using a similar procedure to that described above in Scheme 4.4.3, giving β-keto ester 
364 as a pale yellow foamy solid in 21% yield (Scheme 4.4.7). 
 






To form the desired isocytosine, guanidine carbonate was initially stirred with sodium 
methoxide to liberate free guanidine from the salt and the β-keto ester 364 then 
underwent cyclocondensation with the guanidine in refluxing methanol. Following 
work-up and purification using column chromatography, the isocytosine 365 was 
formed in 40% yield as a pale yellow solid (Scheme 4.4.8). 
  
Photocyclisation of the newly formed isocytosine was then achieved using identical 
conditions to bis-methyl analogue 181, synthesised previously in the group. Isocytosine 
365 was irradiated with a high pressure mercury lamp for 16 hours with a catalytic 
amount of iodine resulting in the formation of fully aromatic isocytosine 366 which was 
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Although the formation of isocytosine 365 was confirmed by proton NMR and mass 
spectrometry data, the 
13
C NMR appeared to be missing 4 quaternary carbon signals. 
NMR analysis of the sample was then run on a more powerful instrument at 150 MHz 
with an increased pulse time delay (τ) of 7 seconds resulting in the appearance of 4 




Figure 4.4.2: Expansion of 
13
C NMR spectra of 365 comparing spectrum run at 150 mHz and  
τ = 7 s (top) with original spectrum run at 75 mHz and τ = 1 s (bottom) 
 
2D NMR experiments were then carried out to identify the origin of these peaks. All 
CH signals were assigned with the aid of DEPT and HSQC experiments (5, 5′ and 6′ 
may be interchanged due to overlapping proton signals). A HMBC experiment was then 

















4′′ 2′′ C=O 
* 5, 5′ or 6′ 




Figure 4.4.3: 2D HMBC spectrum of 365 
 
The peak at 163.7 was assigned as the carbonyl carbon and the peak at 121.04 was 
assigned as the nitrile carbon as it showed a correlation to the neighbouring CH2 
protons. C(5′′) of the isocytosine ring is identified by its correlation to C(2)-H. C(4′′) 
and C(2′′) of the isocytosine do not show any correlations, however it is possible to 
deduce that C(2′′) is the most deshielded of the two as it is bonded to three heteroatoms 
whereas C(4′′) is just bonded to one. The bridgehead carbon C(7a) is easily identified as 
it shows a strong correlation to the methyl protons, as well as showing correlations to 
C(2, 5, 6 and 7)-H. Similarly, C(7a′) shows a strong correlation to the neighbouring CH2 
protons, and also to C(2′, 5′ and 6′)-H (see expansion for aromatic region in Figure 
4.4.4). The bridgehead carbon C(3a′) shows a correlation to C(2′, 5′ and 7′)-H, all of 
which are three bonds away, and also C(6′)-H at four bonds distance. The opposing 
bridgehead carbon C(3a) shows a correlation to C(2, 4, 6 and 7)-H (see expansion for 3a 
and 3a′ in Figure 4.4.5). C(3) shows a correlation to C(2)-H and also to C(7)-H (see 














Figure 4.4.4: Expansion of aromatic region in HMBC spectrum of 365 
 





























Figure 4.4.6: Expansion of C(3) in HMBC spectrum of 365 
 
From the HBMC experiment it was shown that the weak, broad peaks corresponded to 
carbons on the isocytosine moiety or those of neighbouring carbons. 
 
4.5 Routes towards 4,5-bisindolylimidazoles 
 
A route towards the synthesis of imidazoles as novel F-ring heterocycles from a 
bisindolyl-1,2-ethanedione intermediate was also explored. The potential advantages of 
this route were the ability to use non-protected indoles and the very short synthesis to 
the dione intermediates.  
 
4.5.1 Synthesis of 3,3'-(1H-imidazole-4,5-diyl)bis(1H-indole)  
 
The dione intermediate 367 was formed by initially treating a solution of indole 251 in 
diethyl ether with oxalyl chloride. The yellow precipitate was collected after 30 minutes 
by vacuum filtration to give oxoacetyl chloride 368 in 94% yield. This reactive 
intermediate was always used immediately in the next step to avoid degradation. The 
oxoacetyl chloride 368 was then added portionwise to a suspension of aluminium 
chloride in a mixture of 1,2 dichloroethane and heptane, forming a dark red 
heterogeneous mixture. A solution of indole 251 in 1,2-dichloroethane was then added 
dropwise, with vigorous stirring to ensure mixing of the viscous reaction mixture and 
stirring was continued for 16 hours. It was found that on scale-up the yield of the 
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overhead stirrer, which reliably maintained the yield of 367 in the range of 54-60% 





As part of our diversity orientated synthetic strategy, the dione intermediate could then 
be used to form a bisindolyl imidazole using a three-component reaction in one pot. 
Dione 367 was treated with 10 equivalents of ammonium acetate and one equivalent of 
formaldehyde dimethyl acetal in acetic acid which was heated to reflux for 48 hours. 
Column chromatography on silica gel using DCM/methanol as eluent was unsuccessful, 
due to the very long elution time leading to coelution of multiple products. Column 
chromatography on alumina, however, proved successful with imidazole 369 being 
isolated as a dark brown solid in 34% yield (Scheme 4.5.2). Attempts to increase the 
yield by increasing the number of equivalents of formaldehyde dimethyl acetate from 
one equivalent to five were unsuccessful with the yield remaining the same. The 
reaction was also repeated at a lower temperature of 100 °C in an attempt to reduce the 
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4.5.2 Derivatives of 3,3'-(1H-imidazole-4,5-diyl)bis(1H-indole) 
 
4.5.2.1 Oxidative cyclisations 
 
The next target was the fully aromatic analogue 370. Initially cyclisation attempts were 
focussed on the direct cyclisation of novel imidazole 369. This was initially attempted 
using the photocyclisation method, which had proved successful for the cyclisation of 
other bisindolyl compounds. Irradiation of a solution of 369 in a mixture of acetonitrile 
and methanol with a catalytic amount of iodine for 16 hours gave a complex mixture of 
products and, although analysis using mass spectrometry showed that some of the 
desired product 370 had formed, isolation using column chromatography on silica gel or 
alumina was unsuccessful due to coelution of multiple products.  
 
As the addition of iodine made the already dark coloured solution much darker, it was 
suspected that insufficient light was passing through the reaction. These cyclisation 
reactions can sometimes be successful in the absence of iodine and so the reaction was 
repeated without the iodine catalyst. Although analysis of the crude material by proton 
NMR suggested a higher conversion of the bisindolyl compound 369 to the 
indolocarbazole 370 purification was, again, unsuccessful. Attempted cyclisation of the 
compound using heat in the absence of the light source was also unsuccessful and only 
starting material was recovered in this case. 
 
Attention then turned to a palladium based method. Palladium (II) acetate was heated to 
reflux in a solution of the bisindolyl imidazole 369 in acetic acid for 3 hours. Analysis 
using proton NMR and mass spectrometry indicated the desired product had formed but, 
again, the same issues with isolation arose. Two more oxidative reactions were 
attempted using manganese dioxide and using DDQ but unfortunately similar complex 









Oxidant Stoichiometry Conditions Product 












iv Pd(OAc)2 1 eq. AcOH, 120 °C complex mixture 
v MnO2 10 eq. Acetone, r.t. complex mixture 
vi DDQ 1.2 eq. TFA, reflux complex mixture 
 
Table 4.5.1: Summary of cyclisation study for synthesising indolocarbazole 370 from bisindolyl 369 
 
Oxidation of dione 367 to form indolocarbazole 371 was also attempted as it was 
envisaged that the imidazole forming reaction would be more successful if the two 
carbonyl groups were fixed in the same orientation. However, attempted cyclisations 








Work then turned towards the synthesis of novel imidazole compounds with N-
substituted indoles with the intention of probing the effects of this change on the 
biological activity. A bis-methyl substituted dione 372 was first synthesised by treating 
the unsubstituted dione 367 with sodium hydride followed by iodomethane. Following 
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work-up and purification using column chromatography gave dione 372 as a brown 
solid in 83% yield (Scheme 4.5.4). 
 
This N-methylated dione was then treated with formaldehyde dimethyl acetal and 
ammonium acetate in acetic acid in an attempt to form the imidazole 373, but only 
starting material was recovered from the reaction. The reaction was repeated using a 
fresh bottle of formaldehyde dimethyl acetal; however the same result was obtained. It 
is possible that the presence of the two methyl groups prevents the compound from 





To further demonstrate the capricious nature of this reaction, the conversion of the 
unsubstituted dione 367 to the imidazole 369 was unsuccessful when the reaction was 
repeated some time later. Attempts were then made using fresh reagents, with a longer 
reaction time and with dried solvent; however, each time a complex mixture along with 
some starting material was recovered, proving that more robust conditions were 
required.  
  
Chemical Results and Discussion 
154 
 
4.5.3 Alternative routes 
 
As imidazoles formed by the three-component condensation reaction were prone to 
difficulties with isolation and proved unsuccessful with N-substituted indoles, several 
other routes to imidazoles were explored. 
 
4.5.3.1 Reaction with guanidine  
 
A procedure to form an amino imidazole from an aromatic (non-indole) diketone 
precursor through condensation with guanidine via a proposed hydroxy imidazole 
intermediate has been reported by Nishimura et al.
21
 Guanidine was first liberated from 
its carbonate salt by treatment with sodium hydroxide. The isolated guanidine was then 
added to a solution of dione 367 in methanol and the reaction was heated to reflux for 
16 hours. The precipitated solid was collected using vacuum filtration and due to a lack 
of solubility was used without further purification or characterisation in the next step. 
This intermediate was then suspended in methanol and 10% Pd/C was added and the 
suspension was hydrogenated at 10 psi for 24 hours. After filtration through Celite to 
remove the remaining catalyst, the reaction mixture was evaporated to dryness under 
reduced pressure. Analysis using proton NMR and mass spectrometry showed none of 





4.5.3.2 Condensation with ureas 
 
Work towards the condensation of dione 367 with urea was then undertaken. Several 
different reaction additives were selected from the literature including camphorsulfonic 
acid, p-tosic acid, zinc triflate and pyridine (Table 4.5.2) but in all cases only starting 
material was recovered with none of the desired product formed 375. The reaction was 
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also attempted using the more nucleophilic thiourea using trifluoroacetic acid and using 






(eq. of urea) 
Additive Conditions Product 
1 (O) 1.3 CSA (1 eq.) 
















N2, 24 hours 
starting 
material 
4 (O) 5 - 




5 (S) 5 TFA (cat.) 












Table 4.5.2: Reaction conditions for the reaction of dione 367 with urea or thiourea 
 
4.6 Summary of synthetic work 
 
In this work, a panel of 42 novel bisindolylmaleimide and indolocarbazole derivatives 
were prepared for biological evaluation. In the bisindolylmaleimide series, substitution 
on the indole nitrogens of maleic anhydride intermediates led to a large panel of novel 
hydroxymaleimides with substituents incorporating either lipophilicity or hydrophilicity 
(Figure 4.6.1). Development of two other routes involving a β-keto ester or dione 
intermediate led to the synthesis of bisindolylmaleimides with pyrazolone and 
imidazole F-rings, respectively. 
 
 









Figure 4.6.1: Novel five-membered bisindolylmaleimide and indolocarbazole derivatives. 
 
Expanding on these routes to form the fully cyclised indolocarbazole analogues resulted 
in a panel of fifteen novel indolocarbazole derivatives with hydroxymaleimide F-rings 
and a diverse range of N-substituents, as well as a novel pyrazolone derivative (Figure 
4.6.1).  
 
The successful modified Lossen rearrangement resulted in the synthesis of eight novel 
indolocarbazoles with uracil F-rings and a number of different N-substituents (Figure 
4.6.2). Synthesis of both a novel bisindolyl and indolocarbazole derivative with an 






Figure 4.6.2: Novel six membered indolocarbazoles 
 
The results of the biological evaluation of these compounds are discussed in Chapter 5.  
C=O, NH 
NH, N-OH, N-NH2 
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H, Me, Et, iPr 
(CH2)5CN, (CH2)5COOH 
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5.1 NCI-60 Cell Screen 
 
In total, a panel of 42 novel potential anticancer agents were synthesised, 17 
bisindolylmaleimide analogues and 25 indolocarbazoles. Anticancer activity is the most 
extensively studied and reported biological effect of these compounds and given the 
importance of anticancer medicine in modern times, this is the area that was focussed on 




Prospective candidates were initially submitted to the NCI 60-cell line screen, a 
screening program which is run by the Developmental Therapeutics Program (DTP) of 
the NCI. Each compound is screened for activity against 60 human cancer cell lines 
including lines from cancers such as leukaemia, non-small cell lung cancer, melanoma, 
and cancers of the colon, CNS, ovary, kidney, prostate and breast. This gives an overall 
picture of the cytotoxicity of the compounds as well as any specificity of a compound 
towards individual cell lines. The compounds are initially tested at a single dose with a 
concentration of 10 μM, and any compounds with significant activity are taken forward 
to a five dose assay where they are screened at concentrations of 100 μM, 10 μM, 1 μM, 
100 nM and 10 nM. The dose response data is then used to calculate three concentration 
parameters – GI50, TGI and LC50.  
 
The screen was originally set up to identify compounds with growth-inhibitory or 
cytotoxic effects; however, it was soon found that further information could also be 
obtained. The patterns of relative sensitivity and resistance of known drugs tested gave 
an indication to their mechanism of action. As a result, the COMPARE algorithm was 
developed by Paull et al. which could be used to predict the mode of action of potential 
chemotherapeutic agents.
3
 This is achieved by specifying the desired compound using 
its NCI accession number and the algorithm then ranks the entire database of tested 
compounds in order of similarity to the original “seed” compound based on patterns of 
activity. Compounds high in this ranking may possess a similar mechanism of action to 
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5.1.1 Single dose results 
 
In this section, the results of the single dose assays are discussed for all bisindolyl and 
indolocarbazole compounds tested. Although the results are not as detailed as for the 
five dose assay, the single dose screen allows for a higher throughput of compounds and 
is a valuable tool for the identification of novel chemotherapeutic agents. The results are 
displayed as an overall mean graph of cell growth (Figure 5.1.1). The 60 cell lines are 
listed along the left along with the specific growth percent of each cell line measured. 
The central line (marked 0 on the graph) represents the mean growth across all cell lines 
(in this case 77.99% growth). The bars indicate deviation from the mean growth for 
individual cell lines, with bars extending to the right indicating selectivity for that cell 
line. Single dose mean graphs for all the derivatives tested can be found in the 
appendices. 
 




Figure 5.1.1: Single dose data for hydroxymaleimide 285 
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5.1.1.1 Bisindolylmaleimide derivatives  
 
A total of 11 related novel bisindolylmaleimide analogues were submitted for screening 
and the mean growth percent (mean) and deviation from the mean (delta) are displayed 












285 775309 Me H N-OH 78.0 60.9 
286 774887 Me Me N-OH 97.6 24.8 
290 775308 iPr H N-OH 94.4 37.5 
291 775307 iPr Me N-OH 90.8 34.4 
281 776690 (CH2)5CN H N-OH 85.6 42.4 
288 776694 (CH2)5CN Me N-OH 90.8 40.0 
283 776692 (CH2)5COOH H N-OH 97.9 36.9 
289 776691 (CH2)5COOH Me N-OH 96.4 33.1 
282 776693* (CH2)5CN (CH2)5CN N-OH 67.5 52.4 
327 781333 (CH2)5CN (CH2)5CN NH 86.9 39.7 
284 781334 -(CH2)6- N-OH 103.3 24.0 
*Five dose data available  
Table 5.1.1: Mean growth over 60-cell panel on treatment with bisindolylmaleimide derivatives 
 
Compound 285 with one methyl N-substituent  and one unsubstituted indole showed 
some activity with a mean growth of 78.0% (Figure 5.1.1). Selectivity was also 
observed for leukaemia cell lines (growth reduced to 30.9% in SR) and also for 
melanoma cell line MDA-MB-435 (17.1%), renal cancer cell line UO-31 (40.6%) and 
breast cancer cell line MCF7 (30.9%). Addition of a second methyl substituent 
significantly reduced activity with compound 286 being almost completely inactive; 
although some selectivity was observed for leukaemia cell line SR (75.4%), melanoma 
cell line LOX IMVI (72.8%) and renal cancer cell line UO-31 (74.2%). These results 
are similar to those for mono azaindolyl 376 (Figure 5.1.2), synthesised previously 
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within the group, which had a mean growth of 97.8% and also showed selectivity for 





Figure 5.1.2: Structures of compounds 286 and 376 
 
Compounds with an isopropyl substituent (290 and 291) were mostly inactive apart 
from a similar selectivity towards LOX IMVI (58.8% and 61.5%, respectively) and UO-
31 (67.9% and 56.4%, respectively) and for most leukaemia cell lines. 
 
Compounds with one extended alkyl chain with a nitrile or carboxylic acid functional 
group also displayed little activity with nitriles 281 and 288 being slightly more active 
than acids 283 and 289. These compounds again displayed selectivity towards LOX 
IMVI (between 53.3% and 80.4%) and UO-31 (between 50.8 and 63.2%) and 
compound 281 also showed selectivity towards leukaemia cell line RPMI-8226 (43.5%) 
and non-small cell lung cancer cell line HOP-92 (48.0%). 
 
Interestingly, addition of a second nitrile chain significantly increased activity with 
compound 282 displaying a mean growth of 67.5% and being selected to progress to 
five dose screening (Figure 5.1.3). This derivative exhibited considerable activity 
towards a number of individual cell lines, including leukaemia cell lines HL-60(TB) 
(15.1%) and SR (17.8%), melanoma cell lines LOX IMVI (30.4%) and MDA-MB-435 
(16.0%), renal cancer cell line UO-31 (43.8%) and breast cancer cell lines MCF7 
(39.9%) and MDA-MB-231/ATCC (40.3%). Replacement of the hydroxymaleimide 
moiety with an unsubstituted maleimide reduced activity, with compound 327 showing 
a mean growth of 86.9%. 
 




Figure 5.1.3: Structure of hydroxymaleimide 282 
 
The derivative with nitrogens linked by a 6-carbon chain 284 was found to be almost 
completely inactive with a mean growth of 103.3% and little deviation from the mean 
growth across the panel. This was a rather disappointing result as maleimide analogue 
377 shows significant inhibition of a number of kinases including PKCα (Ki = 0.3 μM), 
p70 S6K (Ki = 0.9 μM) and GSK3β (Ki = 0.7 μM), and compound 284 is also an 






Figure 5.1.4: Structures of 284, 377 and 28 
 
5.1.1.2 Indolocarbazoles with 5-membered F-rings 
 
A total of 15 indolocarbazoles with 5-membered F-rings were screened for activity. Of 
these, 9 were found to have significant enough activity to progress to five dose testing. 
The mean growths of a panel of derivatives with methyl or allyl substituents are 
displayed in Table 5.1.2. 
 













305 776701* Me Me N-OH C=O 32.9 79.5 
306 783510* Allyl Allyl N-OH C=O 18.4 116.3 
298 774888 Me H N-OH C=O 76.8 68.0 
299 781337 Me H N-NH2 C=O 89.0 32.0 
321 781338 Me H N-O(CH2)5CN C=O 52.6 90.1 
360 785683* Me H NH NH 23.4 76.2 
*Five dose data available 
Table 5.1.2: Mean growth over 60-cell panel on treatment with indolocarbazoles with methyl or 
allyl substituents 
 
Bis-methyl derivative 305 was found to be considerably more active than its bisindolyl 
counterpart 286. In addition to the low mean growth percent displayed by 305, 
significant selectivity was also observed against a number of cell lines including 
leukaemia cell line MOLT-4, non-small cell lung cancer cell line NCI-H522, melanoma 
cell lines LOX IMVI and SK-MEL-5 and breast cancer cell line MDA-MB-468 (Table 
5.1.3). This compound was more active overall than monoaza 326 but less active than 
the bisaza analogue 236, both synthesised previously within the group.
4
 Interestingly, 
the patterns of selectivity also differed between the three compounds, indicating 
different biological targets.  
  








Selected cell lines 






305 32.9% -28.0% -46.6% -37.4% -27.8% -12.2% 26.6% 
326 37.7% -8.6% 4.02 8.3% 9.0% 41.5% - 
236 20.0% -33.0 4.9% 0.6% - -14.9% -24.8% 
Table 5.1.3: Comparison of single dose data for compounds 305, 326 and 236 
 
Changing from methyl to allyl substituents (306, Figure 5.1.5) further improved activity 
compared to 305, with selectivity towards MOLT-4 (-10.4%), NCI-H522 (-62.5%), 
LOX IMVI (-81.2%) and SK-MEL-5 (-48.5%) being maintained. This compound also 
showed remarkable activity towards non-small cell lung cancer cell line NCI-H226       
(-97.9%) and renal cancer cell line CAKI-1 (-70.6%). Both of these derivatives were 
selected for five dose testing. 
 
 
Figure 5.1.5: Structure of indolocarbazole 306 
 
Compounds 298, 299, 321 and 360 all have identical N-substituents allowing for a 
comparison of the effect of differing F-rings on biological activity. Hydroxymaleimide 
298 displayed only moderate activity with some selectivity towards leukaemia cell lines 
CCRF-CEM (8.8%) and SR (9.1%), a surprising result based on the potent activity of its 
bis-methyl counterpart 305. Changing from a hydroxy to an amino group (299) further 
decreased both overall activity and selectivity. Addition of a 6-hexanenitrile chain to the 
hydroxymaleimide to give compound 321 suprisingly increased activity considerably 
compared to hydroxymaleimide 298, while maintaining a similar selectivity pattern. 
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COMPARE analysis gave a correlation of 0.693, indicating that the mode of biological 
action is not altered significantly by the addition of a bulky chain to this position. 
Compound 321 also showed remarkable activity towards breast cancer cell line MDA-
MB-468 (-37.5%). Removal of the maleimide N-substituent combined with replacement 
of one carbonyl group with a nitrogen gave pyrazolone 360 (Figure 5.1.6) which greatly 
improved activity resulting in a mean growth of 23.4%. The selectivity pattern was 
quite different to that of hydroxymaleimide 298 with COMPARE analysis giving a 
correlation of just 0.357, indicating a different mode of action. Highest activity was 
seen in colon cancer cell line HCT-116 (-52.8%), melanoma cell lines LOX IMVI        
(-30.3%) and SK-MEL-5 (-18.1%) and renal cancer cell lines RXF 393 (-36.7%) and 
UO-31 (-26.9%). Pyrazolone 360 was also accepted for five dose screening. 
 
 
Figure 5.1.6: Structure of pyrazolone 360 
 
A panel of hydroxymaleimide indolocarbazoles with functionalised six-carbon chains 
were also screened and their mean growths are displayed in Table 5.1.4.  
  













308 781336* CN H -7.0 90.0 
322 781335* CN Me 7.6 87.9 
334 783507 CN (CH2)5CN 76.4 75.6 
343 783508 CH2OMe Me 65.9 61.7 
336 783509* CH2Cl H 4.2 74.5 
338 785682* CH2N(CH2CH2)2O.(HCl) H 63.0 151.4 
314 783514* CON(CH2CH2)2O H 41.7 68.2 
315 783515* CON(CH2CH3)2 H 35.1 101.7 
316 783513 CO2Me H 40.0 105.0 
*Five dose data available 
Table 5.1.4: Mean growth over 60-cell panel on treatment with hydroxymaleimide series of 
indolocarbazoles (long chain) 
 
Nitrile derivative 308 (Figure 5.1.7) was found to have the highest activity in the single 
dose screen of the compounds tested in this project, with a mean growth of -7%. This 
compound showed remarkable cytotoxicity against CNS cancer cell line SF-539           
(-95.4%) and melanoma cell line SK-MEL-5 (-97.0%) which are the most potent in 
single cell lines of all the derivatives tested. The compound also displayed selectivity 
for a number of other cell lines, such as non-small cell lung cancer cell line NCI-H522 
(-53.9%), melanoma cell line LOX IMVI (-81.0%) and the mean growth of five renal 
cancer cell lines were reduced to below -30%. Addition of a methyl group to the 
unsubstituted indole to give compound 322 reduced activity slightly while a similar 
pattern of selectivity was maintained. This analogue also displayed selectivity for SF-
539 (-33.0%), SK-MEL-5 (-80.3%), NCI-H522 (-51.9%), LOX IMVI (-66.7%) and 
several renal cancer cell lines (three lines below -20%).  
 




Figure 5.1.7: Structures of 308 and 322 
 
The addition of a second hexane nitrile substituent to give derivative 334 greatly 
reduced activity to 76.4% mean growth. This was a disappointing result as its bisindolyl 
counterpart 282 was the most active of the bisindolylmaleimide analogues with a mean 
growth of 67.5% (Table 5.1.1). Some selectivity was still observed against several cell 
lines including melanoma cell line LOX IMVI (24.1%) and renal cancer cell line CAKI-
1 (0.9%). 
 
Replacement of the nitrile with a methyl ether to give compound 343 led to a reduction 
in activity with a mean growth of 66% instead of 8% for nitrile 322. Compound 343 still 
showed selectivity for leukaemia cell lines (59.7% to 10.9% growth) as well as 
melanoma cell line LOX IMVI (5.8%) and renal cancer cell line CAKI-1 (4.2%). 
 
Chloride 336 (Figure 5.1.8) was another very active derivative which displayed 
cytotoxicity towards a number of cell lines and had an overall mean growth of just 
4.2%. Although possessing an alkyl halide functionality which could allow this 
analogue to work as an alkylating agent, the large delta value of 74.5% suggests that its 
biological effects are affected through a more selective mechanism. The most potent 
selectivity was observed in leukaemia cell line HL-60(TB) (-41.7%) and melanoma cell 
lines LOX IMVI (-70.2%) and SK-MEL-5 (-69.5%). Replacement of the chloride with a 
morpholine salt forming 338 increased mean growth to 63.0% but greatly increased 
selectivity for individual cell lines with a range of 151.4%. This derivative showed 
remarkable selectivity for leukaemia cell lines K-562 (-32.9%) and SR (-26.2%), colon 
cancer cell line HCT-116 (-16.0%), CNS cancer cell line U251 (-23.2%) and melanoma 
cell line LOX IMVI (-88.4%). 
 




Figure 5.1.8: Structures of compounds 336 and 338 
 
The addition of a carbonyl group to amide 338 to form amide 314 (Figure 5.1.9) caused 
an overall increase in activity with the mean growth dropping to 41.7%. The selectivity 
profile was very different to its amine counterpart 338 with LOX IMVI being the only 
cell line to which both compounds showed cytotoxic effects (-16.8% for 314). The 
amide also displayed cytotoxic effects against leukaemia cell line MOLT-4 (-14.9%), 
ovarian cancer cell line IGROV1 (-26.5%) and renal cancer cell line CAKI-1 (-22.9%). 
Diethyl amide derivative 315 maintained a similar level of activity to 314 at 35.1% 
growth; however, the selectivity profile was quite different with COMPARE analysis 
giving a correlation of just 0.554 between the two compounds. While selectivity was 
retained for cell lines LOX IMVI (-59.0%) and CAKI-1 (-59.0%), 315 was also 
particularly active against non-small cell lung cancer cell line NCI-H522 (-66.5%) and 
renal cancer cell lines ACHN (-64.9%) and UO-31 (-50.7%). Interestingly, the activity 
profile of methyl ester 316 was very similar to that of diethyl amide 315, with 
selectivity being retained for cell lines NCI-H522 (-60.0%), LOX IMVI (-65.0%), 
ACHN (-18.5%) and CAKI-1 (-16.8%). COMPARE analysis gave a correlation of 
0.869, indicating that a similar mode of action was likely. 
 
 
Figure 5.1.9: Structures of 314, 315 and 316 
 
Six of the nine compounds in this panel progressed to five dose testing. 
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5.1.1.3 Indolocarbazoles with uracil F-rings 
 
The biological activity of a panel of eight indolocarbazoles with uracil F-rings was also 
assessed and the results are displayed in Table 5.1.5. 
 
 
Compound NSC X R Mean (%) Delta (%) 
345 778802 NH2 H 88.8 32.3 
349 778803 NH2 Me 84.5 70.3 
351 783511 NH2 (CH2)5CN 88.5 34.2 
346 778801 OH H 44.6 52.9 
350 778804* OH Me 30.3 42.9 
348 778805 H H 35.3 45.4 
352 781339* H Me 30.9 69.4 
353 783512 H (CH2)5CN 47.2 55.1 
*Five dose data available 
Table 5.1.5: Mean growth over 60-cell panel on treatment with uracil series of indolocarbazoles  
 
Overall, amino derivatives 345, 349 and 351 were inactive with mean growths of 84-
89% and little deviation from the mean growth across the panel. The only exception was 
compound 349 which showed considerable activity against ovarian cancer cell line 
OVCAR-4 (14.2%).  
 
Hydroxy derivatives 346 and 350 were significantly more active than the amino 
analogues, with the presence of N-methyl substituents increasing activity compared to 
unsubstituted indole nitrogens. Compound 346 with free indole nitrogens reduced 
growth to 44.6% and displayed cytotoxic activity towards non-small cell lung cancer 
cell line HOP-92 (-8.3%) and also selectivity for the leukaemia cell lines (all between 
5.6% and 26.5%), non-small cell lung cancer cell line NCI-H522 (4.3%) and melanoma 
cell line LOX IMVI (10.0%). The highest activity for bis-methyl 350 (Figure 5.1.10) 
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was observed against leukaemia cell lines RPMI-8226 (-12.6%) and SR (4.5%), non-
small cell lung cancer cell lines HOP-92 (-2.9%) and NCI-H23 (-2.7%), colon cancer 
cell line HCT-116 (0.5%) and melanoma cell lines LOX IMVI (-4.9%) and SK-MEL-5 
(2.7%). Interestingly, this compound reduced overall growth to 30.3% and so was 
slightly more active than its hydroxymaleimide counterpart 305 (mean growth 32.9%) 
and was the most active of the uracil compounds tested. Derivative 350 was also 
selected for five dose testing. 
 
 
Figure 5.1.10: Structure of hydroxy uracil 350 
 
Unsubstituted uracil compounds 348, 352 and 353 had similar levels of activity to the 
hydroxy uracil derivatives. Compound 348 which had unsubstituted indole nitrogens 
reduced mean growth to 35.3%, and so was more active than its hydroxy counterpart. 
Selectivity was observed for leukaemia cell line RPMI-8226 (6.0%), non-small cell lung 
cancer cell line HOP-92 (5.7%), renal cancer cell line A498 (-10.1%) and breast cancer 
cell line MDA-MB-468 (6.0%). The addition of N-methyl substituents (352) again 
improved activity, although disappointingly this unsubstituted uracil was no more active 
than its hydroxy analogue. However, with a mean growth of 30.9% it was deemed 
active enough to progress to the five dose assay. Cytotoxic effects were seen against 
several cell lines including non-small cell lung cancer cell line HOP-92 (-4.4%), CNS 
cancer cell line SNB-75 (-38.4%), ovarian cancer cell line OVCAR-4 (-10.1%), renal 
cancer cell line A498 (-4.1%) and breast cancer cell line HS 578T (-7.3%). Addition of 
hexanenitrile N-substituents again reduced activity to 47.2% mean growth, although 
significant selectivity was displayed for a number of cell lines including CNS cancer 
cell line SF-539 (-0.2%), renal cancer cell line 786-0 (0.2%) and breast cancer cell line 
MDA-MB-231/ATCC (-7.9%). 
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5.1.1.4 Analogues with other F-rings 
 
Analogues with two other F-ring types were synthesised during this project, one with an 
imidazole and two with an isocytosine and the results are displayed in Table 5.1.6.  
 
 
Compound NSC Mean (%) Delta (%) 
365 778800 98 37 
366 785684 76 43 
369 763911 78 48 
Table 5.1.6: Mean growth over 60-cell panel on treatment with analogues with other F-rings 
 
Bisindolyl derivative 365 showed very little activity, with modest selectivity observed 
for only one cell line – non-small cell lung cancer cell line HOP-92 (61.2%). 
Conversion to the indolocarbazole (366) improved activity, with mean growth being 
reduced to 76.4%. Disappointingly, this compound was less active than bis-methyl 
derivative 181 (Figure 5.1.11), synthesised previously within the group (mean growth 
58.9%),
7
 despite the presence of a hexanenitrile substituent which had caused a 
dramatic increase in activity in the hydroxymaleimide series. The highest selectivity for 
compound 366 was observed for leukaemia cell line SR (35.5%) and renal cancer cell 
line RXF 393 (33.5%). 
 
 
Figure 5.1.11: Structure of 181 
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Imidazole 369 was the second most active bisindolyl derivative tested in this project 
with a mean growth of 77.7%. This compound displayed good selectivity against CNS 
cancer cell line SF-295, as well as moderate selectivity against a number of other cell 
lines such as renal cancer cell lines CAKI-1 (48.7%) and UO-31 (52.5%) and breast 
cancer cell line MDA-MB-231/ATCC (49.0%). 
 
5.1.2 Five dose results 
 
A total of 12 compounds were selected to progress to five dose testing where they were 
screened at concentrations of 100 μM, 10 μM, 1 μM, 100 nM and 10 nM. The 
concentration parameters GI50 (concentration to inhibit cell growth by 50%) and LC50 
(concentration required for 50% cell death) are extracted from concentration response 
curves by linear extrapolation. TGI (total growth inhibition) is read as the x-axis 
intercept from the five different drug concentrations.
8
 Concentration on the x-axis is 
given as log10 of the sample concentration in moles, i.e. -6 is 1 × 10
-6
 M or 1 μM. 
 
5.1.2.1 Five dose data for bisindolyl derivative 282 
 
Bis-hexanenitrile derivative 282 was the only bisindolyl compound selected for the five 
dose screen. Although this compound had the highest mean growth of the compounds 
that went forward to five dose testing, low micromolar GI50 values were observed for a 
number of cell lines, especially in leukaemia and melanoma cancer types (Figure 
5.1.12). Most cell lines required a concentration of greater than 100 μM for the death of 
50% of cell population (LC50), with only 2 cell lines, SK-MEL-5 and UACC-62, 
showing any appreciable cytotoxicity (Table 5.1.7).  
 
                    
Figure 5.1.12: Dose response curves for bisindolyl derivative 282 
Biological Results and Discussion 
178 
 
Table 5.1.7: Selected GI50, TGI and LC50 values for 282 
 
5.1.2.2 Five dose data for indolocarbazoles 305 and 306 
 
GI50 values were observed at sub micromolar concentrations in a third of all cell lines 
for bis-methyl derivative 305, with the greatest activity observed in the leukaemia cell 
line SR, which had a GI50 value of just 73 nM (Table 5.1.8). Little cytotoxicity is 
observed across the panel, however, with all LC50 values being greater than 100 μM 
apart from CNS cancer cell line SNB-75. 
 
                  
Figure 5.1.13: Dose response curves for 305 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Leukaemia 
CCRF-CEM 0.302 >100 >100 
MOLT-4 0.376 >100 >100 
SR 0.073 >100 >100 
Renal Cancer 
ACHN 0.334 21.1 >100 
CAKI-1 0.402 >100 >100 
CNS Cancer SNB-75 11.3 30.0 79.2 
Table 5.1.8: Selected GI50, TGI and LC50 values for 305 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Leukaemia 
HL-60(TB) 2.54 6.44 >100 
SR 3.55 9.48 >100 
Melanoma 
MDA-MB-435 2.74 8.31 >100 
SK-MEL-5 2.92 10.6 42.8 
UACC-62 3.23 16.0 84.4 
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Monoaza derivative 326 showed similar dose-response curves to 305, with a similar 
number of sub micromolar GI50 values and with no LC50 values less than 100 μM.
4
 
However, bisaza derivative 236 was much more cytotoxic at higher concentrations with 
a quarter of all cell lines possessing LC50 values less than 100 μM and melanoma cell 
line SK-MEL-5 displaying the lowest at 813 nM. This compound was also more active 
at lower concentrations with almost all cell lines having GI50 values of less than 100 
nM. 
 
Despite being similar in structure to 305, bis-allyl derivative 306 exhibited much greater 
cytotoxicity at higher concentrations, with LC50 values for many cell lines in the low 
micromolar range. However, a marked drop-off in activity was observed between the 10 
μM and 1 μM levels, with only 4 cell lines possessing sub micromolar GI50 values 
(Table 5.1.9). Interestingly, both derivative 305 and 306 were most selective for 
leukaemia cell line SR with GI50 values of 73 nM and 363 nM, respectively. 
COMPARE analysis gave a correlation of 0.633 indicating only a moderate similarity in 
their biological mode of action. 
 
         
Figure 5.1.14: Dose response curves for 306 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Leukaemia 
CCRF-CEM 0.971 7.10 >100 
HL-60(TB) 2.09 4.31 8.86 
SR 0.363 5.67 >100 
Melanoma 
LOX IMVI 0.967 2.43 5.95 
SK-MEL-5 1.79 4.10 9.38 
Breast Cancer MCF7 0.674 29.9 >100 
Table 5.1.9: Selected GI50, TGI and LC50 values for 306 
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Pyrazolone 360 exhibited selective cytotoxicity at higher concentrations with two cell 
lines, SF-539 and RXF 393 (Table 5.1.10), possessing low micromolar LC50 values 
despite the majority having values greater than 100 μM. Most cell lines were found to 
have low micromolar GI50 values, although the three cell lines KM12, SNB-75 and 
HS578T displayed sub micromolar values. 
 
          
Figure 5.1.15: Dose-response curves for 360 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Colon cancer 
HCC-2998 2.74 8.10 >100 
KM12 0.493 10.5 47.2 
CNS cancer 
SF-539 1.22 3.12 7.99 
SNB-75 0.355 3.53 30.9 
Renal cancer RXF 393 1.51 3.57 8.49 
Breast cancer HS 578T 0.993 5.88 >100 
Table 5.1.10: Selected GI50, TGI and LC50 values for 360 
 
5.1.2.3 Five dose data for other 5-membered F-ring indolocarbazoles 
 
With the lowest mean growth of any of the compounds in the single dose screen, nitrile 
derivative 308 was a clear candidate for further biological evaluation. Notable cytotoxic 
activity was observed at higher concentrations with several cell lines possessing low 
micromolar LC50 values (Table 5.1.11). However, there is again a steep decrease in 
activity between the 10 μM and 100 nM levels. Notable selectivity was observed for 
non-small cell lung cancer cell line NCI-H522 compared to other cell lines of this 
cancer type, as in the single dose results. 
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Figure 5.1.16: Dose response curves for 308 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Non-small cell 
lung cancer 
NCI-H522 0.164 0.411 1.16 
Melanoma 
LOX IMVI 0.240 1.44 4.88 
M14 0.595 2.51 9.18 
MDA-MB-435 1.19 3.09 8.02 
SK-MEL-5 0.403 1.50 4.96 
Table 5.1.11: Selected GI50, TGI and LC50 values for 308 
 
Addition of a methyl group to form indolocarbazole 322 displayed a similar dose 
response curve to derivative 308. Many cell lines showed cytotoxic activity with low 
micromolar LC50 values but activity rapidly diminished with decreasing concentration 
(Table 5.1.12). Compound 308 and 322 both show selectivity for melanoma cell lines 
LOX IMVI and SK-MEL-5 which agrees with the single dose assay. 
 
          
Figure 5.1.17: Dose response curves for 322 
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Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Melanoma 
LOX IMVI 0.167 1.24 4.74 
SK-MEL-5 0.319 1.09 3.70 
UACC-62 0.465 2.03 7.85 
Renal Cancer 
ACHN 0.317 1.19 5.97 
UO-31 0.374 1.97 8.93 
Table 5.1.12: Selected GI50, TGI and LC50 values for 322 
 
Chloride 336 also had a similar growth response curve with significant cytotoxicity at 
higher concentrations which dropped off steeply towards the lower concentrations 
(Table 5.1.13). The curves were more atypical at lower concentrations with many cell 
lines showing an increase in activity at 100 nM compared to 1 μM (Figure 5.1.18). Due 
to this phenomenon, it was not possible to calculate GI50 values for some cell lines. 
Again, this compound showed selectivity for cell lines LOX IMVI and SK-MEL-5, as 
in the single dose screen. 
  
         
Figure 5.1.18: Dose response curves for 336 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Colon 
COLO 205 1.97 4.70 16.9 
HT29 1.73 3.25 6.12 
Melanoma 
LOX IMVI - 2.59 6.11 
SK-MEL-5 1.48 2.80 5.29 
UACC-62 1.69 4.42 16.1 
Table 5.1.13: Selected GI50, TGI and LC50 values for 336 
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Morpholine salt 338 displayed interesting selectivity towards individual cell lines 
especially at the 10 μM level (Figure 5.1.19). Percentage growth at this concentration 
ranged from -89% (LOX IMVI) to 102% (OVCAR-5), which correlates well with single 
dose data. Although many cell lines experienced a sharp drop-off in activity between 
the 10 μM and 1 μM levels, selectivity for a small number of cell lines remains 
especially for LOX IMVI (percentage growth at 1 μM = -12%). In fact 338 still 
completely inhibits growth (TGI) of LOX IMVI cells at 736 nM, while all other cell 
lines require a concentration of at least 2.85 μM to completely inhibit growth (Table 
5.1.14). 
 
          
Figure 5.1.19: Dose response curves for 338 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
CNS cancer 
SF-539 1.77 3.36 6.38 
SNB-75 1.44 18.5 59.9 
Melanoma 
LOX IMVI 0.210 0.736 3.11 
MALME-3M 1.74 3.76 8.10 
SK-MEL-28 1.96 4.02 8.25 
Renal cancer UO-31 1.38 2.85 5.86 
Table 5.1.14: Selected GI50, TGI and LC50 values for 338 
 
Morpholine amide 314 again displayed cytotoxic activity in a number of cell lines with 
several having low micromolar LC50 values (Table 5.1.15). However, a sharp drop-off 
in activity, similar to that in other compounds in this series, was observed between the 
10 μM and 1 μM levels. No sub-micromolar GI50 values were observed. 
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Figure 5.1.20: Dose response curves for 314 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Melanoma 
LOX IMVI 1.05 2.57 6.27 
SK-MEL-5 1.64 3.06 5.71 
Renal Cancer 
A498 2.07 2.70 5.66 
RXF 393 1.81 3.37 6.25 
Table 5.1.15: Selected GI50, TGI and LC50 values for 314 
 
For diethyl amide 315, significant selectivity was observed for colon cancer cell lines 
COLO 205 and HT29 and melanoma cell lines LOX IMVI and SK-MEL-5 at higher 
concentrations, with selectivity for LOX IMVI being retained to micromolar levels 
(Figure 5.1.21). Again, there was a considerable decrease in activity between the 10 μM 
and 1 μM levels. 
 
          
Figure 5.1.21: Dose response curves for 315 
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Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Colon Cancer 
COLO 205 1.97 4.23 9.09 
HT29 2.21 4.44 8.91 
Melanoma 
LOX IMVI 1.13 2.88 7.38 
SK-MEL-5 2.00 5.02 16.7 
Table 5.1.16: Selected GI50, TGI and LC50 values for 315 
 
5.1.2.4 Five dose data for indolocarbazoles with 6-membered F-rings 
 
Although less cytotoxicity was observed for hydroxyuracil 350 compared to the 
hydroxymaleimide series, cytostatic effects were evident at considerably lower 
concentrations with several cell lines possessing sub micromolar GI50 values (Table 
5.1.17). Greatest activity was seen in melanoma cell lines LOX IMVI and SK-MEL-5 
and a number of non-small cell lung cancer cell lines, which is consistent with the 
single dose screen. 
 
         
Figure 5.1.22: Dose response curves for 350 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
Non-small cell 
lung cancer 
NCI-H23 0.787 6.18 >100 
NCI-H460 0.457 2.39 16.9 
NCI-H522 0.934 47.7 >100 
Melanoma 
LOX IMVI 0.710 5.58 86.5 
SK-MEL-5 1.58 4.65 20.6 
Table 5.1.17: Selected GI50, TGI and LC50 values for 350 
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Despite having the same mean growth in the single dose assay as hydroxyuracil 350, 
uracil 352 showed much more selectivity towards individual cell lines. LC50 values 
ranged from >100 μM down to low micromolar values (Table 5.1.18). Excellent growth 
inhibition was observed against renal cancer cell line A498 which displayed a GI50 
value of just 48 nM, the lowest of any cell line for any of the compounds tested in this 
project. Most other cell lines possessed low micromolar GI50 values. 
 
         
Figure 5.1.23: Dose response curves for 352 
 
Cancer type Cell line GI50 (μM) TGI (μM) LC50 (μM) 
CNS Cancer 
SF-539 1.78 6.61 36.3 
SNB-75 1.49 3.27 7.19 
Renal Cancer 
A498 0.048 4.37 76.8 
UO-31 0.981 - >100 
Table 5.1.18: Selected GI50, TGI and LC50 values for 352 
 
5.1.3 Possible Modes of Action 
 
A number of cell lines consistently appeared to be most active across the panel of 
compounds and information on the known gene mutations and turnover rates of these 
cell lines was obtained.
9
 Cyclin-dependent kinase inhibitor 2 A (CDK2NA) mutations 
were very common, being present in almost all of the most affected cell lines, and 
BRAF and TP53 mutations were also common (Table 5.1.19). No correlation between 
activity and turnover rate was observed. 
  
Biological Results and Discussion 
187 
 
Cell line Gene mutations 
SR CDK2NA 
UO-31 CDK2NA 
LOX IMVI BRAF, CDK2NA 
HOP-92 CDK2NA, TP53 
NCI-H522 TP53 
SK-MEL-5 BRAF, CDK2NA 
CAKI-1 CDK2NA 
Table 5.1.19: Most commonly inhibited cell lines with their known gene mutations 
 
CDK2NA is a tumour suppressor gene which encodes an inhibitor of cyclin dependent 
kinases, indicating that derivatives which affect cells with this mutation could be active 
as inhibitors of a CDK kinase. BRAF is a proto-oncogene encoding a serine/threonine-
protein kinase inhibitor known as B-RAF, which is involved in the MAPK/ERK 
signalling pathway. Drugs that treat cancers possessing a BRAF mutation such as 
vemurafenib and dabrafenib have been approved, and work by interrupting certain steps 
in this pathway. TP53 encodes a major tumour suppressor protein, p53, which is critical 
for the prevention of cancer formation by initiating apoptosis when DNA damage is 
irreparable.  
 
Investigation using COMPARE analysis demonstrates a high correlation between bis-
methyl hydroxymaleimide indolocarbazole 305 and both camptothecin 33 and its 
derivative, topotecan 34, indicating a similar biological mode of action (Table 5.1.20). 
As camptothecin and its derivatives are known topo I inhibitors, this suggests that this 
indolocarbazole could interact with the same enzyme. 
  




Seed (NSC no.) Target Correlation 
305 (776701) topotecan 0.723 
305 (776701) camptothecin 0.780 
308 (781336) topotecan 0.679 
305 (776701) 350 (778804) 0.672 
350 (778804) topotecan 0.334 
Table 5.1.20: COMPARE analysis of indolocarbazole derivatives with camptothecin 33 and 
topotecan 34 
 
The hydroxymaleimide with a hexanenitrile N-substituent (308) also displayed a 
similarly high correlation to topotecan, again indicating action through topo I inhibition. 
Interestingly, hydroxy uracil 350 showed a low correlation to topotecan, despite 
demonstrating a high correlation to hydroxymaleimide 305, suggesting that changing 
the F-ring from a hydroxymaleimide to a hydroxy uracil removes the ability of the 
compound to act as a topo I inhibitor. This is an interesting result as the addition of 
bulky groups to a maleimide F-ring usually has no adverse effect on anti-topo I activity, 
as can be seen from rebeccamycin derivative edotecarin 46 (Figure 5.1.24) which has 
undergone several clinical trials and functions through topo I inhibition. 
 
 
Figure 5.1.24: Structure of edotecarin 46 
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5.2 Kinase Screen 
 
Kinase screening was carried out in collaboration with the Kinase Inhibitor Specialised 
Screening Facility (KISSf) in Station Biologique de Roscoff, France. Since 2001, KISSf 
has offered screening services for the assessment of the biological properties of small 
molecules using a panel of selected disease-related protein kinases. For potential 
anticancer agents, the panel consists of the following kinases: Ld_TLK, Hs_HASPIN, 
Hs_AURKB, Hs_RIPK3, Hs_CDK2/CyclinA, Hs_CDK5/p25, Hs_CDK9/CyclinT, 




To date the results of the kinase screen are available for seven compounds from the 
bisindolyl panel and are displayed in Table 5.2.1, with remaining compounds currently 
undergoing assessment. 
 
Inhibitory action for individual kinases is observed to a certain degree for all the 
compounds in the panel, except for macrocyclic 284 which shows no activity at the 
levels screened in this assay. This was unsurprising as this derivative was also 
completely inactive in the NCI screen, although it is related to ruboxistaurin. 
Ssc_GSK3α/β was the most commonly inhibited kinase, with the other six derivatives 
possessing IC50 values of between 1 and 3 μM. Inhibition of GSK-3β has been shown to 
have effects such as the reduction of apoptosis, making it potentially useful for the 
protection of Alzheimer’s disease and protection against cell death.
10,11
 More recently, a 
group of bisindolylmaleimide GSK-3β inhibitors have been used to show the 
involvement of GSK-3β in the regulation of murine embryonic stem cell self-renewal.
12
 
Although the activity of these derivatives is modest, this could be improved upon in 
future SAR studies. 
 
PIM1 kinase was also inhibited by the six derivatives, with IC50 values of less than 10 
μM. PIM1 is mainly involved in cell cycle progression, apoptosis and transcriptional 
activation, and also more general signal transduction pathways and is highly expressed 
in cell cultures isolated from human tumours.
13
 




 285 286 287 290 291 292 284 
R
1




 H Me Et H Me Et 
Mean Growth (10 μM)* 78.0% 97.6% - 94.4% 90.8% - 103.3% 
Kinase IC50 (μM) 
Ld_TLK >10 >10 >10 >10 >10 >10 >10 
Hs_HASPIN >10 >10 >10 >10 >10 >10 >10 
Hs_AURKB >10 >10 >10 >10 >10 >10 >10 
Hs_RIPK3 >10 >10 >10 >10 >10 >10 >10 
Hs_CDK2/CyclinA >10 >10 >10 >10 6.0 >10 >10 
Hs_CDK5/p25 >10 >10 >10 >10 8.0 >10 >10 
Hs_CDK9/CyclinT 8 >10 9.2 >10 5.0 6 >10 
Mm_CLK1 2 >10 >10 >10 >10 >10 >10 
Hs_DYRK1A >10 >10 >10 >10 >10 >10 >10 
Ssc_GSK3α/β 1 3 1.9 3.0 1.2 2 >10 
Pf_GSK3 >10 >10 >10 >10 >10 >10 >10 
Hs_PIM1 3 8 6.5 5.6 7.0 8 >10 
Ssc_CK1δ/ε >10 >10 >10 >10 >10 >10 >10 
*From NCI single dose screen 
Table 5.2.1: IC50 values of bisindolyl compounds in kinase inhibition assay 
 
 
Although with the limited number of compounds screened so far it is difficult to predict 
the structure-activity relationships, the results of the remaining compounds in this 
kinase assay are eagerly awaited, especially for a number of the indolocarbazole 
derivatives which displayed significant activity and selectivity in the NCI screen.   
  





A total of 37 bisindole and indolocarbazole compounds have been submitted to the NCI 
for screening to date, with 12 compounds judged to have sufficient activity or 
selectivity to progress to five dose testing. Although not as detailed as the five dose 
assay, the single dose screen provided much information on the chemotherapeutic 
potential of these compounds, with a number of promising leads for future work. Little 
anticancer activity was observed in the compounds tested from the bisindole series, with 
only bis-hexanenitrile derivative 282 being selected for five dose screening. The 
indolocarbazoles were generally much more active, with highly cytotoxic activity being 
displayed by several derivatives against a number of cell lines and with eleven in total 
progressing to the five dose screen.  
 
It was apparent that both F-ring modulation and variation of N-substituents had a 
profound effect on the anticancer activity of these compounds. Removal of the F-ring 
hydroxy group combined with replacement of one carbonyl to form pyrazolone 360 
caused a considerable increase in activity compared to its hydroxymaleimide 
counterpart 298. Also the addition of an extra nitrogen atom to the maleimide F-ring 
formed a series of uracil derivatives with significantly different antiproliferative 
profiles. Similarly, very small changes to the N-substituents greatly impacted on the 
single dose data obtained for different candidates. For example, switching from a 
hexanenitrile (308) to a hexylmorpholine (338) substituent causes an increase in mean 
growth from -7% to 63%.  
 
The results from five dose assays on the twelve selected derivatives provided further 
information on biological activity of these compounds. Many of the compounds are 
highly cytotoxic towards specific cell lines at higher concentrations but suffer from a 
drop-off in potency at lower concentrations. However, this decrease in activity is an 
issue which could be addressed with further SAR studies. Despite this, most compounds 
displayed sub-micromolar GI50 values in a number of cell lines with two compounds 
(hydroxymaleimide 305 and uracil 352) exhibiting GI50 values of <100 nM against one 
of the cell lines.  
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Analysis using the COMPARE algorithm showed a strong correlation between two of 
the hydroxymaleimide analogues (305 and 308) and topotecan, indicating the ability of 
these compounds to act as topo I inhibitors. Interestingly, this correlation was not 
retained for the uracil derivatives, which indicated that changing from a five-membered 
to a six-membered F-ring can switch the mechanism of action of these compounds 
while maintaining anticancer activity. Examination of the known gene mutations in the 
cancer cell lines most commonly affected by the compounds tested showed that cell 
lines containing a CDK2NA, BRAF or TP53 mutation were most commonly affected. 
 
To date, seven bisindolylmaleimide derivatives have undergone kinase screening 
against a panel of kinases associated with cancer, with six of the compounds showing 
kinase inhibition at low micromolar concentrations for certain kinases. These results are 
interesting given the low cytotoxicity observed in the NCI screen indicating that this 
type of compound could be used to regulate certain kinase activities without affecting 
cell growth.   
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6 Current Perspectives 
  
Current Perspectives 




The overall objective of this project was to produce selective and highly potent novel 
anticancer agents of structure 378. Three synthetic routes were developed involving 
maleic anhydride 379, β-keto ester 380, or dione 381 intermediates in order to advance 
our goal of diversity-oriented synthesis. In total, a panel of 42 novel potential anticancer 





A route was designed from a maleic anhydride intermediate, formed using Perkin-type 
methodology and this route was utilised to synthesise a panel of both symmetrically and 
unsymmetrically substituted bisindolyl derivatives. Progression of this synthetic 
strategy included the addition of an oxidative cyclisation step to form an 
indolocarbazole intermediate, which was subsequently used to synthesise a panel of 
both symmetrically and unsymmetrically substituted indolocarbazoles, later to prove of 
considerable biological interest. Previous work in the field focussed on routes where the 
cyclisation to the indolocarbazole is the final step in the synthesis. This path is limited 
as the cyclisation of flexible bisindolyl precursors often proves to be a challenging 
transformation. The strategy reported in this thesis overcomes this issue by achieving 
this conversion earlier in the route to form a highly versatile indolocarbazole 
intermediate from which a wide range of derivatives with both 5- and 6-membered F-





A reliable, high-yielding Lossen rearrangement step was developed to form the novel 
six-membered rings in this route from hydroxymaleimide derivatives, the first time this 
type of rearrangement has been achieved with such a sterically hindered substrate. This 
methodology was used to synthesise a panel of novel indolocarbazoles with uracil 
headgroups which is also the first time the synthesis of a panel of indolocarbazoles with 
6-membered F-rings has been accomplished.   
 
This route was also adapted to synthesise derivatives with mono-N-substitution and both 
symmetrical and asymmetrical bis-N-substitution to incorporate a wide range of 
functional groups. Derivatives with alkyl substituents were synthesised to investigate 
the effects of added lipophilicity and derivatives with more polar side-chains were 
synthesised to investigate the effects of additional hydrophilicity and solubility.  
 
A second route was utilised to expand the theme of F-ring modulation to synthesise 
both bisindolyl and indolocarbazole analogues with a pyrazolone or isocytosine 
headgroup. Further advancement of a route containing a β-keto ester intermediate, 
previously developed within the group, was achieved to include a nitrile chain and a 
cleavable protecting group.
1,2
 This resulted in an indolocarbazole with a pyrazolone 
headgroup being synthesised for the first time and also the first synthesis of pyrazolone 
analogues with an unsubstituted indole nitrogen. The first synthesis of an 
indolocarbazole with an isocytosine headgroup and a non-methyl N-substituent was also 
accomplished. Work on a further route involving a dione intermediate resulted in the 
first isolation of a bisindolyl imidazole derivative. 
 
As the vast majority of compounds reported in the literature possess either a lactam or 
maleimide F-ring, modification of this F-ring was one of the main aims of this project. 
Work towards the replacement of this key H-bonding structure within these molecules 
resulted in the formation of analogues with ten different F-rings possessing a range of 
H-bonding motifs (Figure 6.1.1). Heterocyclic elaboration of this ring aimed to expand 
the H-bonding network within the ligand-enzyme complex and exploit discrete 
differences in the active sites of protein kinases. This was undertaken to probe the 
molecular space within proposed binding pockets and to discover key new features of 
the SAR of these indolocarbazole analogues.  
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Figure 6.1.1: F-rings containing novel H-bonding motifs 
 
Preliminary biological evaluation of both bisindole and indolocarbazole derivatives was 
achieved using the NCI-60 cell screen. This has led to the identification of several lead 
compounds with high cytotoxicity and excellent selectivity profiles. Of the 37 
compounds submitted for the single dose screen, 12 were selected to progress to five 
dose testing, representing a very high success rate. Lead compounds from the NCI 
results include hydroxymaleimide 305 and uracil 352 which possessed nanomolar GI50 
values against specific cancer cell lines, and hydroxymaleimides 308 and 336, and 
pyrazolone 360 which displayed low mean growths across the panel and also selective 
























Figure 6.1.2: Novel indolocarbazole derivatives with anticancer activity 
 
Evaluation against a panel of kinases has also been completed for a number of the 
bisindole derivatives which has demonstrated noteworthy selectivity towards GSK3α/β 
and PIM1 kinases, with low micromolar IC50 values being observed for these enzymes.  
 
6.2 Future Work 
 
Solubility is a significant issue in the future development of indolocarbazoles as clinical 
candidates. This problem could be addressed by adding solubilising chains on the indole 
nitrogens and also on the hydroxy group on the hydroxymaleimide headgroup as 
Mean growth (10 μM) 
= 32.9% 
Leukaemia SR GI50 
 = 73 nM 
Mean growth (10 μM) = 23.4% 
Selective cytotoxicity 
CNS SF-539 LC50 = 7.99 μM 
Renal RXF 393 LC50 = 8.49 μM 
Mean growth (10 μM)  
= 35.3% 
Renal cancer A498 GI50  
= 48 nM 
Mean growth (10 μM) = -7.0% 
Selective cytotoxicity 
NSCLC NCI-H522 LC50 = 1.16 μM 
Submicromolar GI50 values 
Mean growth (10 μM) = 4.2% 
Selective cytotoxicity 
Melanoma LOX IMVI LC50 = 6.11 μM 
SK-MEL-5 LC50 = 5.29 μM 
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initiated in this work. As the addition of a hexanenitrile chain to the hydroxymaleimide 
was seen to improve activity, this could be a very useful site for the introduction of 
solubilising groups. The formation of N-glycosidic analogues of compound classes in 
this work to mimic staurosporine and rebeccamycin would also be worthwhile to 
evaluate the effect on their solubility and biological properties. 
 
Pyrazolone derivative 360 displayed a much lower mean growth in the NCI-60 cell 
screen compared to its hydroxymaleimide counterpart, providing a lead compound for 
future work. As the incorporation of a hexanenitrile chain greatly increased activity 
compared to a methyl substituent, it is envisaged that a side chain would increase 
potency and solubility (Figure 6.2.1). The synthesis of the regioisomers of these 





The incorporation of an amine salt functionality to the extended chain N-substituent on 
the hydroxymaleimide indolocarbazole template conferred admirable selectivity 
towards a number of cancer cell lines with the NCI-60 cell screen. It is envisaged that 
further SAR study would examine the use of other amines in place of the morpholine 








Given the interesting and potent activity of uracil 352 in NCI screening, it should also 
function as a lead compound for future work. To expand the panel of indolocarbazoles 
with 6-membered F-rings, the uracil 382 could be converted to a dichloropyrimidine 
383 which could then be reacted with a range of different nucleophiles to form a series 
of substituted pyrimidines 384 (Scheme 6.2.1). 
 
 
Scheme 6.2.1: Proposed synthesis of novel pyrimidine derivatives 
Much potential remains in the field of indolocarbazole chemistry for further F-ring 
modulation in order to diversify H-bonding networks between the molecule and the 
enzyme active site which can lead to derivatives with unique bioactivity profiles. For 
example, the synthesis of a bisindolyl ethyne intermediate 385 could allow access to a 
variety of novel F-rings through reaction with different 1,3-dipoles such as triazoles 386 
through reaction with azides (Scheme 6.2.2). 
  
 
Scheme 6.2.2: Proposed synthesis of bisindolyl derivatives via 1,3 dipolar cycloaddition 
 
Due to time constraints, some of the biological results from the kinase screen were not 
available for inclusion in this thesis. This testing is currently underway and the results 
for the remaining compounds are keenly anticipated. As a number of these derivatives 
were highly active in NCI screening, it is envisaged that these results will provide 
further insight into the biological mode of action of these compounds. 
 
Overall, this project has investigated many different aspects of both the indolocarbazole 
and bisindolylmaleimide pharmacophores and their potential as anticancer agents. It is 
interesting to note that on COMPARE analysis hydroxymaleimide 305, pyrazolone 360 
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or uracil 352 showed low correlations to the current indolocarbazoles in the NCI 
database, including similar compounds synthesised previously within the group even 
though the potency is upheld. This further demonstrates how small changes to the 
structure of the molecules can cause significant effects in the mode of ligand interaction 
with target enzymes. It is evident from the biological results obtained to date that huge 
potential exists within this class of compounds as chemotherapeutic agents and 
combined results from NCI-60 cell line, topo I and kinase screening should be used for 
the rational design of next-generation indolocarbazole derivatives, hopefully ultimately 
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7.1 General Procedures 
 
All solvents were distilled prior to use by the following methods: dichloromethane was 
distilled from phosphorus pentoxide, ethyl acetate was distilled from potassium 
carbonate, hexane was distilled prior to use, methanol was distilled from magnesium in 
the presence of iodine and stored over 3 Å molecular sieves, tetrahydrofuran was 
freshly distilled from sodium and benzophenone. Anhydrous dimethylformamide was 
obtained from Sigma or Acros and stored under nitrogen. Molecular sieves were dried 
by heating to 140 °C for 24 hours. Organic phases were dried over anhydrous 
magnesium sulfate. 
 
All commercial reagents were used without further purification unless stated otherwise. 
Commercially obtained n-butyllithium was titrated prior to use using the Gilman double 
titration
1,2
 as follows: n-butyllithium solution (1.0 mL) was added dropwise via syringe 
to a 100 mL conical flask containing water (25 mL). A second flask, containing dry 
dibromoethane (~2 mL, dried over molecular sieves) stoppered with a SubaSeal and 
flushed with nitrogen with provision for pressure release was also treated dropwise with 
n-butyllithium (1.0 mL). Two drops of phenolphthalein were added to the first flask and 
the solution was titrated with 0.1 M aqueous HCl (standard solution) until the pink 
colour permanently disappeared. The SubaSeal was removed from the second flask and 
water (~25 mL) was added, along with 2 drops of phenolphthalein and titrated as before. 
(Note: this flask was biphasic and required constant swirling.) The first titre is total base 
(n-BuLi + inorganic base) and the second is the free base (inorganic base). Thus, (titre 1 
– titre 2) × molarity of HCl = the molarity of the n-butyllithium solution. 
 
In reactions with n-butyllithium the glassware was flame-dried under nitrogen 
atmosphere prior to use. For smaller quantities (<10 mL) glass syringes were used to 
transfer reagents. For larger quantities (>10 mL) an addition funnel was calibrated to the 
desired volume prior to flame-drying and the reagent was transferred directly from the 
bottle to the addition funnel via cannula. 
 
Low temperature reactions were carried out with cooling mixtures as follows: -10 to -15 




reactions were carried out in a three-necked round-bottomed flask, fitted with a low 
temperature thermometer. The temperatures reported are internal temperatures. 
 
Photochemical reactions were carried out using a Philips HPL-N 80W/542 mercury 
lamp. The reaction flask was fitted with a condenser and the lamp was placed as close 
as possible to the flask. The entire apparatus was wrapped in aluminium foil prior to 
switching on the lamp. 
 
1
H (300 MHz) and 
13
C (75 MHz) NMR spectra were recorded on a Bruker Avance 300 
NMR spectrometer. 
1
H (400 MHz) NMR spectra were recorded on a Bruker Avance 
400 MHz spectrometer. 
13
C (125 MHz) NMR spectra were recorded on a Bruker 
Avance 500 MHz spectrometer. 
1
H (600 MHz) and 
13
C (150 MHz) NMR spectra were 
recorded on a BrukerAvance III 600 MHz spectrometer equipped with a dual CH 
cryoprobe. All spectra were recorded at 20 °C in deuterated dimethylsulfoxide (DMSO-
d6) or deuterated chloroform (CDCl3) using tetramethylsilane (TMS) as an internal 
standard unless otherwise stated. Chemical shifts (δH and δC) are reported in parts per 
million (ppm) relative to the reference peak and coupling constants (J) are expressed in 
Hertz (Hz). Splitting patterns in 
1
H spectra are designated as s (singlet), bs (broad 
singlet), d (doublet), bd (broad doublet), t (triplet), q (quartet), quin (quintet), sept 
(septet), dd (doublet of doublets), dt (doublet of triplets), ddd (doublet of doublet of 
doublets), ddt (doublet of doublet of triplets) and (m) multiplet. COSY (Correlation 
Spectroscopy) and HMBC (Heteronuclear Multiple-Bond Correlation) experiments 
were used to assign ambiguous 
1
H NMR spectra. Carbon spectra were assigned (CH, 
CH2, CH3) with the aid of DEPT (Distortionless Enhancement by Polarisation Transfer) 
experiments.  
  
Infrared spectra were recorded as thin films on sodium chloride plates for oils or as 
potassium bromide (KBr) discs for solids on a Perkin Elmer Spectrum 100 FT-IR 
spectrometer or a Perkin Elmer Spectrum One FT-IR spectrometer.  
 
Nominal mass spectra were recorded on a Waters Quattro Micro triple quadrupole 
spectrometer (QAA1202) in ESI mode using 50% acetonitrile – water containing 0.1% 
formic acid as eluent. High resolution mass spectra (HRMS) were recorded on a Waters 
LCT Premier Time of Flight spectrometer (KD160) in ESI mode using 50% acetonitrile 
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– water containing 0.1% formic acid as eluent. Samples (max. 1 mg) were dissolved in 
acetonitrile, methanol or 1:1 acetonitrile – methanol. 
 
Melting points were measured on a uni-melt Thomas Hoover capillary melting point 
apparatus and are uncorrected. Thin layer chromatography (TLC) was carried out on 
precoated silica gel plates (Merck 60 PF254) or aluminium oxide TLC plates (Sigma). 
Visualisation was achieved by UV light detection (254 and 366 nm). Wet flash column 





7.2 Synthesis and derivatisation of 1-hydroxy-3,4-di(1H-indol-3-yl)-
1H-pyrrole-2,5-diones 
 






To a stirred solution of indol-3-acetic acid 254 (20.011 g, 114 mmol) in 
THF (200 mL) under a nitrogen atmosphere at -70°C was added n-
butyllithium (2.5 M in hexanes, 96 mL, 240 mmol) while maintaining 
the temperature below -70 °C. The mixture was stirred for 1 hour at 
this temperature before a solution of benzenesulfonyl chloride (14.6 
mL, 20.2 g, 240 mmol) in THF (50 mL) was added slowly. Following addition, the 
reaction vessel was allowed to warm to room temperature over ~1 hour and stirred at 
this temperature for a further 16 hours. Water (10 mL) was then added to quench the 
reaction and the solvent was evaporated under reduced pressure. The residue was 
dissolved in ethyl acetate (200 mL) and the organic layer was then washed with 1 M 
aqueous HCl (100 mL × 2), followed by water (120 mL), before being dried over 
anhydrous magnesium sulfate and the solvent evaporated under reduced pressure to 
form a brown solid. Recrystallisation from ethyl acetate gave product as an off-white 
solid (32.210 g, 90%): m.p. 176-178 
o




 (KBr) 3388, 
3055, 1710, 1448, 1362, 1173; δH (300 MHz, DMSO-d6) 3.71 [2H, s, CH2], 7.26 [1H, t, 
J 7.5, C(6)-H], 7.36 [1H, ddd, J 7.5, 7.2, 1.1, C(5)-H], 7.53-7.61 [3H, m, C(3′, 5′, 7)-H], 
7.69 [1H, m, C(4′)-H], 7.74 [1H, s, C(2)-H], 7.92-7.98 [3H, m, C(2′, 6′, 4)-H], 12.47 










To a solution of indole 251 (10.021 g, 85.5 mmol) in diethyl ether 
(150 mL) was added oxalyl chloride (11.0 mL, 16.3 g, 128 mmol) 
dropwise over 10 minutes and the yellow suspension was allowed to 
stir for a further 30 minutes. Saturated aqueous sodium bicarbonate (20 mL) was then 
added with caution and the biphasic mixture was stirred for 16 hours. The product was 
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then collected using vacuum filtration, washed with diethyl ether and dried overnight at 
40
 





 (KBr) 3549, 3195, 1719, 1611, 1268; δH (300 MHz, DMSO-d6) 7.26 [1H, ddd, 
J 9.1, 7.1, 1.7, C(5)-H], 7.29 [1H, ddd, J 9.3, 7.1, 1.9, C(6)-H], 7.52-7.58 [1H, m, C(7)-











A solution of 2-(1H-indol-3-yl)-2-oxoacetic acid 252 (14.205 g, 75.1 
mmol) in ethanol (280 mL) was treated with potassium hydroxide (85 
wt. %, 4.958 g, 75.1 mmol) and stirred at room temperature for 4 
hours. The product was then collected using vacuum filtration and dried overnight at 40
 
°C to give a white solid (14.507 g, 85%): m.p. 291-293 °C (decomposition); νmax/cm
-1
 
(KBr) 3649, 3392, 1632, 1614, 1114; δH (300 MHz, DMSO-d6) 7.12 [1H, ddd, J 8.6, 
7.1, 1.5, C(5)-H], 7.16 [1H, ddd, J 8.8, 7.1, 1.7, C(6)-H], 7.46 [1H, d, J 6.7, C(7)-H], 









A mixture of potassium 2-(1H-indol-3-yl)-2-oxoacetate 253 
(3.677 g, 15.8 mmol), 2-[1-(phenylsulfonyl)-1H-indol-3-
yl]acetic acid 256 (5.020 g, 15.8 mmol) and acetic anhydride 
(30 mL) was stirred at 80
 
°C for 24 hours. The yellow 
suspension was then cooled to room temperature and filtered. 
The solid collected was stirred in boiling ethyl acetate for 30 
minutes before hot filtration removed a white side product. The yellow filtrate was 
concentrated to dryness giving a yellow crystalline solid (2.426 g). The acetic anhydride 
solution from the initial filtration was concentrated under reduced pressure. The residue 
was then washed with saturated sodium bicarbonate solution (50 mL) and extracted into 
ethyl acetate (3 × 30 mL). The organic layer was filtered before being washed with 
saturated sodium bicarbonate solution (30 mL), followed by water (30 mL) and brine 




evaporated under reduced pressure. The crude residue was recrystallised from ethyl 
acetate to give additional product (0.544 g, combined yield 2.970 g, 40%): m.p. 223-225 
°C; νmax/cm
-1
 (KBr) 3139, 1830, 1762, 1718, 1373, 1176; δH (300 MHz, DMSO-d6) 2.69 
(3H, s, CH3), 6.44 [1H, t, J 7.4, C(6′)-H], 6.59 [1H, d, J 7.8, C(7′)-H], 6.95 [1H, t, J 7.3, 
C(6)-H], 7.03 [1H, d, J 7.6, C(7)-H], 7.16 [1H, t, J 7.8, C(5′)-H], 7.27 [1H, t, J 7.7, 
C(5)-H], 7.61-7.71 [2H, m, C(3′′, 5′′)-H], 7.75-7.85 [1H, t, J 7.4, C(4′′)-H], 7.93 [1H, d, 
J 8.6, C(4)-H], 7.98-8.06 [2H, m, C(2′′, 6′′)-H], 8.19 [1H, s, C(2)-H], 8.26 [1H, d, J 8.3, 
C(4′)-H], 8.30 [1H, s, C(2′)-H]; δC (75 MHz, DMSO-d6) 23.9 (CH3), 109.3 (C, aromatic 
C), 111.2 (C, aromatic C), 113.1 (CH, aromatic CH), 115.9 (CH, aromatic CH), 120.5 
(CH, aromatic CH), 121.6 (CH, aromatic CH), 123.1 (CH, aromatic CH), 123.7 (CH, 
aromatic CH), 125.4 (CH, aromatic CH), 125.7 (CH, aromatic CH), 126.6 (C, aromatic 
C), 126.9 (2CH, 2 × aromatic CH), 127.6 (C, aromatic C), 129.6 (CH, aromatic CH), 
130.1 (2CH, 2 × aromatic CH, C, aromatic C), 130.8 (CH, aromatic CH), 131.4 (C, 
aromatic C), 133.6 (C, aromatic C), 134.7 (C, aromatic C), 135.2 (CH, aromatic CH), 





 10%]; HRMS (ESI
+








yl]furan-2,5-dione 257 (0.599 g, 1.17 mmol) was suspended in 
methanol (20 mL) and water (5 mL) and potassium carbonate 
(0.812 g, 5.85 mmol) was added. The mixture was stirred for 1 
hour eventually forming an orange solution. The solvent was 
then removed under reduced pressure and the residue dissolved 
in water (20 mL) before being acidified with 10% aqueous HCl to pH 2 and extracted 
into ethyl acetate (2 × 20 mL). The combined organic layers were washed with water (3 
× 20 mL) before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure to give an orange solid (0.517 g, 92%): m.p. 220-221 
°C; νmax/cm
-1
 (KBr); 3391, 1819, 1746, 1537, 1381, 1177, 1131; δH (300 MHz, DMSO-
d6) 6.16 [1H, ddd, J 8.1, 7.1, 0.9, C(6′)-H], 6.37 [1H, d, J 8.0, C(7′)-H], 6.88-6.99 [3H, 
m, C(5′, 6, 7)-H], 7.25 [1H, ddd, J 8.4, 6.9, 1.6, C(5)-H], 7.34 [1H, d, J 8.1, C(4)-H], 
7.62-7.72 [2H, m, C(3′′, 5′′)-H], 7.81 [1H, m, C(4′′)-H], 7.95 [1H, d, J 8.5, C(4′)-H], 
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8.02-8.07 [2H, m, C(2′′, 6′′)-H], 8.09 [1H, s, C(2)-H], 8.12 [1H, s, C(2′)-H], 12.18 (1H, 
bs, N-H) δH (300 MHz, DMSO-d6); δc (75 MHz, DMSO-d6) 104.6 (C, aromatic C), 
112.1 (C, aromatic C), 112.4 (CH, aromatic CH), 113.1 (CH, aromatic CH), 120.2 (CH, 
aromatic CH), 120.4 (CH, aromatic CH), 121.7 (CH, aromatic CH), 122.3 (C, aromatic 
C), 122.4 (CH, aromatic CH), 123.4 (CH, aromatic CH), 124.4 (C, aromatic C), 125.4 
(CH, aromatic CH), 126.9 (2CH, 2 × aromatic CH), 128.3 (C, aromatic C), 128.4 (CH, 
aromatic CH), 130.0 (2CH, 2 × aromatic CH), 132.3 (CH, aromatic CH), 133.5 (C, 
aromatic C), 134.7 (C, aromatic C), 135.0 (CH, aromatic CH), 136.2 (C, aromatic C), 







): Exact mass calculated for (C26H17N2O5S)
+






A suspension of 3-(1-acetyl-1H-indol-3-yl)-4-[1-
(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 257 (3.611 g, 
7.07 mmol) in a mixture of methanol (100 mL) and water (25 
mL) was treated with potassium hydroxide (85 wt. %, 2.774 g, 
42.4 mmol) and the mixture was heated to reflux for 24 hours. The reaction mixture was 
allowed to cool to room temperature and the solvent evaporated under reduced pressure. 
The residue was acidified to pH 2 using 20% aqueous HCl and extracted using ethyl 
acetate (100 mL). The organic layer was washed once with 1 M aqueous HCl (50 mL), 
followed by water (2 × 50 mL) and brine (50 mL) before being dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under reduced pressure to give a 
red foamy residue. The residue was dissolved in chloroform, allowed to crystallise and 
the red crystalline solid was collected by vacuum filtration (1.981 g, 85%): m.p. 227-




 (KBr) 3389, 1819, 1750, 1530, 1427, 1253; δH 
(300 MHz, DMSO-d6) 6.71 [t, J 7.4, C(6, 6′)-H], 6.86 [d, J 7.9, C(7, 7′)-H], 7.04 [t, J 















To a stirred solution of indole 251 (2.002 g, 17.1 mmol) in anhydrous DMF 
(90 mL) was added sodium hydride (60 wt. % oil dispersion, 1.367 g, 34.2 
mmol) at 0°C under nitrogen and the mixture was stirred for 30 minutes. 
Methyl iodide (1.80 mL, 4.10 g, 28.9 mmol) was then added before the mixture was 
allowed to warm to room temperature and stirred for a further 3 hours. Water (120 mL) 
was then cautiously added and the mixture was extracted with ethyl acetate (3 × 50 
mL). The combined organic layers were washed with 1 M aqueous HCl (3 × 50 mL) 
followed by water (2 × 50 mL) before being dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated to give a pale yellow oil (2.137 g, 95%) which was 
used without further purification: νmax/cm
-1
 (NaCl) 3054, 2917, 1614, 1513, 1316, 1242; 
δH (300 MHz, CDCl3) 3.78 [3H, s, N-CH3], 6.48 [1H, dd, J 3.1, 0.8, C(3)-H], 7.03 [1H, 
d, J 3.1, C(2)-H], 7.10 [1H, ddd, J 8.0, 7.0, 1.1, C(5)-H], 7.22 [1H, ddd, J 8.0, 7.2, 1.1, 











To a solution of 1-methyl-1H-indole 148 (4.503 g, 34.3 mmol) in 
diethyl ether (60 mL) was added oxalyl chloride (4.40 mL, 6.51 g, 
51.5 mmol), dropwise, over 10 minutes. The yellow suspension was 
then stirred for a further 30 minutes. Saturated sodium bicarbonate solution (10 mL) 
was added with caution and the biphasic mixture was stirred for 16 hours. The product 
was collected using vacuum filtration, washed with diethyl ether and dried overnight at 
40
 
°C to give a pale yellow solid (5.158 g, 74%): m.p. 157-158 °C; νmax/cm
-1
 (KBr) 
3249, 3145, 1754, 1619, 1521, 1308, 1210; δH (400 MHz, DMSO-d6) 3.92 (s, CH3), 
7.32 [1H, ddd, J 8.4, 7.2, 1.1, C(5,)-H], 7.36 [1H, ddd, J 8.6, 7.2, 1.4, C(6)-H], 7.61 
[1H, d, J 7.3, C(7)-H], 8.20 [1H, dd, J 7.0, 1.4, C(4)-H], 8.49 [1H, s, C(2)-H], 13.89 
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Potassium 2-(1-methyl-1H-indol-3-yl)-2-oxoacetate 261 
 
A solution of 2-(1-methyl-1H-indol-3-yl)-2-oxoacetic acid 259 (5.011 
g, 24.6 mmol) in ethanol (120 mL) was treated with potassium 
hydroxide (85 wt. %, 1.620 g, 24.6 mmol) and stirred at room 
temperature for 4 hours. The product was then collected using vacuum filtration and 
dried overnight at 40
 
°C to give a white solid (5.646 g, 95%): m.p. >300 °C; νmax/cm
-1
 
(KBr) 3420, 3047, 1623, 1520, 1361, 1204, 1084; δH (400 MHz, DMSO-d6) 3.84 (1H, s, 
CH3), 7.18 [1H, t, J 7.4, C(5)-H], 7.24 [1H, t, J 7.5, C(6)-H], 7.49 [1H, d, J 8.0, C(7)-
H], 8.12 [1H, s, C(2)-H], 8.18 [1H, d, J 7.5, C(4)-H]; δc (75 MHz, DMSO-d6) 32.9 
(CH3), 110.3 (CH, aromatic CH), 113.0 (C, aromatic C), 121.3 (CH, aromatic CH), 
121.4 (CH, aromatic CH), 122.3 (CH, aromatic CH), 126.3 (C, aromatic C), 137.0 (C, 





 20%]. HRMS (ESI
+









To a stirred suspension of sodium hydride (60 wt.% oil suspension, 
7.202 g, 180 mmol) in dry THF (200 mL) at 0 °C under a nitrogen 
atmosphere was added dropwise a solution of indole-3-acetic acid 254 
(10.211 g, 58.3 mmol) in dry THF (50 mL). The mixture was stirred for 30 minutes at 
this temperature before a solution of iodomethane (5.60 mL, 12.77 g, 90.0 mmol) in 
THF (30 mL) was added. The mixture was stirred for 16 hours while warming slowly to 
room temperature. Methanol (10 mL) was then added to quench the reaction, followed 
by water (150 mL). The aqueous solution was washed with diethyl ether (100 mL) 
before being acidified to pH 2 using 10% HCl. The aqueous layer was extracted with 
DCM (3 × 100 mL) and the combined DCM layers were washed with water (150 mL), 
before being dried over anhydrous magnesium sulfate and filtered. The solvent was 
reduced to approximately 50 mL before hexane was added until the solution remained 
cloudy and the mixture was allowed to stand for 16 hours. The precipitate was then 
collected to give desired compound as a light brown solid (6.751 g, 64%): m.p. 126-127 




 (KBr) 2927, 2676, 1698, 1474, 1412, 1304, 941; δH 




1.0, C(5)-H], 7.15 [1H, ddd, J 8.2, 7.0, 1.1, C(6)-H], 7.22 [1H, s, C(2)-H], 7.39 [1H, d, J 













A mixture of potassium 2-(1-methyl-1H-indol-3-yl)-2-
oxoacetate 261 (4.605 g, 19.0 mmol) and 2-[1-
(phenylsulfonyl)-1H-indol-3-yl]acetic acid 256 (6.002 g, 19.0 
mmol) were suspended in acetic anhydride (30 mL) and heated 
to 80 °C for 24 hours. The resulting orange suspension was 
allowed to cool and the solvent evaporated under reduced 
pressure. The residue was washed with saturated aqueous sodium bicarbonate (60 mL) 
before being extracted into ethyl acetate (2 × 40 mL). The organic layer was washed 
with saturated aqueous sodium bicarbonate (4 × 30 mL), followed by water (40 mL), 
before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure. The crude material was purified using column 
chromatography on silica gel with 20% ethyl acetate/hexane to give an orange foamy 
residue. The residue was dissolved in chloroform (20 mL) and diethyl ether was added 
until an orange solid precipitated which was collected by vacuum filtration (2.822 g, 




 (KBr) 3418, 2924, 1822, 
1756, 1634, 1374, 1176; δH (300 MHz, DMSO-d6) 3.92 (3H, s, CH3), 6.16 [1H, t, J 7.6, 
C(6′)-H], 6.29 [1H, d, J 8.0, C(7′)-H], 6.92 [1H, ddd, J 7.9, 7.2, 0.7, C(6)-H], 6.98-7.05 
[2H, m, C(5′, 7)-H], 7.26 [1H, ddd, J 8.4, 7.2, 1.3, C(5)-H], 7.45 [1H, d, J 8.2, C(4′)-H], 
7.64-7.71 [2H, m, C(3′′,5′′)-H], 7.82 [1H, m, C(4′′)-H], 7.96 [1H, d, J 8.3, C(4)-H], 








To a solution of 3-(1H-indol-3-yl)-4-[1-(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 
267 (0.101 g, 0.216 mmol) in anhydrous DMF (8 mL) in a flame-dried flask under 
nitrogen was added sodium hydride (0.010 g, 0.260 mmol) and the mixture was stirred 
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for 30 minutes at room temperature. Iodomethane (0.02 mL, 0.05 g, 0.34 mmol) was 
then added and the mixture was stirred for a further 4 hours. The reaction mixture was 
then poured into water (30 mL) and extracted with ethyl acetate (3 × 20 mL). The 
organic layer was washed with 1 M aqueous HCl (3 × 20 mL), followed by water (20 
mL) before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure to give desired product as an orange foamy solid 






Method A  
To a stirred suspension of 3-(1-methyl-1H-indol-3-yl)-4-[1-
(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 263 (3.930 g, 
8.14 mmol) in methanol (100 mL) and water (25 mL) was 
added potassium hydroxide (2.691 g, 4.07 mmol) and the 
resulting solution was heated to reflux for 24 hours. The reaction mixture was then 
cooled before the solvent was evaporated under reduced pressure. The residue was 
dissolved in water (40 mL) and acidified to pH 2 with 10% aqueous HCl before being 
extracted into ethyl acetate (2 × 40 mL). The organic layer was washed with water (3 × 
30 mL), followed by brine (30 mL) before being dried over anhydrous magnesium 
sulfate, filtered and the solvent evaporated under reduced pressure giving a red solid 




 (KBr) 3372, 3037, 1819, 
1747, 1529, 1248; δH (300 MHz, DMSO-d6) 3.89 (3H, s, CH3), 6.67-6.79 [3H, m, C(6, 
6′, 7′)-H], 6.89 [1H, d, C(7)-H], 7.04 [1H, t, J 7.4, C(5)-H], 7.09 [1H, t, J 7.5, C(5′)-H], 
7.43 [1H, d, J 8.2, C(4)-H], 7.49 [1H, d, J 8.3, C(4′)-H], 7.83 [1H, d, J 2.8, C(2)-H], 






Method B  
A suspension of potassium 2-(1H-indol-3-yl)-2-oxoacetate 253 (6.823 g, 26.6 mmol), 2-
(1-methyl-1H-indol-3-yl)acetic acid 150 (5.030 g, 26.6 mmol) and acetic anhydride (30 
mL) was stirred at 80 °C for 24 hours. The yellow suspension was then cooled to room 
temperature and the solvent evaporated under reduced pressure. The residue was then 
washed with saturated aqueous sodium bicarbonate (50 mL) and extracted into ethyl 




bicarbonate (30 mL), followed by water (30 mL) and brine (30 mL) before being dried 
over anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure. The crude product was then purified using column chromatography on silica 
gel with 10% ethyl acetate/hexane to give the desired product as a red solid (1.849 g, 






To a stirred solution of indole 251 (4.000 g, 34.1 mmol) in anhydrous DMF 
(70 mL), at 0 °C under nitrogen was added sodium hydride (60 wt. % oil 
dispersion, 2.728 g, 68.2 mmol) and the suspension was stirred for 30 
minutes at this temperature. Isopropyl iodide (8.53 mL, 14.53 g, 85.4 mmol) was then 
added to the solution which was then allowed to warm to room temperature and stirred 
for 16 hours. Water (70 mL) was added and the mixture was extracted with ethyl acetate 
(25 mL × 2). The combined organic layers were washed using 1 M aqueous HCl (25 mL 
× 3) and water (25 mL × 2) before being dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated under reduced pressure. The crude product was then 
purified using column chromatography on silica gel with 10% ethyl acetate/hexane to 
give desired product as a pale yellow oil (3.220 g, 59%) which was used without further 
purification: νmax/cm
-1
 (NaCl) 2975, 1462, 1314, 1300, 1223, 739; δH (300 MHz, 
CDCl3) 1.52 [6H, d, J 6.7, CH(CH3)2], 4.68 [1H, sept, J 6.7, CH(CH3)2], 6.51 [1H, dd, J 
3.2, 0.6, C(3)-H], 7.09 [1H, ddd, J 8.0, 7.1, 1.1, C(5)-H], 7.19 [1H, ddd, J 8.3, 7.2, 1.2, 
C(6)-H], 7.22 [1H, d, J 3.2, C(2)-H], 7.38 [1H, dd, J 8.2, 0.6, C(7)-H], 7.63 [1H, dt, J 






2-(1-Isopropyl-1H-indol-3-yl)-2-oxoacetic acid 260 
 
To a solution of 1-isopropyl-1H-indole 258 (2.894 g, 18.0 mmol) in 
diethyl ether (50 mL) was added oxalyl chloride (2.33 mL, 3.45 g, 27.2 
mmol) dropwise, over 10 minutes. The solution was then stirred for a 
further 30 minutes. Saturated aqueous sodium bicarbonate (10 mL) 
was then added with caution and the biphasic mixture was stirred for 16 hours. The 
layers were separated and the aqueous layer was extracted with ethyl acetate (2 × 15 
mL). The combined organic layers were washed with water before being dried over 
Experimental 
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anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure to give the desired product as a yellow solid (3.790 g, 90%): m.p. 113-115 °C; 
νmax/cm
-1
 (KBr) 3287, 2988, 1760, 1605, 1321, 1199, 740; δH (300 MHz, DMSO-d6) 
1.54 [6H, d, J 6.7, CH(CH3)2], 4.88 [1H, sept, J 6.7, CH(CH3)2], 7.31 [1H, ddd, J 8.5, 
7.2, 1.4, C(5)-H], 7.35 [1H, ddd, J 8.6, 7.1, 1.6, C(6)-H], 7.72 [1H, d, J 7.4, C(7)-H], 
8.22 [1H, d, J 6.8, C(4)-H], 8.42 [1H, s, C(2)-H]; δc (75 MHz, DMSO-d6) 21.9 (2 × 
CH3), 48.2 [CH(CH3)2], 111.4 (CH, aromatic CH), 111.6 (C, aromatic C), 121.4 (CH, 
aromatic CH), 123.1 (CH, aromatic CH), 123.7 (CH, aromatic CH), 126.3 (C, aromatic 





 100%]; HRMS (ESI
+
): Exact mass calculated for (C13H14NO3)
+
 
232.0974. Found 232.0970. 
 
Potassium 2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetate 262 
 
A solution of 2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetic acid 260 
(3.499 g, 15.1 mmol) in ethanol (50 mL) was treated with potassium 
hydroxide (85 wt. %, 0.993 g, 15.1 mmol) and the mixture was stirred 
at room temperature for 4 hours. The solvent was removed under 
reduced pressure and the residue dried overnight at 40 °C to give the desired product as 
a pale pink solid (3.961 g, 97%): m.p. 80-84 °C; νmax/cm
-1
 (KBr) 3456, 2981, 1649, 
1607, 1301, 1203, 738; δH (300 MHz, DMSO-d6) 1.48 [d, 6H, J 6.6, CH(CH3)2], 4.80 
[1H, sept, J 6.7, CH(CH3)2], 7.17 [1H, ddd, J 8.2, 7.2, 1.1, C(5)-H], 7.22 [1H, ddd, J 
8.5, 7.1, 1.4, C(6)-H], 7.58 [1H, d, J 7.6, C(7)-H], 8.14 [1H, s, C(2)-H], 8.19 [1H, d, J 
7.3, C(4)-H]; δc (75 MHz, DMSO-d6) 22.2 (2 × CH3), 47.2 [CH(CH3)2], 110.5 (CH, 
aromatic CH), 113.4 (C, aromatic C), 121.4 (CH, aromatic CH), 121.5 (CH, aromatic 
CH), 122.2 (CH, aromatic CH), 126.5 (C, aromatic C), 134.0 (CH, aromatic CH), 135.8 




 100%]; HRMS 
(ESI
+














A mixture of potassium 2-(1-isopropyl-1H-indol-3-yl)-2-
oxoacetate 262 (3.502 g, 13.0 mmol), 2-[1-(phenylsulfonyl)-
1H-indol-3-yl]acetic acid 256 (4.096 g, 13.0 mmol) and acetic 
anhydride (30 mL) was stirred at 80 °C for 24 hours. The 
yellow suspension was then allowed to cool to room 
temperature and the solvent was evaporated under reduced 
pressure. The residue was washed with saturated aqueous sodium bicarbonate (50 mL) 
and extracted into ethyl acetate (2 × 30 mL). The organic layer was washed with 
saturated aqueous sodium bicarbonate (30 mL), followed by water (30 mL) and brine 
(30 mL) before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure. The crude product was then purified using column 
chromatography on silica gel with 10% ethyl acetate/hexane to give a yellow foamy 
residue which was dissolved in chloroform (15 mL) and diethyl ether was added until a 
yellow solid precipitated which was collected by vacuum filtration (1.582 g, 24%): m.p. 
102-105 °C; νmax/cm
-1
 (KBr) 3561, 3135, 2977, 1821, 1755, 1631, 1536, 1372, 1185; δH 
(300 MHz, DMSO-d6) 1.35 [6H, d, J 6.6, CH(CH3)2], 4.80 [1H, sept, J 6.6, CH(CH3)2], 
6.39 [1H, t, J 7.6, C(6′)-H], 6.70 [1H, d, J 8.0, C(7′)-H], 6.83-6.93 [2H, m, C(6, 7)-H], 
7.05 [1H, t, J 7.7, C(5′)-H], 7.26 [1H, ddd, J 8.3, 6.9, 1.5, C(5)-H], 7.54 [1H, d, J 8.4, 
C(4′)-H], 7.63-7.69 [2H, m, C(3′′, 5′′)-H], 7.80 [1H, m, C(4′′)-H], 7.91 [1H, s, C(2)-H], 
7.95 [1H, d, J 8.3, C(4)-H], 8.04-8.07 [2H, m, C(6′′, 2′′)-H], 8.15 [1H, s, C(2′)-H]; δc 
(75 MHz, DMSO-d6) 22.0 (2 × CH3), 47.5 [CH(CH3)2], 104.1 (C, aromatic C), 110.9 
(CH, aromatic CH), 112.0 (C, aromatic C), 113.2 (CH, aromatic CH), 120.7 (CH, 
aromatic CH), 121.0 (CH, aromatic CH), 121.7 (CH, aromatic CH), 122.5 (CH, 
aromatic CH), 122.8 (C, aromatic C), 123.4 (CH, aromatic CH), 125.0 (C, aromatic C), 
125.4 (CH, aromatic CH), 126.9 (2CH, 2 × aromatic CH), 127.6 (C, aromatic C), 128.6 
(CH, aromatic CH), 130.0 (2CH, 2 × aromatic CH), 130.9 (CH, aromatic CH), 133.7 (C, 
aromatic C), 134.2 (C, aromatic C), 135.0 (CH, aromatic CH), 135.7 (C, aromatic C), 







): Exact mass calculated for (C29H23N2O5S)
+








To a stirred suspension of 3-(1-isopropyl-1H-indol-3-yl)-4-[1-
(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 264 (1.353 g, 
2.37 mmol) in a mixture of methanol (60 mL) and water (15 
mL) was added potassium hydroxide (85 wt. %, 1.053 g, 15.9 
mmol). The mixture was then heated to reflux for 24 hours before being allowed to cool 
and the solvent evaporated under reduced pressure. The residue was acidified to pH 2 
using 10% aqueous HCl and extracted with ethyl acetate (3 × 25 mL). the combined 
organic layers were washed with water (3 × 30 mL) and brine (30 mL) before being 
dried over anhydrous magnesium sulfate, filtered and the solvent evaporated under 
reduced pressure to give the desired product as red solid (0.764g, 87%): m.p. 186-188 
°C; νmax/cm
-1
 (KBr) 3118, 2971, 1812, 1745, 1627, 1529, 1247; δH (300 MHz, DMSO-
d6) 1.38 [6H, d, J 6.7, CH(CH3)2], 4.81 [1H, sept, J 6.6, CH(CH3)2], 6.68-6.71 [2H, m, 
C(6, 7)-H], 6.85 [1H, ddd, J 8.1, 6.9, 0.7, C(6′)-H], 7.03-7.17 [3H, m, C(5, 5′, 7′)-H], 
7.44 [1H, d, J 8.1, C(4)-H], 7.59 [1H, d, J 8.2, C(4′)-H], 7.75 [1H, s, C(2′)-H], 7.92 [1H, 
d, J 2.9, C(2)-H], 11.94 (1H, bs, N-H); δc (75 MHz, DMSO-d6) 22.1 (2 × CH3), 47.2 
(CH), 104.4 (C, aromatic C), 104.8 (C, aromatic C), 110.6 (CH, aromatic CH), 112.2 
(CH, aromatic CH), 119.9 (CH, aromatic CH), 120.2 (CH, aromatic CH), 121.4 (CH, 
aromatic CH), 121.6 (CH, aromatic CH), 122.1 (2CH, 2 × aromatic CH), 124.2 (C, 
aromatic C), 125.6 (C, aromatic C), 127.2 (C, aromatic C), 128.5 (C, aromatic C), 129.5 
(CH, aromatic CH), 130.9 (CH, aromatic CH), 135.5 (C, aromatic C), 136.3 (C, 




 100%]; HRMS 
(ESI
+
): Exact mass calculated for (C23H19N2O3)
+








To a solution of 3-(1H-indol-3-yl)-4-[1-(phenylsulfonyl)-1H-
indol-3-yl]furan-2,5-dione 267 (0.202 g, 0.431 mmol) in 
anhydrous DMF (20 mL) in a flame-dried flask under nitrogen 
was added sodium hydride (60 wt. % oil dispersion, 0.019 g, 
0.474 mmol) and the solution was stirred for 30 minutes at 
room temperature. Allyl bromide (0.04 mL, 0.06 g, 0.52 mmol) 
was then added and the mixture was stirred for a further 4 hours. The reaction mixture 
was poured into water (60 mL) and extracted with ethyl acetate (3 × 30 mL). The 
organic layer was washed with 1 M aqueous HCl (3 × 30 mL), followed by water (30 
mL) before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure to give an orange foamy residue. The residue was 
dissolved in chloroform (2 mL) and diethyl ether was added until an orange solid 
precipitated which was collected by vacuum filtration (0.180 g, 82%): m.p. 157-159 °C; 
νmax/cm
-1
 (KBr) 3128, 2926, 1819, 1751, 1636, 1540, 1252, 1176, 923; δH (300 MHz, 
CDCl3) 4.78 (2H, d, J 5.4, CH2-CH=CH2), 5.14 [1H, d, J 17.0, CH2-CH=CH2 (trans)], 
5.29 [1H, d, J 10.2, CH2-CH=CH2 (cis)], 6.00 (1H, ddt, J 17.0, 10.2, 5.3, CH2-
CH=CH2), 6.49 [1H, t, J 7.5, C(6′)-H], 6.61 [1H, d, J 8.1, C(7′)-H], 6.88 [1H, t, J 7.5, 
C(6)-H], 6.97 [1H, d, J 7.7, C(7)-H], 7.08 [1H, t, J 7.7, C(5′)-H], 7.22 [1H, t, J 7.8, 
C(5)-H], 7.28 [1H, d, J 8.2, C(4′)-H], 7.49 [2H, t, J 7.9, C(3′′, 5′′)-H], 7.61 [1H, t, J 7.5, 
C(4′′)-H], 7.88-7.94 [2H, m, C(2′′, 6′′)-H], 7.93 [1H, s, C(2)-H], 7.97 [1H, d, J 8.4, 
C(4)-H], 8.04 [1H, s, C(2′)-H]; δc (75 MHz, CDCl3) 49.5 (CH2-CH=CH2), 105.1 (C, 
aromatic C), 110.5 (CH, aromatic CH), 111.9 (C, aromatic C), 113.5 (CH, aromatic 
CH), 118.8 (CH=CH2), 121.5 (CH, aromatic CH), 121.9 (CH, aromatic CH), 122.1 (CH, 
aromatic CH), 123.15 (C, aromatic C), 123.20 (CH, aromatic CH), 123.4 (CH, aromatic 
CH), 125.4 (CH, aromatic CH), 125.5 (C, aromatic C), 127.1 (2CH, 2 × aromatic CH), 
128.2 (C, aromatic C), 129.0 (CH, aromatic CH), 129.6 (2CH, 2 × aromatic CH), 131.8 
(CH, aromatic CH), 133.3 (C, aromatic C), 134.28 (CH, aromatic CH), 134.30 (CH, 
aromatic CH), 134.4 (C, aromatic C), 136.6 (C, aromatic C), 137.7 (C, aromatic C), 




 30%]; HRMS (ESI
+
): Exact 
mass calculated for (C29H21N2O5S)
+
 509.1171. Found 509.1157.  
1 
Experimental 




A stirred suspension of 3-(1-allyl-1H-indol-3-yl)-4-[1-
(phenylsulfonyl)-1H-indol-3-yl]furan-2,5-dione 268 (0.280 g, 
0.551 mmol) in methanol (20 mL) and water (5 mL) was 
treated with potassium hydroxide (85 wt. %, 0.223 g, 3.30 
mmol) and the resulting solution was heated to reflux for 24 
hours. The reaction mixture was then allowed to cool before the solvent was evaporated 
under reduced pressure. The residue was dissolved in water (20 mL) and acidified to pH 
2 with 10% aqueous HCl before being extracted into ethyl acetate (2 × 20 mL). The 
combined organic layers were washed with water (3 × 30 mL), followed by brine (30 
mL) before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure giving a red solid (0.192 g, 87%): m.p. 174-175 °C; 
νmax/cm
-1 
(KBr) 3384, 2924, 1819, 1746, 1528, 1250, 742; δH (300 MHz, DMSO-d6) 
4.94 (2H, bd, J 5.3, CH2-CH=CH2), 5.04 (1H, dd, J 17.1, 1.5, CH=CH2 trans), 5.19 (1H, 
dd, J 10.3, 1.5, CH=CH2 cis), 6.00 (1H, ddt, J 17.0, 10.4, 5.3, CH=CH2), 6.69 [1H, ddd, 
J 8.0, 7.0, 1.0, C(5)-H], 6.75 [1H, ddd, J 8.0, 7.1, 0.9, C(5′)-H], 6.82 [1H, d, J 8.0, C(7)-
H], 6.90 [1H, d, J 7.8, C(7′)-H], 7.04 [1H, ddd, J 8.1, 7.1, 1.2, C(6)-H], 7.08 [1H, ddd, J 
8.2, 7.1, 1.1, C(6′)-H], 7.43 [1H, d, J 8.1, C(4)-H], 7.46 [1H, d, J 8.3, C(4′)-H], 7.87 
[1H, s, C(2′)-H], 7.89 [1H, d, J 2.6, C(2)-H], 11.93 (1H, bs, NH); δc (75 MHz, DMSO-
d6) 48.3 (NCH2), 104.5 (C, aromatic C), 104.9 (C, aromatic C), 110.8 (CH, aromatic 
CH), 112.1 (CH, aromatic CH), 117.0 (CH=CH2), 119.8 (CH, aromatic CH), 120.1 (CH, 
aromatic CH), 121.1 (CH, aromatic CH), 121.4 (CH, aromatic CH), 122.1 (CH, 
aromatic CH), 122.2 (CH, aromatic CH), 124.8 (C, aromatic C), 125.6 (C, aromatic C), 
127.2 (C, aromatic C), 128.5 (C, aromatic C), 130.6 (CH=CH2), 133.0 (CH, aromatic 
CH), 133.5 (CH, aromatic CH), 135.9 (C, aromatic C), 136.1 (C, aromatic C), 166.38 




 80%]; HRMS (ESI
+
): Exact mass 
calculated for (C23H17N2O3)
+












To a solution of 3,4-di(1H-indol-3-yl)furan-2,5-dione 255 
(5.004 g, 15.2 mmol) in anhydrous DMF (80 mL) at 0°C under 
a nitrogen atmosphere was added sodium hydride (60 wt. % oil 
dispersion, 0.640 g, 16.0 mmol). The dark purple solution was 
stirred for 30 minutes while warming to room temperature 
before 6-bromohexanenitrile (2.62 mL, 3.47 g, 19.7 mmol) was 
added. The solution was stirred for 16 hours before being poured into water (200 mL) 
and extracted with ethyl acetate (3 × 60 mL). The combined organic layers were washed 
with 1 M aqueous HCl (2 × 60 mL) followed by water (60 mL) before being dried over 
anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure. The crude material was purified using column chromatography on silica gel 
with 20:80 – 30:70 ethyl acetate/hexane to give 2 fractions found to be the mono 




270 was isolated as a red solid (0.953 g, 15%): m.p. 102-104 °C; νmax/cm
-1 
(KBr) 3391, 
2935, 2246, 1819, 1748, 1529, 1251, 743; δH (300 MHz, DMSO-d6) 1.32 [2H, m, 
C(4′′)-H2], 1.57 [2H, quin, J 7.3, C(3′′)-H2], 1.74 [2H, quin, J 7.3, C(5′′)-H2], 2.45 [2H, 
t, J 7.1, C(2′′)-H2], 4.26 [2H, t, J 7.0, C(6′′)-H2], 6.69 [1H, ddd, J 7.9, 6.9, 0.9, C(6)-H], 
6.74-6.82 [2H, m, C(6′, 7)-H], 6.95 [1H, d, J 7.8, C(7′)-H], 7.04 [1H, ddd, J 8.2, 7.1, 
1.2, C(5)-H], 7.10 [1H, ddd, J 8.2, 7.2, 1.1, C(5′)-H], 7.43 [1H, d, J 8.2, C(4)-H], 7.55 
[1H, d, J 8.2, C(4′)-H], 7.86 [1H, s, C(2′)-H], 7.89 [1H, s, C(2)-H], 11.92 (1H, bs, NH); 
δc (75 MHz, DMSO-d6) 16.0 (CH2), 24.3 (CH2), 25.2 (CH2), 28.7 (CH2), 45.6 (CH2), 
104.2 (C, aromatic C), 104.9 (C, aromatic C), 110.5 (CH, aromatic CH), 112.1 (CH, 
aromatic CH), 119.8 (CH, aromatic CH), 120.0 (CH, aromatic CH), 120.5 (CN), 121.2 
(CH, aromatic CH), 121.4 (CH, aromatic CH), 122.1 (CH, aromatic CH), 122.2 (CH, 
aromatic CH), 124.7 (C, aromatic C), 125.5 (C, aromatic C), 127.4 (C, aromatic C), 
128.2 (C, aromatic C), 130.6 (CH, aromatic CH), 133.0 (CH, aromatic CH), 135.9 (C, 
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 100%]; HRMS (ESI
+






3,1-diyl))dihexanenitrile 271 was isolated as a red solid (1.658 
g, 21%): m.p. 120-122 °C; νmax/cm
-1
 (KBr) 3435, 2939, 2243, 
1815, 1749, 1525, 1257, 747; δH (300 MHz, DMSO-d6) 1.27-
1.40 [4H, m, 2 × C(4′′)-H2], 1.57 [4H, quin, J 7.4, 2 × C(3′′)-
H2], 1.76 [4H, quin, J 7.3, 2 × C(5′′)-H2], 2.45 [4H, t, J 7.0, 2 × 
C(2′′)-H2], 4.27 [4H, t, 2 × C(6′′)-H2], 6.75 [2H, t, J 7.4, C(6, 6′)-H], 6.87 [2H, d, J 7.9, 
C(7, 7′)-H], 7.10 [2H, t, J 7.7, C(5, 5′)-H], 7.55 [2H, d, J 8.3, C(4, 4′)-H], 7.90 [2H, s, 
C(2, 2′)-H]; δc (75 MHz, DMSO-d6)  16.0 (2 × CH2), 24.3 (2 × CH2), 25.1 (2 × CH2), 
28.7 (2 × CH2), 45.6 (2 × CH2), 104.2 (2C, 2 × aromatic C), 110.6 (2CH, 2 × aromatic 
CH), 120.0 (2CH, 2 × aromatic CH), 120.5 (2 × CN), 121.5 (2CH, 2 × aromatic CH), 
122.2 (2CH, 2 × aromatic CH), 125.3 (2C, 2 × aromatic C), 127.6 (2C, 2 × aromatic C), 





 10%]; HRMS (ESI
+
): Exact mass calculated for (C32H31N4O3)
+
 





To a solution of 6,6'-[3,3'-(2,5-dioxo-2,5-dihydrofuran-3,4-
diyl)bis(1H-indole-3,1-diyl)]dihexanenitrile 271 (1.302 g, 2.51 
mmol) in anhydrous DMF (10 mL) was added 1,1,1,3,3,3 
hexamethyldisilazane (3.53 mL, 0.77 g, 28.4 mmol), followed 
by methanol (0.34 mL, 0.27 g, 8.4 mmol) and the reaction 
mixture was stirred at room temperature for 8 hours. Water (40 
mL) was then added and the product extracted into ethyl acetate 
(3 × 30 mL). The combined organic layers were washed with water (3 × 40 mL) 
followed by brine (40 mL) before being dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated under reduced pressure to give a red solid (1.165 g, 
90%): m.p. 82-84 °C; νmax/cm
-1




δH (300 MHz, CDCl3) 1.39-1.51 [4H, m, 2 × C(4′′)-H2], 1.65 [4H, quin, J 7.3, 2 × 
C(3′′)-H2], 1.87 [4H, quin, J 7.3, 2 × C(5′′)-H2], 2.30 [4H, t, J 7.0, 2 × C(2′′)-H2], 4.15 
[4H, t, J 7.0, 2 × C(6′′)-H2],  6.76 [2H, t, J 7.4, C(6, 6′)-H], 6.99 [2H, d, J 8.0, C(7, 7′)-
H], 7.11 [2H, t, J 7.6, C(5, 5′)-H], 7.28 [2H, d, J 8.3, C(4, 4′)-H], 7.43 (1H, s, NH), 7.63 
[1H, s, C(2, 2′)-H]; δc (75 MHz, CDCl3)  17.0 (2 × CH2), 25.0 (2 × CH2), 25.9 (2 × 
CH2), 29.2 (2 × CH2), 46.3 (2 × CH2), 105.9 (2C, 2 × aromatic C), 109.5 (2CH, 2 × 
aromatic CH), 119.4 (2 × CN), 120.1 (2CH, 2 × aromatic CH), 122.3 (2CH, 2 × 
aromatic CH), 122.4 (2CH, 2 × aromatic CH), 126.2 (2C, 2 × aromatic C), 127.8 (2C, 2 





 100%]; HRMS (ESI
+
): Exact mass calculated for 
(C32H32N5O2)
+






indol-1-yl}hexanenitrile 270 (0.402 g, 0.950 mmol) was 
dissolved in a mixture of methanol (20 mL) and 10% aqueous 
potassium hydroxide solution (20 mL). The solution was 
heated to reflux for 16 hours before being allowed to cool and 
the solvent evaporated under reduced pressure. The residue 
was dissolved in water (20 mL) and acidified to pH 2 using 20% aqueous HCl, and then 
extracted with ethyl acetate (20 mL × 2). The organic layer was washed with water (20 
mL × 2) followed by brine (20 mL) before being dried over anhydrous magnesium 
sulfate, filtered and the solvent evaporated under reduced pressure to give desired 
compound as a red solid (0.335 g, 84%): 198-199 °C; νmax/cm
-1
 (KBr) 3386, 2924, 
1816, 1740, 1699, 1531, 1261; δH (300 MHz, DMSO-d6) 1.23 [2H, quin, J 7.5, C(4′′)-
H2], 1.51 [2H, quin, J 7.5, C(3′′)-H2], 1.72 [2H, quin, J 7.2, C(5′′)-H2], 2.17 [2H, t, J 
7.3, C(2′′)-H2], 4.24 [2H, t, J 7.0, C(6′′)-H2], 6.67 [1H, t, J 7.5, C(6)-H], 6.76 [1H, t, J 
7.8, C(6′)-H], 6.77 [1H, d, J 7.5, C(7)-H], 6.93 [1H, d, J 8.0, C(7′)-H], 7.04 [1H, t, J 8.0, 
C(5)-H], 7.09 [1H, t, J 7.8, C(5′)-H], 7.43 [1H, d, J 8.1, C(4)-H], 7.53 [1H, d, J 8.3, 
C(4′)-H], 7.84 [1H, s, C(2′)-H], 7.89 [1H, s, C(2)-H], 11.92 (1H, bs, NH), 11.99 (1H, bs, 
COOH); δc (75 MHz, DMSO-d6) 24.0 (CH2), 25.6 (CH2), 29.3 (CH2), 33.5 (CH2), 45.7 
(CH2), 104.2 (C, aromatic C), 104.9 (C, aromatic C), 110.5 (CH, aromatic CH), 112.1 
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(CH, aromatic CH), 119.8 (CH, aromatic CH), 120.0 (CH, aromatic CH), 121.2 (CH, 
aromatic CH), 121.4 (CH, aromatic CH), 122.07 (CH, aromatic CH), 122.12 (CH, 
aromatic CH), 124.7 (C, aromatic C), 125.5 (C, aromatic C), 127.4 (C, aromatic C), 
128.2 (C, aromatic C), 130.6 (CH, aromatic CH), 133.0 (CH, aromatic CH), 135.9 (C, 





 100%]; HRMS (ESI
+
): Exact mass calculated for (C26H23N2O5)
+
 





To a solution of 3,4-di(1H-indol-3-yl)furan-2,5-dione 255 
(1.004 g, 3.06 mmol) in anhydrous DMF (150 mL) at 0 °C under 
a nitrogen atmosphere was added sodium hydride (60 wt. % oil 
dispersion, 0.270 g, 6.73 mmol) and the mixture was stirred for 
40 minutes at this temperature. 1,6-Dibromohexane (0.50 mL, 
0.79 g, 3.2 mmol) was then added to the dark blue mixture and the reaction was allowed 
to warm slowly to room temperature and stirred for 16 hours. At this point, the reaction 
mixture was poured into water (400 mL) and extracted with ethyl acetate (5 × 50 mL). 
The organic layer was washed with 1 M aqueous HCl (3 × 50 mL), followed by water 
(2 × 50 mL) before being dried over anhydrous magnesium sulfate, filtered and the 
solvent evaporated under reduced. The crude residue was purified using column 
chromatography on silica gel with 50:50 DCM/hexane to give desired compound as a 
reddish/purple solid (0.364 g, 29%): m.p. >300 °C; νmax/cm
-1
 (KBr) 3431, 2927, 1809, 
1747, 1626, 1528, 1186, 735; δH (300 MHz, DMSO-d6) 1.09 [4H, bs, C(8, 9)-H2], 1.82 
[4H, bs, C(7, 10)-H2], 4.16-4.23 [4H, m, C(6, 11)-H2], 7.15-7.28 [4H, m, C(2, 3, 14, 
15)-H], 7.55 [2H, d, J 7.6, C(4, 13)-H], 7.57 [2H, s, C(22, 23)-H], 7.87 [2H, dd, J 7.1, 
1.2, C(1, 16)-H]; δc (75 MHz, DMSO-d6) 22.5 (2 × CH2), 27.2 (2 × CH2), 44.2 (2 × 
CH2), 101.9 (2C, 2 × aromatic C), 110.7 (2CH, 2 × aromatic CH), 120.7 (2CH, 2 × 
aromatic CH), 121.3 (2CH, 2 × aromatic CH), 122.0 (2CH, 2 × aromatic CH), 126.4 
(2C, 2 × aromatic C), 132.2 (2CH, 2 × aromatic CH), 132.5 (2C, 2 × aromatic C), 135.4 














To a solution of 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-
yl)furan-2,5-dione 265 (0.301 g, 0.879 mmol) in anhydrous 
DMF (15 mL) under nitrogen was added sodium hydride (60 
wt. % oil dispersion, 0.042 g, 1.14 mmol) and the mixture was 
allowed to stir for 40 minutes. Iodomethane (0.08 mL, 0.18 g, 1.3 mmol) was then 
added and the reaction was stirred for a further 16 hours. Water (30 mL) was then added 
and the mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic 
layers were then washed with 1 M aqueous HCl (2 × 20 mL), followed by water (20 
mL) and brine (20 mL). The product was recrystallised from the ethyl acetate solution 
to give desired product as a red solid (0.162 g). Excess solvent was removed from 
filtrate and the residue was purified using column chromatography on silica gel with 
20% ethyl acetate/hexane to give additional product (0.087 g, combined yield 0.249 g, 
80%): m.p. 177-178 °C; νmax/cm
-1
 (KBr) 2924, 2855, 1815, 1740, 1610, 1517, 1226, 
735; δH (300 MHz, DMSO-d6) 3.88 (6H, s, 2 × CH3), 6.74 [2H, ddd, J 7.8, 7.0, 0.7, C(6, 
6′)-H], 6.82 [2H, d, J 7.8, C(7, 7′)-H], 7.11 [2H, ddd, J 8.2, 7.0, 1.2, C(5, 5′)-H], 7.49 
[2H, d, J 8.2, C(4, 4′)-H], 7.92 [2H, s, C(2, 2′)-H]; δc (75 MHz, DMSO-d6) 33.0 (2 × 
CH3), 104.0 (2C, 2 × aromatic C), 110.5 (2CH, 2 × aromatic CH), 120.0 (2CH, 2 × 
aromatic CH), 121.3 (2CH, 2 × aromatic CH), 122.2 (2CH, 2 × aromatic CH), 125.4 
(2C, 2 × aromatic C), 127.3 (2C, 2 × aromatic C), 134.2 (2CH, 2 × aromatic CH), 136.7 












To a solution of 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-
yl)furan-2,5-dione 265 (0.262 g, 0.765 mmol) in anhydrous 
DMF (15 mL) under nitrogen was added sodium hydride (60 
wt. % oil dispersion, 0.037 g, 1.07 mmol) and the mixture was 
allowed to stir for 40 minutes. Iodoethane (0.09 mL, 0.17 g, 1.1 mmol) was then added 
and the reaction was stirred for a further 16 hours. Water (30 mL) was then added and 
the mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic layers 
were then washed with 1 M aqueous HCl (2 × 20 mL), followed by water (20 mL) and 
brine (20 mL) before being dried over anhydrous magnesium sulfate, filtered and the 
solvent evaporated under reduced pressure. The crude residue was purified using 
column chromatography on silica gel with 20% ethyl acetate/hexane to give desired 
product as a red solid (0.204 g, 72%): m.p. 214-216 °C; νmax/cm
-1
 (KBr) 3420, 3133, 
1816, 1758, 1626, 1525, 1219, 737; δH (300 MHz, DMSO-d6) 1.31 (3H, t, J 7.2, 
CH2CH3), 3.89 (3H, s, CH3), 4.26 (2H, q, J 7.2, CH2CH3), 6.67-6.74 [2H, m, C(6′, 7′)-
H], 6.81 [1H, t, J 7.9, C(6)-H], 7.04 [1H, d, J 8.0, C(7)-H], 7.08-7.16 [2H, m, (5, 5′)-H], 
7.50 [1H, d, J 8.4, C(4′)-H], 7.54 [1H, d, J 8.4, C(4)-H], 7.81 [1H, s, C(2)-H], 7.97 [1H, 
s, C(2′)-H]; δc (75 MHz, DMSO-d6) 15.1 (CH2CH3), 33.0 (CH3), 40.8 (CH2CH3), 103.9 
(C, aromatic C), 104.2 (C, aromatic C), 110.4 (CH, aromatic CH), 110.5 (CH, aromatic 
CH), 120.05 (CH, aromatic CH), 120.08 (CH, aromatic CH), 121.5 (CH, aromatic CH), 
121.6 (CH, aromatic CH), 122.2 (2CH, 2 × aromatic CH), 124.9 (C, aromatic C), 125.7 
(C, aromatic C), 127.1 (C, aromatic C), 127.7 (C, aromatic C), 132.5 (CH, aromatic 
CH), 134.4 (CH, aromatic CH), 135.6 (C, aromatic C), 136.8 (C, aromatic C), 166.3 




 100%]; HRMS (ESI
+
): Exact mass 
calculated for (C23H19N2O3)
+









To a solution of 3-(1H-indol-3-yl)-4-(1-methyl-1H-indol-3-
yl)furan-2,5-dione 265 (0.505 g, 1.48 mmol) in anhydrous DMF 
(20 mL) under nitrogen was added sodium hydride (60 wt. % oil 
dispersion, 0.070 g, 1.77 mmol) and the mixture was stirred for 
40 minutes. 6-Bromohexane nitrile (0.30 mL, 0.38 g, 2.2 mmol) 
was then added and the reaction was stirred for a further 16 
hours. Water (40 mL) was then added and the mixture was extracted with ethyl acetate 
(3 × 30 mL). The combined organic layers were then washed with 1 M aqueous HCl (2 
× 30 mL), followed by water (30 mL) and brine (30 mL) before being dried over 
anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure. The crude residue was purified using column chromatography on silica gel 
with 30% ethyl acetate/hexane to give desired product as a red solid (0.258 g, 40%): 
m.p. 78-79 °C; νmax/cm
-1
 (KBr) 3411, 2936, 2244, 1816, 1750, 1529, 1254, 1100, 741; 
δH (400 MHz, DMSO-d6) 1.27-1.35 [2H, m, C(4′′)-H2], 1.56 [2H, quin, J 7.4, C(3′′)-H2], 
1.73 [2H, quin, J 7.4, C(5′′)-H2], 2.44 [2H, t, J 6.9, C(2′′)-H2], 3.89 (3H, s, CH3), 4.24 
[2H, t, J 6.9, C(6′′)-H2], 6.69-6.72 [2H, m, C(6′, 7′)-H], 6.79 [1H, t, J 7.6, C(6)-H], 7.01 
[1H, d, J 8.15, C(7)-H], 7.07-7.13 [2H, m, (5, 5′)-H], 7.49 [1H, d, J 8.15, C(4′)-H], 7.54 
[1H, d, 8.49, C(4)-H], 7.82 [1H, s, C(2)-H], 7.97 [1H, s, C(2′)-H]; δc (75 MHz, DMSO-
d6)  16.0 (CH2), 24.3 (CH2), 25.1 (CH2), 28.7 (CH2), 33.0 (CH3), 45.6 (CH2), 103.9 (C, 
aromatic C), 104.3 (C, aromatic C), 110.50 (CH, aromatic CH), 110.54 (CH, aromatic 
CH), 120.0 (CH, aromatic CH), 120.1 (CH, aromatic CH), 120.5 (CN), 121.4 (CH, 
aromatic CH), 121.5 (CH, aromatic CH), 122.1 (CH, aromatic CH), 122.2 (CH, 
aromatic CH), 125.0 (C, aromatic C), 125.7 (C, aromatic C), 127.0 (C, aromatic C), 
127.9 (C, aromatic C), 132.9 (CH, aromatic CH), 134.3 (CH, aromatic CH), 135.9 (C, 





 12%]; HRMS (ESI
+
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6-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H-indol-1-
yl}hexanoic acid 279 
 
6-{3-[4-(1-Methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydro furan-
3-yl]-1H-indol-1-yl}hexanenitrile 274 (0.103 g, 0.235 mmol) 
was dissolved in a mixture of methanol (8 mL) and 10% 
aqueous potassium hydroxide solution (8 mL). The solution 
was heated to reflux for 16 hours before being allowed to cool 
and the solvent evaporated. The residue was dissolved in water 
(10 mL) and acidified to pH 2 using 20% aqueous HCl, and was then extracted with 
ethyl acetate (10 mL × 2). The organic layer was washed with water (10 mL × 2) 
followed by brine (10 mL) before being dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated under reduced pressure to give desired compound as 
a red solid (0.082 g, 76%): m.p. 95-97 °C; νmax/cm
-1
 (KBr) 3050, 2937, 1816, 1751, 
1705, 1611, 1528, 1255, 740; δH (300 MHz, DMSO-d6) 1.18-1.29 [2H, m, C(4′′)-H2], 
1.51 [2H, quin, J 7.4, C(3′′)-H2], 1.71 [2H, quin, J 7.3, C(5′′)-H2], 2.17 [2H, t, J 7.4, 
C(2′′)-H2], 3.90 (3H, s, CH3), 4.23 [2H, t, J 6.7, C(6′′)-H2], 6.68 [2H, m, C(6′, 7′)-H], 
6.78 [1H, t, J 7.6, C(6)-H], 7.00 [1H, d, J 8.0, C(7)-H], 7.06-7.14 [2H, m, (5, 5′)-H], 
7.48 [1H, d, J 8.3, C(4′)-H], 7.53 [1H, d, J 8.3, C(4)-H], 7.81 [1H, s, C(2)-H], 7.99 [1H, 
s, C(2′)-H], 11.99 (COOH); δc (75 MHz, DMSO-d6) 24.1 (CH2), 25.9 (CH2), 29.3 
(CH2), 33.0 (CH3), 33.8 (CH2), 45.7 (CH2), 103.9 (C, aromatic C), 104.2 (C, aromatic 
C), 110.48 (CH, aromatic CH), 110.52 (CH, aromatic CH), 120.0 (2CH, 2 × aromatic 
CH), 121.4 (2CH, 2 × aromatic CH), 122.1 (2CH, 2 × aromatic CH), 125.0 (C, aromatic 
C), 125.7 (C, aromatic C), 127.0 (C, aromatic C), 127.8 (C, aromatic C), 132.9 (CH, 
aromatic CH), 134.3 (CH, aromatic CH), 135.9 (C, aromatic C), 136.7 (C, aromatic C), 




 100%]; HRMS 
(ESI
+
): Exact mass calculated for (C27H25N2O5)
+








To a solution of 3-(1H-indol-3-yl)-4-(1-isopropyl-1H-indol-3-
yl)furan-2,5-dione 266 (0.302 g, 0.815 mmol) in anhydrous 
DMF (15 mL) under nitrogen was added sodium hydride (60 wt. 
% oil dispersion, 0.037 g, 1.47 mmol) and the mixture was 
stirred for 40 minutes. Iodomethane (0.06 mL, 0.14 g, 0.97 mmol) was then added and 
the reaction was allowed to stir for a further 16 hours. Water (30 mL) was then added 
and the mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic 
layers were then washed with 1 M aqueous HCl (2 × 20 mL), followed by water (20 
mL) and brine (20 mL) before being dried over anhydrous magnesium sulfate, filtered 
and the solvent evaporated under reduced pressure. The crude residue was purified 
using column chromatography on silica gel with 20% ethyl acetate/hexane to give 
desired product as a red solid (0.140 g, 46%): m.p. 164-167 °C; νmax/cm
-1
 (KBr) 3118, 
3048, 2970, 1812, 1745, 1627, 1529, 1247, 739; δH (300 MHz, DMSO-d6) 1.37 [6H, d, 
J 6.7, 2 × CH3], 3.90 (3H, s, CH3), 4.81 [1H, sept, J 6.6, CH(CH3)2], 6.60 [1H, d, J 8.0, 
C(7)-H], 6.72 [1H, t, J 8.0, C(6)-H], 6.87 [1H, t, J 7.8, C(6′)-H], 7.09-7.19 [3H, m, C(5, 
5′, 7′)-H], 7.50 [1H, d, J 8.4, C(4)-H], 7.59 [1H, d, J 8.4, C(4′)-H], 7.73 [1H, s, C(2′)-
H], 8.01 [1H, s, C(2)-H]; δc (75 MHz, DMSO-d6) 22.0 (2 × CH3), 33.0 [CH(CH3)2], 
47.2 (CH3), 103. 9 (C, aromatic C), 104.5 (C, aromatic C), 110.5 (CH, aromatic CH), 
110.6 (CH, aromatic CH), 120.1 (CH, aromatic CH), 120.2 (CH, aromatic CH), 121.5 
(CH, aromatic CH), 121.6 (CH, aromatic CH), 122.15 (CH, aromatic CH), 122.18 (CH, 
aromatic CH), 124.5 (C, aromatic C), 125.7 (C, aromatic C), 126.9 (C, aromatic C), 
128.1 (C, aromatic C), 129.1 (CH, aromatic CH), 134.65 (CH, aromatic CH), 134.69 (C, 





 100%]; HRMS (ESI
+











To a solution of 3-(1H-indol-3-yl)-4-(1-isopropyl-1H-indol-3-
yl)furan-2,5-dione 266 (0.167 g, 0.451 mmol) in anhydrous 
DMF (10 mL) under nitrogen was added sodium hydride (60 
wt. % oil dispersion, 0.019 g, 0.811 mmol) and the mixture was 
stirred for 40 minutes. Iodoethane (0.06 mL, 0.12 g, 0.69 mmol) was then added and the 
reaction was allowed to stir for a further 16 hours. Water (20 mL) was then added and 
the mixture was extracted with ethyl acetate (3 × 15 mL). The combined organic layers 
were then washed with 1 M aqueous HCl (2 × 15 mL), followed by water (15 mL) and 
brine (15 mL) before being dried over anhydrous magnesium sulfate, filtered and the 
solvent evaporated under reduced pressure. The crude residue was purified using 
column chromatography on silica gel with 20% ethyl acetate/hexane to give desired 
product as an orange solid (0.091 g, 51%): m.p. 165-167 °C; νmax/cm
-1 
(KBr) 2978, 
1817, 1746, 1524, 1211, 741; δH (400 MHz, DMSO-d6) 1.34 (3H, t, J 7.1, CH2CH3) 
1.40 [6H, d, J 6.7, 2 × CH3], 4.30 (2H, q, J 7.2, CH2CH3), 4.82 [1H, sept, J 6.6 
CH(CH3)2], 6.75-6.86 [3H, m, C(6, 6′, 7)-H), 7.04 [1H, d, J 7.7, C(7′)-H] 7.10-7.16 [2H, 
m, C(5, 5′)-H), 7.56 [1H, d, J 8.1, C(4)-H], 7.60 [1H, d, J 8.3, C(4′)-H], 7.80 [1H, s, 
C(2′)-H], 7.93 [1H, s, C(2)-H]; δc (75 MHz, DMSO-d6) 15.1 (CH3), 22.1 (2 × CH3), 
40.9 (CH2), 47.2 (CH), 104.1 (C, aromatic C), 104.4 (C, aromatic C), 110.5 (CH, 
aromatic CH), 110.7 (CH, aromatic CH), 120.1 (CH, aromatic CH), 120.2 (CH, 
aromatic CH), 121.65 (CH, aromatic CH), 121.73 (CH, aromatic CH), 122.1 (CH, 
aromatic CH), 122.2 (CH, aromatic CH), 125.0 (C, aromatic C), 125.3 (C, aromatic C), 
127.4 (C, aromatic C), 127.9 (C, aromatic C), 129.3 (CH, aromatic CH), 132.9 (CH, 





 100%]; HRMS (ESI
+
): Exact mass calculated for 
(C25H23N2O3)
+










To a solution of 3-(1H-indol-3-yl)-4-(1-isopropyl-1H-indol-3-
yl)furan-2,5-dione 266 (0.303 g, 0.818 mmol) in anhydrous 
DMF (15 mL) under nitrogen was added sodium hydride (60 
wt. % oil dispersion, 0.049 g, 2.025 mmol) and the mixture 
was stirred for 40 minutes. 6-Bromohexane nitrile (0.17 mL, 
0.23 g, 1.28 mmol) was then added and the reaction was 
allowed to stir for a further 16 hours. Water (20 mL) was then added and the mixture 
was extracted with ethyl acetate (3 × 15 mL). The combined organic layers were then 
washed with 1 M aqueous HCl (2 × 15 mL), followed by water (15 mL) and brine (15 
mL) before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure. The crude residue was purified using column 
chromatography on silica gel with 30% ethyl acetate/hexane to give desired product as 
an orange solid (0.127 g, 33%): m.p. 186-189 °C; νmax/cm
-1 
(KBr) 2937, 2247, 1830, 
1754, 1529, 1257, 748; δH (300 MHz, DMSO-d6) 1.34 [2H, quin, J 7.4, C(4′′)-H2] 1.40 
(6H, d, J 6.6, 2 × CH3), 1.58 [2H, quin, J 7.5, C(3′′)-H2], 1.78 [2H, quin, J 7.5, C(5′′)-
H2], 2.45 [2H, t, J 7.0, C(2′′)-H2], 4.29 [2H, t, J 7.0, C(6′′)-H2], 4.82 [1H, sept, J 6.6, 
CH(CH3)2], 6.73-6.84 [3H, m, C(6, 6′, 7)-H], 7.05 [1H, d, J 8.0, C(7′)-H] 7.10-7.15 [2H, 
m, C(5, 5′)-H], 7.56 [1H, d, J 8.3, C(4)-H], 7.59 [1H, d, J 8.3, C(4′)-H], 7.80 [1H, s, J 
8.4, C(2′)-H], 7.94 [s, 1H, C(2)-H]; δc (75 MHz, DMSO-d6) 16.0 (CH2), 22.1 (2 × CH3), 
24.3 (CH2), 25.2 (CH2), 28.7 (CH2), 45.6 (CH2), 47.2 [CH(CH3)2], 104.1 (C, aromatic 
C), 104.4 (C, aromatic C), 110.6 (2CH, 2 × aromatic CH), 120.1 (CH, aromatic CH), 
120.2 (CH, aromatic CH), 120.5 (CN), 121.59 (CH, aromatic CH), 121.62 (CH, 
aromatic CH), 122.1 (CH, aromatic CH), 122.2 (CH, aromatic CH), 124.9 (C, aromatic 
C), 125.6 (C, aromatic C), 127.5 (C, aromatic C), 127.8 (C, aromatic C), 129.3 (CH, 
aromatic CH), 133.4 (CH, aromatic CH), 135.5 (C, aromatic C), 136.1 (C, aromatic C), 




 20%]; HRMS (ESI
+
): Exact 
mass calculated for (C29H28N3O3)
+
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7.2.3 Synthesis of hydroxymaleimide analogues 
 
General procedure (i): To a solution of the maleic anhydride (1 eq.) in anhydrous 
DMF (30 mL/mmol) was added hydroxylamine hydrochloride (5 eq.) followed by 
triethylamine (5 eq.). The mixture was then heated to 70 °C and stirred at this 
temperature for 24 hours. After cooling, water (100 mL/mmol) was added and the 
mixture was extracted with ethyl acetate (3 × 40 mL/mmol). The organic layer was 
washed with 1 M aqueous HCl (2 × 50 mL/mmol), followed by water (50 mL/mmol) 
and brine (50 mL/mmol) before being dried over anhydrous magnesium sulfate, filtered 






Following general procedure (i) starting from 3,4-di(1H-indol-3-
yl)furan-2,5-dione 255 (0.505 g, 1.54 mmol) in anhydrous DMF 
(50 mL) with hydroxylamine hydrochloride (0.529 g, 7.69 
mmol) and triethylamine (1.06 mL, 0.77 g, 7.69 mmol) gave 





 (KBr) 3397, 2837, 1767, 1705, 1524, 1414, 1118; δH (300 MHz, DMSO-d6) 
6.65 [2H, t, J 7.5, C(6, 6′)-H], 6.79 [2H, d, J 8.0, C(7, 7′)-H], 6.99 [2H, t, J 7.6, C(5, 5′)-
H], 7.39 [2H, d, J 8.1, C(4, 4′)-H], 7.77 [2H, d, J 2.7, C(2, 2′)-H], 10.41 (1H, s, N-OH), 













Following general procedure (i) starting from 6-{3-[4-(1H-
indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H-indol-1-yl} 
hexanenitrile 270 (0.150 g, 0.354 mmol) in anhydrous DMF 
(10 mL) with hydroxylamine hydrochloride (0.123 g, 1.77 
mmol) and triethylamine (0.25 mL, 0.18 g, 1.8 mmol) gave 
desired product as a dark red solid (0.134 g, 86%): m.p. 142-
143 °C; νmax/cm
-1
 (KBr) 3377, 2933, 2247, 1770, 1706, 1527, 
1121, 735; δH (300 MHz, DMSO-d6) 1.25-1.36 [2H, m, C(4′′)-H2], 1.56 [2H, quin, J 
7.3, C(3′′)-H2], 1.73 [2H, quin, J 7.1, C(5′′)-H2], 2.44 [2H, t, J 7.0, C(2′′)-H2], 4.23 [2H, 
t, J 6.7, C(6′′)-H2], 6.62 [1H, t, J 7.3, C(6)-H], 6.67-6.74 [2H, m, C(6′, 7)-H], 6.87 [1H, 
d, J 8.0, C(7′)-H], 6.99 [1H, t, J 7.8, C(5)-H], 7.05 [1H, t, J 7.9, C(5′)-H], 7.39 [1H, d, J 
8.1, C(4)-H], 7.49 [1H, d, J 8.2, C(4′)-H], 7.77 [1H, s, C(2′)-H], 7.82 [1H, d, J 1.8, 
C(2)-H], 10.48 (1H, bs, N-OH), 11.76 (1H, bs, NH); δc (75 MHz, DMSO-d6) 16.0 
(CH2), 24.3 (CH2), 25.1 (CH2), 28.8 (CH2), 45.4 (CH2), 104.7 (C, aromatic C), 105.3 
(C, aromatic C), 110.3 (CH, aromatic CH), 111.9 (CH, aromatic CH), 119.4 (CH, 
aromatic CH), 119.6 (CH, aromatic CH), 120.6 (CN), 120.9 (CH, aromatic CH), 121.1 
(CH, aromatic CH), 121.7 (CH, aromatic CH), 121.8 (CH, aromatic CH), 123.7 (C, 
aromatic C), 124.6 (C, aromatic C), 125.0 (C, aromatic C), 125.8 (C, aromatic C), 129.5 
(CH, aromatic CH), 132.1 (CH, aromatic CH), 135.7 (C, aromatic C), 136.0 (C, 




 100%]; HRMS 
(ESI
+
): Exact mass calculated for (C26H23N4O3)
+









Following general procedure (i) starting from 6,6'-[3,3'-(2,5-
dioxo-2,5-dihydrofuran-3,4-diyl)bis(1H-indole-3,1-diyl)]di 
hexanenitrile 271 (0.084g, 0.162 mmol) in anhydrous DMF (8 
mL) with hydroxylamine hydrochloride (0.056 g, 0.809 mmol) 
and triethylamine (0.11 mL, 0.08 g, 0.81 mmol) gave desired 
product as a dark red solid (0.076 g, 87%): m.p. 83-84 °C; 
νmax/cm
-1
 (KBr) 3257, 2936, 2244, 1771, 1713, 1530, 1392, 
1159, 743; δH (300 MHz, DMSO-d6) 1.25-1.38 [4H, m, 2 × C(4′′)-H2], 1.57 [4H, quin, J 
7.4, 2 × C(3′′)-H2], 1.75 [4H, quin, J 7.2, 2 × C(5′′)-H2], 2.45 [4H, t, J 7.1, 2 × C(2′′)-
H2], 4.25 [4H, t, J 6.9, × C(6′′)-H2], 6.68 [2H, t, J 7.4, C(6, 6′)-H], 6.80 [2H, d, J 7.7, 
C(7, 7′)-H], 7.05 [2H, t, J 7.6, C(5, 5′)-H], 7.50 [2H, d, J 8.3, C(4, 4′)-H], 7.82 [2H, s, 
C(2, 2′)-H], 10.43 (N-OH); δc (75 MHz, DMSO-d6)  16.0 (2 × CH2), 24.3 (2 × CH2), 
25.2 (2 × CH2), 28.7 (2 × CH2), 45.4 (2 × CH2), 104.7 (2C, 2 × aromatic C), 110.3 
(2CH, 2 × aromatic CH), 119.6 (2CH, 2 × aromatic CH), 120.5 (2 × CN), 121.2 (2CH, 2 
× aromatic CH), 121.8 (2CH, 2 × aromatic CH), 124.0 (2C, 2 × aromatic C), 125.6 (2C, 





 40%]; HRMS (ESI
+
): Exact mass calculated for 
(C32H32N5O3)
+







indol-1-yl}hexanoic acid 283 
 
Following general procedure (i) starting from 6-{3-[4-(1H-
indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H-indol-1-yl} 
hexanoic acid 278 (0.120 g, 0.271 mmol) in anhydrous DMF 
(10 mL) with hydroxylamine hydrochloride (0.094 g, 1.36 
mmol) and triethylamine (0.19 mL, 0.14 g, 1.4 mmol) gave 
desired product as a dark red solid (0.107 g, 86%): m.p. 133-
135 °C; νmax/cm
-1
 (KBr) 3372, 2935, 1768, 1703, 1612, 1527, 
1391, 1097, 735; δH (400 MHz, DMSO-d6) 1.18-1.27 [2H, m, C(4′′)-H2], 1.51 [2H, 
quin, J 7.5, C(3′′)-H2], 1.71 [2H, quin, J 7.3, C(5′′)-H2], 2.18 [2H, t, J 7.4, C(2′′)-H], 
4.22 [2H, t, J 6.9, C(6′′)-H], 6.60 [1H, t, J 7.6, C(6)-H], 6.67-6.73 [2H, m, C(6′, 7)-H], 
6.87 [1H, d, J 8.2, C(7′)-H], 6.98 [1H, t, J 7.6, C(5)-H], 7.04 [1H, t, J 7.7, C(5′)-H], 7.38 
[1H, d, J 8.2, C(4)-H], 7.48 [1H, d, J 8.3, C(4′)-H], 7.77 [1H, s, C(2′)-H], 7.82 [1H, d, J 
2.9, C(2)-H], 10.45 (1H, s, NOH), 11.75 (1H, bd, J 2.4, NH), 12.02 (1H, bs, COOH); δc 
(75 MHz, DMSO-d6) 24.0 (CH2), 25.6 (CH2), 29.3 (CH2), 33.5 (CH2), 45.6 (CH2), 
104.7 (C, aromatic C), 105.4 (C, aromatic C), 110.2 (CH, aromatic CH), 111.8 (CH, 
aromatic CH), 119.4 (CH, aromatic CH), 119.6 (CH, aromatic CH), 120.9 (CH, 
aromatic CH), 121.1 (CH, aromatic CH), 121.7 (CH, aromatic CH), 121.8 (CH, 
aromatic CH), 123.8 (C, aromatic C), 124.6 (C, aromatic C), 125.0 (C, aromatic C), 
125.9 (C, aromatic C), 129.5 (CH, aromatic CH), 132.0 (CH, aromatic CH), 135.8 (C, 





 100%]; HRMS (ESI
+
): Exact mass calculated for (C26H24N3O5)
+
 









Following general procedure (i) starting from 6,7,8,9,10,11-
hexahydro-5,21:12,17-dimethenodibenzo[i,o]furo[3,4-l][1,8]
diazacyclohexadecine-18,20-dione 272 (0.151 g, 0.368 mmol) 
in anhydrous DMF (10 mL) with hydroxylamine hydrochloride 
(0.127 g, 1.84 mmol) and triethylamine (0.26 mL, 0.19 g, 1.8 
mmol) gave desired product as a purple solid (0.129 g, 82%): 
m.p. >300 °C; νmax/cm
-1
 (KBr) 3373, 2924, 1768, 1712, 1619, 1534, 1470, 1390, 735; 
δH (300 MHz, DMSO-d6) 1.06 [4H, bs, C(8, 9)-H2], 1.80 [4H, bs, C(7, 10)-H2], 4.12-
4.22 [4H, m, C(6, 11)-H2], 7.14 [2H, ddd, J 7.9, 7.2, 1.0, C(2, 15)-H], 7.21 [2H, ddd, J 
8.2, 7.1, 1.2, C(3, 14)-H], 7.39 [2H, s, C(22, 23)-H], 7.51 [2H, d, J 7.8, C(4, 13)-H], 
7.81 [2H, dd, J 7.1, 0.9, C(1, 16)-H], 10.47 (N-OH); δc (75 MHz, DMSO-d6)  22.7 (2 × 
CH2), 27.3 (2 × CH2), 44.2 (2 × CH2), 102.5 (2C, 2 × aromatic C), 110.5 (2CH, 2 × 
aromatic CH), 120.2 (2CH, 2 × aromatic CH), 121.4 (2CH, 2 × aromatic CH), 121.7 
(2CH, 2 × aromatic CH), 126.8 (2C, 2 × aromatic C), 128.6 (2C, 2 × aromatic C), 131.9 





 10%]; HRMS (ESI
+
): Exact mass calculated for (C26H24N3O3)
+
 




Following general procedure (i) starting from 3-(1H-indol-3-
yl)-4-(1-methyl-1H-indol-3-yl)furan-2,5-dione 265 (0.104 g, 
0.304 mmol) in anhydrous DMF (8 mL) with hydroxylamine 
hydrochloride (0.101 g, 1.52 mmol) and triethylamine (0.20 
mL, 0.15 g, 1.5 mmol) gave desired product as a dark red solid (83%): m.p. 137-139 °C; 
νmax/cm
-1
 (KBr) 3332, 2930, 1767, 1706, 1612, 1529, 1460, 1023; δH (300 MHz, 
DMSO-d6) 3.87 (3H, s, CH3), 6.61-6.74 [3H, m, C(6, 6′, 7′)-H], 6.83 [1H, d, J 8.0, C(7)-
H], 6.99 [1H, t, J 7.5, C(5)-H], 7.04 [1H, t, J 7.5, C(5′)-H], 7.39 [1H, d, J 8.0, C(4)-H], 
7.44 [1H, d, J 8.1, C(4′)-H], 7.77 [1H, d, J 7.8, C(2)-H], 7.87 [1H, s, C(2′)-H], 10.45 
(1H, s, N-OH), 11.74 (1H, bs, NH); δc (75 MHz, DMSO-d6)  32.9 (CH3), 104.5 (C, 




CH), 119.4 (CH, aromatic CH), 119.7 (CH, aromatic CH), 120.8 (CH, aromatic CH), 
121.0 (CH, aromatic CH), 121.7 (CH, aromatic CH), 121.8 (CH, aromatic CH), 123.9 
(C, aromatic C), 124.0 (C, aromatic C), 125.4 (C, aromatic C), 125.6 (C, aromatic C), 
129.3 (CH, aromatic CH), 133.2 (CH, aromatic CH), 135.9 (C, aromatic C), 136.5 (C, 




 50%]; HRMS (ESI
-
): Exact 
mass calculated for (C21H14N3O3)
-




Following general procedure (i) starting from 3,4-bis(1-methyl-
1H-indol-3-yl)furan-2,5-dione 147 (0.092 g, 0.258 mmol) in 
anhydrous DMF (10 mL) with hydroxylamine hydrochloride 
(0.090 g, 1.29 mmol) and triethylamine (0.18 mL, 0.13 g, 1.3 
mmol) gave desired product as a dark red solid (0.081 g, 84%): m.p. >300 °C; νmax/cm
-1
 
(KBr) 3224, 1764, 1694, 1610, 1519, 1367, 1097; δH (300 MHz, DMSO-d6) 3.86 (6H, s, 
2 × CH3), 6.67 [2H, t, J 7.4, C(6, 6′)-H], 6.76 [2H, d, J 7.9, C(7, 7′)-H], 7.05 [2H, t, J 
7.4, C(5, 5′)-H], 7.44 [2H, d, J 8.2, C(4, 4′)-H], 7.84 (2H, s, C(2, 2′)-H], 10.44 (1 H, s, 
N-OH); δc (75 MHz, DMSO-d6)  32.9 (2 × CH3), 104.6 (2C, 2 × aromatic C), 110.2 
(2CH, 2 × aromatic CH), 119.6 (2CH, 2 × aromatic CH), 121.1 (2CH, 2 × aromatic 
CH), 121.8 (2CH, 2 × aromatic CH), 123.7 (2C, 2 × aromatic C), 125.7 (2C, 2 × 





 100%]; HRMS (ESI
+
): Exact mass calculated for 
(C22H18N3O3)
+





Following general procedure (i) starting from 3-(1-ethyl-1H-
indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-2,5-dione 273 
(0.103 g, 0.278 mmol) in anhydrous DMF (10 mL) with 
hydroxylamine hydrochloride (0.094 g, 1.39 mmol) and 
triethylamine (0.2 mL, 0.14 g, 1.4 mmol) gave desired product 
as a dark red solid (0.072 g, 69%): m.p. 236-238 °C; νmax/cm
-1
 (KBr) 3239, 2932, 1763, 
1699, 1523, 1219, 739; δH (300 MHz, DMSO-d6) 1.30 (3H, t, J 7.6, CH2CH3), 3.87 (3H, 
Experimental 
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s, CH3), 4.24 (2H, q, J 7.1 CH2CH3), 6.62-6.69 [2H, m, C(6′, 7′)-H], 6.75 [1H, t, J 7.6, 
C(6)-H], 6.96 [1H, d, J 8.15, C(7)-H], 7.03-7.11 [2H, m, (5, 5′)-H], 7.45 [1H, d, J 8.15, 
C(4′)-H], 7.50 [1H, d, 8.49, C(4)-H], 7.74 [1H, s, C(2)-H], 7.90 [1H, s, C(2′)-H], 10.47 
(N-OH); δc (75 MHz, DMSO-d6)  15.2 (CH2CH3), 32.9 (CH3), 40.7 (CH2CH3), 104.4 
(C, aromatic C), 104.8 (C, aromatic C), 110.18 (CH, aromatic CH), 110.23 (CH, 
aromatic CH), 119.65 (CH, aromatic CH), 119.67 (CH, aromatic CH), 121.2 (CH, 
aromatic CH), 121.3 (CH, aromatic CH), 121.8 (2CH, 2 × aromatic CH), 123.4 (C, 
aromatic C), 124.1 (C, aromatic C), 125.2 (C, aromatic C), 126.0 (C, aromatic C), 131.6 
(CH, aromatic CH), 133.4 (CH, aromatic CH), 135.4 (C, aromatic C), 136.6 (C, 




 100%]; HRMS 
(ESI
+
): Exact mass calculated for (C23H20N3O3)
+





Following general procedure (i) starting from 6-(3-(4-(1-methyl  
-1H-indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl)-1H-indol-1-
yl)hexanenitrile 274 (0.103 g, 0.235 mmol) in anhydrous DMF 
(8 mL) with hydroxylamine hydrochloride (0.079 g, 1.18 mmol) 
and triethylamine (0.16 mL, 0.12 g, 1.2 mmol) gave desired 
product as a dark red solid (0.087 g, 82%): m.p. 123-125 °C; 
νmax/cm
-1
 (KBr) 3229, 2935, 2244, 1769, 1708, 1529, 1099, 742; 
δH (300 MHz, DMSO-d6) 1.22-1.39 [2H, m, C(4′′)-H2], 1.57 [2H, quin, J 7.27, C(3′′)-
H2], 1.73 [2H, quin, J 7.04, C(5′′)-H2], 2.45 [2H, t, J 7.2, C(2′′)-H2], 3.88 (3H, s, CH3), 
4.23 [2H, t, J 6.9, C(6′′)-H2], 6.62-6.68 [2H, m, C(6′, 7′)-H], 6.73 [1H, t, J 7.7, C(6)-H], 
6.94 [1H, d, J 7.8, C(7)-H], 7.01-7.10 [2H, m, (5, 5′)-H], 7.45 [1H, d, J 8.0, C(4′)-H], 
7.50 [1H, d, J 8.2, C(4)-H], 7.75 [1H, s, C(2)-H], 7.90 [1H, s, C(2′)-H], 10.43 (1H, s, N-
OH); δc (75 MHz, DMSO-d6) 16.0 (CH2), 24.3 (CH2), 25.2 (CH2), 28.8 (CH2), 32.9 
(CH3), 45.9 (CH2), 104.4 (C, aromatic C), 104.9 (C, aromatic C), 110.2 (CH, aromatic 
CH), 110.3 (CH, aromatic CH), 119.6 (2 × CH, 2 aromatic CH), 120.6 (CN), 121.1 
(CH, aromatic CH), 121.2 (CH, aromatic CH), 121.77 (CH, aromatic CH), 121.81 (CH, 
aromatic CH), 123.5 (C, aromatic C), 124.2 (C, aromatic C), 125.3 (C, aromatic C), 
126.0 (C, aromatic C), 132.0 (CH, aromatic CH), 133.3 (CH, aromatic CH), 135.7 (C, 








 50%]; HRMS (ESI
-
): Exact mass calculated for (C27H23N4O3)
-




yl]-1H-indol-1-yl}hexanoic acid 289 
 
Following general procedure (i) starting from 6-{3-[4-(1-
methyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H -
indol-1-yl}hexanoic acid 279 (0.101 g, 0.221 mmol) in 
anhydrous DMF (8 mL) with hydroxylamine hydrochloride 
(0.076 g, 1.11 mmol) and triethylamine (0.15 mL, 0.11 g, 1.1 
mmol) gave desired compound as a dark red solid (0.085 g, 
79%): m.p. 196-197 °C; νmax/cm
-1
 (KBr) 3114, 2935, 1710, 
1609, 1529, 1098, 741; δH (300 MHz, DMSO-d6) 1.16-1.29 [2H, m, C(4′′)-H2], 1.51 
[2H, quin, J 7.4, C(3′′)-H2], 1.70 [2H, quin, J 7.1, C(5′′)-H2], 2.17 [2H, t, 7.3, C(2′′)-H2], 
3.87 (3H, s, CH3), 4.21 [2H, t, J 6.7, C(6′′)-H2], 6.58-6.66 [2H, m, C(6′, 7′)-H], 6.72 
[1H, t, J 7.4, C(6)-H], 6.93 [1H, d, J 8.0, C(7)-H], 7.00-7.09 [2H, m, (5, 5′)-H], 7.43 
[1H, d, J 8.3, C(4′)-H], 7.48 [1H, d, J 8.3, C(4)-H], 7.73 [1H, s, C(2)-H], 7.90 [1H, s, 
C(2′)-H], 10.43 (1H, bs, NH), 11.99 (1H, bs, COOH); δc (75 MHz, DMSO-d6) 24.0 
(CH2), 25.6 (CH2), 29.3 (CH2), 32.9 (CH3), 33.5 (CH2), 45.6 (CH2), 104.4 (C, aromatic 
C), 104.8 (C, aromatic C), 110.17 (CH, aromatic CH), 110.24 (CH, aromatic CH), 
119.57 (CH, aromatic CH), 119.59 (CH, aromatic CH), 121.10 (CH, aromatic CH), 
121.12 (CH, aromatic CH), 121.8 (2CH, 2 × aromatic CH), 123.5 (C, aromatic C), 
124.3 (C, aromatic C), 125.3 (C, aromatic C), 126.0 (C, aromatic C), 132.0 (CH, 
aromatic CH), 133.3 (CH, aromatic CH), 135.7 (C, aromatic C), 136.6 (C, aromatic C), 




 100%]; HRMS 
(ESI
+
): Exact mass calculated for (C27H26N3O5)
+









Following general procedure (i) starting from 3-(1H-indol-3-yl)-
4-(1-isopropyl-1H-indol-3-yl)furan-2,5-dione 266 (0.120 g, 
0.323 mmol) in anhydrous DMF (8 mL) with hydroxylamine 
hydrochloride (0.11 g, 1.62 mmol) and triethylamine (0.23 mL, 
0.17 g, 1.6 mmol) gave desired product as a dark red solid 
(0.097 g, 77%): m.p. 106-109 °C; νmax/cm
-1 
(KBr) 3118, 3135, 2970, 1812, 1745, 1627, 
1529, 1247; δH (300 MHz, DMSO-d6) 1.38 (6H, d, J 6.6, 2 × CH3), 4.78 [1H, sept, J 6.7 
CH(CH3)2], 6.63 (2H, m, C(6, 7)-H], 6.78 [1H, t, J 7.2, C(6′)-H], 6.96-7.10 [3H, m, C(5, 
5′, 7′)-H], 7.39 [1H, d, J 8.1, C(4)-H], 7.53 [1H, d, J 8.3, C(4′)-H], 7.69 [1H, s, C(2′)-
H], 7.83 [1H, d, J 2.8, C(2)-H], 10.42 (1H, s, N-OH), 11.74 (1H, s, N-H); δc (75 MHz, 
DMSO-d6) 22.1 [CH(CH3)2], 47.0 [CH(CH3)2], 105.0 (C, aromatic C), 105.2 (C, 
aromatic C), 110.3 (CH, aromatic CH), 111.9 (CH, aromatic CH), 119.5 (CH, aromatic 
CH), 119.8 (CH, aromatic CH), 121.1 (CH, aromatic CH), 121.3 (CH, aromatic CH), 
121.71 (CH, aromatic CH), 121.73 (CH, aromatic CH), 123.6 (C, aromatic C), 124.6 (C, 
aromatic C), 124.9 (C, aromatic C), 125.9 (C, aromatic C), 128.2 (CH, aromatic CH), 
129.8 (CH, aromatic CH), 135.3 (C, aromatic C), 136.1 (C, aromatic C), 168.37 (C=O), 




 100%]; HRMS (ESI
+
): Exact mass calculated 
for (C23H20N3O3)
+





Following general procedure (i) starting from 3-(1-isopropyl-
1H-indol-3-yl)-4-(1-methyl-1H-indol-3-yl)furan-2, 5-dione 275 
(0.099 g, 0.258 mmol) in anhydrous DMF (8 mL) with 
hydroxylamine hydrochloride (0.089 g, 1.29 mmol) and 
triethylamine (0.18 mL, 0.13 g, 1.29 mmol) gave desired 
product as a dark red solid (0.096 g, 93%): m.p. 84-86 °C; νmax/cm
-1 
(KBr) 3118, 2930, 
1712, 1654, 1463, 1220, 741; δH (300 MHz, DMSO-d6) 1.41 (6H, d, J 6.6, 2 × CH3), 
3.93 (3H, s, CH3), 4.78 [1H, sept, J  6.6, CH(CH3) 2], 6.52 [1H, d, J 7.7, C(7)-H] 6.63 




[1H, d, J 8.2, C(4)-H], 7.54 [1H, d, J 8.5, C(4′)-H], 7.67 [1H, s, C(2′)-H], 7.93 [1H, s, 
C(2)-H], 10.48 (1H, s, N-OH); δc (75 MHz, DMSO-d6)  22.1 (2 × CH3), 32.9 
[CH(CH3)2], 47.0 (CH3), 104.3 (C, aromatic C), 105.1 (C, aromatic C), 110.2 (CH, 
aromatic CH), 110.3 (CH, aromatic CH), 119.7 (CH, aromatic CH), 119.8 (CH, 
aromatic CH), 121.3 (2CH, 2 × aromatic CH), 121.75 (CH, aromatic CH), 121.77 (CH, 
aromatic CH), 123.4 (C, aromatic C), 124.6 (C, aromatic C), 124.9 (C, aromatic C), 
126.0 (C, aromatic C), 128.2 (CH, aromatic CH), 133.6 (CH, aromatic CH), 135.3 (C, 





 100%]; HRMS (ESI
+








Following general procedure (i) starting from 3-(1-ethyl-      
1H-indol-3-yl)-4-(1-isopropyl-1H-indol-3-yl)furan-2,5-dione 
276 (0.068 g, 0.171 mmol) in anhydrous DMF (8 mL) with 
hydroxylamine hydrochloride (0.059 g, 0.853 mmol) and 
triethylamine (0.12 mL, 0.87 g, 0.85 mmol) gave desired 
product as a dark red solid (0.056 g, 80%): m.p. 83-85 °C; νmax/cm
-1 
(KBr) 3125, 2975, 
1769, 1713, 1527, 1214, 741; δH (300 MHz, DMSO-d6,) 1.34 (3H, t, J 7.2, CH2CH3) 
1.39 (6H, d, J 6.6, 2 × CH3), 4.27 (2H, q, J 7.2, CH2CH3), 4.79 [1H, sept, J 6.6 
CH(CH3)2], 6.66-6.72 [2H, m, C(6, 7)-H], 6.76 [1H, t, J 7.6, C(6′)-H], 6.95 [1H, d, J 
7.8, C(7′)-H], 7.04-7.11 [2H, m, C(5, 5′)-H], 7.50 [1H, d, J 8.3, C(4)-H], 7.55 [1H, d, J 
8.4, C(4′)-H], 7.74 [1H, s, C(2′)-H], 7.85 [1H, s, C(2)-H], 10.47 (1H, s, N-OH), δc (75 
MHz, DMSO-d6) 15.2 (CH3), 22.1 (2 × CH3), 40.7 (CH2), 47.0 (CH), 104.6 (C, 
aromatic C), 105.0 (C, aromatic C), 110.2 (CH, aromatic CH), 110.4 (CH, aromatic 
CH), 119.7 (CH, aromatic CH), 119.8 (CH, aromatic CH), 121.38 (CH, aromatic CH), 
121.44 (CH, aromatic CH), 121.7 (CH, aromatic CH), 121.8 (CH, aromatic CH), 123.9 
(C, aromatic C), 124.3 (C, aromatic C), 125.3 (C, aromatic C), 125.7 (C, aromatic C), 
128.4 (CH, aromatic CH), 131.9 (CH, aromatic CH), 135.4 (C, aromatic C), 135.6 (C, 




 100%]; HRMS 
(ESI
+
): Exact mass calculated for (C25H24N3O3)
+
 414.1818. Found 414.1814. 
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Following general procedure (i) starting from 6-{3-[4-(1-
isopropyl-1H-indol-3-yl)-2,5-dioxo-2,5-dihydrofuran-3-yl]-1H 
-indol-1-yl}hexanenitrile 277  (0.104 g, 0.223 mmol) in 
anhydrous DMF (8 mL) with hydroxylamine hydrochloride 
(0.077 g, 1.12 mmol) and triethylamine (0.16 mL, 1.2 g, 1.1 
mmol) gave desired product as a dark red solid (0.083 g, 77%): 
m.p. 80-82 °C; νmax/cm
-1 
(KBr) 3230, 2929, 2244, 1789, 1713, 
1528, 1216, 742; δH (300 MHz, DMSO-d6) 1.34 [2H, m, C(4′′)-H], 1.39 (6H, d, J 6.6, 2 
× CH3), 1.57 [2H, quin, J 7.5, C(3′′)-H], 1.76 [2H, quin, J 7.2, C(5′′)-H], 2.45 [2H, t, J 
7.1, C(2′′)-H], 4.26 [2H, t, J 6.9, C(6′′)-H], 4.79 [1H, sept, J 6.7, CH(CH3)2], 6.64-6.77 
[3H, m, C(6, 6′, 7)-H], 6.96 [1H, d, J 8.0, C(7′)-H], 7.03-7.10 [2H, m, C(5, 5′)-H], 7.49-
7.55 [2H, m, C(4, 4′)-H], 7.74 [1H, s, C(2′)-H], 7.85 [1H, s, C(2)-H], 10.47 (1H, s, N-
OH); δc (75 MHz, DMSO-d6)  16.0 (CH2), 22.1 (2 × CH3), 24.3 (CH2), 25.2 (CH2), 28.8 
(CH2), 45.4 (CH2), 47.0 (CH), 104.6 (C, aromatic C), 105.0 (C, aromatic C), 110.3 
(2CH, 2 × aromatic CH), 119.6 (CH, aromatic CH), 119.7 (CH, aromatic CH), 120.5 
(CN), 121.3 (2CH, 2 × aromatic CH), 121.7 (CH, aromatic CH), 121.8 (CH, aromatic 
CH), 124.0 (C, aromatic C), 124.3 (C, aromatic C), 125.3 (C, aromatic C), 125.7 (C, 
aromatic C), 128.3 (CH, aromatic CH), 132.3 (CH, aromatic CH), 135.4 (C, aromatic 







): Exact mass calculated for (C29H29N4O3)
+







7.3 Synthesis of indolo[2,3-a]carbazoles 
 






3,4-Di(1H-indol-3-yl)furan-2,5-dione 255 (1.001 g, 30.5 mmol) 
was dissolved in acetonitrile (1 L) giving a bright red solution 
which was irradiated using a standard high pressure mercury 
lamp, with a catalytic amount of iodine in the presence of air for 
24 hours. At this point, a yellow precipitate had formed and the suspension was allowed 
to cool to room temperature. The precipitate was collected using vacuum filtration and 
washed with saturated aqueous sodium thiosulfate (10 mL), followed by water (10 mL) 
and allowed to dry to give desired product as a yellow solid (0.723 g, 72%): m.p. >300 




 (KBr); 3408, 1817, 1752, 1405, 1258, 738; δH (300 
MHz, DMSO-d6) 7.33 [2H, t, J 7.6, C(3, 9)-H], 7.55 [2H, ddd, J 8.3, 7.2, 1.2, C(2, 10)-












To a solution of furo[3,4-c]indolo[2,3-a]carbazole-
5,7(12H,13H)-dione 76 (0.434 g, 1.33 mmol) in anhydrous 
DMF (50 mL) was added hydroxylamine hydrochloride (0.464 
g, 6.65 mmol) followed by triethylamine (0.93 mL, 0.67 g, 6.7 
mmol). The reaction mixture was then heated to 70 °C and stirred at this temperature for 
24 hours. After cooling, water (50 mL) was added and the precipitate collected using 
vacuum filtration and was washed with 1 M aqueous HCl (10 mL) and water (10 mL) 
before being allowed to dry to give the desired product as a red solid (0.418 g, 92%): 




 (KBr) 3399, 3209, 1738, 1695, 1563, 1403, 
1063, 748; δH (400 MHz, DMSO-d6) 7.38 [2H, t, J 7.5, C(3, 9)-H], 7.58 [2H, t, J 7.6, 
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C(2, 10)-H], 7.83 [2H, d, J 8.2, C(1, 11)-H], 8.98 [2H, d, J 8.0, C(4, 8)-H], 10.58 (1H, s, 











265 (0.250 g, 0.735 mmol) was dissolved in acetonitrile (250 
mL) and irradiated using a standard high pressure mercury lamp, 
with a catalytic amount of iodine in the presence of air for 16 
hours. At this point a yellow precipitate had formed and the suspension was allowed to 
cool to room temperature. The precipitate was collected using vacuum filtration and 
washed with saturated sodium thiosulfate, followed by water and allowed to dry to give 
desired product as a yellow solid (0.103 g, 41%): m.p. >300 °C; νmax/cm
-1
 (KBr) 3391, 
1820, 1730, 1399, 1341, 1251, 738; δH (600 MHz, DMSO-d6)  4.23  (3H, s, CH3), 7.29 
[1H, t, J  7.5, C(3 or 9)-H], 7.33 [1H, t, J 7.5, C(3 or 9)-H], 7.52 [1H, ddd, J 8.0, 7.1, 
0.9, C(2 or 10)-H], 7.59 [1H, ddd, J 8.1, 7.1, 0.9, C(2 or 10)-H], 7.70-7.73 [2H, m, C(1, 
11)-H], 8.68 [1H, d, J 8.3, C(4 or 8)-H], 8.70 [1H, d, J 8.6, C(4 or 8)-H], 12.14 [1H, bs, 
N(13)-H]; δc (150 MHz, DMSO-d6, 37 °C) 31.9 (CH3), 110.0 (CH, aromatic CH), 112.1 
(CH, aromatic CH), 115.3 (C, aromatic C), 116.5 (C, aromatic C), 117.1 (C, aromatic 
C), 117.3 (C, aromatic C), 120.2 (2C, 2 × aromatic C), 120.6 (CH, aromatic CH), 120.7 
(CH, aromatic CH), 123.2 (CH, aromatic CH), 123.4 (CH, aromatic CH), 127.2 (2CH, 2 
× aromatic CH), 129.2 (C, aromatic C), 130.9 (C, aromatic C), 141.0 (C, aromatic C), 







): Exact mass calculated for (C21H11N2O3)
-









To a solution of 12-methylfuro[3,4-c]indolo[2,3-a]carbazole-
5,7(12H,13H)-dione 297 (0.093 g, 0.273 mmol) in anhydrous 
DMF (10 mL) was added hydroxylamine hydrochloride (0.095 
g, 1.37 mmol) and triethylamine (0.20 mL, 0.15 g, 1.4 mmol). 
The reaction mixture was then heated to 80 °C and stirred at this temperature for 24 
hours. After cooling, water (20 mL) was added and the precipitate collected using 
vacuum filtration and was washed with 1 M aqueous HCl (5 mL) followed by water (5 
mL) before being allowed to dry to give gave desired product as an orange solid (0.084 
g, 87%): m.p. >300 °C; νmax/cm
-1
 (KBr) 3333, 2840, 1744, 1693, 1567, 1397, 1108, 
733; δH (300 MHz, DMSO-d6) 4.39 (3H, s, CH3), 7.35 [2H, t, J 7.5, C(3, 9)-H], 7.56 
[1H, t, J 7.6, C(2 or 10)-H], 7.60 [1H, t, J 7.7, C(2 or 10)-H], 7.77 [1H, d, J 8.1, C(1 or 
11)-H], 7.78 [1H, d, J 8.3, C(1 or 11)-H], 9.02 [2H, d, J 8.0, C(4, 8)-H], 10.43 (1H, bs, 
N-OH) 12.07 [1H, bs, N(13)-H]; δc (75 MHz, DMSO-d6) 31.9 (CH3), 109.7 (CH, 
aromatic CH), 112.0 (CH, aromatic CH), 115.0 (C, aromatic C), 115.3 (C, aromatic C), 
115.5 (C, aromatic C), 116.7 (C, aromatic C), 120.1 (CH, aromatic CH), 120.2 (CH, 
aromatic CH), 120.59 (C, aromatic C), 120.63 (C, aromatic C), 124.0 (CH, aromatic 
CH), 124.2 (CH, aromatic CH), 126.87 (CH, aromatic CH), 126.91 (CH, aromatic CH), 
128.5 (C, aromatic C), 130.3 (C, aromatic C), 141.1 (C, aromatic C), 141.5 (C, aromatic 




 100%]; HRMS (ESI
-
): 
Exact mass calculated for (C21H12N3O3)
-





To a stirred suspension of 12-methylfuro[3,4-c]indolo[2,3-
a]carbazole-5,7(12H,13H)-dione 297 (0.102 g, 0.300 mmol) in 
THF (20 mL) was added hydrazine hydrate (0.10 mL, 0.10 g, 1.4 
mmol) and the mixture was heated to reflux and stirred at this 
temperature for 16 hours. After cooling the precipitate was collected by vacuum 
filtration, washed with water and allowed to dry to give an orange solid (0.070 g, 67%): 
m.p. >300 °C; νmax/cm
-1
 (KBr) 3375, 1687, 1568, 1398, 739; δH (300 MHz, DMSO-d6) 
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4.31 (3H, s, CH3), 4.83 (2H, s, NH2), 7.32 [2H, t, J 7.5, C(3, 9)-H], 7.50-7.63 [2H, m, 
C(2, 10)-H], 7.72 [1H, d, J 8.4, C(1 or 11)-H], 7.75 [1H, d, J 8.2, C(1 or 11)-H], 9.02 
[1H, d, J 7.8, C(4 or 8)-H], 9.03 [1H, d, J 7.8, C(4 or 8)-H], 11.53 [1H, bs, N(13)-H]; δc 
(150 MHz, DMSO-d6) 31.9 (CH3), 109.6 (CH, aromatic CH), 111.9 (CH, aromatic CH), 
115.3 (C, aromatic C), 116.52 (C, aromatic C), 116.54 (C, aromatic C), 116.8 (C, 
aromatic C), 120.0 (CH, aromatic CH), 120.1 (CH, aromatic CH), 120.68 (C, aromatic 
C), 120.74 (C, aromatic C), 124.1 (CH, aromatic CH), 124.2 (CH, aromatic CH), 126.7 
(CH, aromatic CH), 126.8 (CH, aromatic CH), 128.3 (C, aromatic C), 130.1 (C, 





 60%]; HRMS (ESI
+
): Exact mass calculated for 
(C21H15N4O2)
+





(0.707 g, 1.92 mmol) was dissolved in acetonitrile (700 mL) and 
irradiated using a standard high pressure mercury lamp with a 
catalytic amount of iodine in the presence of air for 24 hours. 
The yellow precipitate was collected using vacuum filtration and 
washed with saturated aqueous sodium thiosulfate, followed by water and allowed to 
dry to give a yellow solid (0.360 g) which analysis showed to be furo[3,4-c]indolo[2,3-
a]carbazole-5,7(12H,13H)-dione (57% recovery). The filtrate was concentrated to 
roughly 20 mL and the resulting precipitate was collected using vacuum filtration and 
washed with saturated aqueous sodium thiosulfate, followed by water to give a yellow 
solid which the crude NMR showed to be impure desired product (0.072 g): δH (300 
MHz, DMSO-d6) 4.67 [1H, d, J 17.1, CH=CH2 (trans)], 5.05 [1H, d, J 10.3, CH=CH2 
(cis)], 5.56 (2H, bs, CH2), 6.11-6.24 (1H, m, CH=CH2), 7.32-7.45 [2H, m, C(3, 9)-H], 
7.55-7.67 [2H, m, C(2, 10)-H], 7.79 [2H, d, J 8.3, C(1, 11)-H], 8.83 [1H, d, J 8.0, C(4 





 100%]; HRMS (ESI
+
): Exact mass calculated for (C23H15N2O3)
+









To a stirred suspension of furo[3,4-c]indolo[2,3-a]carbazole-
5,7(12H,13H)-dione 76 (0.504 g, 1.54 mmol) in anhydrous DMF 
(20 mL) in a flame-dried flask under nitrogen was added sodium 
hydride (60 wt. % oil dispersion, 0.180 g, 4.63 mmol). After 
stirring for 40 minutes, iodomethane (0.29 mL, 0.66 g, 4.6 mmol) was added to the dark 
blue solution and the mixture was stirred for 16 hours resulting in a pale yellow 
solution. Due to the presence of starting material in TLC analysis a further portion of 
sodium hydride (60 wt. % oil dispersion, 0.183 g, 4.63 mmol) was added followed after 
40 minutes by iodomethane (0.29 mL, 0.66 g, 4.6 mmol) and the mixture was stirred for 
a further 6 hours. The reaction mixture was then poured into water (50 mL) and the off-
white precipitate was collected by vacuum filtration, washed with 1 M aqueous HCl (5 
mL) followed by water (2 × 2 mL) and allowed to dry to give an off-white solid which 
on analysis was identified as dimethyl 11,12-dimethyl-11,12-dihydroindolo[2,3-
a]carbazole-5,6-dicarboxylate 188 (0.507 g, 1.3 mmol, 82%): 




 (KBr) 2952, 
2852, 1713, 1549, 1480, 1261, 1070, 733; δH (300 MHz, DMSO-
d6) 4.03 (6H, s, 2 × OCH3), 4.24 (6H, s, 2 × NCH3), 7.33 [2H, 
ddd, J 8.1, 7.1, 1.0, C(3, 8)-H], 7.60 [2H, ddd, J 8.3, 7.1, 1.1, C(2, 9)-H], 7.78 [2H, d, J 







A stirred suspension of furo[3,4-c]indolo[2,3-a]carbazole-5,7(12H,13H)-dione 76 
(1.004 g, 3.08 mmol) in anhydrous DMF (30 mL) in a flame-dried flask under nitrogen 
was cooled to -12 °C using an ice/salt bath. Sodium hydride (60 wt. % oil dispersion, 
0.260 g, 6.47 mmol) was then added and the mixture was stirred for 45 minutes. At this 
point, iodomethane (0.42 mL, 0.96 g, 6.5 mmol) was added dropwise and the mixture 
was allowed to slowly warm to room temperature and stirred for 16 hours. The reaction 
mixture was poured into 1 M aqueous HCl (60 mL) and the precipitate collected using 
vacuum filtration, washed with water and allowed to dry. The crude product was 
recrystallised from DMSO to give desired product as a bright yellow solid (0.775 g, 
71%): m.p. > 300 °C; νmax/cm
-1
 (KBr) 3058, 2934, 1817, 1747, 1566, 1250, 745; δH 
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(600 MHz, DMSO-d6) 4.34 (6H, s, 2 × CH3), 7.48 [2H, t, J 7.1, C(3, 9)-H], 7.72 [2H, 
ddd, J 8.2, 7.1, 1.1, C(2, 10)-H], 7.88 [2H, d, J 8.3, C(1, 11)-H], 8.95 [2H, d, J 7.9, C(4, 
8)-H]; δc (150 MHz, DMSO-d6) 37.1 (2 × CH3), 111.4 (2CH, 2 × aromatic CH), 117.9 
(2C, 2 × aromatic C), 118.1 (2C, 2 × aromatic C), 120.8 (2C, 2 × aromatic C), 121.4 
(2CH, 2 × aromatic CH), 123.5 (2CH, 2 × aromatic CH), 128.0 (2CH, 2 × aromatic 





 20%]; HRMS (ESI
+
): Exact mass calculated for (C22H14N2O3)
+
 
354.1004. Found 354.1003. 
 
Method C 
To a stirred suspension of dimethyl 11,12-dimethyl-11,12-dihydroindolo[2,3-
a]carbazole-5,6-dicarboxylate 188 (0.479 g, 1.20 mmol) in methanol (45 mL) was 
added 50% aqueous sodium hydroxide (5 mL) and the mixture was heated to reflux for 
24 hours. The reaction mixture was then allowed to cool and the solvent was evaporated 
under reduced pressure. The residue was suspended in water (20 mL) and the mixture 
was acidified to pH 2 with 10% aqueous HCl. The product was then collected using 
vacuum filtration and washed with water (10 mL) before being allowed to dry. The off-
white solid was then dissolved in acetic anhydride (10 mL) and heated to reflux for 4 
hours. After cooling, the solvent was evaporated under reduced pressure and the residue 
suspended in saturated aqueous sodium bicarbonate solution (20 mL). The product was 
collected by vacuum filtration, washed with water (5 mL) and allowed to dry yielding 
desired compound as a bright yellow powder (0.340 g, 80%). Analysis was identical to 





To a stirred suspension of 12,13-dimethylfuro[3,4-c]indolo[2,3-
a]carbazole-5,7(12H,13H)-dione 301 (0.320 g, 0.903 mmol) in 
anhydrous DMF (25 mL) was added hydroxylamine 
hydrochloride (0.311 g, 4.52 mmol) and triethylamine (0.60 mL, 
0.44 g, 4.5 mmol) and the mixture was heated to 80 °C for 24 hours. At this point the 
orange solution was allowed to cool before being poured into 1 M aqueous HCl (40 mL) 




give desired product as an orange solid (0.302 g, 91%); m.p. >300 °C; νmax/cm
-1
 (KBr) 
3194, 2926, 1752, 1692, 1470, 1007, 747; δH (400 MHz, DMSO-d6) 4.26 (6H, s, 2 × 
CH3), 7.35 [2H, t, J 7.6, C(3, 9)-H], 7.62 [2H, ddd, J 8.2, 7.2, 1.1, C(2, 10)-H], 7.76 
[2H, d, J 8.3, C(1, 11)-H], 9.03 [2H, d, J 7.8, C(4, 8)-H], 10.65 (1H, bs, N-OH); δc (150 
MHz, DMSO-d6) 36.9 (2 × CH3) 110.9 (2CH, 2 × aromatic CH), 115.5 (2C, 2 × 
aromatic C), 118.2 (2C, 2 × aromatic C), 120.8 (2CH, 2 × aromatic CH), 121.2 (2 C, 2 × 
aromatic C), 124.2 (2CH, 2 × aromatic CH), 127.5 (2CH, 2 × aromatic CH), 132.0 (2C, 





 5%]; HRMS (ESI
+








To a stirred suspension of furo[3,4-c]indolo[2,3-a]carbazole-
5,7(12H,13H)-dione 76 (0.198 g, 0.607 mmol) in anhydrous 
DMF (20 mL) in a flame-dried flask at room temperature under 
nitrogen was added sodium hydride (60 wt. %, 0.054 g, 1.27 
mmol) carefully and the mixture was stirred at this temperature 
for 40 minutes. Allyl bromide (0.12 mL, 0.17 g, 1.4 mmol) was then added and the 
mixture was stirred for 16 hours. At this point TLC analysis showed that some starting 
material still remained and so a second portion of sodium hydride was added (60 wt. %, 
0.030 g, 0.750 mmol) followed by a second portion of allyl bromide (0.12 mL, 0.17 g, 
1.4 mmol) and the mixture was stirred for a further 16 hours. The reaction mixture was 
then poured cautiously into water (60 mL) and the precipitate collected by vacuum 
filtration. The solid was washed with 1 M aqueous HCl (10 mL), followed by water (10 
mL) before being allowed to dry to give a pale yellow solid 
which analysis showed to be diallyl 11,12-diallyl-11,12-
dihydroindolo[2,3-a]carbazole-5,6-dicarboxylate 303 (0.228 g, 
74%): m.p. 179-181 °C; νmax/cm
-1
 (KBr) 3079, 1820, 1722, 1334, 
1237, 1195, 937, 741; δH (300 MHz, DMSO-d6) 4.98 [4H, dt, J 
5.7, 1.3, 2 × OCH2], 5.10 [4H, bs, 2 × NCH2], 5.25 [2H, dd, J 
17.2, 1.2, 2 × OCH2CH=CH2 (trans)], 5.35 [4H, dd, J 10.4, 1.6, 4 × CH=CH2 (cis)], 
5.47 [2H, dq, J 17.2, 1.6, 2 × NCH2CH=CH2 (trans)], 6.03-6.18 [4H, m, 4 × CH=CH2], 
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7.32 [2H, ddd, J 8.1, 7.1, 1.0, C(3, 8)-H], 7.55 [2H, ddd, J 8.3, 7.1, 1.1, C(2, 9)-H], 7.64 
[2H, d, J 8.2, C(1, 10)-H], 8.07 [2H, d, J 7.9, C(4, 7)-H]; δc (150 MHz, DMSO-d6) 50.7 
(2 × CH2), 66.7 (2 × CH2), 112.8 (2CH, 2 × aromatic CH), 117.6 (2CH2, 2 × CH=CH2), 
119.4 (2CH2, 2 × CH=CH2), 119.5 (2C, 2 × aromatic C), 119.7 (2C, 2 × aromatic C), 
121.5 (2CH, 2 × aromatic CH), 122.0 (2CH, 2 × aromatic CH), 123.0 (2C, 2 × aromatic 
C), 127.1 (2CH, 2 × aromatic CH), 130.6 (2C, 2 × aromatic C), 132.5 (2CH, 2 × 





 5%]; HRMS (ESI
+
): Exact mass calculated for 
(C32H29N2O4)
+
 505.2127. Found 505.2137. 
 
Method B 
A stirred suspension of furo[3,4-c]indolo[2,3-a]carbazole-5,7(12H,13H)-dione 76 
(0.201 g, 0.616 mmol) in anhydrous DMF (20 mL) in a flame-dried flask under nitrogen 
was cooled to -12 °C using an ice/salt bath. Sodium hydride (60 wt. % oil dispersion, 
0.054 g, 1.27 mmol) was then added and the mixture was stirred for 45 minutes. At this 
point, allyl bromide (0.11 mL, 0.15 g, 1.3 mmol) was added and the mixture was 
allowed to slowly warm to room temperature and stirred for 16 hours. The reaction 
mixture was poured into 1 M aqueous HCl (50 mL) and the precipitate collected using 
vacuum filtration and washed with water (5 mL) and allowed to dry. The crude product 
was recrystallised from DMSO to give desired product as a bright yellow solid (0.176 g, 
72%): m.p. >300 °C; νmax/cm
-1
 (KBr) 3426, 3014, 1819, 1750, 1569, 1335, 1216, 747; 
δH (600 MHz, DMSO-d6) 5.22 (4H, bt, J 2.0, 2 × NCH2), 5.27 [2H, dd, J 17.3, 1.1, 2 × 
CH=CH2 (trans)], 5.40 [2H, dd, J 10.8, 1.1, 2 × CH=CH2 (cis)], 6.19 [2H, ddt, J 17.3, 
10.7, 4.0, 2 × CH=CH2], 7.52 [2H, dt, J 7.4, 1.0, C(3, 9)-H], 7.69 [2H, dt, J 7.6, 1.1, 
C(2, 10)-H], 7.73 [2H, d, J 8.2, C(1, 11)-H], 9.02 [2H, d, J 7.9, C(4, 8)-H]; δc (150 
MHz, DMSO-d6) 51.1 (2 × CH2), 113.0 (2CH, 2 × aromatic CH), 117.8 (2 × CH=CH2), 
119.7 (2C, 2 × aromatic C), 120.0 (2C, 2 × aromatic C), 122.2 (2C, 2 × aromatic C), 
122.5 (2CH, 2 × aromatic CH), 124.2 (2CH, 2 × aromatic CH), 128.7 (2CH, 2 × 
aromatic CH), 133.6 (2 × CH=CH2, and 2C, 2 × aromatic C), 144.6 (2C, 2 × aromatic 




 5%]; HRMS (ESI
+
): Exact mass 
calculated for (C26H18N2O3)
+









To a stirred solution of 12,13-diallyl-12,13-dihydrofuro[3,4-
c]indolo[2,3-a]carbazole-5,7-dione 304 (0.150 g, 0.369 mmol) 
in anhydrous DMF (15 mL) was added hydroxylamine 
hydrochloride (0.128 g, 1.85 mmol) and triethylamine (0.26 mL, 
0.19 g, 1.9 mmol) and the resulting mixture was stirred at 80 °C 
for 24 hours. The orange solution was then allowed to cool and poured into 1 M 
aqueous HCl (60 mL) and the precipitate collected using vacuum filtration. The solid 
was suspended in a mixture of water (5 mL) and methanol (5 mL) and allowed to stir 
for 2 hours before the solid was collected using vacuum filtration and allowed to dry. 
This gave desired product as an orange solid (0.141 g, 90%): m.p. 248-250 °C; νmax/cm
-
1
 (KBr) 3294, 3082, 1757, 1693, 1442, 1330, 1113, 750; δH (300 MHz, DMSO-d6) 5.06 
(4H, bs, 2 × NCH2), 5.25 (2H, bd, J 17.8, CH=CH2 trans), 5.37 (2H, bd, J 11.3, 
CH=CH2 cis), 6.14 (ddt, J 17.3, 10.7, 3.8, CH=CH2), 7.38 [2H, ddd, J 8.0, 5.0, 3.1, C(3, 
9)-H], 7.55-7.62 [4H, m, C(1, 2, 10, 11)-H], 9.09 [2H, d, J 7.9, C(4, 8)-H], 10.67 (N-
OH); δc (75 MHz, DMSO-d6) 51.0 (2 × CH2CH=CH2), 112.5 (2CH, 2 × aromatic CH), 
116.5 (2C, 2 × aromatic C), 117.7 (2 × CH=CH2), 120.0 (2C, 2 × aromatic C), 121.9 
(2CH, 2 × aromatic CH), 122.6 (2C, 2 × aromatic C), 124.9 (2CH, 2 × aromatic CH), 
128.2 (2CH, 2 × aromatic CH), 132.8 (2C, 2 × aromatic C), 133.8 (2 × CH=CH2), 144.8 




 95%]; HRMS 
(ESI
+
): Exact mass calculated for (C26H20N3O3)
+
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(0.403 g, 1.24 mmol) was suspended in anhydrous DMF (20 
mL) in a flame-dried flask under nitrogen and at 0 °C. To this 
was added sodium hydride (60 wt. % oil dispersion, 0.074 g, 
1.85 mmol) resulting in a dark purple solution which was stirred 
at this temperature for 30 minutes. At this point, 6-bromohexane 
nitrile (0.27 mL, 0.35 g, 2.0 mmol) was added, followed by sodium iodide (0.278 g, 
1.85 mmol) and the mixture was allowed to warm to room temperature and stirred for 
16 hours. Water was then added cautiously to quench the reaction and the reaction 
mixture was poured into 1 M aqueous HCl (50 mL) and stirred for 2 hours. The 
resulting precipitate was collected using vacuum filtration, washed with copious 
amounts of water and allowed to dry to give a bright yellow solid (0.327 g, 65%): m.p. 
>300 °C; νmax/cm
-1
 (KBr) 3392, 2240, 1808, 1743, 1335, 1252, 747; δH (600 MHz, 
DMSO-d6) 1.35-1.42 [2H, m, C(4′)-H2], 1.50 [2H, quin, J 7.3, C(3′)-H2] , 1.83 [2H, 
quin, J 7.0, C(5′)-H2], 2.36 [2H, t, J 7.0, C(2′)-H2], 4.88 [2H, t, J 6.9, C(6′)-H2], 7.34 
[1H, t, J 7.5, C(3 or 9)-H], 7.36 [1H, t, J 7.6, C(3 or 9)-H], 7.59 [1H, t, J 7.7, C(2 or 
10)-H], 7.62 [1H, t, J 7.7, C(2 or 10)-H], 7.82 [1H, d, J 8.1, C(1 or 11)-H], 7.82 [1H, d, 
J 8.2, C(1 or 11)-H], 8.77 [1H, d, J 8.0, C(4 or 8)-H], 8.80 [1H, d, J 7.9, C(4 or 8)-H], 
12.15 [1H, s, N(13)-H]; δc (75 MHz, DMSO-d6) 16.0 (CH2), 24.5 (CH2), 25.1 (CH2), 
29.7 (CH2), 43.9 (CH2), 110.4 (CH, aromatic CH), 112.4 (CH, aromatic CH), 116.0 (C, 
aromatic C),116.9 (C, aromatic C), 117.3 (C, aromatic C), 117.5 (C, aromatic C), 120.3 
(C, aromatic C), 120.4 (C, aromatic C), 120.5 (CN), 120.79 (CH, aromatic CH), 120.84 
(CH, aromatic CH), 123.3 (CH, aromatic CH), 123.5 (CH, aromatic CH), 127.35 (CH, 
aromatic CH), 127.39 (CH, aromatic CH), 128.8 (C, aromatic C), 130.1 (C, aromatic C), 





 10%]; HRMS (ESI
+
): Exact mass calculated for (C26H20N3O3)
+
 








To a stirred solution of 6-[5,7-dioxofuro[3,4-c]indolo[2,3-
a]carbazol-12(5H,7H,13H)-yl]hexanenitrile 307 (0.203 g, 0.482 
mmol) in pyridine (20 mL) was added hydroxylammonium 
hydrochloride (0.164 mg, 2.41 mmol). The mixture was heated 
to reflux for 24 hours before being allowed to cool to room 
temperature. The orange solution was poured carefully into 1 M 
aqueous HCl (50 mL) before being extracted with 10% 
MeOH/DCM (3 × 30 mL). The organic layer was washed with 1 M aqueous HCl (50 
mL), followed by water (2 × 50 mL), before being dried with anhydrous magnesium 
sulfate, filtered and the solvent evaporated under reduced pressure. The crude product 
was purified using column chromatography on silica gel with 2% MeOH/DCM to give 
an orange solid (0.056 g, 27%): m.p. 266-267 °C; νmax/cm
-1
 (KBr) 3278, 2933, 2243, 
1757, 1699, 1406, 1334, 747; δH (300 MHz, DMSO-d6) 1.36-1.59 [4H, m, C(3′, 4′)-H2], 
1.86 [2H, quin, J 7.2, C(5′)-H2], 2.38 [2H, t, J 6.9, C(2′)-H2], 4.97 [2H, t, J 6.9, C(6′)-
H2], 7.39 [2H, t, J 7.2, C(3, 9)-H], 7.57-7.67 [2H, m, C(2, 10)-H], 7.82 [1H, d, J 8.2, 
C(1 or 11)-H], 7.86 [1H, d, J 8.3, C(1 or 11)-H], 9.08 [1H, d, J 7.4, C(4 or 8)-H], 9.10 
[1H, d, J 7.3, C(4 or 8)-H], 10.63 (1H, bs, N-OH), 11.97 [1H, bs, N(13)-H]; δc (75 
MHz, DMSO-d6) 16.0 (CH2), 24.9 (CH2), 25.2 (CH2), 29.6 (CH2), 43.8 (CH2), 110.2 
(CH, aromatic CH), 112.1 (CH, aromatic CH), 115.3 (C, aromatic C), 115.5 (C, 
aromatic C), 116.2 (C, aromatic C), 117.1 (C, aromatic C), 120.4 (2 × CH, aromatic 
CH), 120.5 (CN), 120.8 (C, aromatic C), 120.9 (C, aromatic C), 124.1 (CH, aromatic 
CH), 124.4 (CH, aromatic CH), 127.10 (CH, aromatic CH), 127.14 (CH, aromatic CH), 
128.3 (C, aromatic C), 129.6 (C, aromatic C), 141.2 (C, aromatic C), 141.3 (C, aromatic 




 30%]; HRMS (ESI
+
): Exact mass 
calculated for (C26H21N4O3)
+




  258 
 
6-(5,7-Dioxofuro[3,4-c]indolo[2,3-a]carbazol-12(5H,7H,13H)-yl)hexanoic acid 309 
 
To a stirred suspension of 6-(5,7-dioxofuro[3,4-c]indolo[2,3-
a]carbazol-12(5H,7H,13H)-yl)hexanenitrile 307 (0.211 g, 0.501 
mmol) in a mixture of methanol (20 mL) and water (5 mL) was 
added potassium hydroxide (85 wt. %, 0.320 g, 5.01 mmol) and 
the mixture was heated to reflux for 60 hours until TLC analysis 
showed complete consumption of starting material. After 
cooling, the solvent was evaporated under reduced pressure and 10% aqueous HCl was 
added to the residue and the suspension was stirred for 10 minutes before the yellow 
solid was collected using vacuum filtration, washed with water (5 mL) and allowed to 
dry. The crude product was recrystallised from acetone to give desired product as a 
yellow solid (0.172 g, 77%): m.p. 289-291 °C; νmax/cm
-1
 (KBr) 3388, 2933, 1816, 1749, 
1337, 1250, 744; δH (300 MHz, DMSO-d6) 1.26-1.37 [2H, m, C(4′)-H2], 1.46 [2H, quin, 
J 7.2, C(3′)-H2], 1.83 [2H, quin, J 7.3, C(5′)-H2], 2.08 [2H, t, J 7.1, C(2′)-H2], 4.91 [2H, 
t, J 6.7, C(6′)-H2], 7.38 [1H, t, J 7.0, C(3 or 9)-H], 7.40 [1H, t, J 7.0, C(3 or 9)-H], 7.57-
7.68 [2H, m, C(2, 10)-H], 7.84 [2H, d, J 8.1, C(1, 11)-H], 8.83 [1H, d, J 9.1, C(4 or 8)-
H], 8.86 [1H, d, J 8.7, C(4 or 8)-H], 12.18 [1H, bs, N(13)-H]; δc (75 MHz, DMSO-d6) 
24.2 (CH2), 25.4 (CH2), 30.0 (CH2), 33.5 (CH2), 43.9 (CH2), 110.3 (CH, aromatic CH), 
112.3 (CH, aromatic CH), 115.9 (C, aromatic C), 116.8 (C, aromatic C), 117.2 (C, 
aromatic C), 117.4 (C, aromatic C), 120.3 (C, aromatic C), 120.4 (C, aromatic C), 
120.67 (CH, aromatic CH), 120.70 (CH, aromatic CH), 123.2 (CH, aromatic CH), 123.5 
(CH, aromatic CH), 127.2 (CH, aromatic CH), 127.3 (CH, aromatic CH), 128.7 (C, 
aromatic C), 130.0 (C, aromatic C), 140.9 (2C, 2 × aromatic C), 164.36 (C=O), 164.43 




 70%]; HRMS (ESI
+
): Exact mass 
calculated for (C26H21N2O5)
+







12(13H)-yl]hexanoic acid 310 
 
To a stirred solution of 6-[5,7-dioxofuro[3,4-c]indolo[2,3-
a]carbazol-12(5H,7H,13H)-yl]hexanoic acid 309 (0.120 g, 0.272 
mmol) in anhydrous DMF (15 mL) was added hydroxylamine 
hydrochloride (0.095 g, 1.36 mmol) and triethylamine (0.20 mL, 
0.15 g, 1.4 mmol) and the mixture was heated to 80 °C for 24 
hours. After cooling, the reaction mixture was poured into 1 M 
aqueous HCl (40 mL) and extracted using 10% methanol/DCM 
(3 × 30 mL). The organic layer was washed with 1 M aqueous HCl (40 mL) followed 
by water (3 × 30 mL) before being dried over anhydrous magnesium sulfate, filtered 
and the solvent evaporated under reduced pressure. A red precipitate formed during 
extraction was collected using vacuum filtration and found to be desired product (0.021 
g). The extraction residue was purified using column chromatography on silica gel with 
10% methanol/DCM with acetic acid (4 drops per 100 mL) to give desired product as a 
red solid (0.039 g, combined yield 0.060 g, 49%): m.p. 225-227 °C; νmax/cm
-1
 (KBr) 
3378, 2938, 1749, 1715, 1405, 1015, 735; δH (300 MHz, DMSO-d6) 1.28-1.40 [2H, m, 
C(4′)-H2], 1.48 [2H, quin, J 7.1, C(3′)-H2], 1.84 [2H, quin, J 6.9, C(5′)-H2], 2.09 [2H, t, 
J 7.0, C(2′)-H2], 4.94 [2H, t, J 6.6, C(6′)-H2], 7.37 [1H, t, J 7.5, C(3 or 9)-H], 7.38 [1H, 
t, J 7.6, C(3 or 9)-H], 7.55-7.66 [2H, m, C(2, 10)-H], 7.82 [2H, d, J 8.2, C(1, 11)-H], 
9.06 [1H, d, J 8.0, C(4 or 8)-H], 9.09 [1H, d, J 7.9, C(4 or 8)-H], 10.97 (1H, bs, N-OH), 
11.99 [1H, bs, N(13)-H]; δc (75 MHz, DMSO-d6) 24.3 (CH2), 25.5 (CH2), 30.0 (CH2), 
33.6 (CH2), 43.9 (CH2), 110.1 (CH, aromatic CH), 112.2 (CH, aromatic CH), 115.3 (C, 
aromatic C), 115.5 (C, aromatic C), 116.1 (C, aromatic C), 117.1 (C, aromatic C), 120.4 
(CH, aromatic CH), 120.7 (CH, aromatic CH), 120.9 (2C, 2 × aromatic C), 124.1 (CH, 
aromatic CH), 124.4 (CH, aromatic CH), 127.1 (2CH, 2 × aromatic CH), 128.3 (C, 
aromatic C), 129.6 (C, aromatic C), 141.2 (C, aromatic C), 141.3 (C, aromatic C), 166.3 




 20%]; HRMS (ESI
+
): Exact 
mass calculated for (C26H22N3O5)
+










To a stirred suspension of 6-(5,7-dioxofuro[3,4-c]indolo[2,3-
a]carbazol-12(5H,7H,13H)-yl)hexanoic acid 309 (0.122 g, 
0.277 mmol) in DCM (25 mL) in a flame-dried flask under 
nitrogen was added oxalyl chloride (0.04 mL, 0.06 g, 0.42 
mmol) followed by a drop of anhydrous DMF. The mixture 
was allowed to stir for 2 hours resulting in a pale yellow 
solution before the solvent and excess oxalyl chloride were removed under reduced 
pressure. Morpholine (3 mL) was then added slowly to the residue while stirring and the 
reaction mixture was stirred for a further 2 hours. At this point, water (20 mL) was 
added and the mixture was acidified to pH 2 using 10% HCl. The crude product was 
extracted into 10% methanol/DCM (2 × 15 mL) and the organic layer was washed with 
water (3 × 20 mL), followed by brine (20 mL) before being dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under reduced pressure. The 
crude product was washed with hot acetone (15 mL) and allowed to dry to give desired 
product as a bright yellow solid (0.082 g, 60%): m.p. 259-261 °C; νmax/cm
-1
 (KBr) 3288, 
2859, 1817, 1762, 1624, 1337, 1247, 739; δH (300 MHz, DMSO-d6) 1.19-1.32 [2H, m, 
C(3′)-H2], 1.43 [2H, quin, J 7.2, C(4′)-H2], 1.85 [2H, quin, J 7.0, C(2′)-H2], 2.12 [2H, t, 
J 7.4, C(5′)-H2], 3.18-3.46 [8H, H2O, m, N(CH2CH2)2O], 4.92 [2H, t, J 6.5, C(1′)-H2], 
7.37 [1H, t, J 7.1, C(3 or 9)-H], 7.40 [1H, J 7.1, C(3 or 9)-H], 7.61 [1H, t, J 8.2, C(2 or 
10)-H], 7.64 [1H, t, J 8.3, C(2 or 10)-H], 7.84 [2H, d, J 8.1, C(1, 11)-H], 8.83 [1H, d, J 
8.8, C(4 or 8)-H], 8.86 [1H, d, J 8.6, C(4 or 8)-H], 12.16 [1H, bs, N(13)-H]; δc (75 
MHz, DMSO-d6) 25.0 (CH2), 26.1 (CH2), 30.6 (CH2), 32.1 (CH2), 41.8 [one of 
(NCH2)2], 44.5 (CH2), 45.7 [one of (NCH2)2], 66.5 (2 × OCH2), 110.8 (CH, aromatic 
CH), 112.8 (CH, aromatic CH), 116.3 (C, aromatic C), 117.3 (C, aromatic C), 117.6 (C, 
aromatic C), 117.8 (C, aromatic C), 120.7 (C, aromatic C), 120.9 (C, aromatic C), 121.2 
(2CH, 2 × aromatic CH), 123.7 (CH, aromatic CH), 124.0 (CH, aromatic CH), 127.7 
(CH, aromatic CH), 127.8 (CH, aromatic CH), 129.2 (C, aromatic C), 130.5 (C, 
aromatic C), 141.38 (C, aromatic C), 141.40 (C, aromatic C), 164.8 (C=O), 164.9 




 40%]; HRMS (ESI
+
): Exact mass 
calculated for (C30H28N3O5)
+








To a stirred solution of 12-(6-morpholino-6-oxohexyl)furo[3,4-
c]indolo[2,3-a]carbazole-5,7(12H,13H)-dione 311 (0.092 g, 
0.181 mmol) in anhydrous DMF (10 mL) was added 
hydroxylamine hydrochloride (0.064 g, 0.903 mmol) and 
triethylamine (0.13 mL, 0.09 g, 0.92 mmol) and the mixture 
was heated to 80 °C for 24 hours. After cooling, the reaction 
mixture was poured into 1 M aqueous HCl (20 mL) and 
extracted using 10% methanol/DCM (3 × 15 mL). The organic layer was washed with 1 
M aqueous HCl (20 mL) followed by water (3 × 15 mL) before being dried over 
anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure. The crude product was purified using column chromatography on silica gel 
with 1% MeOH/DCM to give desired product as a red solid (0.054 g, 57%): m.p. 164-
166 °C; νmax/cm
-1
 (KBr) 3381, 2929, 1759, 1709, 1618, 1336, 1116, 733; δH (300 MHz, 
DMSO-d6) 1.20-1.33 [2H, m, C(3′)-H2], 1.43 [2H, quin, J 7.1, C(4′)-H2], 1.86 [2H, 
quin, J 7.0, C(2′)-H2], 2.12 [2H, t, J 7.1, C(5′)-H2], 3.19-3.46 [8H, H2O, m, 
N(CH2CH2)2O], 4.96 [2H, t, J 6.1, C(1′)-H2], 7.39 [2H, t, J 7.2, C(3, 9)-H], 7.60 [1H, t, 
J 8.0, C(2 or 10)-H], 7.63 [1H, t, J 8.1, C(2 or 10)-H], 7.82 [1H, d, J 8.3, C(1 or 11)-H], 
7.85 [1H, d, J 8.4, C(1 or 11)-H], 9.07 [1H, d, J 7.5, C(4 or 8)-H], 9.10 [1H, d, J 7.4, 
C(4 or 8)-H], 10.65 (1H, bs, N-OH), 11.99 [1H, bs, N(13)-H]; δc (75 MHz, DMSO-d6) 
24.6 (CH2), 25.6 (CH2), 30.1 (CH2), 31.6 (CH2), 41.3 [one of (NCH2)2], 44.0 (CH2), 
45.3 [one of (NCH2)2], 66.0 (2 × OCH2), 110.2 (CH, aromatic CH), 112.1 (CH, 
aromatic CH), 115.3 (C, aromatic C), 115.5 (C, aromatic C), 116.1 (C, aromatic C), 
117.1 (C, aromatic C), 120.4 (2CH, 2 × aromatic CH), 120.8 (C, aromatic C), 120.9 (C, 
aromatic C), 124.1 (CH, aromatic CH), 124.4 (CH, aromatic CH), 127.07 (CH, aromatic 
CH), 127.14 (CH, aromatic CH), 128.3 (C, aromatic C), 129.7 (C, aromatic C), 141.2 





 100%]; HRMS (ESI
+
): Exact mass calculated for (C30H29N4O5)
+
 









To a stirred suspension of 6-(5,7-dioxofuro[3,4-c]indolo[2,3-
a]carbazol-12(5H,7H,13H)-yl)hexanoic acid 309 (0.121 g, 
0.275 mmol) in DCM (25 mL) in a flame-dried flask under 
nitrogen was added oxalyl chloride (0.04 mL, 0.06 g, 0.41 
mmol) followed by a drop of anhydrous DMF. The mixture 
was allowed to stir for 2 hours resulting in a pale yellow 
solution before the solvent and excess oxalyl chloride were removed under reduced 
pressure. Diethylamine (3 mL) was then added and the mixture was stirred for 2 hours 
before DCM (10 mL) was added. The resulting solution was stirred for a further 1 hour 
before excess solvent was removed under reduced pressure. The residue was acidified to 
pH 2 and stirred for 30 minutes before the yellow solid was collected using vacuum 
filtration, washed with water and allowed to dry. Washes with hot acetone (2 × 10 mL) 
gave desired product as a yellow solid (0.098 g, 73%): m.p. 113-114 °C; νmax/cm
-1
 
(KBr) 3280, 2933, 1818, 1752, 1616, 1249, 742; δH (300 MHz, DMSO-d6) 0.83 (3H, t, J 
6.9, one of CH2CH3), 0.84 (3H, t, J 6.9, one of CH2CH3), 1.17-1.29 [2H, m, C(4′)-H2], 
1.43 [2H, quin, J 7.2, C(3′)-H2], 1.84 [2H, quin, J 7.5, C(5′)-H2], 2.06 [2H, t, J 7.0, 
C(2′)-H2], 3.00-3.15 [4H, m, 2 × CH2CH3), 4.91 [2H, t, J 6.3, C(6′)-H2], 7.34-7.43 [2H, 
m, C(3, 9)-H], 7.61 [1H, t, J 7.9, C(2 or 10)-H], 7.63 [1H, t, J 8.0, C(2 or 10)-H], 7.83 
[1H, d, J 8.1, C(1 or 11)-H], 7.84 [1H, d, J 8.4, C(1 or 11)-H], 8.82 [1H, d, J 8.6, C(4 or 
8)-H], 8.85 [1H, d, J 8.5, C(4 or 8)-H], 12.18 [1H, bs, N(13)-H]; δc (75 MHz, DMSO-
d6) 13.4 (CH3), 14.6 (CH3), 25.2 (CH2), 26.0 (CH2), 30.6 (CH2), 32.1 (CH2), 39.7 (CH2), 
41.6 (CH2), 44.4 (CH2), 110.8 (CH, aromatic CH), 112.8 (CH, aromatic CH), 116.3 (C, 
aromatic C), 117.3 (C, aromatic C), 117.6 (C, aromatic C), 117.8 (C, aromatic C), 120.7 
(C, aromatic C), 120.9 (C, aromatic C), 121.2 (2CH, 2 × aromatic CH), 123.7 (CH, 
aromatic CH), 124.0 (CH, aromatic CH), 127.7 (CH, aromatic CH), 127.8 (CH, 
aromatic CH), 129.2 (C, aromatic C), 130.5 (C, aromatic C), 141.3 (C, aromatic C), 





 100%]; HRMS (ESI
+
): Exact mass calculated for (C30H30N3O4)
+
 








To a stirred solution of 6-(5,7-dioxo-7,13-dihydrofuro[3,4-
c]indolo[2,3-a]carbazol-12(5H)-yl)-N,N-diethylhexanamide 
312 (0.077 g, 0.155 mmol) in anhydrous DMF (8 mL) was 
added hydroxylamine hydrochloride (0.054 g, 0.777 mmol) 
and triethylamine (0.11 mL, 0.08 g, 0.78 mmol) and the 
mixture was heated to 80 °C for 24 hours. After cooling, the 
reaction mixture was poured into 1 M aqueous HCl (20 mL) 
and stirred for 30 minutes before the orange solid was collected using vacuum filtration. 
The solid was washed with water (10 mL), followed by methanol (5 mL) to give a 
yellow/orange solid (0.063 g, 76%): m.p. 239-240 °C; νmax/cm
-1
 (KBr) 3353, 2934, 
1748, 1701, 1623, 1461, 1335, 745; δH (300 MHz, DMSO-d6) 0.83 (3H, t, J 7.0, one of 
CH2CH3), 0.85 (3H, t, J 7.0, one of CH2CH3), 1.21-1.33 [2H, m, C(4′)-H2], 1.46 [2H, 
quin, J 7.3, C(3′)-H2], 1.85 [2H, quin, J 7.0, C(5′)-H2], 2.07 [2H, t, J 7.1, C(2′)-H2], 3.04 
(2H, q, J 6.9, one of CH2CH3), 3.11 (2H, q, J 6.9, one of CH2CH3), 4.96 [2H, t, J 6.5, 
C(6′)-H2], 7.35-7.43 [2H, m, C(3, 9)-H], 7.56-7.67 [2H, m, C(2, 10)-H], 7.81 [1H, d, J 
7.4, C(1 or 11)-H], 7.84 [1H, d, J 7.8, C(1 or 11)-H], 9.08 [1H, d, J 7.9, C(4 or 8)-H], 
9.1 [1H, d, J 7.7, C(4 or 8)-H], 10.60 (1H, bs, N-OH), 11.96 [1H, bs, N(13)-H]; δc (75 
MHz, DMSO-d6) 13.4 (CH3), 14.6 (CH3), 25.2 (CH2), 26.1 (CH2), 30.6 (CH2), 32.1 
(CH2), 39.7 (CH2), 41.6 (CH2), 44.5 (CH2), 110.7 (CH, aromatic CH), 112.6 (CH, 
aromatic CH), 115.8 (C, aromatic C), 116.0 (C, aromatic C), 116.6 (C, aromatic C), 
117.6 (C, aromatic C), 120.87 (CH, aromatic CH), 120.89 (CH, aromatic CH), 121.2 (C, 
aromatic C), 121.4 (C, aromatic C), 124.6 (CH, aromatic CH), 124.9 (CH, aromatic 
CH), 127.5 (CH, aromatic CH), 127.6 (CH, aromatic CH), 128.8 (C, aromatic C), 130.2 
(C, aromatic C), 141.7 (C, aromatic C), 141.8 (C, aromatic C), 166.8 (2C, 2 × C=O), 




 70%]; HRMS (ESI
+
): Exact mass 
calculated for (C30H31N4O4)
+










To a stirred suspension of 6-(5,7-dioxofuro[3,4-c]indolo[2,3-
a]carbazol-12(5H,7H,13H)-yl)hexanoic acid 309 (0.122 g, 0.277 
mmol) in DCM (25 mL) in a flame-dried flask under nitrogen 
was added oxalyl chloride (0.04 mL, 0.06 g, 0.41 mmol) 
followed by a drop of anhydrous DMF. The mixture was 
allowed to stir for 2 hours resulting in a pale yellow solution 
before the solvent and excess oxalyl chloride were removed under reduced pressure. 
Methanol (3mL) was added slowly to the residue while stirring and the reaction mixture 
was stirred for a further 2 hours under nitrogen. The yellow precipitate was then 
collected by vacuum filtration and washed with hot acetone (10 mL) to give desired 
product as a yellow solid (0.092 g, 75%): m.p. 263-265 °C; νmax/cm
-1
 (KBr) 3377, 2949, 
1819, 1750, 1704, 1406, 1340, 1253, 737; δH (300 MHz, DMSO-d6) 1.23-1.34 [2H, m, 
C(4′)-H2], 1.46 [2H, quin, J 7.3, C(3′)-H2], 1.82 [2H, quin, J 7.3, C(5′)-H2], 2.15 [2H, t, 
J 7.2, C(2′)-H2], 3.45 (3H, s, CH3), 4.90 [2H, t, J 6.7, C(6′)-H2], 7.34-7.43 [2H, m, C(3 
and 9)-H], 7.61 [1H, t, J 8.0, C(2)-H], 7.63 [1H, t, J 8.0, C(10)-H], 7.83 [2H, d, J 8.2, 
C(1, 11)-H], 8.81 [1H, d, J 8.5, C(4)-H], 8.84 [1H, d, J 8.4, C(8)-H], 12.17 [1H, bs, 
N(13)-H]; δc (75 MHz, DMSO-d6) 24.7 (CH2), 25.8 (CH2), 30.4 (CH2), 33.5 (CH2), 44.4 
(CH2), 51.5 (CH3), 110.8 (CH, aromatic CH), 112.8 (CH, aromatic CH), 116.3 (C, 
aromatic C), 117.3 (C, aromatic C), 117.7 (C, aromatic C), 117.9 (C, aromatic C), 120.7 
(C, aromatic C), 120.9 (C, aromatic C), 121.2 (2CH, 2 × aromatic CH), 123.7 (CH, 
aromatic CH), 124.0 (CH, aromatic CH), 127.7 (CH, aromatic CH), 127.8 (CH, 
aromatic CH), 129.2 (C, aromatic C), 130.5 (C, aromatic C), 141.35 (C, aromatic C), 





 40%]; HRMS (ESI
+












 To a stirred solution of methyl 6-(5,7-dioxo-7,13-
dihydrofuro[3,4-c]indolo[2,3-a]carbazol-12(5H)-yl)hexanoate 
313 (0.070 g, 0.154 mmol) in anhydrous DMF (8 mL) was added 
hydroxylamine hydrochloride (0.054 g, 0.770 mmol) and 
triethylamine (0.11 mL, 0.08 g, 0.77 mmol) and the mixture was 
heated to 80 °C for 24 hours. After cooling, the reaction mixture 
was poured into 1 M aqueous HCl (20 mL) and extracted using 10% methanol/DCM (3 
× 15 mL). The organic layer was washed with 1 M aqueous HCl (20 mL) followed by 
water (3 × 15 mL) before being dried over anhydrous magnesium sulfate, filtered and 
the solvent evaporated under reduced pressure to give a red solid (crude yield 0.056 g). 
The crude product was purified using column chromatography on silica gel with 1% 
MeOH/DCM to give a red solid (0.020 g, 28%): m.p. 243-244 °C; νmax/cm
-1
 (KBr) 
3402, 2944, 1750, 1704, 1405, 1334, 741; δH (300 MHz, DMSO-d6) 1.26-1.38 [2H, m, 
C(4′)-H2], 1.49 [2H, quin, J 7.3, C(3′)-H2], 1.84 [2H, quin, J 7.2, C(5′)-H2], 2.17 [2H, t, 
J 7.3, C(2′)-H2], 3.46 (3H, s, CH3), 4.95 [2H, t, J 6.8, C(6′)-H2], 7.38-7.42 [2H, m, C(3, 
9)-H], 7.60 [1H, ddd, J 8.2, 7.1, 1.1, C(2)-H], 7.64 [1H, ddd, J 8.2, 7.1, 1.1, C(10)-H], 
7.82 [1H, d, J 7.3, C(1 or 11)-H], 7.84 [1H, d, J 7.8, C(1 or 11)-H], 9.08 [1H, d, J 7.8, 
C(4)-H], 9.11 [1H, d, J 7.7, C(8)-H], 10.59 (1H, bs, N-OH), 11.95 [1H, bs, N(13)-H]; δc 
(150 MHz, DMSO-d6) 24.7 (CH2), 25.8 (CH2), 30.4 (CH2), 33.5 (CH2), 44.4 (CH2), 
51.5 (CH3), 110.7 (CH, aromatic CH), 112.7 (CH, aromatic CH), 115.8 (C, aromatic C), 
116.0 (C, aromatic C), 116.7 (C, aromatic C), 117.6 (C, aromatic C), 121.0 (2CH, 2 × 
aromatic CH), 121.2 (C, aromatic C), 121.3 (C, aromatic C), 124.6 (CH, aromatic CH), 
124.9 (CH, aromatic CH), 127.6 (CH, aromatic CH), 127.7 (CH, aromatic CH), 128.8 
(C, aromatic C), 130.1 (C, aromatic C), 141.7 (C, aromatic C), 141.8 (C, aromatic C), 




 100%]; HRMS (ESI
+
): 
Exact mass calculated for (C27H24N3O5)
+





  266 
 






Sodium iodide (1.201 g, 8.01 mmol) was suspended in a solution of 
6-bromohexane nitrile 318 (0.70 mL, 0.93 g, 5.3 mmol) in acetone 
(40 mL) and the mixture was heated to reflux for 16 hours. The mixture was then 
cooled, filtered and the filtrate concentrated to dryness under reduced pressure. The 
residue was dissolved in DCM (40 mL) and the organic layer washed with saturated 
aqueous sodium thiosulfate (30 mL), followed by water (3 × 30 mL), before being dried 
over anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure to give desired product as a clear oil which was used without further 
purification (0.989 g, 84%): νmax/cm
-1
 (KBr) 2937, 2865, 2246, 1459, 1426, 1206, 726, 
503; δH (400 MHz, CDCl3) 1.54-1.63 [2H, m, C(4)-H2], 1.70 [2H, quin, J 7.2, C(3)-H2], 






To a solution of 6-bromohexane nitrile 318 (1.00 mL, 1.32 g, 7.50 
mmol) in THF (20 mL) was added 10% aqueous sodium hydroxide 
(5 mL). The biphasic mixture was stirred for 2 hours before the layers were separated 
and the aqueous layer was extracted with 10% MeOH/DCM (3 × 15 mL). The organic 
layer was washed with 1 M aqueous HCl (20 mL), followed by water (2 × 20 mL) 
before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure to give a colourless oil which was used without 
further purification  (0.760 g, 89%): νmax/cm
-1
 (NaCl) 3536, 2941, 2868, 2246, 1461, 
1428, 1271, 1242, 731; δH (300 MHz, CDCl3) 1.56-1.76 [4H, m, C(3, 4)-H2], 1.91 [2H, 















To a stirred suspension of 12-methylfuro[3,4-c]indolo[2,3-
a]carbazole-5,7(12H,13H)-dione 297 (0.104 g, 0.306 mmol) in 
anhydrous DMF (10 mL) under nitrogen was added sodium 
hydride (60 wt. % oil suspension, 0.015 g, 0.367 mmol) and the 
dark purple solution was stirred for 30 minutes. A solution of 6-
iodohexanenitrile 319 (0.089 g, 0.40 mmol) in anhydrous DMF 
(1 mL) was then added and the mixture was stirred for a further 16 hours. Water (30 
mL) was then added and the resulting precipitate was collected using vacuum filtration 
and washed with 1 M aqueous HCl (5 mL), followed by water (10 mL) and allowed to 
dry to give a yellow solid. NMR analysis showed only starting material to be present. 
 
Method B 
A suspension of 12-methylfuro[3,4-c]indolo[2,3-a]carbazole-5,7(12H,13H)-dione 297 
(0.102 g, 0.306 mmol), triphenylphosphine (0.234 g, 0.892 mmol) and 6-
hydroxyhexanenitrile 320 (0.999 g, 0.883 mmol) in dry THF (10 mL) was cooled to -78 
°C under a nitrogen atmosphere. Diisopropyl azodicarboxylate (0.175 g, 0.865 mmol) 
was then added at this temperature and the mixture was allowed to warm to room 
temperature over 16 hours. The reaction mixture was poured into 0.1 M HCl (10 mL) 
before the yellow suspension was collected by vacuum filtration, washed with water (5 
mL) and allowed to dry. NMR analysis showed only starting material to be present. 
 
Method C 
To a stirred suspension of 6-[5,7-dioxofuro[3,4-c]indolo[2,3-a]carbazol-
12(5H,7H,13H)-yl]hexanenitrile 307 (0.201 g, 0.477 mmol) in anhydrous DMF (15 mL) 
under nitrogen was added sodium hydride (0.021 g, 0.525 mmol) and the dark purple 
solution was stirred for 30 minutes. Iodomethane (0.04 mL, 0.09 g, 0.57 mmol) was 
then added and the reaction mixture was stirred for a further 20 hours before pouring 
into water (40 mL). The yellow precipitate was collected using vacuum filtration, 
washed with 1 M aqueous HCl (10 mL), followed by water (5 mL) and allowed to dry. 
The crude product was purified using column chromatography on silica gel with DCM 
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as eluent to give a yellow solid (0.067 g, 33%): m.p. 208-209 °C; νmax/cm
-1
 (KBr) 3431, 
2944, 2243, 1819, 1752, 1335, 1252, 742; δH (300 MHz, DMSO-d6) 1.02-1.14 [2H, m, 
C(4′′)-H2], 1.39 [2H, quin, J 7.4, C(3′′)-H2], 1.68 [2H, quin, J 7.6, C(5′′)-H2], 2.28 [2H, 
t, J 7.1, C(2′′)-H2], 4.25 (3H, s, CH3), 4.79 [2H, t, J 7.5, C(6′′)-H2], 7.43 [1H, t, J 7.7, 
C(9)-H], 7.46 [1H, t, J 7.8, C(3)-H], 7.67 [1H, ddd, J 8.3, 7.2, 1.2, C(10)-H], 7.70 [1H, 
ddd, J 8.3, 7.1, 1.1, C(2)-H], 7.83 [1H, d, J 8.3, C(1)-H], 7.95 [1H, d, J 8.3, C(11)-H], 
8.88 [1H, d, J 7.9, C(4)-H], 8.89 [1H, d, J 7.8, C(8)-H]; δc (150 MHz, DMSO-d6) 16.3 
(CH2), 24.6 (CH2), 25.4 (CH2), 28.1 (CH2), 37.1 (CH3), 48.5 (CH2), 112.0 (CH, 
aromatic CH), 112.9 (CH, aromatic CH), 118.2 (C, aromatic C), 118.7 (C, aromatic C), 
118.9 (C, aromatic C), 119.6 (C, aromatic C), 120.9 (CN), 121.4 (C, aromatic C), 122.1 
(2 CH, 2 × aromatic CH), 122.2 (C, aromatic C), 124.0 (CH, aromatic CH), 124.2 (CH, 
aromatic CH), 128.3 (CH, aromatic CH), 128.5 (CH, aromatic CH), 132.8 (C, aromatic 





 10%]; HRMS (ESI
+
): Exact mass calculated for 
(C27H22N3O3)
+







To  a solution of 6-hydroxy-12-methyl-12,13-dihydro-5H-
indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 308 (0.090 
g, 0.25 mmol) in anhydrous DMF (15 mL) under a nitrogen 
atmosphere was added sodium hydride (0.033 g, 0.75 mmol) 
and the mixture was allowed to stir for 30 minutes. At this point 
6-iodohexanenitrile (0.082 g, 0.36 mmol) was added and the 
mixture was allowed to stir for 16 hours. Water (5 mL) was then 
added cautiously to quench the reaction before the reaction mixture was poured into 1 
M aqueous HCl (25 mL). The precipitate was collected by vacuum filtration and 
washed with water (2 × 5 mL) before being allowed to dry to give a yellow/orange solid 
which analysis showed to be 6-[(12-methyl-5,7-dioxo-5H-indolo[2,3-a]pyrrolo[3,4-
c]carbazol-6(7H,12H,13H)-yl)oxy]hexanenitrile 321 (0.090 g, 80%): m.p. 240-243 °C; 
νmax/cm
-1




(300 MHz, DMSO-d6) 1.60-1.76 [4H, m, C(3′, 4′)-H2], 1.82 
[2H, quin, J 6.5, C(5′)-H2], 2.59 [2H, t, J 6.6, C(2′)-H2], 
4.27 [2H, t, J 6.1, C(6′)-H2], 4.32 (3H, s, CH3), 7.28-7.38 
[2H, m, C(3, 9)-H], 7.54 [1H, t, J 7.5, C(2 or 10)-H], 7.59 
[1H, t, J 7.5, C(2 or 10)-H], 7.73 [1H, d, J 8.3, C(1 or 11)-
H], 7.74 [1H, d, J 7.8, C(1 or 11)-H], 8.95 [2H, d, J 7.9, C(4, 8)-H], 12.02 [1H, bs, 
N(13)-H]; δc (75 MHz, DMSO-d6) 16.6 (CH2), 25.0 (CH2), 25.1 (CH2), 27.5 (CH2), 32.3 
(CH3), 77.7 (CH2), 110.0 (CH, aromatic CH), 112.4 (CH, aromatic CH), 115.1 (C, 
aromatic C), 115.4 (C, aromatic C), 115.9 (C, aromatic C), 117.1 (C, aromatic C), 120.6 
(CH, aromatic CH), 120.6 (CH, aromatic CH), 121.95 (C, aromatic C), 120.98 (C, 
aromatic C), 121.2 (CN), 124.4 (CH, aromatic CH), 124.6 (CH, aromatic CH), 127.3 
(CH, aromatic CH), 127.4 (CH, aromatic CH), 129.0 (C, aromatic C), 130.7 (C, 





 20%]; HRMS (ESI
+
): Exact mass calculated for (C27H23N4O3)
+
 
451.1770. Found 451.1761. 
 
Method B 
To a suspension of 6-[13-methyl-5,7-dioxofuro[3,4-c]indolo[2,3-a]carbazol-
12(5H,7H,13H)-yl]hexanenitrile 317 (0.110 g, 0.25 mmol) in anhydrous DMF (10 mL) 
was added hydroxylamine hydrochloride (0.088 g, 1.3 mmol) and triethylamine (0.18 
mL, 0.13 g, 1.3 mmol) and the resulting mixture was heated to 80 °C and stirred for 24 
hours at this temperature. At this point, TLC analysis showed incomplete consumption 
of starting material and so further portions of both hydroxylamine hydrochloride (0.089 
g, 1.3 mmol) and triethylamine (0.18 mL, 0.13 g, 1.3 mmol) were added and the 
temperature was increased to 120 °C for a further 48 hours until TLC analysis showed 
no starting material remained. The reaction mixture was then cooled to room 
temperature and poured into 1 M aqueous HCl (20 mL). The precipitate was collected 
by vacuum filtration and washed with water (2 × 5 mL) before being allowed to dry. 
The crude product was purified using column chromatography on silica gel with 2% 
MeOH/DCM as eluent to give an orange solid (0.071 g, 63%): m.p. 225-227 °C; 
νmax/cm
-1
 (KBr) 3226, 2936, 2247, 1758, 1705, 1453, 1332, 1007, 752; δH (300 MHz, 
DMSO-d6) 1.00-1.12 [2H, m, C(4′)-H2], 1.37 [2H, quin, J 7.4, C(3′)-H2], 1.63 [2H, 
quin, J 7.4, C(5′)-H2], 2.27 [2H, t, J 7.1, C(2′)-H2], 4.23 (3H, s, CH3), 4.78 [2H, t, J 7.4, 
C(6′)-H2], 7.38-7.47 [2H, m, C(3, 9)-H], 7.65 [1H, ddd, J 8.3, 7.0, 1.2, C(10)-H], 7.67 
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[1H, ddd, J 8.3, 7.2, 1.2, C(2)-H], 7.79 [1H, d, J 8.2, C(1)-H], 7.91 [1H, d, J 8.3, C(11)-
H], 9.09 [1H, d, J 7.9, C(4 )-H], 9.12 [1H, d, J 7.8, C(8)-H], 10.71 (N-OH); δc (75 MHz, 
DMSO-d6) 16.3 (CH2), 24.6 (CH2), 25.4 (CH2), 27.9 (CH2), 37.1 (CH3), 48.4 (CH2), 
111.7 (CH, aromatic CH), 112.7 (CH, aromatic CH), 116.1 (C, aromatic C), 116.6 (C, 
aromatic C), 119.2 (C, aromatic C), 119.8 (C, aromatic C), 120.8 (CN), 121.6 (2CH, 2 × 
aromatic CH), 122.0 (C, aromatic C), 122.8 (C, aromatic C), 124.8 (CH, aromatic CH), 
125.0 (CH, aromatic CH), 127.9 (CH, aromatic CH), 128.2 (CH, aromatic CH), 132.4 
(C, aromatic C), 133.5 (C, aromatic C), 144.1 (C, aromatic C), 145.3 (C, aromatic C), 




 20%]; HRMS (ESI
+
): Exact 
mass calculated for (C27H23N4O3)
+






To a solution of furo[3,4-c]indolo[2,3-a]carbazole-
5,7(12H,13H)-dione 76 (0.933 g, 2.86 mmol) in anhydrous DMF 
(15 mL) was added 1,1,1,3,3,3-hexamethyldisilazane (6.0 mL, 
4.6 g, 28.6 mmol), followed by methanol (0.58 mL, 0.45 g, 14.3 
mmol). The reaction mixture was then stirred for 16 hours before pouring into water (40 
mL). The precipitate was collected by vacuum filtration and allowed to dry. The solid 
was then suspended in methanol and stirred for 2 hours before being collected by 
vacuum filtration and allowed to dry to give an orange solid (0.849 g, 91%): m.p. > 300 




 (KBr) 3583, 3364, 3226, 1719, 1681, 1567, 1405, 1332, 
748; δH (300 MHz, DMSO-d6) 7.34 [2H, t, J 7.6, C(3, 9)-H], 7.54 [2H, ddd, J 8.2, 7.2, 
1.2, C(2, 10)-H], 7.80 [2H, d, J 8.1, C(1, 11)-H], 8.99 [2H, d, J 7.84, C(4, 8)-H], 10.96 











6-carboxylate  329 
 
To a stirred suspension of 12,13-dihydro-5H-indolo[2,3-
a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 58 (0.503 g, 1.54 
mmol) in acetonitrile (50 mL) was added di-tert-butyl 
dicarbonate (0.42 mL, 0.40 g, 1.8 mmol) followed by DMAP 
(0.019 g, 0.15 mmol) and the reaction mixture was stirred at 
room temperature for 2 hours. At this point, TLC analysis showed incomplete 
consumption of starting material and so a further 1 equivalent of di-tert-butyl 
dicarbonate (0.34 mL, 0.33 g, 1.5 mmol) was added and stirring was continued for a 
further 1 hour. The solvent was removed under reduced pressure and the yellow residue 
suspended in a mixture of water (20 mL) and methanol (20 mL). The solid was 
collected by vacuum filtration and allowed to dry to give a yellow solid found on 
analysis to be di-tert-butyl 5,7-dioxo-7,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-
c]carbazole-6, 12-dicarboxylate 330
17
 (0.615 g, 78%): m.p. >300 
°C; νmax/cm
-1
 (KBr) 3358, 3209, 1702, 1573, 1321, 1146, 749; 
δH (300 MHz, CDCl3) 1.74 [9H, s, C(CH3)3], 1.84 [9H, s, 
C(CH3)3], 7.36 [1H, ddd, J 8.1, 5.0, 2.8, C(3)-H], 7.42-7.59 [4H, 
m, C(1, 2, 9, 10)-H], 8.09 [1H, d, J 8.2, C(11)-H], 9.19 [1H, d, J 
8.1, C(4)-H], 9.37 [1H, d, J 7.9, C(8)-H], 11.31 (1H, bs, NH); δc 
(75 MHz, CDCl3) 28.1 (3 × CH3), 28.3 (3 × CH3), 84.7 
[C(CH3)3], 87.0 [C(CH3)3], 111.2 (CH, aromatic CH), 115.9 (CH, aromatic CH), 116.6 
(C, aromatic C), 119.6 (C, aromatic C), 120.9 (C, aromatic C), 121.07 (C, aromatic C), 
121.10 (CH, aromatic CH), 122.6 (C, aromatic C), 124.2 (CH, aromatic CH), 124.3 (C, 
aromatic C), 125.77 (CH, aromatic CH), 125.84 (CH, aromatic CH), 127.30 (C, 
aromatic C), 128.1 (CH, aromatic CH), 128.3 (CH, aromatic CH), 131.4 (C, aromatic 
C), 138.3 (C, aromatic C), 139.6 (C, aromatic C), 147.3 (C=O), 151.9 (C=O), 164.9 











To a suspension of furo[3,4-c]indolo[2,3-a]carbazole-
5,7(12H,13H)-dione 76 (0.150 g, 0.460 mmol) in anhydrous 
DMF (8 mL) was added benzylamine (0.25 mL, 0.25 g, 2.3 
mmol) and the mixture was heated to 100 °C for 16 hours. After 
cooling, the precipitate was collected by vacuum filtration, 
washed with 1 M aqueous HCl (3 × 5 mL), followed by water (5 





 (KBr) 3528, 3372, 1742, 1674, 1651, 1559, 1380, 1245, 742; δH 
(300 MHz, DMSO-d6) 4.90 (2H, s, CH2), 7.24-7.31 [1H, m, C(4′)-H], 7.32-7.39 [4H, m, 
C(3, 9, 3′, 5′)-H], 7.41-7.46 [2H, m, C(2′, 6′)-H], 7.56 [2H, ddd, J 8.2, 7.2, 1.1, C(2, 10)-












5,7(6H)-dione 166 (0.553 g, 1.33 mmol) was suspended in 
anhydrous DMF (20 mL) in a flame-dried flask under nitrogen 
and at 0 °C. To this was added sodium hydride (60 wt. % oil 
suspension, 0.117 g, 2.93 mmol) resulting in a dark blue 
suspension which was stirred at this temperature for 30 minutes. 
At this point, a solution of 6-iodohexane nitrile (0.690 g, 3.09 
mmol) in anhydrous DMF (2 mL) was added and the mixture was 
allowed to warm to room temperature and stirred for 24 hours. A small amount of water 
was then added cautiously to quench the reaction before the reaction mixture was 
poured into water (60 mL) and extracted using 10% MeOH/DCM (3 × 30 mL). The 
organic layer was washed with water (4 × 30 mL), followed by brine (30 mL) before 




under reduced pressure to give a yellow solid found on analysis to be  mono alkylated 
6-(6-benzyl-5,7-dioxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbaz ol-
12-yl)hexanenitrile 331 (0.562 g, 85%): νmax/cm
-1
 (KBr) 3391, 
2933, 2252, 1743, 1692, 1573, 1403, 1338, 743; δH (300 MHz, 
DMSO-d6) 1.35-1.45 [2H, m, C(4′′)-H2], 1.51 [2H, quin, J 7.2, 
C(3′′)-H2], 1.85 [2H, quin, J 6.9, C(5′′)-H2], 2.36 [2H, t, J 6.9, 
C(2′′)-H2], 4.87 (2H, s, CH2), 4.93 [2H, t, J 6.7, C(6′′)-H2], 7.23-
7.46 [7H, m, C(3, 9, 2′, 3′, 4′, 5′, 6′)-H], 7.59 [1H, t, J 7.4, C(2 or 
10)-H], 7.62 [1H, t, J 7.6, C(2 or 10)-H], 7.82 [2H, d, J 8.3, C(1, 
11)-H], 9.08 [1H, d, J 7.8, C(4 or 8)-H], 9.10 [1H, d, J 7.8, C(4 or 8)-H], 11.94 [1H, s, 
N(13)-H]; δc (75 MHz, DMSO-d6) 16.5 (CH2), 25.1 (CH2), 25.6 (CH2), 30.1 (CH2), 41.1 
(CH2), 44.2 (CH2), 110.5 (CH, aromatic CH), 112.6 (CH, aromatic CH), 116.6 (C, 
aromatic C), 117.5 (C, aromatic C), 118.8 (C, aromatic C), 118.9 (C, aromatic C), 120.8 
(2CH, 2 × aromatic CH), 121.0 (CN), 121.3 (C, aromatic C), 121.4 (C, aromatic C), 
124.7 (CH, aromatic CH), 124.9 (CH, aromatic CH), 127.4 (CH, aromatic CH), 127.5 
(CH, aromatic CH), 127.7 (CH, aromatic CH), 127.9 (2CH, 2 × aromatic CH), 128.7 (C, 
aromatic C), 129.1 (2CH, 2 × aromatic CH), 129.9 (C, aromatic C), 138.0 (C, aromatic 





 40%]; HRMS (ESI
+






To a suspension of 6-benzyl-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-
5,7(6H)-dione 166 (0.179, 0.431 mmol) in anhydrous DMF (20 mL) under nitrogen was 
added caesium carbonate (0.350 g, 1.07 mmol) and the mixture was stirred for 40 
minutes slowly becoming a dark purple solution. To this was added a solution of 6-
iodohexanenitrile (0.243 g, 1.09 mmol) in anhydrous DMF (2 mL) and the reaction 
mixture was allowed to stir for 60 hours until TLC analysis showed the reaction was 
complete. Water (50 mL) was then added and the aqueous layer extracted with 10% 
MeOH/DCM (2 × 30 mL). The organic layer was washed with 1 M aqueous HCl (2 × 
40 mL) followed by water (40 mL) before being dried over anhydrous magnesium 
sulfate, filtered and the solvent evaporated under reduced pressure. The crude residue 
was purified using column chromatography on silica gel with DCM to give desired 
product as an orange solid (0.228 g, 87%): m.p. 207-208 °C; νmax/cm
-1
 (KBr) 3423, 
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2936, 2244, 1748, 1693, 1574, 1332, 748; δH (300 MHz, CDCl3) 0.93-1.06 [4H, m, 2 × 
C(4′′)-H2], 1.35 [4H, quin, J 7.4, 2 × C(3′′)-H2], 1.42 [4H, quin, J 7.4, 2 × C(5′′)-H2], 
2.02 [4H, t, J 7.0, 2 × C(2′′)-H2], 4.63 [4H, t, J 7.3, 2 × C(6′′)-H2], 5.00 (2H, s, CH2), 
7.22-7.29 [1H, m, C(4′)-H], 7.30-7.37 [2H, m, C(3′, 5′)-H], 7.43 [2H, ddd, 8.0, 5.6, 2.3, 
C(3, 9)-H], 7.54-7.64 [6H, m, C(1, 2, 10, 11, 2′, 6′)-H], 9.27 [2H, d, J 7.9, C(4, 8)-H]; δc 
(75 MHz, CDCl3)  16.8 (2 × CH2), 24.7 (2 × CH2), 25.5 (2 × CH2), 27.2 (2 × CH2), 41.6 
(CH2 benzyl), 48.5 (2 × CH2), 112.0 (2CH, 2 × aromatic CH), 119.2 (2C, 2 × aromatic 
C), 120.6 (2C, 2 × aromatic C), 121.4 (2C, 2 × aromatic C), 122.1 (2CH, 2 × aromatic 
CH), 124.5 (4C, 2 × aromatic C, 2 × CN), 126.1 (2CH, 2 × aromatic CH), 127.6 (CH, 
aromatic CH), 127.7 (2CH, 2 × aromatic CH), 128.6 (2CH, 2 × aromatic CH), 128.7 
(2CH, 2 × aromatic CH), 133.6 (2C, 2 × aromatic C), 137.3 (C, aromatic C), 144.5 (2C, 




 15%]; HRMS (ESI
+
): 
Exact mass calculated for (C39H36N5O2)
+





To a stirred suspension of 6,6'-(6-benzyl-5,7-dioxo-6,7-dihydro-
5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12,13-diyl)dihexane 
nitrile 332 (0.190 g, 0.314 mmol) in a mixture of ethanol (20 
mL) and water (5 mL) was added potassium hydroxide (85 wt. 
%, 0.197 g, 2.98 mmol) and the mixture was heated to reflux for 
24 hours. After cooling, the solvent was evaporated under 
reduced pressure and the residue acidified with 10% aqueous 
HCl. The aqueous layer was extracted with 10% MeOH/DCM (2 × 30 mL) and the 
organic layer was then washed with water (3 × 30 mL), dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under reduced pressure. The 
crude product was purified using column chromatography on silica gel with 2% 
MeOH/DCM to give desired product as a yellow solid (0.090 g, 56%): m.p. 123-124 
°C; νmax/cm
-1
 (KBr) 3435, 2941, 2254, 1820, 1751, 1473, 1336, 746; δH (300 MHz, 
DMSO-d6) 0.89-1.02 [4H, m, 2 × C(4′)-H2], 1.31 [4H, quin, J 7.4, 2 × C(3′)-H2], 1.55 
[4H, quin, J 7.4, 2 × C(5′)-H2], 2.22 [4H, t, J 7.1, 2 × C(2′)-H2], 4.80 [4H, t, J 7.2, 2 × 
C(6′)-H2], 7.50 [2H, t, J 7.5, C(3, 9)-H], 7.71 [2H, t, J 7.8, C(2, 10)-H], 8.00 [2H, d, J 




CH2), 24.4 (2 × CH2), 25.3 (2 × CH2), 27.8 (2 × CH2), 48.5 (2 × CH2), 113.6 (2CH, 2 × 
aromatic CH), 119.2 (2C, 2 × aromatic C), 120.2 (2C, 2 × aromatic C), 120.8 (2 × CN), 
122.4 (2CH, 2 × aromatic CH), 122.8 (2C, 2 × aromatic C), 124.4 (2CH, 2 × aromatic 
CH), 128.5 (2CH, 2 × aromatic CH), 134.0 (2C, 2 × aromatic C), 144.2 (2C, 2 × 




 10%]; HRMS (ESI
+
): Exact 
mass calculated for (C32H28N4O3Na)
+





To a stirred suspension of 6,6'-(5,7-dioxo-5,7-dihydrofuro[3,4-
c]indolo[2,3-a]carbazole-12,13-diyl)dihexanenitrile 333 (0.110 
g, 0.207 mmol) in anhydrous DMF (8 mL) was added 
hydroxylamine hydrochloride (0.074 g, 1.03 mmol) and 
triethylamine (0.15 mL, 0.11 g, 1.0 mmol) and the mixture was 
heated to 80 °C for 24 hours. After cooling, the reaction mixture 
was poured into 1 M aqueous HCl (20 mL) and the precipitate 
collected by vacuum filtration. The orange solid was suspended in a mixture of 1 M 
aqueous HCl (10 mL) and methanol (10 mL) and stirred for 2 hours before the solid was 
collected using vacuum filtration, washed with water (5 mL) and allowed to dry to give 
desired product as an orange solid (0.083 g, 73%): m.p. 199-201 °C; νmax/cm
-1
 (KBr) 
3321, 2935, 2245, 1761, 1708, 1447, 1332, 1113, 750; δH (300 MHz, DMSO-d6) 0.89-
1.02 [4H, m, 2 × C(4′)-H2], 1.31 [4H, quin, J 7.3, 2 × C(3′)-H2], 1.49 [4H, quin, J 7.3, 2 
× C(5′)-H2], 2.22 [4H, t, J 7.0, 2 × C(2′)-H2], 4.73 [4H, t, J 7.1, 2 × C(6′)-H2], 7.44 [2H, 
t, J 7.5, C(3, 9)-H], 7.66 [2H, t, J 7.7, C(2, 10)-H], 7.92 [2H, d, J 8.3, C(1, 11)-H], 9.11 
[2H, d, J 7.8, C(4, 8)-H], 10.70 (1H, bs, N-OH); δc (150 MHz, DMSO-d6) 16.3 (2 × 
CH2), 24.5 (2 × CH2), 25.4 (2 × CH2), 27.6 (2 × CH2), 48.4 (2 × CH2), 113.3 (2CH, 2 × 
aromatic CH), 116.8 (2C, 2 × aromatic C), 120.3 (2C, 2 × aromatic C), 120.8 (2 × CN), 
122.0 (2CH, 2 × aromatic CH), 123.4 (2C, 2 × aromatic C), 125.2 (2CH, 2 × aromatic 
CH), 128.1 (2CH, 2 × aromatic CH), 133.4 (2C, 2 × aromatic C), 144.6 (2C, 2 × 




 20%]. HRMS (ESI
+
): 
Exact mass calculated for (C32H30N5O3)
+
 532.2349. Found 532.2343. 
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(0.101 g, 0.309 mmol) was suspended in anhydrous DMF (10 
mL) in a flame-dried flask and the mixture was cooled to 0 °C 
under nitrogen. Sodium hydride (60 wt. % oil suspension, 0.027 
g, 0.67 mmol) was then added carefully and the mixture was 
stirred at this temperature for 1 hour resulting in a dark blue 
solution. A solution of 1,6 dibromohexane (0.24 mL, 0.38 g, 1.5 mmol) in anhydrous 
DMF (40 mL) was prepared in a separate flame-dried flask and to this was added the 
dark blue solution, dropwise over 90 minutes at room temperature. The resulting dark 
purple solution was stirred for a further 16 hours. The reaction mixture was then poured 
into water (400 mL) and extracted with 10% MeOH/DCM (4 × 50 mL). The organic 
layer was washed with water (4 × 50 mL), followed by brine (50 mL) before being dried 
over anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure. The sticky residue was triturated with methanol (10 mL) and the product 
collected by vacuum filtration giving a bright yellow solid (0.097 g, 65%): m.p. > 300 
°C; νmax/cm
-1
 (KBr) 3364, 2931, 1818, 1738, 1336, 1251, 746; δH (300 MHz, DMSO-d6) 
1.26 [4H, m, C(3′, 4′)-H2], 1.64 [2H, quin, J 6.7, C(5′)-H2], 1.76-1.89 [2H, m, C(2′)-H2], 
3.39 [2H, t, J 6.6, C(6′)-H2], 4.90 [2H, t, J 6.7, C(1′)-H2], 7.37 [1H, t, J 7.6, C(3 or 9)-
H], 7.38 [1H, t, J 7.5, C(3 or 9)-H], 7.60 [1H, t, J 8.0, C(2 or 10)-H], 7.63 [ 1H, t, J 7.7, 
C(2 or 10)-H], 7.84 [2H, d, J 8.3, C(1, 11)-H], 8.81 [1H, d, J 8.2, C(4 or 8)-H], 8.84 
[1H, d, J 8.2, C(4 or 8)-H], 12.13 [1H, bs, N(13)-H]; δc (150 MHz, DMSO-d6) 25.4 
(CH2), 27.7 (CH2), 30.6 (CH2), 32.5 (CH2), 35.4 (CH2), 44.5 (CH2), 111.0 (CH, 
aromatic CH), 112.9 (CH, aromatic CH), 116.5 (C, aromatic C), 117.4 (C, aromatic C), 
117.9 (C, aromatic C), 118.2 (C, aromatic C), 120.9 (C, aromatic C), 121.0 (C, aromatic 
C), 121.4 (CH, aromatic CH), 121.4 (CH, aromatic CH), 123.8 (CH, aromatic CH), 
124.1 (CH, aromatic CH), 127.87 (CH, aromatic CH), 127.93 (CH, aromatic CH), 129.4 








 80%]; HRMS (ESI
+










To a solution of 12-(6-bromohexyl)-12,13-dihydrofuro[3,4-
c]indolo[2,3-a]carbazole-5,7-dione 335 (0.898 g, 1.84 mmol) in 
anhydrous DMF (40 mL) was added hydroxylamine 
hydrochloride (0.637 g, 9.18 mmol) and triethylamine (1.30 mL, 
0.95 g, 9.2 mmol) and the resulting mixture was stirred at 80 °C 
for 2 hours. The orange solution was then allowed to cool and 
poured into water (200 mL) which was extracted using 10% 
MeOH/DCM (3 × 50 mL). The organic layer was washed with water (4 × 50 mL) 
followed by brine (50 mL) before being dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated under reduced pressure. The crude product was 
purified using column chromatography on silica gel using ethyl acetate as eluent to give 
a red solid which was identified on analysis to be 12-(6-chlorohexyl)-6-hydroxy-12,13-
dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 
336 (0.327 g, 40%): m.p. 298-300 °C; νmax/cm
-1
 (KBr) 3421, 
2933, 1755, 1695, 1403, 1332, 1112, 748; δH (300 MHz, 
DMSO-d6) 1.28-1.37 [4H, m, C(3′, 4′)-H2], 1.57 [2H, quin, J 
6.5, C(5′)-H2], 1.78-1.90 [2H, m, C(2′)-H2], 3.50 [2H, t, J 6.6, 
C(6′)-H2], 4.95 [2H, t, J 6.7, C(1′)-H2], 7.38 [2H, t, J 7.6, C(3, 
9)-H], 7.60 [1H, t, J 8.0, C(2 or 10)-H], 7.62 [1H, t, J 8.0, C(2 or 
10)-H], 7.82 [1H, d, J 8.1, C(1 or 11)-H], 7.84 [1H, d, J 8.3, C(1 or 11)-H], 9.07 [1H, d, 
J 7.2, C(4 or 8)-H], 9.10 [1H, d, J 7.3, C(4 or 8)-H], 10.63 (1H, bs, N-OH), 11.95 [1H, 
bs, N(13)-H]; δc (75 MHz, DMSO-d6) 25.6 (CH2), 26.5 (CH2), 30.6 (CH2), 32.3 (CH2), 
44.4 (CH2), 45.6 (CH2), 110.6 (CH, aromatic CH), 112.6 (CH, aromatic CH), 115.8 (C, 
aromatic C), 116.0 (C, aromatic C), 116.6 (C, aromatic C), 117.6 (C, aromatic C), 
120.89 (CH, aromatic CH), 120.91 (CH, aromatic CH), 121.2 (C, aromatic C), 121.3 (C, 
aromatic C), 124.6 (CH, aromatic CH), 124.9 (CH, aromatic CH), 127.56 (CH, aromatic 
CH), 127.64 (CH, aromatic CH), 128.8 (C, aromatic C), 130.1 (C, aromatic C), 141.7 



















To a stirred suspension of 12-(6-bromohexyl)-12,13-
dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione 335 (0.201 
g, 0.411 mmol) in absolute ethanol (20 mL) was added 
morpholine (0.35 mL, 0.35 g, 4.1 mmol) and the mixture was 
heated to reflux for 24 hours. After cooling, the solvent was 
evaporated under reduced pressure and the residue was dissolved 
in 10% MeOH/DCM (30 mL). The organic layer was washed 
with 1 M aqueous HCl (30 mL), followed by saturated aqueous sodium bicarbonate (30 
mL) and then water (2 × 30 mL) before being dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated under reduced pressure. The crude product was 
recrystallised from acetone to give a yellow solid (0.110 g, 55%): m.p. 259-261 °C; 
νmax/cm
-1
 (KBr) 3308, 2933, 1819, 1752, 1405, 1338, 1252, 1116, 742; δH (300 MHz, 
DMSO-d6) 1.14-1.29 [6H, m, C(3′, 4′, 5′)-H2], 1.84 [2H, quin, J 7.3, C(2′)-H2], 2.04 
[2H, t, J 6.7, C(6′)-H2], 2.14 [4H, t, J 4.4, N(CH2CH2)2O], 3.43 [4H, t, J 4.6, 
N(CH2CH2)2O], 4.94 [2H, t, J 6.6, C(1′)-H2], 7.40 [1H, t, J 7.5, C(3 or 9)-H], 7.41 [1H, 
t, J 7.4, C(3 or 9)-H], 7.62 [1H, t, J 8.0, C(2 or 10)-H], 7.65 [1H, t, J 8.0, C(2 or 10)-H], 
7.85 [1H, d, J 8.2, C(1 or 11)-H], 7.86 [1H, d, J 8.3, C(1 or 11)-H], 8.86 [1H, d, J 8.2, 
C(4 or 8)-H], 8.89 [1H, d, J 8.3, C(4 or 8)-H], 12.18 [1H, bs, N(13)-H]; δc (75 MHz, 
DMSO-d6) 26.0 (CH2), 26.1 (CH2), 27.0 (CH2), 30.6 (CH2), 44.5 (CH2), 53.7 (2 × CH2), 
58.5 (CH2), 66.5 (2 × CH2), 110.6 (CH, aromatic CH), 112.8 (CH, aromatic CH), 116.4 
(C, aromatic C), 117.4 (C, aromatic C), 117.8 (C, aromatic C), 118.0 (C, aromatic C), 
120.8 (C, aromatic C), 120.9 (C, aromatic C), 121.2 (2CH, 2 × aromatic CH), 123.7 
(CH, aromatic CH), 124.0 (CH, aromatic CH), 127.7 (CH, aromatic CH), 127.8 (CH, 
aromatic CH), 129.3 (C, aromatic C), 130.7 (C, aromatic C), 141.4 (C, aromatic C), 




 30 %]; 
HRMS (ESI
+
): Exact mass calculated for (C30H30N3O4)
+







c]carbazol-12-yl)hexyl]morpholin-4-ium chloride 338 
 
To a solution of 12-(6-morpholinohexyl)furo[3,4-c]indolo[2,3-
a]carbazole-5,7(12H,13H)-dione 337 (0.093 g, 0.19 mmol) in 
anhydrous DMF (10 mL) was added hydroxylamine 
hydrochloride (0.065 g, 0.94 mmol) and triethylamine (0.13 
mL, 0.09 g, 0.94 mmol) and the resulting mixture was stirred 
at 80 °C for 24 hours. After cooling, the reaction mixture was 
poured into 1M aqueous HCl (20 mL) and the precipitate 
collected by vacuum filtration, washed with water (5 mL) and 
allowed to dry to give desired product as an orange solid (0.056 g, 54%): m.p. 226-228 
°C; νmax/cm
-1
 (KBr) 3383, 3244, 2931, 1757, 1705, 1571, 1401, 1336, 1108, 749, 732; 
δH (300 MHz, DMSO-d6) 1.17-1.42 [4H, m, C(3′, 4′)-H2], 1.46-1.59 [2H, m, C(5′)-H2], 
1.86 [2H, quin, J 7.3, C(2′)-H2], 2.83-2.96 [4H, m, C(6′)-H2, one of each of 
O(CH2CH2)2N], 3.28 [2H, d, J 12.2, one of each of O(CH2CH2)2N], 3.69 [2H, t, J 12.1, 
one of each of O(CH2CH2)2N], 3.87 [2H, dd, J 12.5, 2.6, one of each of O(CH2CH2)2N], 
5.01 [2H, t, J 6.6, C(1′)-H], 7.39 [1H, t, J 7.6, C(3 or 9)-H], 7.41 [1H, t, J 7.6, C(3 or 9)-
H], 7.60 [1H, ddd, J 8.3, 7.2, 1.2, C(2 or 10)-H], 7.64 [1H, ddd, J 8.3, 7.2, 1.2, C(2 or 
10)-H], 7.87 [1H, d, J 8.3, C(1 or 11)-H], 7.88 [1H, d, J 8.2, C(1 or 11)-H], 9.08 [1H, d, 
J 8.3, C(4 or 8)-H], 9.11 [1H, d, J 8.7, C(4 or 8)-H], 10.52 [1H, bs, NH (salt)], 10.61 
(1H, bs, N-OH), 12.16 [1H, bs, N(13)-H]; δc (75 MHz, DMSO-d6) 22.9 (CH2), 25.9 
(CH2), 26.3 (CH2), 30.5 (CH2), 44.5 (CH2), 51.3 (2 × CH2), 56.2 (CH2), 63.6 (2 × CH2), 
110.7 (CH, aromatic CH), 112.8 (CH, aromatic CH), 115.8 (C, aromatic C), 115.9 (C, 
aromatic C), 116.6 (C, aromatic C), 117.5 (C, aromatic C), 120.9 (2CH, 2 × aromatic 
CH), 121.2 (C, aromatic C), 121.4 (C, aromatic C), 124.6 (CH, aromatic CH), 124.9 
(CH, aromatic CH), 127.6 (2CH, 2 × aromatic CH), 128.8 (C, aromatic C), 130.1 (C, 





 80%]; HRMS (ESI
+
): Exact mass calculated for (C30H31N4O4)
+
 










To a stirred suspension of 12-(6-bromohexyl)-12,13-
dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione 335 (0.637 
g, 1.30 mmol) in anhydrous DMF (30 mL) in a flame-dried flask 
under nitrogen was added sodium hydride (60 wt. % oil 
dispersion, 0.120 g, 3.00 mmol) carefully, and the purple 
mixture was stirred for 40 minutes. Iodomethane (0.19 mL, 0.44 
g, 3.1 mmol) was then added and the mixture was stirred for a further 16 hours. At this 
point TLC analysis showed that some starting material remained and so a further 
portion of sodium hydride (60 wt. % oil dispersion, 0.061 g, 1.53 mmol) was added 
followed by a further portion of iodomethane (0.10 mL, 0.23 g, 1.6 mmol) and the 
mixture was stirred for a further 16 hours. The reaction mixture was then cautiously 
poured into water (70 mL) and the precipitate collected using vacuum filtration. The 
solid was washed with copious amounts of water and allowed to dry. The crude residue 
was purified using column chromatography on silica gel using DCM to give a pale 
yellow solid which on analysis was shown to be dimethyl 11-(6-iodohexyl)-12-methyl-
11,12-dihydroindolo[2,3-a]carbazole-5,6-dicarboxylate 339 
(0.442 g, 57%): m.p. 134-136 °C; νmax/cm
-1
 (KBr) 3431, 2945, 
1720, 1333, 1256, 1068, 739; δH (300 MHz, DMSO-d6) 0.81-0.93 
[2H, m, C(3′)-H2], 1.11 [2H, quin, J 7.3, C(4′)-H2], 1.39-1.58 
[4H, m, C(2′, 5′)-H2], 3.00 [2H, t, J 6.9, C(6′)-H2], 4.03 (6H, s, 2 
× OCH3), 4.16 (3H, s, NCH3), 4.74 [2H, t, J 7.0, C(1′)-H2], 7.28-
7.36 [2H, m, C(3, 8)-H], 7.57 [1H, t, J 7.7, C(9)-H], 7.59 [1H, t, J 7.5, C(2)-H], 7.76 
[1H, d, J 8.3, C(1)-H], 7.85 [1H, d, J 8.3, C(10)-H], 8.05 [1H, d, J 8.0, C(4 or 7)-H], 
8.06 [1H, d, J 7.9, C(4 or 7)-H]; δc (75 MHz, DMSO-d6) 8.8 (CH2), 25.0 (CH2), 28.0 
(CH2), 29.5 (CH2), 33.0 (CH2), 36.9 (CH3), 48.0 (CH2), 53.3 (2 × CH3), 112.0 (CH, 
aromatic CH), 113.0 (CH, aromatic CH), 119.0 (C, aromatic C), 119.4 (C, aromatic C), 
119.57 (C, aromatic C), 119.62 (C, aromatic C), 121.3 (2CH, 2 × aromatic CH), 121.9 
(CH, aromatic CH), 122.2 (CH, aromatic CH), 122.6 (C, aromatic C), 123.4 (C, 
aromatic C), 126.8 (CH, aromatic CH), 127.1 (CH, aromatic CH), 130.4 (C, aromatic 








 20%]; HRMS (ESI
+





 597.1250. Found 597.1245. 
 
Method B 
To a stirred suspension of 12-(6-bromohexyl)-12,13-dihydrofuro[3,4-c]indolo[2,3-
a]carbazole-5,7-dione 335 (0.350 g, 0.715 mmol) in anhydrous DMF (30 mL) in a 
flame-dried flask under nitrogen was added sodium hydride (60 wt. % oil suspension, 
0.034 g, 0.85 mmol) and the mixture was stirred for 40 minutes. Iodomethane (0.14 mL, 
0.32 g, 2.3 mmol) was then added and the mixture was stirred for a further 48 hours. 
The reaction mixture was then cautiously poured into water (70 mL) and the precipitate 
collected using vacuum filtration. The solid was washed with copious amounts of water 
and allowed to dry. The crude product was recrystallised from acetone to give a yellow 
solid which on analysis was found to be 12-(6-iodohexyl)-13-methyl-12,13-
dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione (0.203 g, 
52%): m.p. 186-187 °C; νmax/cm
-1
 (KBr) 2932, 1819, 1753, 
1480, 1334, 1250, 1203, 741; δH (300 MHz, DMSO-d6) 0.86-
0.98 [2H, quin, J 7.4, C(3′)-H2], 1.08-1.19 [2H, quin, J 7.4, 
C(4′)-H2], 1.47 [2H, quin, J 7.2, C(5′)-H2], 1.65 [2H, quin, J 7.3, 
C(2′)-H2], 3.02 [2H, t, J 6.9, C(6′)-H2], 4.26 (3H, s, CH3), 4.81 
[2H, t, J 7.3, C(1′)-H2], 7.42-7.51 [2H, m, C(3, 9)-H], 7.68 [1H, 
ddd, J 8.4, 7.2, 1.2, C(10) -H], 7.72 [1H, ddd, J 8.3, 7.1, 1.2, C(2)-H], 7.85 [1H, d, J 8.3, 
C(1)-H], 7.95 [1H, d, J 8.3, C(11)-H], 8.91 [1H, d, J 7.7, C(4)-H], 8.93 [1H, d, J 7.5, 
C(8)-H]; δc (75 MHz, DMSO-d6) 8.9 (CH2), 24.9 (CH2), 28.5 (CH2), 29.6 (CH2), 32.9 
(CH2), 37.0 (CH3), 48.6 (CH2), 111.8 (CH, aromatic CH), 112.8 (CH, aromatic CH), 
118.1 (C, aromatic C), 118.5 (C, aromatic C), 118.9 (C, aromatic C), 119.4 (C, aromatic 
C), 121.4 (C, aromatic C), 121.95 (CH, aromatic CH), 121.97 (CH, aromatic CH), 122.1 
(C, aromatic C), 123.9 (CH, aromatic CH), 124.2 (CH, aromatic CH), 128.2 (CH, 
aromatic CH), 128.5 (CH, aromatic CH), 132.8 (C, aromatic C), 133.7 (C, aromatic C), 





 20%]; HRMS (ESI
+














To a solution of 12-(6-iodohexyl)-13-methyl-12,13-
dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione 340 (0.120 
g, 0.218 mmol) in anhydrous DMF (12 mL) was added 
hydroxylamine hydrochloride (0.083 g, 1.19 mmol) and 
triethylamine (0.17 mL, 0.12 g, 1.2 mmol) and the resulting 
mixture was stirred at 80 °C for 2 hours. After cooling, the 
reaction mixture was poured into 1M aqueous HCl (20 mL) and 
the precipitate collected by vacuum filtration, washed with water (5 mL) and allowed to 
dry. The crude residue was purified using column chromatography on silica gel with 1% 
MeOH/DCM to give desired product as an orange solid (0.076 g, 74%): m.p. 123-125 
°C; νmax/cm
-1
 (KBr) 3199, 2934, 1762, 1702, 1450, 1331, 1006, 750; δH (300 MHz, 
DMSO-d6) 0.91 [2H, quin, J 7.5, C(3′)-H2], 1.15 [2H, quin, J 7.5, C(4′)-H2], 1.40 [2H, 
quin, J 7.0, C(5′)-H2], 1.60 [2H, quin, J 7.2, C(2′)-H2], 3.36 [2H, t, J 6.6, C(6′)-H2], 4.19 
(3H, s, CH3), 4.75 [2H, t, J 6.9, C(1′)-H2], 7.38 [1H, t, J 7.5, C(9)-H], 7.40 [1H, t, J 7.6, 
C(3)-H], 7.62 [1H, t, J 8.4, C(10)-H], 7.65 [1H, t, J 8.2, C(2)-H], 7.77 [1H, d, J 8.2, 
C(1)-H], 7.86 [1H, d, J 8.3, C(11)-H], 9.06 [1H, d, J 7.5, C(4)-H], 9.09 [1H, d, J 7.5, 
C(8)-H], 10.70 (1H, bs, OH); δc (75 MHz, DMSO-d6) 25.4 (CH2), 26.0 (CH2), 28.3 
(CH2), 32.1 (CH2), 37.2 (CH3), 45.4 (CH2), 48.4 (CH2), 111.8 (CH, aromatic CH), 112.7 
(CH, aromatic CH), 116.2 (C, aromatic C), 116.6 (C, aromatic C), 119.2 (C, aromatic 
C), 119.8 (C, aromatic C), 121.6 (2CH, 2 × aromatic CH), 122.1 (C, aromatic C), 122.9 
(C, aromatic C), 124.8 (CH, aromatic CH), 125.0 (CH, aromatic CH), 127.9 (CH, 
aromatic CH), 128.2 (CH, aromatic CH), 132.6 (C, aromatic C), 133.6 (C, aromatic C), 





 50%]; HRMS (ESI
+














To a stirred suspension of 11-(6-iodohexyl)-12-methyl-11,12-
dihydroindolo[2,3-a]carbazole-5,6-dicarboxylate 339 (0.411 g, 
0.689 mmol) in a mixture of methanol (8 mL) and water (2 mL) 
was added potassium hydroxide (85 wt. %, 0.306 g, 4.64 mmol) 
and the mixture was heated to reflux for 24 hours. After cooling, 
the solvent was evaporated under reduced pressure and the 
residue suspended in 1 M aqueous HCl (20 mL). The solid was collected using vacuum 
filtration and dried overnight at 50 °C. The pale yellow solid was suspended in acetic 
anhydride (10 mL) and heated to reflux for 2 hours. After cooling, the solvent was 
evaporated under reduced pressure and the residue was washed with saturated sodium 
bicarbonate solution (30 mL). The crude product was extracted with 10% MeOH/DCM 
(2 × 20 mL) and the organic layer was then washed with saturated sodium bicarbonate 
solution (20 mL), followed by water (3 × 20 mL) before being dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under reduced pressure. The 
crude product was purified using column chromatography on silica gel with DCM to 
give desired product as a bright yellow solid (0.153 g, 49%): m.p. 168-169 °C; νmax/cm
-1
 
(KBr) 2932, 1818, 1753, 1334, 1251, 741; δH (300 MHz, DMSO-d6) 0.90 [2H, quin, J 
7.4, C(4′)-H2], 1.03-1.14 [2H, m, C(3′)-H2], 1.21 [2H, quin, J 6.6, C(5′)-H2], 1.65 [2H, 
quin, J 7.3, C(2′)-H2], 3.04 [2H, t, J 6.6, C(6′)-H2], 3.06 (3H, s, OCH3), 4.21 (3H, s, 
NCH3), 4.74 [2H, t, J 7.4, C(1′)-H2], 7.40 [1H, t, J 7.6, C(3 or 9)-H], 7.44 [1H, t, J 7.6, 
C(3 or 9)-H], 7.65 [1H, ddd, J 8.4, 7.2, 1.2, C(2 or 10)-H], 7.69 [1H, ddd, J 8.3, 7.1, 1.1, 
C(2 or 10)-H], 7.82 [1H, d, J 8.3, C(11)-H], 7.90 [1H, d, J 8.4, C(1)-H], 8.85 [2H, d, J 
7.9, C(4, 8)-H]; δc (150 MHz, DMSO-d6) 25.3 (CH2), 25.8 (CH2), 28.6 (CH2), 29.1 
(CH2), 37.1 (CH3), 48.5 (CH2), 58.1 (CH3), 72.0 (CH2), 112.0 (CH, aromatic CH), 112.9 
(CH, aromatic CH), 118.2 (C, aromatic C), 118.6 (C, aromatic C), 118.9 (C, aromatic 
C), 119.5 (C, aromatic C), 121.4 (C, aromatic C), 122.0 (CH, aromatic CH), 122.1 (CH, 
aromatic CH), 122.2 (C, aromatic C), 124.0 (CH, aromatic CH), 124.2 (CH, aromatic 
CH), 128.3 (CH, aromatic CH), 128.5 (CH, aromatic CH), 132.9 (C, aromatic C), 133.8 





 50%]; HRMS (ESI
+
): Exact mass calculated for (C28H27N2O4)
+
 
455.1971. Found 455.1966. 
Experimental 





To a solution of 12-(6-methoxyhexyl)-13-methyl-12,13-
dihydrofuro[3,4-c]indolo[2,3-a]carbazole-5,7-dione  342 (0.110 
g, 0.242 mmol) in anhydrous DMF (10 mL) was added 
hydroxylamine hydrochloride (0.079 g, 1.21 mmol) and 
triethylamine (0.16 mL, 0.12 g, 1.1 mmol) and the resulting 
mixture was stirred at 80 °C for 24 hours. The orange solution 
was then allowed to cool and poured into 1 M aqueous HCl (60 mL) and the precipitate 
collected using vacuum filtration.  The solid was suspended in a mixture of water (5 
mL) and methanol (5 mL) and allowed to stir for 2 hours before the solid was collected 
using vacuum filtration and allowed to dry. This gave desired product as an orange solid 
(0.083 g, 73%): m.p. 180-182 °C; νmax/cm
-1
 (KBr) 2934, 2836, 1760, 1709, 1473, 1333, 
1104, 727; δH (300 MHz, DMSO-d6) 0.85 [2H, quin, J 7.3, C(4′)-H2], 0.98-1.10 [2H, m, 
C(3′)-H2], 1.16 [2H, quin, J 6.7, C(5′)-H2], 1.60 [2H, quin, J 7.1, C(2′)-H2], 2.98 [2H, t, 
J 6.3, C(6′)-H2], 3.03 (3H, s, OCH3), 4.21 (3H, s, NCH3), 4.78 [2H, t, J 7.0, C(1′)-H2], 
7.41 [1H, t, J 7.2, C(3 or 9)-H], 7.43 [1H, t, J 7.1, C(3 or 9)-H], 7.64 [1H, t, J 8.1, 
C(10)-H], 7.67 [1H, t, J 7.8, C(2)-H], 7.79 [1H, d, J 8.2, C(1 or 11)-H], 7.88 [1H, d, J 
8.2, C(1 or 11)-H], 9.08 [1H, d, J 8.0, C(4)-H], 9.11 [1H, d, J 8.1, C(8)-H], 10.73 (N-
OH); δc (150 MHz, DMSO-d6) 25.3 (CH2), 25.8 (CH2), 28.4 (CH2), 29.0 (CH2), 37.2 
(CH3), 48.4 (CH2), 58.1 (CH3), 71.1 (CH2), 111.9 (CH, aromatic CH), 112.9 (CH, 
aromatic CH), 116.2 (C, aromatic C), 116.6 (C, aromatic C), 119.3 (C, aromatic C), 
119.8 (C, aromatic C), 121.67 (CH, aromatic CH), 121.71 (CH, aromatic CH), 122.1 (C, 
aromatic C), 122.9 (C, aromatic C), 124.8 (CH, aromatic CH), 125.1 (CH, aromatic 
CH), 128.0 (CH, aromatic CH), 128.3 (CH, aromatic CH), 132.7 (C, aromatic C), 133.7 





 50%]; HRMS (ESI
+
): Exact mass calculated for 
(C28H28N3O4)
+











To a stirred suspension of 6-hydroxy-12,13-dihydro-5H-
indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 296 (0.152 
g, 0.455 mmol) in pyridine (15 mL) was added DMAP (0.062 g, 
0.490 mmol) and p-toluenesulfonyl chloride (0.096 g, 0.490 
mmol). The solution was stirred for 2 hours at room temperature before hydrazine 
hydrate (0.07 mL, 0.07 g, 2.3 mmol) was added and the mixture was heated to 80 °C for 
16 hours. After cooling, the solvent was evaporated under reduced pressure. The residue 
was suspended in ethanol (10 mL) and the precipitate collected by vacuum filtration. 
Washes with ethanol (2 × 2 mL) gave the product as a grey solid (0.111 g, 69%): m.p. 
>300 °C; νmax/cm
-1
 (KBr) 3274, 1702, 1651, 1575, 1443, 1389, 740; δH (300 MHz, 
DMSO-d6) 5.73 (2H, bs, NH2), 7.22 [1H, t, J 7.4, C(10)-H], 7.34 [1H, t, J 7.5, C(3)-H], 
7.44 [1H, t, J 7.8, C(11)-H], 7.50 [1H, t, J 7.8, C(2)-H], 7.72 [1H, d, J 8.0, C(12)-H], 
7.79 [1H, d, J 8.0, C(1)-H], 8.69 [1H, d, J 8.0, C(4)-H], 9.57 [1H, d, J 8.2, C(9)-H], 
10.53 [1H, bs, N(5)-H], 11.45 (1H, s, NH), 11.82 (1H, s, NH); δc (75 MHz, DMSO-d6) 
101.8 (C, aromatic C), 106.7 (C, aromatic C), 111.9 (CH, aromatic CH), 112.3 (CH, 
aromatic CH), 116.4 (C, aromatic C), 119.2 (CH, aromatic CH), 120.7 (CH, aromatic 
CH), 122.1 (C, aromatic C), 122.4 (CH, aromatic CH), 123.3 (C, aromatic C), 123.5 (C, 
aromatic C), 125.5 (CH, aromatic CH), 125.6 (CH, aromatic CH), 127.4 (CH, aromatic 
CH), 130.8 (C, aromatic C), 131.4 (C, aromatic C), 139.4 (C, aromatic C), 140.2 (C, 




 20%]; HRMS (ESI
-
): 
Exact mass calculated for (C20H12N5O2)
-
 354.0991. Found 354.0982. 
 
Method B 
To a stirred suspension of 6-hydroxy-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-
c]carbazole-5,7(6H)-dione 296 (0.100 g, 0.293 mmol) in pyridine (10 mL) was added 
DMAP (0.038 g, 0.322 mmol) and p-toluenesulfonyl chloride (0.059 g, 0.322 mmol) 
and the resulting solution was stirred for 2 hours at room temperature. Water (20 mL) 
Experimental 
  286 
 
was then added and the yellow precipitate was collected using vacuum filtration and 
washed with water (2 × 2 mL) to give tosylate ester as a yellow solid (0.120 g, 82%) 
which was used without further purification or full characterisation: νmax/cm
-1
 (KBr) 
3398, 1772, 1732, 1406, 1327, 1178, 744, 566; δH (300 MHz, DMSO-d6) 2.48 (3H, s, 
CH3), 7.37 [2H, t, J 7.7, C(3, 9)-H], 7.55-7.62 [4H, m, C(2, 10, 3′, 5′)-H], 7.84 [2H, d, J 
8.2, C(1, 11)-H], 8.03 [2H, d, J 8.4, C(2′, 6′)-H], 8.75 [2H, d, J 8.0, C(4, 8)-H], 11.91 
[2H, s, N(12, 13)-H]. Tosylate ester (0.102 g, 0.21 mmol) was then suspended in 
ethanol (10 mL) and hydrazine hydrate (0.02 mL, 0.02 g, 0.62 mmol) was added. The 
reaction mixture was heated to reflux for 16 hours before cooling. Water (20 mL) was 
then added and the red precipitate collected using vacuum filtration. Analysis showed 





To a stirred suspension of 6-hydroxy-12,13-dihydro-5H-
indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 296 (0.154 
g, 0.451 mmol) in pyridine (15 mL) was added DMAP (0.063 g, 
0.496 mmol) and p-toluenesulfonyl chloride (0.097 g, 0.496 
mmol). The solution was stirred for 2 hours at this temperature before 
hydroxylammonium hydrochloride (0.160 g, 2.26 mmol) was added and the mixture 
was heated to 80 °C. After 16 hours the mixture was cooled and the solvent evaporated 
under reduced pressure. The residue was suspended in ethanol (10 mL) and the 
precipitate collected by vacuum filtration. Washes with ethanol gave the desired product 
as a light brown solid (0.116 g, 71%): m.p. >300 °C; νmax/cm
-1
 (KBr) 3305, 1699, 1648, 
1577, 1371, 1184, 725; δH (300 MHz, DMSO-d6) 7.22 [1H, t, J 7.7, C(10)-H], 7.35 [1H, 
t, J 7.3, C(3)-H], 7.45 [1H, t, J 8.0, C(11)-H], 7.51 [1H, t, J 7.9, C(2)-H], 7.74 [1H, d, J 
8.0, C(12)-H], 7.81 [1H, d, J 8.0, C(1)-H], 8.67 [1H, d, J 8.1, C(4)-H], 9.52 [1H, d, J 
8.2, C(9)-H], 10.49 [1H, s, N(5)-H], 10.59 (1H, bs, O-H), 11.47 (1H, s, NH), 11.84 (1H, 
s, NH); δc (75 MHz, DMSO-d6) 102.4 (C, aromatic C), 106.8 (C, aromatic C), 111.9 
(CH, aromatic CH), 112.3 (CH, aromatic CH), 116.6 (C, aromatic C), 119.3 (CH, 
aromatic CH), 120.7 (CH, aromatic CH), 122.1 (C, aromatic C), 122.4 (CH, aromatic 
CH), 123.3 (C, aromatic C), 123.4 (C, aromatic C), 125.6 (CH, aromatic CH), 125.7 









 90%]; HRMS (ESI
-
): Exact mass calculated for (C20H11N4O3)
-
 





6,8(5H,7H)-dione 345 (0.150 g, 0.421 mmol) was suspended in a 
mixture of acetic acid (5 mL) and water (5 mL). Sodium nitrite 
(0.150 g, 2.11 mmol) was added and the mixture was stirred at 
50 °C for 2 hours. Further portions of sodium nitrite (0.150 g, 2.11 mmol) were added at 
2 hours and 4 hours and the mixture was then stirred for 16 hours. Water was then 
added and the precipitate collected by filtration and allowed to dry. The off-white solid 
was then suspended in DMSO (5 mL) and heated to 80 °C for 1 hour resulting in a 
clear, brown solution. After cooling, water (15 mL) was added and the precipitate 
collected using vacuum filtration. Washes with water (2 × 2 mL) resulted in an off-
white solid (0.122 g, 85%): m.p. >300 °C; νmax/cm
-1
 (KBr) 3250, 3052, 1696, 1652, 
1576, 1444, 1388, 1325, 743; δH (300 MHz, DMSO-d6) 7.20 [1H, ddd, J 8.2, 7.0, 1.1, 
C(10)-H], 7.33  [1H, t, J 7.6, C(3)-H], 7.43 [1H, ddd, J 8.2, 7.0, 1.2, C(11)-H], 7.50 
[1H, ddd, J 8.0, 7.3, 0.9, C(2)-H], 7.71 [1H, d, J 8.0, C(12)-H], 7.80 [1H, d, J 7.9, C(1)-
H], 8.67 [ 1H, d, J 8.0, C(4)-H], 9.50 [1H, d, J 8.2, C(9)-H], 10.09 [1H, bs, N(5)-H], 
11.30 [1H, bs, N(7)-H], 11.40 (1H, s, NH), 11.81 (1H, s, NH); δc (150 MHz, DMSO-d6) 
102.5 (C, aromatic C), 106.9 (C, aromatic C), 111.8 (CH, aromatic CH), 112.3 (CH, 
aromatic CH), 116.9 (C, aromatic C), 119.1 (CH, aromatic CH), 120.7 (CH, aromatic 
CH), 122.2 (C, aromatic C), 122.4 (CH, aromatic CH), 123.1 (C, aromatic C), 123.5 (C, 
aromatic C), 125.5 (CH, aromatic CH), 125.6 (CH, aromatic CH), 127.6 (CH, aromatic 
CH), 131.0 (C, aromatic C), 134.2 (C, aromatic C), 139.4 (C, aromatic C), 140.2 (C, 




 100%]; HRMS 
(ESI
+
): Exact mass calculated for (C20H13N4O2)
+









To a stirred suspension of 6-hydroxy-12,13-dimethyl-12,13-
dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 
305 (0.151 g, 0.409 mmol) in pyridine (15 mL) was added 
DMAP (0.055 g, 0.450 mmol) and p-toluenesulfonyl chloride 
(0.085 g, 0.450 mmol). The solution was stirred for 2 hours at room temperature before 
hydrazine hydrate (0.10 mL, 0.10 g, 2.4 mmol) was added and the mixture was heated 
to 80 °C for 16 hours. After cooling, the solvent was evaporated under reduced pressure. 
The residue was suspended in ethanol (10 mL) and the precipitate collected by vacuum 
filtration. Washes with ethanol (2 × 2 mL) gave the desired product as a cream solid 
(0.122 g, 87%): m.p. >300 °C; νmax/cm
-1
 (KBr) 3365, 2918, 1709, 1651, 1442, 1088, 
734; δH (300 MHz, DMSO-d6) 4.13 (3H, s, CH3), 4.23 (3H, s, CH3), 5.70 (2H, bs, NH2), 
7.29 [1H, ddd, J 8.0, 7.1, 1.0, C(10)-H], 7.42 [1H, t, J 7.2, C(3)-H], 7.55 [1H, ddd, J 
8.1, 7.0, 1.0, C(11)-H], 7.60 [1H, t, J 7.7, C(2)-H], 7.70 [1H, d, J 8.1, C(12)-H], 7.78 
[1H, d, J 8.2, C(1)-H], 8.66 [1H, d, J 8.0, C(4)-H], 9.59 [1H, d, J 8.0, C(9)-H], 10.63 
(1H, s, NH); δc (150 MHz, DMSO-d6) 36.7 (CH3), 37.5 (CH3), 102.2 (C, aromatic C), 
109.1 (C, aromatic C), 111.3 (CH, aromatic CH), 111.4 (CH, aromatic CH), 119.5 (C, 
aromatic C), 120.1 (CH, aromatic CH), 121.4 (CH, aromatic CH), 121.9 (C, aromatic 
C), 122.1 (C, aromatic C), 122.3 (CH, aromatic CH), 123.9 (C, aromatic C), 126.0 (CH, 
aromatic CH), 126.3 (CH, aromatic CH), 126.9 (C, aromatic C), 127.5 (CH, aromatic 
CH), 133.8 (C, aromatic C), 143.2 (C, aromatic C), 145.1 (C, aromatic C), 149.0 (C=O), 




 100%]; HRMS (ESI
+
): Exact mass calculated 
for (C22H18N5O2)
+









To a stirred suspension of 6-hydroxy-12,13-dimethyl-12,13-
dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 
305 (0.204 g, 0.552 mmol) in pyridine (15 mL) was added 
DMAP (0.079 g, 0.662 mmol) and p-toluenesulfonyl chloride 
(0.123 g, 0.662 mmol). The solution was stirred for 2 hours at this temperature before 
hydroxylammonium hydrochloride (0.188 g, 2.76 mmol) was added and the mixture 
was heated to 80 °C for 16 hours. After cooling, the solvent was evaporated under 
reduced pressure. The residue was suspended in ethanol (10 mL) and the precipitate 
collected by vacuum filtration. Washes with ethanol (2 × 2 mL) gave the desired 
product as a light brown solid (0.119 g, 57%): m.p. >300 °C; νmax/cm
-1
 (KBr) 3391, 
2917, 1712, 1664, 1596, 1456, 1325, 739; δH (300 MHz, DMSO-d6) 4.14 (3H, s, CH3), 
4.24 (3H, s, CH3), 7.29 [1H, t, J 7.4, C(10)-H], 7.43 [1H, t, J 7.4, C(3)-H], 7.55 [1H, t, J 
7.2, C(11)-H], 7.60 [1H, t, J 7.5, C(2)-H], 7.71 [1H, d, J 8.2, C(12)-H], 7.79 [1H, d, J 
8.2, C(1)-H], 8.64 [1H, d, J 7.9, C(4)-H], 9.54 [1H, d, J 8.2, C(9)-H], 10.59 (1H, bs, 
OH), 10.60 (1H, s, NH); δc (150 MHz, DMSO-d6) 36.7 (CH3), 37.5 (CH3), 102.8 (C, 
aromatic C), 109.1 (C, aromatic C), 111.3 (CH, aromatic CH), 111.4 (CH, aromatic 
CH), 119.7 (C, aromatic C), 120.1 (CH, aromatic CH), 121.4 (CH, aromatic CH), 122.1 
(2C, 2 × aromatic C), 122.3 (CH, aromatic CH), 123.8 (C, aromatic C), 126.1 (CH, 
aromatic CH), 126.4 (CH, aromatic CH), 126.9 (C, aromatic C), 127.4 (CH, aromatic 
CH), 133.8 (C, aromatic C), 143.2 (C, aromatic C), 145.1 (C, aromatic C), 149.4 (C=O), 




 1%]; HRMS (ESI
+
): Exact mass calculated for 
(C22H17N4O3)
+










[4,5-c]carbazole-6,8(5H,7H)-dione 349 (0.102 g, 0.266 mmol) 
was suspended in a mixture of acetic acid (6 mL) and water (6 
mL). Sodium nitrite (0.090 g, 1.33 mmol) was added and the 
mixture was stirred at 50 °C for 2 hours. Further portions of sodium nitrite (0.090 g, 
1.33 mmol) were added at 2 hours and 4 hours and the mixture was then stirred for 16 
hours at this temperature. Water (20 mL) was then added and the precipitate collected 
by filtration and allowed to dry. The off-white solid was then suspended in DMSO (5 
mL) and heated to 80 °C for 1 hour resulting in a clear, brown solution. After cooling, 
water (20 mL) was added and the precipitate collected using vacuum filtration. Washes 
with water (2 × 2 mL) gave desired product as an off-white solid (83 mg, 86%): m.p. 
>300 °C; νmax/cm
-1
 (KBr); 3462, 3162, 3046, 2827, 1690, 1618, 1447, 1321, 738; δH 
(300 MHz, DMSO-d6) 4.11 (3H, s, CH3), 4.21 (3H, s, CH3), 7.26 [1H, t, J 7.5, C(10)-
H], 7.40 [1H, t, J 7.4, C(3)-H], 7.53 [1H, t, J 7.7, C(11)-H], 7.58 [1H, t, J 7.9, C(2)-H], 
7.67 [1H, d, J 8.1, C(12)-H, 7.76 [1H, d, J 8.1, C(1)-H], 8.62 [1H, d, J 7.8, C(4)-H], 
9.53 [1H, d, J 8.3, C(9)-H], 10.16 [1H, bs, N(5)-H], 11.34 [1H, bs, N(7)-H]; δc (75 
MHz, DMSO-d6) 36.7 (CH3), 37.5 (CH3), 102.9 (C, aromatic C), 109.1 (C, aromatic C), 
111.2 (CH, aromatic CH), 111.3 (CH, aromatic CH), 119.99 (CH, aromatic CH), 120.03 
(C, aromatic C), 121.4 (CH, aromatic CH), 122.1 (C, aromatic C), 122.2 (CH, aromatic 
CH), 123.9 (C, aromatic C), 126.0 (CH, aromatic CH), 126.4 (CH, aromatic CH), 126.7 
(C, aromatic C), 127.6 (CH, aromatic CH), 134.0 (C, aromatic C), 134.7 (C, aromatic 





 10%]; HRMS (ESI
+
): Exact mass calculated for (C22H17N4O2)
+
 









To a stirred suspension of 6,6'-(6-hydroxy-5,7-dioxo-6,7-
dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12,13-diyl)di 
hexanenitrile 334 (0.130 g, 0.245 mmol) in pyridine (13 mL) 
was added DMAP (0.033 g, 0.269 mmol) and p-toluenesulfonyl 
chloride (0.051 g, 0.269 mmol). The solution was stirred for 2 
hours at room temperature before hydrazine hydrate (0.04 mL, 
0.04 g, 1.2 mmol) was added and the mixture was heated to 80 
°C for 16 hours. After cooling, the solvent was evaporated under reduced pressure. The 
residue was suspended in methanol (10 mL) and the precipitate collected by vacuum 
filtration. Washes with methanol (2 × 2 mL) gave the desired product as an off-white 
solid (0.080 g, 61%): m.p. 135-137 °C; νmax/cm
-1 
(KBr) 3330, 2937, 2243, 1713, 1648, 
1594, 1432, 1336, 749; δH (300 MHz, DMSO-d6) 0.79-0.98 [4H, m, C(4′, 4′′)-H2], 1.16-
1.33 [6H, m, C(3′, 3′′, 5′)-H2], 1.42 [2H, quin, J 7.2, C(5′′)-H2], 2.16 [2H, t, J 6.9, C(2′ 
or 2′′)-H2], 2.17 [2H, t, J 6.9, C(2′ or 2′′)-H2], 4.64 [2H, t, J 6.9, C(6′)-H2], 4.74 [2H, t, J 
7.0, C(6′′)-H2], 5.71 (2H, bs, NH2), 7.30 [1H, t, J 7.7, C(10)-H], 7.42 [1H, t, J 7.5, C(3)-
H], 7.53 [1H, t, J 7.3, C(11)-H], 7.58 [1H, t, J 7.5, C(2)-H], 7.83 [1H, d, J 8.2, C(12)-
H], 7.89 [1H, d, J 8.2, C(1)-H], 8.69 [1H, d, J 7.9, C(4)-H], 9.60 [1H, d, J 8.2, C(9)-H], 
10.66 (1H, bs, NH); δc (75 MHz, DMSO-d6) 16.2 [2 × CH2], 24.4 [CH2], 24.5 [CH2], 
25.4 [CH2], 25.5 [CH2], 26.8 [CH2], 27.6 [CH2], 47.7 [CH2], 48.4 [CH2], 102.9 (C, 
aromatic C), 110.1 (C, aromatic C), 113.0 (CH, aromatic CH), 113.1 (CH, aromatic 
CH), 120.6 (CH, aromatic CH), 120.7 (2 × CN), 121.4 (C, aromatic C), 121.7 (CH, 
aromatic CH), 122.7 (CH, aromatic CH), 123.5 (C, aromatic C), 125.8 (C, aromatic C), 
126.0 (CH, aromatic CH), 126.3 (CH, aromatic CH), 127.3 (C, aromatic C), 127.9 (CH, 
aromatic CH), 132.2 (C, aromatic C), 134.5 (C, aromatic C), 142.5 (C, aromatic C), 







): Exact mass calculated for (C32H32N7O2)
+











ido[4,5-c]carbazole-13,14-diyl)dihexanenitrile 351 (0.070 g, 
0.13 mmol) was suspended in a mixture of acetic acid (3 mL) 
and water (3 mL). Sodium nitrite (0.044 g, 0.64 mmol) was 
added and the mixture was stirred at 50 °C for 2 hours. Further 
portions of sodium nitrite (0.044 g, 0.64 mmol) were added at 2 
hours and 4 hours and the mixture was then stirred for 16 hours 
at this temperature. Water (15 mL) was then added and the precipitate collected by 
filtration and allowed to dry. The light brown solid was then suspended in DMSO (3 
mL) and heated to 80 °C for 1 hour resulting in a clear, brown solution. After cooling, 
water (10 mL) was added and the aqueous layer was extracted with 20% MeOH/DCM 
(15 mL). The organic layer was washed once with water (10 mL) before being dried 
over anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure. Methanol (4 mL) was added to the residue and the mixture was stirred for 30 
minutes before the precipitate was collected using vacuum filtration to give an off-white 
solid (0.042 g, 61%): m.p. 124-126 °C; νmax/cm
-1
 (KBr) 3419, 3190, 2939, 2244, 1706, 
1594, 1460, 1369, 750; δH (300 MHz, DMSO-d6) 0.82-0.99 [4H, m, C(4′, 4′′)-H2], 1.15-
1.34 [6H, m, C(3′, 3′′, 5′)-H2], 1.42 [2H, quin, J 6.7, C(5′′)-H2], 2.18 [2H, t, J 6.8, 
C(either 2′ or 2′′)-H2], 2.19 [2H, t, J 6.8, C(either 2′ or 2′′)-H2], 4.63 [2H, t, J 7.0, C(6′)-
H2], 4.74 [2H, t, J 7.1, C(6′′)-H2], 7.27 [1H, t, J 7.6, C(10)-H], 7.41 [1H, t, J 7.6, C(3)-
H], 7.52 [1H, t, J 7.9, C(11)-H], 7.58 [1H, t, J 7.9, C(2)-H], 7.82 [1H, d, J 8.2, C(12)-
H], 7.89 [1H, d, J 8.2, C(1)-H], 8.65 [1H, d, J 8.0, C(4)-H], 9.53 [1H, d, J 8.1, C(9)-H], 
10.20 (1H, bs, NH), 11.36 (1H, bs, C=ONHC=O); δc (125 MHz, DMSO-d6) 16.2 (CH2), 
16.3 (CH2), 24.46 (CH2), 24.49 (CH2), 25.4 (CH2), 25.6 (CH2), 26.8 (CH2), 27.5 (CH2), 
47.7 (CH2), 48.4 (CH2), 103.7 (C, aromatic C), 110.2 (C, aromatic C), 113.0 (CH, 
aromatic CH), 113.1 (CH, aromatic CH), 120.6 (CH, aromatic CH), 120.8 (2 × CN), 
121.75 (CH, aromatic CH), 121.84 (C, aromatic C), 122.7 (CH, aromatic CH), 123.6 (C, 
aromatic C), 125.8 (C, aromatic C), 125.9 (CH, aromatic CH), 126.4 (CH, aromatic 
CH), 127.1 (C, aromatic C), 128.0 (CH, aromatic CH), 134.7 (C, aromatic C), 135.0 (C, 








 40%]; HRMS (ESI
+
): Exact mass calculated for 
(C32H31N6O2)
+
 531.2508. Found 531.2495. 
 
7.5 Synthesis and derivatisation of novel methyl 2,3-di(1H-indol-3-yl)-
3-oxopropanoates 
 







To a suspension of 2-[1-(phenylsulfonyl)-1H-indol-3-yl]acetic acid 256 
(13.846 g, 43.9 mmol) in distilled methanol (200 mL) was added 
dropwise thionyl chloride (4.78 mL, 7.84 g, 65.9 mmol) and the mixture 
was heated to reflux for 16 hours. After cooling, the solvent and excess 
thionyl chloride were evaporated under reduced pressure. Saturated 
aqueous sodium bicarbonate solution (60 mL) was added to the residue 
which was then extracted was ethyl acetate (2 × 40 mL). The organic layer was washed 
with saturated aqueous sodium bicarbonate (40 mL) followed by water (2 × 40 mL), 
before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure. The crude product was purified using column 
chromatography on silica gel with 20% ethyl acetate/ hexane gave desired product as a 
pale yellow solid (11.859 g, 82%): m.p  64-65 °C; νmax/cm
-1
 (KBr) 3150, 2949, 1742, 
1447, 1366, 1180, 755, 724; δH (300 MHz, CDCl3) 3.69 (2H, d, J 1.1, CH2), 3.70 (3H, s, 
CH3), 7.25 [1H, ddd, J 8.0, 7.0, 1.1, C(6)-H], 7.33 [1H, ddd, J 8.4, 7.3, 1.4, C(5)-H], 
7.39-7.46 [2H, m, C(3′, 5′)-H], 7.47-7.55 [2H, m, C(7, 4′)-H], 7.57 [1H, s, C(2)-H], 

















To a suspension of 1-methyl-1H-indole-3-carboxylic acid 361 (1.910 g, 
10.9 mmol) in DCM (100 mL) at 0 °C under nitrogen was added 
dropwise oxalyl chloride (0.93 mL, 1.38 g, 21.8 mmol) and the mixture 
was stirred for 16 hours at room temperature eventually becoming a light brown 
solution. The solvent and excess oxalyl chloride were removed under reduced pressure 
to give desired compound as an off-white solid which was used without further 
purification: νmax/cm
-1





A stirred solution of diisopropylamine (5.90 mL, 4.26 g, 42.1 
mmol) in THF (200 mL) in a flame-dried three necked flask 
under nitrogen was cooled to -60 °C. n-Butyllithium (2.5 M, 16 
mL, 40 mmol) was then added slowly and the mixture was 
stirred for 30 minutes at this temperature. The mixture was then 
cooled to -78 °C before a solution of methyl 2-[1-
(phenylsulfonyl)-1H-indol-3-yl]acetate 355 (6.004 g, 18.2 mmol) in THF (30 mL) was 
added slowly and then mixture was stirred for 1 hour at this temperature. A suspension 
of 1-methyl-1H-indole-3-carbonyl chloride 176 (21.8 mmol) in THF (50 mL) was then 
added slowly and the mixture was allowed to warm to room temperature and stirred for 
16 hours. At this point, water (5 mL) was added to quench the reaction and the solvent 
was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (200 
mL) which was washed with saturated aqueous sodium bicarbonate solution (100 mL), 
water (3 × 100 mL) and then brine (100 mL) before being dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under reduced pressure. The 
crude product was purified using column chromatography on silica gel using 40% ethyl 
acetate/ hexane followed by recrystallisation from ethyl acetate to give desired product 
as a white solid (3.985 g, 45%): m.p. 169-171 °C; νmax/cm
-1
 (KBr) 1748, 1634, 1525, 
1369, 1176, 1130, 752, 728; δH (300 MHz, CDCl3) 3.74 (3H, s, CH3), 3.75 (3H, s, CH3), 
5.54 (1H, d, J 0.7, CH), 7.19-7.39 [7H, m, C(5, 5′, 6, 6′, 7′, 3′′, 5′′)-H], 7.43-7.50 [1H, 




6′′)-H], 7.89 [1H, d, J 0.5, C(2′)-H], 7.95 [1H, d, J 7.5, C(4)-H], 8.35-8.41 [1H, m, 
C(4′)-H]; δc (75 MHz, CDCl3) 33.7 (N-CH3), 52.9 (O-CH3), 53.7 (CH), 109.8 (CH, 
aromatic CH), 113.7 (CH, aromatic CH), 114.8 (C, aromatic C), 116.0 (C, aromatic C), 
119.8 (CH, aromatic CH), 122.8 (CH, aromatic CH), 123.2 (CH, aromatic CH), 123.5 
(CH, aromatic CH), 123.9 (CH, aromatic CH), 125.0 (CH, aromatic CH), 125.9 (CH, 
aromatic CH), 126.7 (C, aromatic C), 126.8 (2CH, 2 × aromatic CH), 129.3 (2CH, 2 × 
aromatic CH), 130.0 (C, aromatic C), 133.8 (CH, aromatic CH), 134.9 (C, aromatic C), 
136.2 (CH, aromatic CH), 137.4, (C, aromatic C), 138.2 (C, aromatic C), 169.0 (C=O), 




 100%]; HRMS (ESI
+
): Exact mass calculated 
for (C27H23N2O5S)
+





To a stirred suspension of methyl 3-(1-methyl-1H-indol-3-yl)-3-
oxo-2-[1-(phenylsulfonyl)-1H-indol-3-yl]propanoate 357 (0.102 
g, 0.210 mmol) in ethanol (20 mL) was added camphoric acid 
(0.040 g, 0.210 mmol) and hydrazine hydrate (0.013 mL, 0.013 
g, 0.21 mmol). The mixture was heated to reflux for 2 hours 
before an excess of hydrazine hydrate (0.026 mL, 0.026 g, 0.42 
mmol) was added and the mixture was heated at reflux for a further 24 hours. The 
mixture was then cooled and the solvent evaporated under reduced pressure. The 
residue was dissolved in ethyl acetate (30 mL) and washed with saturated aqueous 
sodium bicarbonate (30 mL), followed by water (2 × 30 mL) and brine (30 mL) before 
being dried over anhydrous magnesium sulfate, filtered and the solvent evaporated 
under reduced pressure. The crude residue was purified using column chromatography 
on silica gel with ethyl acetate as eluent to give desired product as a white solid (0.044 
g, 45%): m.p. 257-259 °C; νmax/cm
-1
 (KBr) 3353, 2598, 1637, 1520, 1358, 1177, 1131, 
742, 593; δH (300 MHz, DMSO-d6) 3.76 (3H, s, CH3), 6.72 [1H, t, J 7.5, C(6′)-H], 7.03 
[1H, t, J 7.7, C(6)-H], 7.07-7.14 [2H, m, C(5′, 7′)-H], 7.20-7.28 [2H, m, C(5, 7)-H], 
7.41 [1H, s, C(2′)-H], 7.43 [1H, d, J 8.7, C(4′)-H], 7.50-7.58 [2H, m, C(3′′, 5′′)-H], 7.53 
[1H, s, C(2)-H], 7.65-7.72 [1H, m, C(4′′)-H], 7.81-7.86 [2H, m, C(2′′, 6′′)-H], 7.88 [1H, 
d, J 8.3, C(4)-H], 10.24 (1H, bs, NH), 11.75 (1H, bs, NH); δc (75 MHz, DMSO-d6) 33.1 
(CH3), 94.3 (C, aromatic C), 105.1 (C, aromatic C), 110.4 (CH, aromatic CH), 113.4 
Experimental 
  296 
 
(CH, aromatic CH), 115.9 (C, aromatic C), 119.9 (CH, aromatic CH), 120.0 (CH, 
aromatic CH), 122.0 (CH, aromatic CH), 122.1 (CH, aromatic CH), 123.4 (CH, 
aromatic CH), 124.2 (CH, aromatic CH), 125.0 (CH, aromatic CH), 126.0 (C, aromatic 
C), 127.01 (2CH, 2 × aromatic CH), 129.1 (CH, aromatic CH), 130.2 (2CH, 2 × 
aromatic CH), 130.8 (C, aromatic C), 134.6 (C, aromatic C),  134.9 (CH, aromatic CH), 





 100%]; HRMS (ESI
+
): Exact mass calculated for (C26H21N4O3S)
+
 




To a suspension of 5-(1-methyl-1H-indol-3-yl)-4-[1-
(phenylsulfonyl)-1H-indol-3-yl]-1H-pyrazol-3(2H)-one 358 
(0.706 g, 1.51 mmol) in a mixture of methanol (40 mL) and 
water (10 mL) was added potassium hydroxide (85 wt.%, 0.366 
g, 6.03 mmol) and the mixture was heated to reflux for 60 hours until reaction was 
complete. After cooling, the solvent was evaporated under reduced pressure. The 
residue was then dissolved in water (40 mL) and acidified to pH 2 using 20% aqueous 
HCl before being extracted with ethyl acetate (2 × 30 mL). The organic layer was 
washed with water (3 × 30 mL) followed by brine (30 mL) before being dried over 
anhydrous magnesium sulfate, filtered and the solvent evaporated under reduced 
pressure. The crude product was purified using column chromatography on silica gel 
with 2% MeOH/DCM to give desired product as a light brown solid (0.142 g, 28%): 
m.p. 192-194 °C; νmax/cm
-1
 (KBr) 3401, 3051, 2685, 1704, 1614, 1566, 1248, 739; δH 
(300 MHz, DMSO-d6) 3.64 (3H, s, CH3), 6.72 [1H, ddd, J 7.9, 7.1, 0.9, C(6)-H], 6.79 
[1H, ddd, J 7.9, 7.1, 0.9, C(6′)-H], 6.92 [1H, ddd, J 8.1, 7.0, 1.0, C(5)-H], 6.99-7.06 
[2H, m, C(2, 5′)-H], 7.16 [1H, d, J 7.9, C(7)-H], 7.19-7.26 [2H, m, C(4, 7′)-H], 7.23 
[1H, s, C(2′)-H], 7.32 [1H, d, J 8.2, C(4′)-H], 9.91 (1H, bs, NH), 10.82 [1H, s, N(1)-H], 
11.18 (1H, bs, NH); δc (75 MHz, DMSO-d6) 33.0 (CH3), 96.9 (C, aromatic C), 106.2 
(C, aromatic C), 107.2 (C, aromatic C), 110.2 (CH, aromatic CH), 111.6 (CH, aromatic 
CH), 118.5 (CH, aromatic CH), 119.7 (CH, aromatic CH), 120.6 (CH, aromatic CH), 
120.7 (CH, aromatic CH), 121.1 (CH, aromatic CH), 121.9 (CH, aromatic CH), 124.4 
(CH, aromatic CH), 126.2 (C, aromatic C), 127.5 (C, aromatic C), 128.8 (CH, aromatic 








 20%]; HRMS (ESI
+
): Exact mass calculated for 
(C20H17N4O)
+





yl]-1H-pyrazol-3(2H)-one (0.120 g, 0.256 mmol) 358 was 
dissolved in methanol (100 mL) and irradiated using a standard 
high pressure mercury lamp in the presence of air for 2 hours. 
The solvent was then evaporated under reduced pressure and the residue dissolved in 
10% MeOH/DCM (30 mL). The organic layer was washed with water (3 × 20 mL) 
before being dried over anhydrous magnesium sulfate, filtered and the solvent 
evaporated under reduced pressure. The crude product was recrystallised from 
MeOH/DCM to give desired product as a light brown solid (0.021 g, 25%): m.p. >300 
°C; νmax/cm
-1
 (KBr) 3407, 3267, 3052, 1618, 1602, 1328, 741; δH (300 MHz, DMSO-d6) 
4.43 (3H, s, CH3), 7.20 [1H, t, J 7.5, C(9)-H], 7.32 [1H, t, J 7.5, C(3)-H], 7.37 [1H, t, J 
7.6, C(10)-H], 7.47 [1H, t, J 7.7, C(2)-H], 7.68 [1H, d, J 8.1, C(11)-H], 7.76 [1H, d, J 
8.2, C(1)-H], 8.46 [1H, d, J 7.7, C(4)-H], 8.94 [1H, d, J 7.9, C(8)-H], 10.78 (1H, bs, 
NH), 11.51 [1H, s, N(12)-H], 11.66 (1H, bs, NH); δc (150 MHz, DMSO-d6) 32.5 (CH3), 
101.0 (C, aromatic C), 104.3 (C, aromatic C), 109.9 (CH, aromatic CH), 112.0 (CH, 
aromatic CH), 114.0 (C, aromatic C), 119.2 (CH, aromatic CH), 120.2 (CH, aromatic 
CH), 121.3 (CH, aromatic CH), 121.6 (C, aromatic C), 121.8 (C, aromatic C), 123.1 (C, 
aromatic C), 123.9 (CH, aromatic CH), 124.2 (CH, aromatic CH), 124.5 (CH, aromatic 
CH), 129.5 (C, aromatic C), 136.0 (C, aromatic C), 139.6 (C, aromatic C), 139.7 (C, 




 100%]; HRMS (ESI
+
): Exact 
mass calculated for (C20H15N4O)
+
 327.1246. Found 327.1234. 
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To a solution of indole-3-acetic acid 254 (5.001 g, 28.5 mmol) in 
anhydrous DMF (50 mL) was added potassium carbonate (5.903 g, 42.8 
mmol) and dimethyl carbonate (8.40 mL, 7.64 g, 100 mmol) and the 
mixture was heated to 130 °C and stirred for 16 hours at this 
temperature. After cooling to room temperature, water (100 mL) was added and the 
crude product was extracted into ethyl acetate (60 mL). The organic layer was then 
washed with water (3 × 50 mL) and brine (50 mL) before being dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under reduced pressure. The 
crude product was purified using column chromatography with 10% ethyl acetate/ 
hexane to give the desired product as a light brown oil which was used without further 
purification (4.563 g, 79%): νmax/cm
-1
 (KBr) 2950, 1737, 1475, 1333, 1163, 742; δH 
(300 MHz, CDCl3) 3.69 (3H, s, CH3), 3.75 (3H, s, CH3), 3.77 (2H, d, J 0.7, CH2), 7.03 
[1H, s, C(2)-H], 7.12 [1H, ddd, J 8.0, 6.8, 1.3, C(5)-H], 7.23 [1H, ddd, 8.0, 6.8, 1.2, 







1-(5-Cyanopentyl)-1H-indole-3-carboxylic acid 362 
 
To a solution of indole-3-carboxylic acid 361 (3.002 g, 18.6 mmol) 
in anhydrous DMF (50 mL) at 0 °C under nitrogen was added 
sodium hydride (1.561 g, 39.0 mmol) cautiously. The mixture was 
stirred at this temperature for 30 minutes before a solution of 6-
bromohexane nitrile 318 (2.70 mL, 3.58 g, 20.4 mmol) in 
anhydrous DMF (10 mL) was added. The mixture was stirred for a 
further 16 hours before water was added cautiously to quench the reaction. The solution 
was then poured into water (120 mL) and acidified to pH 2 with 10% HCl. The aqueous 
mixture then extracted with ethyl acetate (3 × 50 mL) and the organic layer was washed 
with water (60 mL × 3) followed by brine (60 mL) before being dried over anhydrous 




desired product as a white solid (4.442 g, 93%): m.p. 107-108 °C; νmax/cm
-1
 (KBr) 3047, 
2947, 2692, 2248, 1647, 1523, 1193, 757; δH (300 MHz, DMSO-d6) 1.28-1.40 [2H, m, 
C(3′)-H2], 1.58 [2H, quin, J 7.3, C(4′)-H2], 1.81 [2H, quin, J 7.4, C(2′)-H2], 2.46 [2H, t, 
J 7.1, C(5′)-H2], 4.25 [2H, t, J 7.0, C(1′)-H2], 7.16-7.27 [2H, m, C(5, 6)-H], 7.58 [1H, d, 
J 7.5, C(7)-H], 8.03 [1H, dd, J 6.8, 1.4, C(4)-H], 8.08 [1H, s, C(2)-H], 11.92 (1H, bs, 
COOH); δc (75 MHz, DMSO-d6) 16.5 (CH2), 24.8 (CH2), 25.8 (CH2), 29.2 (CH2), 46.2 
(CH2), 106.9 (C, aromatic C), 111.2 (CH, aromatic CH), 121.1 (CN), 121.3 (CH, 
aromatic CH), 121.7 (CH, aromatic CH), 122.6 (CH, aromatic CH), 127.0 (C, aromatic 





 100%]; HRMS (ESI
+





1-(5-Cyanopentyl)-1H-indole-3-carbonyl chloride 363 
 
To a solution of 1-(5-cyanopentyl)-1H-indole-3-carboxylic acid 362 
(3.572 g, 13.9 mmol) in DCM (120 mL) at 0 °C under nitrogen was 
added oxalyl chloride (2.40 mL, 3.55 g, 27.9 mmol) dropwise. The 
mixture was then allowed to warm to room temperature and stirred 
for a further 16 hours. Excess oxalyl chloride and solvent were then 
removed under reduced pressure to give the acyl chloride as a 
brown oil which was used directly in the next reaction: νmax/cm
-1
 (CDCl3) 2943, 2245, 





A stirred solution of diisopropylamine (3.80 mL, 2.74 g, 27.1 
mmol) in THF (150 mL) in a flame-dried three necked flask 
under nitrogen was cooled to -60 °C. n-Butyllithium (2.5 M, 
10.2 mL, 25.5 mmol) was then added slowly and the mixture 
was stirred for 30 minutes at this temperature. The mixture was 
then cooled to -78 °C before a solution of methyl 2-(1-methyl-
1H-indol-3-yl)acetate 177 (2.363 g, 11.6 mmol) in THF (20 mL) was added slowly and 
then mixture was stirred for 1 hour at this temperature. A suspension of 1-(5-
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cyanopentyl)-1H-indole-3-carbonyl chloride 363 (3.821 g, 13.9 mmol) in THF (30 mL) 
was then added while maintaining the temperature and then the mixture was allowed to 
warm to room temperature overnight while stirring. At this point, water (5 mL) was 
added to quench the reaction and the solvent was evaporated under reduced pressure. 
The residue was dissolved in ethyl acetate (150 mL) and washed with saturated aqueous 
sodium bicarbonate solution (70 mL), water (3 × 70 mL) and then brine (70 mL) before 
being dried over anhydrous magnesium sulfate, filtered and the solvent evaporated 
under reduced pressure. The crude product was purified using column chromatography 
on silica gel using DCM to give desired product as a pale yellow foamy solid (1.098 g, 
21%): m.p. 68-70 °C; νmax/cm
-1
 (KBr) 2946, 2244, 1747, 1642, 1526, 1383, 1152, 745; 
δH (300 MHz, CDCl3) 1.23-1.36 [2H, m, C(3′′)-H2], 1.55 [2H, quin, J 7.3, C(4′′)-H2], 
1.80 [2H, quin, J 7.5, C(2′′)-H2], 2.19 [2H, t, J 7.0, C(5′′)-H2], 3.74 (3H, s, CH3), 3.77 
(3H, s, CH3), 4.07 [2H, t, J 7.0, C(1′′)-H2], 5.71 (1H, s, CH), 7.15 [1H, ddd, J 8.0, 6.9, 
1.3, C(5′)-H], 7.23 [1H, ddd, J 8.1, 6.9, 1.2, C(6′)-H], 7.27-7.32 [4H, m, C(5, 6, 7, 7′)-
H], 7.33 [1H, s, C(2)-H], 7.69 [1H, d, J 7.8, C(4)-H], 7.80 [1H, s, C(2′)-H], 8.41-8.47 
[1H, m, C(4′)-H]; δc (75 MHz, CDCl3) 17.0 (CH2), 24.8 (CH2), 25.8 (CH2), 28.9 (CH2), 
33.0 (CH3), 46.8 (CH2), 52.7 (CH3), 53.2 (CH), 107.5 (C, aromatic C), 109.6 (CH, 
aromatic CH), 109.7 (CH, aromatic CH), 115.04 (C, aromatic C), 118.2 (CH, aromatic 
CH), 119.4 (CN), 119.6 (CH, aromatic CH), 121.8 (CH, aromatic CH), 122.98 (CH, 
aromatic CH), 123.00 (CH, aromatic CH), 123.7 (CH, aromatic CH), 127.0 (C, aromatic 
C), 127.1 (C, aromatic C), 129.0 (CH, aromatic CH), 135.0 (CH, aromatic CH), 136.5 





 40%]; HRMS (ESI
+












Sodium metal (0.622 g, 27.0 mmol) was added in small 
portions to distilled methanol (12 mL) in a flame-dried flask 
under nitrogen and stirred until fully dissolved. Guanidine 
carbonate (2.451 g, 13.6 mmol) was then added and the reaction 
mixture was stirred for 30 minutes. A solution of methyl 3-[1-
(5-cyanopentyl)-1H-indol-3-yl]-2-(1-methyl-1H-indol-3-yl)-3-
oxopropanoate 364 (0.605 g, 1.37 mmol) in distilled methanol 
(3 mL) was then added and the reaction mixture was heated to reflux for 48 hours. After 
cooling, the solvent was evaporated under reduced pressure. The residue was dissolved 
in water (20 mL), acidified to pH 7 using 10% aqueous HCl and the resulting precipitate 
was collected using vacuum filtration. The crude product was purified using column 
chromatography on silica gel with a gradient of 2-4% MeOH/DCM to give a pale 
yellow solid (0.245 g, 40%): m.p. 169-170 °C; νmax/cm
-1
 (KBr) 3317, 3049, 2933, 2243, 
1635, 1517, 1461, 1390, 1225, 740; δH (300 MHz, DMSO-d6) 0.73-0.86 [2H, m, C(4′′)-
H2], 1.14 [2H, quin, J 6.8, C(5′′)-H2], 1.29 [2H, quin, J 7.3, C(3′′)-H2], 2.30 [2H, t, J 
7.2, C(2′′)-H2], 3.77 [2H, t, J 6.0, C(6′′)-H2], 3.82 (3H, s, CH3), 6.45 (2H, bs, NH2), 6.58 
[1H, s, C(2′)-H], 6.75 [1H, t, J 7.3, C(6)-H], 6.88 [1H, d, J 7.8, C(7)-H], 6.99-7.12 [3H, 
m, C(5, 5′, 6′)-H], 7.24 [1H, s, C(2)-H], 7.32 [1H, d, J 8.0, C(7′)-H], 7.41 [1H, d, J 8.2, 
C(4)-H], 8.45 [1H, d, J 7.5, C(4′)-H], 10.85 (1H, bs, NH); δc (75 MHz, DMSO-d6) 16.3 
(CH2), 24.7 (CH2), 25.2 (CH2), 28.8 (CH2), 32.9 (CH3), 45.2 (CH2), 103.2 (C, aromatic 
C), 109.5 (C, aromatic C), 109.7 (CH, aromatic CH), 109.9 (CH, aromatic CH), 113.4 
(C, aromatic C), 118.8 (CH, aromatic CH), 120.0 (CH, aromatic CH), 120.2 (CH, 
aromatic CH), 121.01 (CH, aromatic CH), 121.04 (CN), 121.7 (CH, aromatic CH), 
123.8 (CH, aromatic CH), 127.4 (C, aromatic C), 127.6 (C, aromatic C), 130.4 (CH, 
aromatic CH), 131.7 (CH, aromatic CH), 135.9 (C, aromatic C), 137.1 (C, aromatic C), 







): Exact mass calculated for (C27H27N6O)
+











pyrimidin-4-yl]-1H-indol-1-yl}hexanenitrile 365 (0.100 g, 
0.222 mmol) was dissolved in a mixture of acetonitrile (60 mL) 
and methanol (40 mL) along with a catalytic amount of iodine 
and irradiated using a standard high pressure mercury lamp in 
the presence of air for 16 hours. The solvent was then 
evaporated under reduced pressure and the residue dissolved in 10% MeOH/DCM (30 
mL). The organic layer was washed with saturated aqueous sodium thiosulfate (20 mL), 
followed by water (3 × 20 mL) before being dried over anhydrous magnesium sulfate, 
filtered and the solvent evaporated under reduced pressure. The crude product was 
purified using column chromatography on silica gel with 2% MeOH/DCM to give 
desired product as a light brown solid (0.032 g, 32%): m.p. 181-183 °C; νmax/cm
-1
 (KBr) 
3369, 2927, 2244, 1638, 1600, 1439, 1324, 748; δH (300 MHz, DMSO-d6) 0.97-1.10 
[2H, m, C(4′)-H2], 1.36 [2H, quin, J 7.3, C(3′)-H2], 1.59 [2H, quin, J 7.2, C(5′)-H2], 
2.25 [2H, t, J 7.1, C(2′)-H2], 4.06 (3H, s, CH3), 4.74 [2H, t, J 7.1, C(6′)-H2], 6.42 (2H, s, 
NH2), 7.24 [1H, t, J 7.5, C(10)-H], 7.32 [1H, t, J 7.4, C(3)-H], 7.48 [2H, t, J 7.6, C(2, 
11)-H], 7.64 [1H, d, J 8.1, C(12)-H], 7.80 [1H, d, J 8.2, C(1)-H], 9.09 [1H, d, J 7.6, 
C(4)-H], 9.66 [1H, d, J 8.2, C(9)-H], 10.95 [1H, s, N(7)-H]; δc (75 MHz, DMSO-d6) 
16.3 (CH2), 24.6 (CH2), 25.6 (CH2), 28.0 (CH2), 37.2 (CH3), 47.7 (CH2), 105.9 (C, 
aromatic C), 111.2 (CH, aromatic CH), 112.0 (CH, aromatic CH), 116.6 (C, aromatic 
C), 119.8 (CH, aromatic CH), 120.3 (C, aromatic C), 120.8 (CN), 121.0 (CH, aromatic 
CH), 124.4 (CH, aromatic CH), 125.0 (CH, aromatic CH), 125.2 (C, aromatic C), 125.7 
(CH, aromatic CH), 126.3 (C, aromatic C), 127.6 (C, aromatic C), 127.7 (CH, aromatic 
CH), 133.5 (C, aromatic C), 142.5 (C, aromatic C), 145.5 (C, aromatic C), 147.7 (C, 







): Exact mass calculated for (C27H25N6O)
+






7.6 Routes towards 3,3'-(1H-imidazole-4,5-diyl)bis(1H-indole)s 
 






To a solution of indole 251 (1.006 g, 8.59 mmol) in diethyl ether (20 
mL) was added oxalyl chloride (1.10 mL, 1.63 g, 12.8 mmol) dropwise 
over 10 minutes. The yellow suspension was then stirred for a further 
30 minutes. The product was collected using vacuum filtration and washed with cool 
















Note: this reaction was carried out using a 3-necked flask fitted 
with an overhead stirrer. 
2-(1H-Indol-3-yl)-2-oxoacetyl chloride 368 (16.123 g, 78.0 
mmol) was added portionwise to a suspension of aluminium chloride (45.307 g, 340 
mmol) in a mixture of 1,2 dichloroethane (100 mL) and heptane (50 mL) over 5 minutes 
with stirring  at room temperature. A solution of indole 251 (13.576 g, 116 mmol) in 1,2 
dichloroethane (100 mL) was added dropwise under vigorous stirring to the dark brown 
mixture and then stirred for a further 16 hours. The reaction mixture was poured onto 
ice water (400 mL) and extracted with ethyl acetate (3 × 300 mL). The combined 
extracts were washed with water (2 × 300 mL) before being, dried over magnesium 
sulfate, filtered and evaporated under reduced pressure. The brown residue was 
triturated with ether (200 mL) and the product was collected by vacuum filtration as a 





3305, 1604, 1511, 1422, 1240, 1114, 778, 732; δH (300 MHz, DMSO-d6) 7.26-7.32 [4H, 
m, C(5, 5', 6, 6')-H], 7.51-7.58 [2H, m, C(7, 7')-H], 8.28 [2H, d, J 3.2, C(2, 2')-H], 8.25-











To a suspension of 1,2-bis(1H-indol-3-yl)ethane-1,2-dione 367 
(4.009 g, 13.9 mmol) and ammonium acetate (10.467 g, 139 
mmol) in acetic acid (120 mL) was added formaldehyde 
dimethyl acetal (1.16 mL, 1.00 g, 13.9 mmol) and the mixture was stirred at reflux for 
48 hours. The reaction mixture was then allowed to cool and concentrated under 
reduced pressure. The residue was washed with saturated aqueous sodium bicarbonate 
(100 mL) and extracted with 10% MeOH/DCM (3 × 100 mL). The organic layer was 
dried over magnesium sulfate, filtered and evaporated under reduced pressure. The 
crude product was purified using column chromatography on alumina with 4% 
MeOH/DCM to give desired product as a dark brown solid (1.396 g, 34%): m.p. 113-
114 °C; νmax/cm
-1
 (KBr) 3386, 3052, 1559, 1455, 742; δH (300 MHz, DMSO-d6) 6.92 
[2H, ddd, J 8.0, 7.1, 0.9, C(5, 5′)-H], 7.08 [2H, ddd, J 8.1, 7.1, 1.1, C(6, 6′)-H], 7.31 
[2H, d, J 2.4, C(2, 2′)-H], 7.39 [2H, d, J 8.1, C(7, 7′)-H], 7.55 [2H, d, J 7.9, C(4, 4′)-H], 
8.02 [1H, s, N-CH-N], 11.17 [2H, s, N(1, 1′)-H]; δc (75 MHz, DMSO-d6) 107.3 (2C, 2 × 
aromatic C), 111.5 (2CH, 2 × aromatic CH), 118.8 (2CH, 2 × aromatic CH), 120.3 
(2CH, 2 × aromatic CH), 121.2 (2CH, 2 × aromatic CH), 123.9 (2CH, 2 × aromatic 
CH), 125.4 (2C, 2 × aromatic C), 125.9 (2C, 2 × aromatic C), 134.11 (CH, aromatic 




 100%]; HRMS (ESI
+
): 
Exact mass calculated for (C19H15N4)
+













Oxidant Stoichiometry Conditions Product 















4 Imidazole Pd(OAc)2 1 eq. AcOH, 120 °C 
complex 
mixture 
5 Imidazole MnO2 10 eq. Acetone, r.t. 
complex 
mixture 
6 Imidazole DDQ 1.2 eq. TFA, reflux 
complex 
mixture 
7 Dione hν/I2 0.1 eq. CH3CN, reflux 
starting 
material 




Reactions 1, 2 and 7: A solution of either imidazole 369 or dione 367 (0.100 g) with or 
without a catalytic amount of iodine was irradiated using a standard high pressure 
mercury lamp in the presence of air for 16 hours. The solvent was then evaporated 
under reduced pressure and the residue dissolved in 10% MeOH/DCM (30 mL). The 
organic layer was washed with saturated aqueous sodium thiosulfate (20 mL), followed 
by water (3 × 20 mL) before being dried over anhydrous magnesium sulfate, filtered 
and the solvent evaporated under reduced pressure. 
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Reaction 3: A solution of imidazole 369 (0.100 g) in acetonitrile/methanol was heated 
to reflux for 16 hours before the solvent was evaporated under reduced pressure. 
 
 
Reactions 4, 5 and 8: A solution of imidazole 369 or dione 367 (0.100 g) with the 
required oxidant was stirred using the conditions given above. After cooling, the 
reaction mixture was filtered through a pad of Celite
®
 and washed with further portions 
of solvent (3 × 10 mL). The solvent was removed under reduced pressure.  
 
Reaction 6: Imidazole 369 (0.100 g, 0.33 mmol) and 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (0.092 g, 0.40 mmol) were suspended in trifluoroacetic acid (10 mL) and 
the reaction was heated to reflux for 24 hours. After cooling, the solvent was removed 
under reduced pressure and the residue washed with saturated aqueous sodium 
bicarbonate solution and extracted into 10% MeOH/DCM. The organic layer was 
washed with saturated aqueous sodium bicarbonate solution, followed by brine before 
being dried over anhydrous magnesium sulfate, filtered and the solvent evaporated 
under reduced pressure. 
 
Purification: As HRMS indicated some formation of desired indolocarbazole product, 
crude reaction mixtures from reactions 1, 2, 4, 5 and 6 were subjected to careful column 
chromatography on silica gel with a gradient of 2-5% MeOH/DCM. Unfortunately, no 
pure samples were obtained. Column chromatography on alumina with a gradient of 2-






To a solution of 1,2-bis(1H-indol-3-yl)ethane-1,2-dione 367 
(1.005 g, 3.47 mmol) in anhydrous DMF (35 mL) under 
nitrogen was added sodium hydride (60 wt. % oil suspension, 
0.606 g, 13.9 mmol) and the reaction mixture was allowed to stir for 30 minutes. 
Iodomethane (0.90 mL, 2.05 g, 14.6 mmol) was then added and the reaction was stirred 
for a further 16 hours. Water (60 mL) was then added and the product was extracted 
into ethyl acetate (3 × 50 mL). The organic layer was washed with 1 M aqueous HCl (2 




sulfate, filtered and the solvent evaporated under reduced pressure. The crude material 
was purified using column chromatography on silica gel with 20% ethyl acetate/hexane 





 (KBr) 2931, 1623, 1607, 1525, 1373, 1077, 738; δH (300 MHz, DMSO-
d6) 3.89 [6H, s, N-CH3], 7.31-7.40 [4H, m, C(5, 5', 6, 6')-H], 7.59-7.64 [2H, m, C(7, 7')-








Formaldehyde dimethyl acetal (0.17 mL, 0.15 g, 1.9 mmol) was 
added to a suspension of 1,2-bis(1-methyl-1H-indol-3-
yl)ethane-1,2-dione 372 (0.601 g, 1.9 mmol) and ammonium 
acetate (1.467 g, 19 mmol) in acetic acid (20 mL) and the 
mixture was stirred at reflux for 48 hours. The reaction mixture was then concentrated 
under reduced pressure. The residue washed with saturated sodium bicarbonate solution 
(10 mL) and extracted with 10% MeOH/DCM (3 × 10 mL). The organic layer was then 
dried over magnesium sulfate, filtered and evaporated under reduced pressure to give a 
dark brown residue which on analysis was shown to be starting material. 
 




Guanidine carbonate (2.00 g, 11.1 mmol) was suspended in a 
solution of sodium hydroxide (0.9641 g, 22.2 mmol) in 
methanol (25 mL) and the mixture was stirred for 1 hour before 
being filtered. The filtrate was evaporated to dryness under 
reduced pressure. The residue was then dissolved in ethanol (17 mL) and filtered. The 
ethanol was then evaporated under reduced pressure to give guanidine as a semi 
crystalline material. Guanidine (0.5361 g, 9.0 mmol) was then added to a solution of 
1,2-bis(1H-indol-3-yl)ethane-1,2-dione 367 (2.441 g, 8.5 mmol) in methanol (15 mL) 
and the mixture was refluxed for 48 hours. The precipitated solid was then collected 
using vacuum filtration and washed with methanol. The light brown solid (0.21 g, 0.61 
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mmol) was then suspended in methanol (10 mL) and 10% Pd/C (0.036 g) was added. 
The suspension was agitated under a hydrogen atmosphere at 10 psi for 24 hours. The 
reaction mixture was filtered through a pad of Celite
®
 and washed with a further portion 
of methanol (20 mL). The filtrate was then evaporated to dryness under reduced 
pressure. Analysis using 
1
H NMR and mass spectrometry showed no product had 
formed. 
 







(eq. of urea) 
Additive Conditions Product 
1 (O) 1.3 CSA (1 eq.) 
















N2, 24 hours 
starting 
material 
4 (O) 5 - 




5 (S) 5 TFA (cat.) 













General Procedure: A mixture of 1,2-bis(1H-indol-3-yl)ethane-1,2-dione 367 (0.100 




reacted under the conditions given above. After cooling, the solvent was evaporated 
under reduced pressure and the residue dissolved in ethyl acetate (20 mL). The organic 
layer was washed with water (3 × 10 mL) before being dried over anhydrous 
magnesium sulfate, filtered and the solvent evaporated under reduced pressure. In all 
cases 
1
H NMR analysis showed only starting material to be present. 
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7.7 Protocol for Biological Evaluation 
7.7.1 NCI-60 Cell Screen Experimental Methodology 
 
Cell lines are initially grown in RPMI 1640 culture medium containing 10% heat-
inactivated fetal bovine serum under standard culture conditions (37 °C, 5% CO2, 95% 
air and 100% humidity).
22
 Prior to the addition of the candidate compound, the cells are 
dispensed into 96-well microtiter plates in 100 μL of culture medium at plating densities 
ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual 
cell lines before being incubated under standard culture conditions for 24 hours. Two 
plates of each cell line are then fixed in situ with trichloroacetic acid (TCA) to represent 
a measurement of the cell population for each cell line at the time of drug addition (Tz).  
 
Candidate compounds are dissolved in DMSO at 400-fold the desired final test 
concentration and stored frozen until required. This stock solution can then be diluted to 
the necessary concentrations – single dose screening is carried out at 10 μM and five 
dose screening at five different concentrations (100 μM, 10 μM, 1 μM, 100 nM and 10 
nM).  
 
Following the addition of 100 μL of the drug solution to the appropriate wells and the 
plates are incubated for a further 48 hours under standard culture conditions. The assay 
is terminated by the addition of 50 μL of cold TCA (50% TCA for adherent cells and 
80% TCA for settled suspension cells), which fixes the cells in situ, and incubation for 
60 minutes at 4 °C. The supernatant is discarded and the plates are washed with water 
before staining with sulforhodamine B solution (100 μL) at 4% (w/v) in 1% acetic acid 
is added to each well, and the plates are incubated at room temperature for 10 minutes. 
The absorbance is read on an automated plate reader at a wavelength of 515 nm, and 
using the absorbance measurements for time zero (Tz), control growth (C), and test 
growth in the presence of the drug at the particular concentration level (Ti) the 
percentage growth is calculated. For the single dose assay the results are given as 
percentage growth. For the five dose assay, the percentage growths at each 
concentration are used to form a concentration response curve from which the 
concentration parameters GI50 (concentration to inhibit cell growth by 50%) and LC50 




(total growth inhibition) is read as the x-axis intercept from the five different drug 
concentrations. 
7.7.2 Kinase Screen Experimental Methodology 
 
All kinase assays were performed in 96-well plates in appropriate buffer, with either 
protein or peptide as substrate in the presence of 15µM [γ-
33
P] ATP (3,000 Ci/mmol; 10 
mCi/ml) in a final volume of 30 µl using the following method.
23
 The reaction mixture 
was pipetted in four steps in the following order: (i) 20 μL of buffer (see below), (ii) 5 
μL of [γ-
33
P] ATP solution (in water), (iii) 5 μL of test compound (in 10% DMSO) and 
(iv) 10 μL of substrate/ 10 μL of enzyme solution (premixed). The final DMSO 
concentration was 1% in all assays. The mixtures were incubated at 30 °C for 80 
minutes before the reaction was stopped with 50 μL of 2% (v/v) phosphoric acid and the 
plates were washed with water or 0.9% (w/v) sodium chloride solution. Determination 
of incorporated 
33
Pi was achieved with a microplate scintillation counter. IC50 values 
were then calculated from the residual activities (in %) obtained for each concentration. 
 
Buffers:  
(A) 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl pH 7.5, 50 µg/mL 
heparin. 
(B) 60 mM β-glycerophosphate, 30 mM p-nitrophenyl-phosphate, 25 mM MOPS (pH 
7), 5 mM EGTA, 15 mM MgCl2, 1 mM DTT, 0.1 mM sodium orthovanadate. 
(D) 25 mM MOPS, pH 7.2, 12.5 mM β-glycerolphosphate, 25 mM MgCl2, 5 mM 
EGTA, 2 mM EDTA, 0.25 mM DTT.  
(H) MOPS 25 mM pH 7.5, 10 mM MgCl2.  
(K) Tris 50 mM pH 7.5, 20 mM MgCl2, 2 mM MnCl2.  
(R) 5 mM MOPS pH 7.2, 2.5 mM -glycerophosphate, 4 mM MgCl2, 2.5 mM MnCl2, 1 
mM EGTA, 0.4 mM EDTA, 50 μg/mL BSA, 0.05 mM DTT. 
 
HsRIPK3 (human, recombinant, expressed by baculovirus in Sf9 insect cells) was 
assayed in buffer R with 0.1 µg/µL of MBP as substrate.  
 
HsPIM1 (human proto-oncogene, recombinant, expressed in bacteria) was assayed in 
buffer B with 0.8 µg/µL of histone H1 (Sigma #H5505) as substrate. 
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HsHaspin-kd (human, kinase domain, amino acids 470 to 798, recombinant, expressed 
in bacteria) was assayed in buffer H with 0.007 µg/µL of Histone H3 (1-21) peptide 
(ARTKQTARKSTGGKAPRKQLA) as substrate; 
 
HsCDK2/CyclinA (cyclin-dependent kinase-2, human, kindly provided by Dr. A. 
Echalier-Glazer, Leicester, UK) was assayed in buffer A (+ 0.15 mg/mL of BSA + 0.23 
mg/mL of DTT) with 0.8 µg/µL of histone H1 as substrate. 
 
HsCDK9/CyclinT (human, recombinant, expressed by baculovirus in Sf9 insect cells) 
was assayed in buffer A (+ 0.15 mg/mL of BSA + 0.23 mg/mL of DTT) with 0.27 
µg/µL of the following peptide: YSPTSPSYSPTSPSYSPTSPSKKKK, as substrate. 
 
HsCDK5/p25 (human, recombinant, expressed in bacteria) was assayed in buffer B, 
with 0.8 µg/µL of histone H1 as substrate. 
 
HsAuroraB (human, recombinant, expressed by baculovirus in Sf9 insect cells, 
SignalChem, product #A31-10G) was assayed in buffer D with 0.2 µg/µL of MBP as 
substrate. 
 
SscGSK-3α/β (glycogen synthase kinase-3, porcine brain, native, affinity purified) was 
assayed in buffer A (+ 0.15 mg/mL of BSA + 0.23 mg/mL of DTT), with 0.010 µg/µL 
of GS-1 peptide, a GSK-3-selective substrate (YRRAAVPPSPSLSRHSSPHQSpE 
DEEE, “Sp” stands for phosphorylated serine). 
 
SscCK1δ/ε (casein kinase 1δ/ε, porcine brain, native, affinity purified) was assayed in 
buffer B, with 0.022 µg/µL of the following peptide: RRKHAAIGSpAYSITA as CK1-
specific substrate. 
 
RnDYRK1A-kd (Rattus norvegicus, amino acids 1 to 499 including the kinase domain, 
recombinant, expressed in bacteria, DNA vector kindly provided by Dr. W. Becker, 
Aachen, Germany) was assayed in buffer A (+ 0.5 mg/mL of BSA + 0.23 mg/mL of 





MmCLK1 (from Mus musculus, recombinant, expressed in bacteria) was assayed in 
buffer A (+ 0.15 mg/mL of BSA + 0.23 mg/mL of DTT) with 0.027 μg/µL of the 
following peptide: GRSRSRSRSRSR. 
 
PfGSK-3 (from Plasmodium falciparum, recombinant, expressed in bacteria) was 
assayed in buffer A (+ 0.15 mg/mL of BSA +0.23 mg/mL of DTT) with 0.010 µg/µL 
GS-1 peptide, a GSK-3-selective substrate (YRRAAVPPSPSLSRHSSPHQSpEDEEE, 
“Sp” stands for phosphorylated serine). 
 
LdTLK (tousled-like kinase, from Leishmania donovani, recombinant, expressed in 
bacteria), was assayed in buffer K with 0.6 µg/µL of casein dephosphorylated from 
bovine milk (Sigma #C4032). 
  
Experimental 




1. H. Gilman and F. K. Cartledge, J. Organomet. Chem., 1964, 2, 447–454. 
2. H. Gilman and A. H. Haubein, J. Am. Chem. Soc., 1944, 66, 1515–1516. 
3. S. Roy and G. W. Gribble, Synth. Commun., 2007, 37, 1879–1886. 
4. K. N. F. Shaw, A. McMillan, A. G. Gudmundson, and M. D. Armstrong, J. Org. 
Chem., 1958, 23, 1171–1178. 
5. F. Millich and E. I. Becker, J. Org. Chem., 1958, 23, 1096–1102. 
6. M. Brenner, H. Rexhausen, B. Steffan, and W. Steglich, Tetrahedron, 1988, 44, 
2887–2892. 
7. S. Roy, A. Eastman, and G. W. Gribble, Tetrahedron, 2006, 62, 7838–7845. 
8. M. S. Morales-Ríos, J. Espiñeira, and P. Joseph-Nathan, Magn. Reson. Chem., 1987, 
25, 377–395. 
9. S. Roy, A. Eastman, and G. W. Gribble, Org. Biomol. Chem., 2006, 4, 3228–3234. 
10. M. Botta, F. De Angelis, and R. Nicoletti, J. Heterocycl. Chem., 1979, 16, 501–504. 
11. P. D. Davis and R. A. Bit, Tetrahedron Lett., 1990, 31, 5201–5204. 
12. E. R. Pereira, S. Fabre, M. Sancelme, M. Prudhomme, and M. Rapp, J. Antibiot. 
(Tokyo), 1995, 48, 863–868. 
13. P. Torney, R. Shirsat, and S. Tilve, Synlett, 2014, 25, 2121–2126. 
14. U. Pindur, Y. S. Kim, and D. Schollmeyer, J. Heterocycl. Chem., 1995, 32, 1335–
1339. 
15. K. Yasui, K. Fugami, S. Tanaka, and Y. Tamaru, J. Org. Chem., 1995, 60, 1365–
1380. 
16. H. M. Deutsch, X. Ye, Q. Shi, Z. Liu, and M. M. Schweri, Eur. J. Med. Chem., 2001, 
36, 303–311. 
17. M. J. Slater, R. Baxter, R. W. Bonser, S. Cockerill, K. Gohil, N. Parry, E. Robinson, 
R. Randall, C. Yeates, W. Snowden, and A. Walters, Bioorg. Med. Chem. Lett., 
2001, 11, 1993–1995. 
18. I. Hughes, W. P. Nolan, and R. A. Raphael, J. Chem. Soc. [Perkin 1], 1990, 2475–
2480. 
19. A. P. Chandrasekharappa, S. E. Badiger, P. K. Dubey, S. K. Panigrahi, S. R. V. V. V. 
Manukonda, Res. J. Chem. Sci., 2012, 2, 63–71. 
20. L. T. Pierce, M. M. Cahill, and F. O. McCarthy, Tetrahedron, 2010, 66, 9754–9761. 
21. M. Krayushkin, V. Yarovenko, I. Sedishev, I. Zavarzin, L. Vorontsova, and Z. 
Starikova, Russ. J. Org. Chem., 2005, 41, 875–883. 
22. M. C. Alley, D. A. Scudiero, A. Monks, M. L. Hursey, M. J. Czerwinski, D. L. Fine, 
B. J. Abbott, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd, Cancer Res., 1988, 48, 
589–601. 
23. S. Bach, M. Knockaert, J. Reinhardt, O. Lozach, S. Schmitt, B. Baratte, M. Koken, S. 
P. Coburn, L. Tang, T. Jiang, D. Liang, H. Galons, J.-F. Dierick, L. A. Pinna, F. 
Meggio, F. Totzke, C. Schächtele, A. S. Lerman, A. Carnero, Y. Wan, N. Gray, and 

































































































































































































































































































































































































































































































































c]carbazol-12-yl)hexyl]morpholin-4-ium chloride 338 
 
 
 
 
Appendices 
lvi 
 
6-Hydroxy-12-(6-morpholino-6-oxohexyl)-12,13-dihydro-5H-indolo[2,3-
a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 314 
 
 
 
 
 
Appendices 
lvii 
 
6-Hydroxy-12-(6-morpholino-6-oxohexyl)-12,13-dihydro-5H-indolo[2,3-
a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione 314 
 
 
 
 
Appendices 
lviii 
 
N,N-Diethyl-6-(6-hydroxy-5,7-dioxo-5,6,7,13-tetrahydro-12H-indolo[2,3-
a]pyrrolo[3,4-c]carbazol-12-yl)hexanamide 315 
 
 
 
 
 
Appendices 
lix 
 
N,N-Diethyl-6-(6-hydroxy-5,7-dioxo-5,6,7,13-tetrahydro-12H-indolo[2,3-
a]pyrrolo[3,4-c]carbazol-12-yl)hexanamide 315 
 
 
 
 
Appendices 
lx 
 
7-Hydroxy-13,14-dimethyl-13,14-dihydroindolo[2,3-a]pyrimido[4,5-c]carbazole-
6,8(5H,7H)-dione 350 
 
 
 
 
 
Appendices 
lxi 
 
7-Hydroxy-13,14-dimethyl-13,14-dihydroindolo[2,3-a]pyrimido[4,5-c]carbazole-
6,8(5H,7H)-dione 350 
 
 
 
 
Appendices 
lxii 
 
13,14-Dimethyl-13,14-dihydroindolo[2,3-a]pyrimido[4,5-c]carbazole-6,8(5H,7H)-
dione 352 
 
 
 
 
 
Appendices 
lxiii 
 
13,14-Dimethyl-13,14-dihydroindolo[2,3-a]pyrimido[4,5-c]carbazole-6,8(5H,7H)-
dione 352 
 
 
 
 
